
<html lang="en"     class="pb-page"  data-request-id="9f8ee53e-492c-4e84-a7bf-a23a2f947737"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01199;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma" /></meta><meta name="dc.Creator" content="David  Smil" /></meta><meta name="dc.Creator" content="Jong Fu  Wong" /></meta><meta name="dc.Creator" content="Eleanor P.  Williams" /></meta><meta name="dc.Creator" content="Roslin J.  Adamson" /></meta><meta name="dc.Creator" content="Alison  Howarth" /></meta><meta name="dc.Creator" content="David A.  McLeod" /></meta><meta name="dc.Creator" content="Ahmed  Mamai" /></meta><meta name="dc.Creator" content="Soyoung  Kim" /></meta><meta name="dc.Creator" content="Brian J.  Wilson" /></meta><meta name="dc.Creator" content="Taira  Kiyota" /></meta><meta name="dc.Creator" content="Ahmed  Aman" /></meta><meta name="dc.Creator" content="Julie  Owen" /></meta><meta name="dc.Creator" content="Gennady  Poda" /></meta><meta name="dc.Creator" content="Kurumi Y.  Horiuchi" /></meta><meta name="dc.Creator" content="Ekaterina  Kuznetsova" /></meta><meta name="dc.Creator" content="Haiching  Ma" /></meta><meta name="dc.Creator" content="J. Nicole  Hamblin" /></meta><meta name="dc.Creator" content="Sue  Cramp" /></meta><meta name="dc.Creator" content="Owen G.  Roberts" /></meta><meta name="dc.Creator" content="Aled M.  Edwards" /></meta><meta name="dc.Creator" content="David  Uehling" /></meta><meta name="dc.Creator" content="Rima  Al-awar" /></meta><meta name="dc.Creator" content="Alex N.  Bullock" /></meta><meta name="dc.Creator" content="Jeff A.  O’Meara" /></meta><meta name="dc.Creator" content="Methvin B.  Isaac" /></meta><meta name="dc.Description" content="There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brai..." /></meta><meta name="Description" content="There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brai..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 11, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01199" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01199" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01199" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01199" /></link>
        
    
    

<title>Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01199" /></meta><meta property="og:title" content="Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0017.jpeg" /></meta><meta property="og:description" content="There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brainstem. Radiation therapy is beneficial but not curative, with the condition being uniformly fatal. Analysis of the genomic landscape surrounding DIPG has revealed that activin receptor-like kinase-2 (ALK2) constitutes a potential target for therapeutic intervention given its dysregulation in the disease. We adopted an open science approach to develop a series of potent, selective, orally bioavailable, and brain-penetrant ALK2 inhibitors based on the lead compound LDN-214117. Modest structural changes to the C-3, C-4, and C-5 position substituents of the core pyridine ring afforded compounds M4K2009, M4K2117, and M4K2163, each with a superior potency, selectivity, and/or blood–brain barrier (BBB) penetration profile. Robust in vivo pharmacokinetic (PK) properties and tolerability mark these inhibitors as advanced preclinical compounds suitable for further development and evaluation in orthotopic models of DIPG." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01199"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01199">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01199&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01199&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01199&amp;href=/doi/10.1021/acs.jmedchem.0c01199" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 10061-10085</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01161" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01267" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">David Smil</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Smil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#9ffbfee9f6fbb1ecf2f6f3dff0f6fcedb1f0f1b1fcfe"><span class="__cf_email__" data-cfemail="563237203f3278253b3f3a16393f3524783938783537">[email protected]</span></a>. Phone: +1 (647) 260-6454.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Smil">David Smil</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6232-6087" title="Orcid link">http://orcid.org/0000-0002-6232-6087</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jong Fu Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jong Fu Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jong+Fu++Wong">Jong Fu Wong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eleanor P. Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eleanor P. Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eleanor+P.++Williams">Eleanor P. Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roslin J. Adamson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roslin J. Adamson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roslin+J.++Adamson">Roslin J. Adamson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alison Howarth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alison Howarth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alison++Howarth">Alison Howarth</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David A. McLeod</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David A. McLeod</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++McLeod">David A. McLeod</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ahmed Mamai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahmed Mamai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahmed++Mamai">Ahmed Mamai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Soyoung Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Soyoung Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Soyoung++Kim">Soyoung Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian J. Wilson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian J. Wilson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+J.++Wilson">Brian J. Wilson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Taira Kiyota</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Taira Kiyota</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Taira++Kiyota">Taira Kiyota</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ahmed Aman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahmed Aman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahmed++Aman">Ahmed Aman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie Owen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Owen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Owen">Julie Owen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gennady Poda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gennady Poda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gennady++Poda">Gennady Poda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kurumi Y. Horiuchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kurumi Y. Horiuchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reaction Biology Corp., Suite 2, 1 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kurumi+Y.++Horiuchi">Kurumi Y. Horiuchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ekaterina Kuznetsova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ekaterina Kuznetsova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reaction Biology Corp., Suite 2, 1 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ekaterina++Kuznetsova">Ekaterina Kuznetsova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haiching Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haiching Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reaction Biology Corp., Suite 2, 1 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haiching++Ma">Haiching Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Nicole Hamblin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Nicole Hamblin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Charles River Discovery, Chesterford Research Park, Saffron Waldon, Essex CB10 1XL, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Nicole++Hamblin">J. Nicole Hamblin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sue Cramp</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sue Cramp</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Charles River Discovery, 8-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sue++Cramp">Sue Cramp</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Owen G. Roberts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Owen G. Roberts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">M4K Pharma, 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Owen+G.++Roberts">Owen G. Roberts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aled M. Edwards</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aled M. Edwards</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">M4K Pharma, 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aled+M.++Edwards">Aled M. Edwards</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4782-6016" title="Orcid link">http://orcid.org/0000-0002-4782-6016</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Uehling</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Uehling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Uehling">David Uehling</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rima Al-awar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rima Al-awar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Department of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, Room 4207, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rima++Al-awar">Rima Al-awar</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4185-055X" title="Orcid link">http://orcid.org/0000-0002-4185-055X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alex N. Bullock</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alex N. Bullock</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alex+N.++Bullock">Alex N. Bullock</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6757-0436" title="Orcid link">http://orcid.org/0000-0001-6757-0436</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff A. O’Meara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff A. O’Meara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">M4K Pharma, 101 College Street, MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff+A.++O%E2%80%99Meara">Jeff A. O’Meara</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Methvin B. Isaac</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Methvin B. Isaac</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1d707869756b747333746e7c7c7e5d72747e6f337273337e7c"><span class="__cf_email__" data-cfemail="8ee3ebfae6f8e7e0a0e7fdefefedcee1e7edfca0e1e0a0edef">[email protected]</span></a>. Phone: +1 (416) 673-6655.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Methvin+B.++Isaac">Methvin B. Isaac</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01199&amp;href=/doi/10.1021%2Facs.jmedchem.0c01199" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 10061–10085</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 11, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 July 2020</li><li><span class="item_label"><b>Published</b> online</span>11 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01199" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01199</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01199"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2332</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01199" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Smil&quot;},{&quot;first_name&quot;:&quot;Jong&quot;,&quot;last_name&quot;:&quot;Fu Wong&quot;},{&quot;first_name&quot;:&quot;Eleanor&quot;,&quot;last_name&quot;:&quot;P. Williams&quot;},{&quot;first_name&quot;:&quot;Roslin&quot;,&quot;last_name&quot;:&quot;J. Adamson&quot;},{&quot;first_name&quot;:&quot;Alison&quot;,&quot;last_name&quot;:&quot;Howarth&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. McLeod&quot;},{&quot;first_name&quot;:&quot;Ahmed&quot;,&quot;last_name&quot;:&quot;Mamai&quot;},{&quot;first_name&quot;:&quot;Soyoung&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;J. Wilson&quot;},{&quot;first_name&quot;:&quot;Taira&quot;,&quot;last_name&quot;:&quot;Kiyota&quot;},{&quot;first_name&quot;:&quot;Ahmed&quot;,&quot;last_name&quot;:&quot;Aman&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Owen&quot;},{&quot;first_name&quot;:&quot;Gennady&quot;,&quot;last_name&quot;:&quot;Poda&quot;},{&quot;first_name&quot;:&quot;Kurumi&quot;,&quot;last_name&quot;:&quot;Y. Horiuchi&quot;},{&quot;first_name&quot;:&quot;Ekaterina&quot;,&quot;last_name&quot;:&quot;Kuznetsova&quot;},{&quot;first_name&quot;:&quot;Haiching&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Nicole Hamblin&quot;},{&quot;first_name&quot;:&quot;Sue&quot;,&quot;last_name&quot;:&quot;Cramp&quot;},{&quot;first_name&quot;:&quot;Owen&quot;,&quot;last_name&quot;:&quot;G. Roberts&quot;},{&quot;first_name&quot;:&quot;Aled&quot;,&quot;last_name&quot;:&quot;M. Edwards&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Uehling&quot;},{&quot;first_name&quot;:&quot;Rima&quot;,&quot;last_name&quot;:&quot;Al-awar&quot;},{&quot;first_name&quot;:&quot;Alex&quot;,&quot;last_name&quot;:&quot;N. Bullock&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;A. O’Meara&quot;},{&quot;first_name&quot;:&quot;Methvin&quot;,&quot;last_name&quot;:&quot;B. Isaac&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10061-10085&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01199&quot;},&quot;abstract&quot;:&quot;There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brainstem. Radiation therapy is beneficial but not curative, with the condition being uniformly fatal. Analysis of the genomic landscape surrounding DIPG has revealed that activin receptor-like kinase-2 (ALK2) constitutes a potential target for therapeutic intervention given its dysregulation in the disease. We adopted an open science approach to develop a series of potent, selective, orally bioavailable, and brain-penetrant ALK2 inhibitors based on the lead compound LDN-214117. Modest structural changes to the C-3, C-4, and C-5 position substituents of the core pyridine ring afforded compounds M4K2009, M4K2117, and M4K2163, each with a superior potency, selectivity, and/or blood–brain barrier (BBB) penetration profile. Robust in vivo pharmacokinetic (PK) properties and tolerability mark these inhibitors as advanced pre&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01199&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01199" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01199&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01199" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01199&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01199" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01199&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01199&amp;href=/doi/10.1021/acs.jmedchem.0c01199" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01199" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01199" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01199%26sid%3Dliteratum%253Aachs%26pmid%3D32787083%26genre%3Darticle%26aulast%3DSmil%26date%3D2020%26atitle%3DLeveraging%2Ban%2BOpen%2BScience%2BDrug%2BDiscovery%2BModel%2Bto%2BDevelop%2BCNS-Penetrant%2BALK2%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BDiffuse%2BIntrinsic%2BPontine%2BGlioma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D10061%26epage%3D10085%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292006" title="Potassium">Potassium</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brainstem. Radiation therapy is beneficial but not curative, with the condition being uniformly fatal. Analysis of the genomic landscape surrounding DIPG has revealed that activin receptor-like kinase-2 (ALK2) constitutes a potential target for therapeutic intervention given its dysregulation in the disease. We adopted an open science approach to develop a series of potent, selective, orally bioavailable, and brain-penetrant ALK2 inhibitors based on the lead compound <b>LDN-214117</b>. Modest structural changes to the C-3, C-4, and C-5 position substituents of the core pyridine ring afforded compounds <b>M4K2009</b>, <b>M4K2117</b>, and <b>M4K2163</b>, each with a superior potency, selectivity, and/or blood–brain barrier (BBB) penetration profile. Robust <i>in vivo</i> pharmacokinetic (PK) properties and tolerability mark these inhibitors as advanced preclinical compounds suitable for further development and evaluation in orthotopic models of DIPG.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42872" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42872" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pediatric central nervous system (CNS) tumors constitute a heterogeneous group of diseases, and patient survival rates vary greatly among tumor subtypes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Diffuse intrinsic pontine glioma (DIPG), a grade IV tumor originating in glial tissue of the pons and typically affecting children between 5 and 7 years of age,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> is highly infiltrative with a 5-year relative survival rate of less than 1%.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> While accounting for 10% of all pediatric brain tumors, a median survival of just 9–12 months means that the prognosis for children with DIPG is particularly poor relative to those with other brainstem cancers.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Given that the pons contains cranial nerve nuclei and nuclei critical for life-sustaining functions such as respiration and sleep, damage by the tumor or treatment has potentially severe repercussions.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Sensitivity of the affected pons region renders it unsuitable for surgical resection, so the current standard of care is limited to focal radiation therapy providing only limited and temporary benefit for patient survival.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Chemotherapeutic agents have also met with little success in prolonging patient survival,<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a> in part because CNS drug exposure is limited by the endothelial tight junctions and elevated expression levels of efflux transporters at the blood–brain barrier (BBB), making it difficult to reach therapeutically relevant drug concentrations at lesion sites.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> A number of brain-penetrant chemotherapeutic agents such as temozolomide and vincristine have been explored as complements to radiotherapy, but no significant improvement in outcomes has been observed.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p">The advent of modern stereotactic procedures to safely biopsy DIPG tumors<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> has opened new avenues for molecular characterization and overturned old orthodoxies relating to the classification and treatment of both adult and childhood gliomas as similar tumors.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In contrast to the <i>IDH1</i>/<i>2</i>, <i>BRAF</i>, or <i>FGFR</i> oncogenic driver mutations found in adult gliomas, mutations in histone and developmental signaling proteins are characteristic of DIPG.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Somatic missense mutations in the bone morphogenetic protein (BMP) type I receptor <i>ACVR1</i> gene encoding activin receptor-like kinase-2 (ALK2), one of the seven (ALK1–7) type I receptors in the transforming growth factor β (TGFβ)/BMP signaling pathway, have been reported in approximately 33% of children with DIPG.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> The <i>ACVR1</i> gene, widely expressed in a variety of tissues including bone, cartilage, heart, CNS, and the reproductive system, is located in chromosome 2q23-q24 and encodes for the 509 amino acid protein.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Although rare in other human cancers, similar <i>ACVR1</i> mutations are found in individuals with fibrodysplasia ossificans progressiva (FOP), a monogenic developmental disorder whose primary features are skeletal abnormalities and heterotopic ossification.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> In DIPG, mutant <i>ACVR1</i> is ubiquitous throughout the tumors and strongly associated with K27M mutations in <i>HIST1H3B</i>, suggesting a partnership with H3K27M mutations during clonal evolution.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">Comprising an extracellular ligand binding domain and an intracellular serine/threonine (Ser/Thr) kinase domain, ALK2 functions as a transmembrane receptor.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> When BMP ligands bind to a complex of ALK2 and type II BMP receptors, the resultant activation of ALK2 by transphosphorylation of its juxtamembrane glycine–serine (GS)-rich domain promotes the recruitment and phosphorylation of downstream transcription factors SMAD1/5/8 by ALK2 and subsequent induction of BMP-response genes such as <i>ID1-3</i> (known mediators of gliomagenesis).<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> Heterozygous somatic nonsynonymous missense gain-of-function mutations present exclusively in the cytoplasmic GS (20% R206H and 2% Q207E) and Ser/Thr kinase domains (13% R258G, 24% G328E, 28% G328V, 4% G328W, and 9% G356D)<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> of ALK2 not only result in hypersensitivity to canonical BMP ligands but also induce responsiveness to activin ligands.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Each <i>ACVR1</i> mutant was found to increase basal canonical BMP pathway signaling when overexpressed in cultured mouse primary astrocytes, suggesting a role for these mutations during neurodevelopment.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Although mutant ALK2 alone is not sufficient to drive tumor formation (<i>i.e</i>., FOP patients with somatic ALK2 mutations do not develop DIPG) and the mechanistic role of ALK2 in DIPG pathogenesis has not yet been fully elucidated,<a onclick="showRef(event, 'ref2 ref26'); return false;" href="javascript:void(0);" class="ref ref2 ref26">(2,26)</a> significant cooperation between mutant ALK2 and the oncohistone H3.1K27M has been demonstrated in neurospheres, with a strong influence of ALK2 on gliomagenesis (initiation, proliferation, and survival) observed.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In H3.3K27M <i>ACVR1</i><sup><i>R206H</i></sup> HSJD-DIPG-007 cells, shRNA knockdown of <i>ACVR1</i> not only caused reduction in cell viability but also resulted in increased apoptotic cell death. While mutated histone H3 is not directly druggable, ALK2 is a classical protein kinase constituting a suitable target for a drug discovery program.</div><div class="NLM_p">Following the discovery that an adenosine monophosphate (AMP)-activated kinase inhibitor, <b>Dorsomorphin</b>, could block BMP signaling through SMAD1/5/8 phosphorylation,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> a number of related inhibitors centered around the pyrazolo[1,5-<i>a</i>]pyrimidine chemotype were reported (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Inhibitors of ALK2 such as <b>LDN-193189</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and <b>LDN-212854</b><a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> showed efficacy in FOP mouse models<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> although their activity against a number of kinase off-targets<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and dose-limiting toxicity (a 10% body weight loss in animal models)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> ultimately constrain their clinical utility. Biochemical screening using recombinant ALK2 protein subsequently yielded a new series of inhibitors based on the 3,5-diphenylpyridine chemotype, typified by <b>K02288</b>,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>LDN-213844</b>, and <b>LDN-214117</b>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> More recently, the toolbox of compounds has been expanded through the discovery of a 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-<i>a</i>]pyrimidine (modified <b>LDN-193189</b>) analog (<b>Compound 23</b>),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> as well as inhibitors based on quinazolinone (<b>Compound 24</b>),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> bis-heteroaryl pyrazole (<b>Compound 18p</b>),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and macrocyclic (<b>OD36</b>) scaffolds.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> At the time of writing, a number of ALK2 inhibitors such as <b>BLU-782</b> (<b>IPN60130</b>), <b>BCX9250</b>, and <b>KER-047</b> are being explored for FOP,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and another, <b>Itacnosertib</b> (<b>TP-0184</b> from Sumitomo-Tolero Pharma), has progressed into clinical trials (Phase I) as a treatment for DIPG.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Reported ALK2 inhibitors based on pyrazolo[1,5-<i>a</i>]pyrimidine (blue), 3,5-diphenylpyridine (black), bis-heteroaryl pyrazole (red), quinazolinone (magenta), and macrocyclic (green) scaffolds. (B) Cocrystal structure of prototypic 3,5-diphenylpyridine inhibitor <b>LDN-213844</b> (yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Of the existing preclinical ALK2 inhibitors, <b>LDN-193189</b>, <b>LDN-212854</b>, and <b>LDN-214117</b> have been examined in orthotopic <i>in vivo</i> models of DIPG owing to their suitable brain penetration, pharmacokinetic (PK) properties, and general tolerability.<a onclick="showRef(event, 'ref27 ref43'); return false;" href="javascript:void(0);" class="ref ref27 ref43">(27,43)</a> While <b>LDN-212854</b> was found to be beneficial in a viral infection <i>ACVR1</i><sup><i>R206H</i></sup> mouse model,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> both <b>LDN-193189</b> and <b>LDN-214117</b> showed significant 15 day prolongation of progression-free survival in mice bearing <i>ACVR1</i><sup><i>R206H</i></sup> patient-derived xenografts.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Given the positive <i>in vivo</i> outcome, we became interested in developing analogs of the lead compound <b>LDN</b>-<b>214117</b> into potential clinical candidates. To expedite efforts, we adopted an open science model centered on the newly created M4K (Medicines4Kids) Pharma Inc., itself owned by the Agora Trust Fund.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a></div><div class="NLM_p">Although <b>LDN-214117</b> has been demonstrated to have reasonable kinome-wide selectivity and low toxicity,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> we were particularly interested in increasing not only potency against ALK2 (to achieve a biochemical IC<sub>50</sub> < 20 nM and cellular IC<sub>50</sub> < 100 nM) but also the selectivity over the closely related type I TGFβ pathway receptor ALK5. Documented adverse effects of ALK5 inhibition include cardiotoxicity (valvular lesions), effects on bone growth (physeal dysplasia), and gastrointestinal inflammation,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> so >50-fold selectivity for ALK2 over ALK5 in biochemical and cell-based assays was deemed essential to establish a desired safety profile and mitigate potential toxicity associated with long-term dosing. Parallel selectivity over ALK4 and ALK7 would be beneficial for similar reasons, particularly since ALK4 is also involved in myostatin signaling, the impairment of which can result in muscle atrophy.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Off-target toxicity related to other type I BMP pathway receptors may also be a concern given that inhibition of ALK1 has been associated with vascular effects (telangiectasia, edema, and congestive cardiac failure),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and ALK3 is implicated in the regulation of iron storage.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> It should be noted, however, that ALK1-specific monoclonal antibody treatment administered to cancer patients did show a manageable safety profile with dosing up to 4.6 mg/kg being well tolerated.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> A particular challenge in the development of selective, adenosine triphosphate (ATP)-competitive small-molecule kinase inhibitors is the high degree of structural homology evident in the conserved ATP binding domains. For example, the ALK3 kinase domain possesses 66% sequence identity with that of ALK5, illustrative of the high structural homology among type I receptors of both the BMP and TGFβ signaling pathways.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Within the BMP or TGFβ families, even greater kinase domain sequence identity is evident between homologues such as ALK1–ALK2 (79%), ALK3–ALK6 (86%), and ALK4–ALK5 (90%).</div><div class="NLM_p">Additional considerations for inhibitor design included adjusting the molecular weight, number of hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) atoms, number of rotatable bonds, cLog <i>P</i>, p<i>K</i><sub>a</sub>, topological polar surface area (tPSA), metabolic stability, and effective permeability to within the generally accepted parameters for successful CNS-directed drugs.<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51−53)</a></div><div class="NLM_p last">Using the well-characterized pyrazolo[1,5-<i>a</i>]pyrimidine inhibitor <b>LDN-193189</b> as a control, we conducted the primary assessment of compound potency and selectivity against ALK1, ALK2, ALK2 mutants (G328V, R206H, and R258G), ALK3, ALK4, ALK5, and ALK6 using the radiometric <i>in vitro</i> kinase assay performed by Reaction Biology Corporation. Cellular activity against ALK2 in HEK-293 cells was determined by means of a NanoBRET assay employing competitive displacement of a fluorescent tracer (PBI-6908) from the binding pocket by test compounds and generation of IC<sub>50</sub> values from the resultant reductions in bioluminescence resonance energy transfer (BRET) ratios. A dual luciferase assay (DLA) was used to determine cellular activity against ALK5.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of C-4 Position Analogs</h3><div class="NLM_p">With reference to the cocrystal structure of the prototypic 3,5-diphenylpyridine inhibitor <b>LDN-213844</b> bound to ALK2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> it was anticipated that substitutions at the C-4 position could potentially allow for stronger hydrogen bonding to the amide of H286 in the hinge region through exertion of an electronic effect at the nitrogen of the pyridyl ring. Furthermore, the inhibitor’s bioactive conformation appears to involve a dihedral angle between the pyridyl and C-3 position 3,4,5-trimethoxyphenyl rings approaching 90°, a relatively high energy conformation (2.5 kcal/mol) that would be stabilized with the torsional restriction imposed by a sterically bulky C-4 position substituent in a manner analogous to that of the C-2 position methyl substituent in <b>LDN-214117</b>. However, unlike in <b>LDN-214117</b>, this locking of the conformation would also impact the dihedral angle between the pyridyl ring and the C-5 position 4-piperazinophenyl ring, currently around 45°, pushing it toward 90° and potentially setting up a more favorable π–π stacking interaction of the phenyl ring between residues G289 and V214.</div><div class="NLM_p">All C-4 position substituted analogs of <b>LDN-213844</b> for our structure–activity relationship (SAR) study were synthesized using a route comprising an initial Suzuki–Miyaura coupling between commercially available 3,5-dihalopyridines (<b>1a</b>–<b>i</b>) and 3,4,5-trimethoxyphenylboronic acid (<b>2</b>) to yield intermediates <b>3a</b>–<b>i</b>, followed by a second coupling with 4-(4-<i>tert</i>-butoxycarbonylpiperazinyl)phenylboronic acid pinacol ester (<b>4</b>) and subsequent carbamate-protecting group removal from intermediates <b>5a</b>–<b>i</b> to yield the final inhibitors <b>6a</b>–<b>i</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Although step <i>a</i> produced a significant amount of undesired dicoupling product (∼50%) when starting with symmetrical 3,5-dichloro- or 3,5-dibromopyridines (<b>1b</b>–<b>d</b> and <b>1f</b>–<b>h</b>), all steps were uniformly high yielding (>70%) and purification of intermediates <b>3a</b>–<b>i</b> was not required. A range of electron donating group (EDG) and electron withdrawing group (EWG) substitutions at the C-4 position (R<sub>1</sub>) was readily accessible, and the corresponding inhibitors <b>6a</b>–<b>i</b> are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> alongside reference compounds <b>LDN-213844</b> and <b>LDN-214117</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>6a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), Pd(dppf)Cl<sub>2</sub>·dichloromethane (DCM), Na<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF)/H<sub>2</sub>O, 100 °C, 16 h for <b>1a</b>, <b>1d–e</b>, <b>1g</b>, <b>1i</b> and XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h for <b>1b–c</b>, <b>1f</b>, <b>1h</b>; (b) <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (<b>4</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h; (c) 4 M HCl in dioxane, MeOH, room temperature (rt), 30 min.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory and Off-Target Activities of <b>LDN-213844</b>, <b>LDN-214117</b>, and <b>6a</b>–<b>i</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0019.gif" alt="" id="GRAPHIC-d7e1132-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Literature values.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Measured values were determined using a radioactive biochemical kinase assay.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">ALK2 mutants are identified in parentheses.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Average of duplicate measurements.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Average of triplicate measurements.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> C-4 Position Analog SAR</h3><div class="NLM_p">Interestingly, the SAR of inhibitors <b>6a–i</b> revealed a generally higher potency against ALK2 for inhibitors bearing an EWG at the C-4 position (<b>6f</b>–<b>i</b>), with values near or below our set biochemical and cellular assay limits (20 and 100 nM, respectively). Compound <b>6h</b> was an outlier, perhaps due to negation of the trifluoromethyl group’s strong EWG character by a presumptive, unfavorable steric effect. Compounds with a weak or strong EDG at the C-4 position (<b>6a</b>–<b>c</b> and <b>6d</b>–<b>e</b>, respectively) were generally less potent, although methyl substituted <b>6a</b> was a notable exception. Overall, this observed electronic effect was counter to what was anticipated, with the compounds bearing an EDG at the C-4 position expected to have a more basic pyridyl nitrogen capable of forming a stronger hydrogen bond interaction with the backbone amide of H286. Compounds <b>6a</b> and <b>6f</b>–<b>g</b> exhibited potencies similar to those reported for <b>LDN-213844</b> and <b>LDN-214117</b><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> although they were all considerably more potent than the later inhibitor was in our hands (ALK2 IC<sub>50</sub> = 115 nM). Inhibitor <b>6i</b> was particularly potent, and we believe it is the first reported IC<sub>50</sub> < 5 nM inhibitor of ALK2.</div><div class="NLM_p last">Gratifyingly, all compounds showed an impressive level of selectivity for ALK2 over ALK5, equaling or exceeding levels exhibited by lead compounds <b>LDN-213844</b> and <b>LDN-214117</b>. While generally high, this selectivity was relatively low in the biochemical assay for <b>6f</b> with R<sub>1</sub> = F. Given that this was the sterically smallest C-4 position substituent screened and resulted in ALK2 selectivity comparable to that of <b>LDN-213844</b> where R<sub>1</sub> = H, increased steric bulk at the C-4 position may be at least a partial driver of selectivity through the enforcement of a favorable binding conformation. The same steric effect is likely seen in <b>LDN-214117</b> where the C-2 position methyl group restricts rotation of the C-3 position trimethoxyphenyl moiety relative to the pyridyl core and produces an ALK2 selectivity that is both significantly greater than that of <b>LDN-213844</b> and more in line with that of <b>6a</b> where R<sub>1</sub> = Me exerts a comparable steric influence.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structural Basis for ALK2 Inhibition and Selectivity</h3><div class="NLM_p">Crystallographic efforts yielded a high-resolution (1.42 Å) cocrystal structure of <b>6a</b> in the ATP pocket of the ALK2 Ser/Thr kinase domain (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM">6SZM</a>), confirming binding to the active A-loop DLG-in/αC-helix-in conformation by means of a key ATP-mimetic hydrogen bond between the core pyridine nitrogen and the backbone amide of H286 in the hinge region. The C-3 position 3,4,5-trimethoxyphenyl moiety of <b>6a</b> occupies the hydrophobic pocket of ALK2 as expected, and the <i>meta</i>-methoxy group participates in a water-mediated hydrogen bond with K235. The aryl ring of the C-5 position 4-piperazinophenyl substituent stacks between G289 and V214, while the protonated secondary amine of the piperazine is in close proximity to D293 (5.11 Å between the 1-position piperazine nitrogen and D293 oxygen), suggestive of a solvent-mediated electrostatic ionic interaction.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystal structure of <b>6a</b> (yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM">6SZM</a>). Hydrogen bonds are established with H286 and K235. The 3,4,5-trimethoxyphenyl moiety of <b>6a</b> occupies a hydrophobic pocket (green) of ALK2 and is flanked by several hydrogen bond-donating (blue; K235) and hydrogen bond-accepting residues (red; D354 and E248). The protonated piperazine motif is in close proximity to D293, indicative of an electrostatic interaction. (B) Plot detailing the interactions of <b>6a</b> (black) within the ALK2 pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As we were unable to obtain a cocrystal structure of <b>6a</b> with ALK5, it is difficult to fully rationalize the compound’s evident selectivity for ALK2. With reference to <b>LDN-213844</b>, it was suggested that selectivity may be a consequence of dynamic conformational differences between ALK2 and ALK5 in tandem with effects exerted by the small number of sequence changes in the ATP pocket (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Figure S1</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> It can also be argued that the ATP pocket in many available ALK5 cocrystal structures shows a more open conformation than that of ALK2, the possible result of a smaller gatekeeper residue [S280 (ALK5 numbering) <i>versus</i> T283 (ALK2 numbering)]. Noticeable movement of the N-lobe away from the C-lobe in ALK5 structures changes the shape, volume, and dynamics of the ATP pocket, all of which have an effect on inhibitor binding. In addition, the conformational lock imposed on <b>6a</b> by the presence of the C-4 position methyl substituent enforces significant torsional angles (≥45°) evident between the core pyridine and the C-3 and C-5 position substituents, potentially aiding a preferential fit within the ALK2 pocket.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> C-4 Position Analog Off-Target Activity</h3><div class="NLM_p">Compounds <b>6a</b>, <b>6f</b>–<b>g</b>, and <b>6i</b> remained of interest given that they satisfied our ALK2 potency and selectivity criteria in both the biochemical and cell-based assays. Choosing <b>6a</b> as an exemplar from this smaller set, we first determined the compound’s potency against available ALK2 mutants (G328V, R206H, and R258G) in the biochemical assay. As expected, potency was in line with that observed against wild-type (WT) ALK2, comparable to the values obtained for <b>LDN-213844</b>, and superior to those recorded for <b>LDN-214117</b>. Inhibitor <b>6a</b> also performed well when evaluated against ALK2 mutants (G328V, G356D, Q207D, and R206H) using the NanoBRET assay, showing that this favorable level of activity was undiminished in cells. It had previously been demonstrated that mutations in both the GS and Ser/Thr kinase domains of ALK2 had negligible effects on the kinase’s affinity for ATP and type I kinase inhibitors,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> so for reasons of protein availability and assay expense, we opted to screen the inhibitory activity of all other compounds in our studies exclusively against WT ALK2.</div><div class="NLM_p">In addition to the primary focus of limiting activity against ALK5, we hoped for a degree of selectivity for ALK2 over other off-targets of concern such as ALK1, ALK3, and ALK4. Profiling of representative compound <b>6a</b> revealed it to be equipotent on ALK1 (IC<sub>50</sub> = 15 nM) but with modest 33-fold selectivity over ALK3 (IC<sub>50</sub> = 428 nM) and substantial 103-fold selectivity over ALK4 (IC<sub>50</sub> = 1336 nM). This later selectivity over ALK4 is a notable improvement over the 36-fold selectivity exhibited by <b>LDN-213844</b> (IC<sub>50</sub> = 462 nM), again suggesting a possible role for the C-4 position methyl as a selectivity element. Compounds of interest <b>6f</b> (ALK4 IC<sub>50</sub> = 630 nM), <b>6g</b> (ALK4 IC<sub>50</sub> = 962 nM), and <b>6i</b> (ALK4 IC<sub>50</sub> = 257 nM) also show improved 42-, 60-, and 86-fold selectivities (respectively) over ALK4, but all were less selective than <b>6a</b>. Although of less concern as an off-target, screening of <b>6a</b> against ALK6 revealed only slight selectivity on the order of 5-fold (ALK6 IC<sub>50</sub> = 68 nM). All of these values are fully consistent with the aforementioned high degrees of structural homology among type I receptors of both the BMP and TGFβ signaling pathways,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> but the selectivity windows relating to critical off-targets ALK3, ALK4, and ALK5 suggest the possibility of a meaningful safety profile. Although potent against ALK1, based on past work, it is anticipated that any ALK1-driven toxicity arising from an inhibitor similar to <b>6a</b> could be managed through an appropriate dosing level or regimen.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> We did not have access to ALK7 during the course of this study and hence did not measure the potency of <b>6a</b> against that target.</div><div class="NLM_p">As previously mentioned, <b>LDN-214117</b> was demonstrated to have reasonable kinome-wide selectivity,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> with improvement over pyrazolo[1,5-<i>a</i>]pyrimidine inhibitors such as <b>LDN-193189</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> At 1 μM, <b>LDN-214117</b> inhibited only 3.6% of kinases (∼200) profiled by more than 50%, with ABL1, RIPK2, and TNIK being the most inhibited after ALK2.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> We screened <b>6a</b> at 1 μM against a significantly larger 374-member kinase set, finding remarkable selectivity with greater than 50% inhibition against only 2.1% of kinases (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Table S1</a>). Of the eight kinases inhibited (ABL1, BRK, DDR1, MINK, NLK, SIK2, TNIK, and ZAK), <b>6a</b> was only significantly potent against DDR1 (IC<sub>50</sub> = 41 nM) and TNIK (IC<sub>50</sub> = 96 nM) (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Note S1</a>), with IC<sub>50</sub> values against the remaining six kinases in the 336–924 nM range.</div><div class="NLM_p">To gauge the potential risk from another off-target related adverse drug reaction, <b>6a</b> was screened in the Eurofins Cerep-Panlabs <i>in vitro</i> SafetyScreen 44 panel (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Table S2</a>). At 10 μM, only five targets were inhibited more than 50%, with <b>6a</b> being the most potent against the cannabinoid CB<sub>1</sub> (97%) and adrenergic α<sub>2A</sub> (90%) receptors, followed by activity against the sodium channel site 2 (72%), the human ether-a-go-go (hERG) potassium channel (69%), and the adrenergic α<sub>1A</sub> (65%) receptor. A dose–response follow-up at 3 μM on the highly inhibited targets showed a cannabinoid CB<sub>1</sub> receptor IC<sub>50</sub> = 1.72 μM and an adrenergic α<sub>2A</sub> receptor IC<sub>50</sub> = 2.18 μM. With <b>6a</b> showing greater than 100-fold selectivity for ALK2 over these two targets, no significant concerns were registered in relation to these receptors.</div><div class="NLM_p">Inhibition of the hERG potassium channel by <b>6a</b> warranted further investigation given that loss of function is associated with long-QT syndrome type-2 (LQT2) and increased risk of potentially fatal <i>torsades de pointes</i> cardiac arrhythmia <i>in vivo</i>.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Evaluation in the Charles River Laboratories ScreenPatch (patch clamp) assay found <b>6a</b> to be only a moderate inhibitor of the hERG potassium channel (IC<sub>50</sub> = 8.3 μM). To see if hERG potassium channel inhibition could be further attenuated through the incorporation of an EWG at the C-4 position, we also evaluated <b>6g</b> and <b>6i</b> but unfortunately found that both compounds were slightly more active with IC<sub>50</sub> = 2.7 μM and IC<sub>50</sub> = 6.0 μM, respectively. Although an hERG potassium channel IC<sub>50</sub> > 10 μM was desirable to limit the likelihood of cardiac toxicity, historic data pertaining to FDA-approved (tyrosine) kinase inhibitor drugs has shown that an IC<sub>50</sub> < 1 μM is regarded as problematic, while an IC<sub>50</sub> > 3 μM is generally acceptable.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> As such, we considered these compounds to have a manageable hERG potassium channel inhibition profile, which could be further derisked in a preclinical setting through <i>in vivo</i> canine electrophysiology studies. In addition, we engaged in structural modifications to the C-3 position 3,4,5-trimethoxyphenyl moiety and the C-5 position 4-piperazinophenyl moiety, anticipating that those changes could potentially exert an influence on binding to the hERG potassium channel.</div><div class="NLM_p last">Screening of <b>6a</b> by colleagues at Charles River Laboratories against seven major cytochrome P450 (CYP) enzyme isoforms (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4M/3A4T) in human liver microsomes at 30 μM showed the compound to be clean, with IC<sub>50</sub> > 30 μM on all targets except 3A4T (IC<sub>50</sub> > 9 μM). To evaluate the mutagenic potential of <b>6a</b>, a Mini-Ames assay was conducted at WuXi AppTec, concluding that the compound was negative for mutagenicity under the conditions of this study.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> C-4 Position Substituent Selection</h3><div class="NLM_p last">The activity and selectivity of inhibitors <b>6a</b>, <b>6f</b>–<b>g</b>, and <b>6i</b> provided us with four C-4 position substituents that appeared suitable for inclusion in further analogs. Given the inefficiency inherent in the synthesis of <b>6f</b>–<b>g</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, step a) and their highly similar biochemical and cellular activity profiles in relation to <b>6a</b>, we opted to move forward only with analogs of compounds <b>6a</b> and <b>6i</b>. The C-4 position methyl scaffold of <b>6a</b> was of particular interest given its favorable kinome-wide selectivity and off-target profiles detailed above, although <b>6i</b>, despite its reduced cellular ALK2 selectivity, remained of interest because of its potency.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Synthesis of C-3 Position Analogs</h3><div class="NLM_p">Foundational SAR studies on <b>K02288</b>, <b>LDN-213844</b>, and <b>LDN-214117</b> done by our collaborators led to discovery of the C-3 position 3,4,5-trimethoxyphenyl substituent, an optimal group for providing interactions in the hydrophobic pocket as well as a water-mediated hydrogen bond to K235.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Critical to this hydrogen bond formation is the methoxy group at the 3-position of the phenyl ring, with both the 3- and 4-position methoxy groups engaged in bidentate hydrogen bonding evident in select cocrystal structures. Deletion of the 4-position methoxy group to produce a 3,5-dimethoxyphenyl moiety was tolerated, yielding almost equipotent compounds and suggesting that the phenyl ring was amendable to transformation.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Our own extensive efforts to modify the 3,4,5-trimethoxyphenyl moiety in the context of <b>LDN-213844</b> and <b>6a</b> analogs by eliminating or altering substituents were largely unproductive,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> although limited success was achieved through replacement with a 2-fluoro-6-methoxybenzamide moiety to yield equipotent inhibitors with reduced off-target affinity for the hERG potassium channel (IC<sub>50</sub> > 30 μM).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> While the benzamide effectively recapitulated the water-mediated hydrogen bond to K235, its increased polarity had the unfortunate ancillary effect of making the compounds poorly brain-penetrant and limiting their usefulness for the treatment of DIPG.</div><div class="NLM_p">The only suitable, novel modification to the 3,4,5-trimethoxyphenyl group that emerged from our SAR studies on the <b>LDN-213844</b> scaffold was replacement of the 4-position methoxy with fluorine, putatively capable of participating in an analogous water-mediated hydrogen bond to K235. We then looked to incorporate the required 4-fluoro-3,5-dimethoxyphenyl group at the C-3 position of <b>6a</b> and <b>6i</b>, alongside the aforementioned 3,5-dimethoxyphenyl group. This was readily accomplished by modifying the iterative Suzuki–Miyaura coupling sequence previously used for preparing the C-4 position analogs, yielding compounds <b>11a</b>–<b>c</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Common intermediates <b>7a</b>–<b>b</b>, prepared first by attaching the C-5 position <i>tert</i>-butyl-4-phenylpiperazine-1-carboxylate moiety, allowed for flexible, subsequent coupling of the C-3 position substituted phenyl group of choice (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>11a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (<b>4</b>), Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O, 100 °C, 16 h; (b) 3,5-dimethoxyphenylboronic acid (<b>8</b>) or (4-fluoro-3,5-dimethoxyphenyl)boronic acid (<b>9</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h; (c) 4 M HCl in dioxane, MeOH, rt, 30 min.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory and Off-Target Activities of <b>6a</b> and <b>11a–c</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0008.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0020.gif" alt="" id="GRAPHIC-d7e1724-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">LipE (lipophilic efficiency) = pIC<sub>50</sub> – cLog <i>P</i>, where pIC<sub>50</sub> = −log ALK2 IC<sub>50</sub> (nM).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Average of triplicate measurements.</p></div></div><div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> C-3 Position Analog SAR, Off-Target Activity, and Substituent Selection</h3><div class="NLM_p">While inhibitor <b>11a</b> exhibited considerably reduced activity against ALK2 in cells, inhibitors <b>11b</b>–<b>c</b> were found to have activity profiles very similar to those of <b>6a</b> and <b>6i</b>. Although potency against ALK2 was only slightly lower for <b>11b</b>–<b>c</b>, selectivity over ALK5 in the biochemical assay dropped in both cases, with the effect being more pronounced for <b>11c</b> (a drop from 244-fold to 44-fold) than for <b>11b</b> (a drop from 187-fold to 116-fold). Interestingly, even though cellular activity against ALK2 was more than halved for both compounds, selectivity over ALK5 remained comparable at 74-fold and 31-fold for <b>11b</b> and <b>11c</b>, respectively. The less than 50-fold selectivity over ALK5 evident for <b>11c</b> in both assays led us to prioritize <b>11b</b> as an analog of interest for which we also confirmed a slightly decreased 79-fold selectivity over ALK4 (IC<sub>50</sub> = 1503 nM). We did not screen <b>11b</b> against ALK1, ALK2 mutants, ALK3, or ALK6 given the expectation of equipotency against these targets based on the patterns of activity evident from the screening of other compounds.</div><div class="NLM_p">Screening of <b>11b</b> at 1 μM against a 374-member kinase set, unsurprisingly, yielded greater than 50% inhibition against seven of the eight kinases inhibited by <b>6a</b> (ABL1, BRK, DDR1, MINK, SIK2, TNIK, and ZAK) although activity against NLK was diminished. In addition, <b>11b</b> registered marginal activity (51–61% inhibition) against six other kinases (HGK, KHS, LCK, LYN, MLCK2, and SIK3) for a profile that involved an overall inhibition rate of 3.5% (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Table S1</a>).</div><div class="NLM_p">Activity against the hERG potassium channel as determined in the Charles River Laboratories ScreenPatch assay found <b>11b</b> to be a more potent inhibitor than <b>6a</b> with an IC<sub>50</sub> = 2.5 μM. While disappointing, this increased affinity for the hERG potassium channel was still within acceptable limits and viewed as a parameter that could potentially be impacted by replacement of the C-5 position 4-piperazinophenyl moiety in subsequent SAR studies. Compound <b>11b</b> was also marginally more active when screened in the seven-member CYP panel. While <b>6a</b> had an IC<sub>50</sub> > 30 μM against six of the isoforms, <b>11b</b> showed an IC<sub>50</sub> > 20 μM against only four targets with the 2C9 IC<sub>50</sub> = 7.3 μM, 2C19 IC<sub>50</sub> = 7.7 μM, and 3A4T IC<sub>50</sub> = 14.3 μM.</div><div class="NLM_p last">While <b>11b</b> was, in aggregate, a slightly inferior inhibitor with respect to <b>6a</b> by the parameters detailed above, it constituted the only viable C-3 position analog that warranted further development. Aside from its comparable biochemical and cell-based activity on ALK2, <b>11b</b> is a less polar compound (cLog <i>P</i> = 3.72 and tPSA = 46 Å<sup>2</sup>) than <b>6a</b> (cLog <i>P</i> = 3.29 and tPSA = 55 Å<sup>2</sup>),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> suggesting it could potentially achieve a greater degree of brain penetration. As with the possibility to modify affinity toward the hERG potassium channel, changes in the C-5 position 4-piperazinophenyl moiety of <b>6a</b> were also viewed as a way to achieve tPSA values similar to that of <b>11b</b> while preserving the C-3 position 3,4,5-trimethoxyphenyl moiety.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthesis of C-5 Position Analogs</h3><div class="NLM_p">With the C-3 and C-4 position substituents set, we endeavored to make changes to the C-5 position 4-piperazinophenyl moiety in an attempt to maintain or increase the activity against ALK2 shown by <b>6a</b> and decrease the activity against the hERG potassium channel while remaining cognizant of several physiochemical parameters. In order for small-molecule inhibitors to penetrate the BBB and exert a pharmacological effect, their lipophilicity (cLog <i>P</i>), basicity (p<i>K</i><sub>a</sub>), tPSA, and number of HBD/HBA (among other factors) ideally fall within a range of recommended values.<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51−53)</a> Although enhanced drug potency and permeability are often a function of increased lipophilicity, a cLog <i>P</i> < 5 is considered optimal to avoid potential concomitant increases in nonspecific tissue binding, which would ultimately decrease the concentration of free drug at its intended site of action within the brain. Possession of a positive charge at physiological pH 7–8 favors brain permeation, so amine-containing compounds with a p<i>K</i><sub>a</sub> = 7.5–10.5 are ideal despite the potential for issues with hERG potassium channel binding. Keeping the tPSA < 60–70 Å<sup>2</sup>, the number of HBD < 3 (CNS drugs have a mean of 1.1), and the number of HBA < 7 are also favorable for BBB penetration and limiting recognition by efflux transporters such as P-glycoprotein (P-gp).<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> The calculated values for these primary metrics<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> informed our selection of suitable C-5 position substituents, the focus being on groups that would recapitulate, improve on, or not grossly deviate from the parameters of <b>6a</b> with a cLog <i>P</i> = 3.29, p<i>K</i><sub>a</sub> = 8.60, tPSA = 55 Å<sup>2</sup>, HBD = 1, and HBA = 6.</div><div class="NLM_p">The binding mode evident in the ALK2·<b>6a</b> cocrystal structure (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) has the phenyl ring of the C-5 position 4-piperazinophenyl substituent stacking between G289 and V214, so we opted to retain the unmodified phenyl ring in future analogs while focusing on changes to the piperazine consistent with the physiochemical parameters detailed above. Again, published SAR studies pertaining to the C-5 position<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> as well as our own wide-ranging exploratory efforts<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> built confidence in further narrowing the scope of our modifications. The challenge, however, was to attenuate the activity on the hERG potassium channel under these constraints, given that the C-5 position 4-piperazinophenyl substituent constitutes an ideal pharmacophore against the channel based on known ligand-based pharmacophore and QSAR models.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> While it is known that increasing the polarity of the drug molecule (lowering the cLog <i>P</i>) effectively reduces activity against the hERG potassium channel, our efforts to employ this strategy met with limited success as they produced a concomitant decrease in BBB penetration.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Consequently, we focused our efforts on discrete structural modifications to the putative hERG potassium channel binding motif, which would affect the sterics and/or conformation around the 1-position piperazine nitrogen or reduce its basicity (lower the p<i>K</i><sub>a</sub>). These later strategies are known to effectively disrupt the cation π-stacking interactions between the basic amine-containing hERG potassium channel blockers and aromatic residues within the cavity of the channel at physiological pH and could be executed within the optimal parameters for CNS drugs described above.</div><div class="NLM_p">Analogs were accessed efficiently via common intermediates <b>3a</b> and <b>6a</b> incorporating the C-3 position 3,4,5-trimethoxyphenyl group, with the idea that analogs incorporating the alternate 4-fluoro-3,5-dimethoxyphenyl group could subsequently be prepared using only the optimal C-5 position substituents. Once again, the same sequential Suzuki–Miyaura coupling approach used for all previous analogs was employed to prepare new C-5 position analogs <b>14a</b>–<b>c</b> and <b>14h</b>–<b>q</b>, with analogs <b>14d</b>–<b>g</b> accessed directly from <b>6a</b> through straightforward alkylation, acetylation, carbamoylation, or sulfonylation, respectively (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Synthesis was facilitated by the commercial availability of the requisite 4-substituted phenylboronic acids or pinacol esters (<b>12a</b>–<b>c</b> and <b>12h</b>–<b>q</b>), and the generally high coupling yields (>70%) were encouraging for potential future scale-up requirements. An additional carbamate-protecting group removal step was required for the conversion of intermediates <b>13c</b>, <b>13j</b>, <b>13l</b>, <b>13n</b>, and <b>13p</b> to final inhibitors <b>14c</b>, <b>14j</b>, <b>14l</b>, <b>14n</b>, and <b>14p</b>, but additional purification of the final product was not required if previously conducted on the respective intermediate (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>14a</b>–<b>q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O, 100 °C, 16 h; (b) 4-(R<sub>1</sub>)phenylboronic acid or pinacol ester (<b>12a</b>–<b>c</b> and <b>12h</b>–<b>q</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h; (c) [<b>13c</b>, <b>13j</b>, <b>13l</b>, <b>13n</b>, <b>13p</b>], 4 M HCl in dioxane, MeOH, rt, 30 min; (d) <b>R</b><sub><b>2</b></sub><b>OTs</b>, triethylamine (TEA), acetonitrile, 100 °C, 16 h for <b>14d</b>; (e) <b>R</b><sub><b>2</b></sub><b>Cl</b>, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), tetrahydrofuran (THF), rt, 1 h.</p></p></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory and Off-Target Activities of <b>6a</b> and <b>14a–q</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0010.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0011.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">LipE (lipophilic efficiency) = pIC<sub>50</sub> – cLog <i>P</i>, where pIC<sub>50</sub> = -log ALK2 IC<sub>50</sub> (nM).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Average of triplicate measurements.</p></div></div><div></div></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> C-5 Position Analog SAR, Off-Target Activity, and Substituent Selection</h3><div class="NLM_p">While unsurprising that methylation of <b>6a</b> resulted in a compound with an almost identical activity and selectivity profile (<b>14a</b>), we were disappointed to find that sterically shielding the 1-position piperazine nitrogen with a larger isopropyl group (<b>14b</b>) adversely impacted both the cellular activity on ALK2 and selectivity over ALK5. When the steric bulk was made adjacent to the same nitrogen through methylation of the C-2 and C-6 piperazine ring positions (<b>14c</b>), cellular activity against ALK2 was preserved, but selectivity over ALK5 still remained below our set 50-fold lower limit. While not entirely satisfactory, <b>14b</b>–<b>c</b> did still show reasonable levels of activity against ALK2 while maintaining cLog <i>P</i>, p<i>K</i><sub>a</sub>, and tPSA values close to those of <b>6a</b>, so we used them to evaluate whether steric shielding of the 1-position piperazine nitrogen held any potential for mitigating activity on the hERG potassium channel. Unfortunately, both compounds were slightly more potent with hERG IC<sub>50</sub> = 3.1 μM for <b>14b</b> and hERG IC<sub>50</sub> = 5.9 μM for <b>14c</b>.</div><div class="NLM_p">Reluctant to further increase the overall molecular weight by exploring bulkier alkylic substituents, we turned our attention to attenuating the basicity of the 1-position piperazine nitrogen. It is known that introduction of fluorine as a hydrogen atom replacement in alkyl substituted amines can effectively modulate their basicity, with significant p<i>K</i><sub>a</sub> shifts observed when the fluorine is installed at either the <i>β</i>-position (Δp<i>K</i><sub>a</sub> −1.7) or the <i>γ</i>-position (Δp<i>K</i><sub>a</sub> −0.7).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> To that end, we prepared compound <b>14d</b> bearing a 2-fluoroethyl group whose calculated p<i>K</i><sub>a</sub> = 7.49 was a full 1.11 units lower than that of <b>6a</b>. While comparably active against ALK2 in the biochemical assay, cellular activity (IC<sub>50</sub> = 178 nM) was greatly diminished, placing the compound well beyond our acceptable limit. Acetylation, carbamoylation, and sulfonylation of the nitrogen designed to effectively abolish basicity while introducing oxygen atoms with HBA potential afforded compounds <b>14e</b>–<b>g</b>. Inhibitors <b>14e</b>–<b>f</b> were poorly active against ALK2 in cells, while <b>14g</b> exhibited activity similar to that of <b>6a</b> with the benefit of a near doubling in selectivity over ALK5 to 108-fold. Significantly, <b>14g</b> had an hERG IC<sub>50</sub> > 50 μM, likely resulting from both the decrease in basicity and a 26 Å<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> increase in tPSA over <b>6a</b> to 81 Å<sup>2</sup>. Although this value was beyond the generally favorable tPSA < 60–70 Å<sup>2</sup> range for CNS drugs, we felt that further evaluation of this compound was warranted.</div><div class="NLM_p">Having demonstrated with compound <b>14g</b> that it was possible to achieve potency against ALK2 in the absence of a basic piperazine nitrogen, we endeavored to replace the piperazine with morpholine (<b>14h</b>) and thiomorpholine 1,1-dioxide (<b>14i</b>). Designed to remove the 1-position piperazine nitrogen entirely and access the potential HBA capacity offered by oxygen, these compounds showed poor cellular activity against ALK2 despite having reasonable values in the biochemical assay. Removal of the other, less basic 4-position piperazine nitrogen was also examined <i>via</i> the synthesis of piperidine-containing inhibitors <b>14j</b>–<b>k</b> and 1,2,3,6-tetrahydropyridine-containing inhibitors <b>14l</b>–<b>m</b>, both with different ring topology and conformation in an attempt to influence hERG potassium channel binding. Inhibitor <b>14j</b> was found to have an activity and selectivity profile almost identical to that of <b>6a</b>, but we were particularly attracted by its methylated analog <b>14k</b>, which exhibited superior cellular activity (ALK2 IC<sub>50</sub> = 29 nM) and selectivity over ALK5 (115-fold). Interestingly, in the 1,2,3,6-tetrahydropyridine containing inhibitor pair, unmethylated analog <b>14l</b> was superior to <b>14m</b> in both activity (ALK2 IC<sub>50</sub> = 47 nM) and selectivity over ALK5 (160-fold). Unfortunately, neither the changed electronics nor the conformation embodied in the piperidine and 1,2,3,6-tetrahydropyridine rings of <b>14k</b>–<b>l</b> served to decrease activity against the hERG potassium channel, with the compounds registering an hERG IC<sub>50</sub> = 4.8 μM and hERG IC<sub>50</sub> = 3.4 μM, respectively. However, in contrast to <b>6a</b> (cLog <i>P</i> = 3.29, tPSA = 55), <b>14k</b> was of particular interest given its increased lipophilicity (cLog <i>P</i> = 4.21, tPSA = 43) and attendant potential for greater BBB penetration. We replaced the C-3 position 3,4,5-trimethoxyphenyl group of <b>14k</b> with the previously explored 4-fluoro-3,5-dimethoxyphenyl group to access an even more lipophilic analog (cLog <i>P</i> = 4.65, tPSA = 35) but did not pursue the resulting compound further as it showed decreased cell-based activity (ALK2 IC<sub>50</sub> = 77 nM) and poorer selectivity over ALK (61-fold).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p">Further attempts at instituting conformational changes around the piperazine ring involved its enlargement to homopiperazine (<b>14n</b>) and introduction of a benzylic carbon linker between it and the C-5 position phenyl ring (<b>14o</b>). Both changes produced slightly less active and selective compounds in cells, but the activity of <b>14o</b> raised the possibility of employing an analogous spacer in combination with the piperidine moiety found to be potent in compounds <b>14j</b>–<b>k</b>. To overcome the potential metabolic liabilities associated with benzylic carbons, we switched to a phenolic oxygen linker for the synthesis of <b>14p</b>–<b>q</b>. We were pleasantly surprised to see that <b>14p</b> in particular had an activity and selectivity profile comparable to that of <b>6a</b> and that this profile extended its activity against the hERG potassium channel (IC<sub>50</sub> = 8.1 μM). While there was no reduction in the hERG potassium channel binding affinity, <b>14p</b> did still offer a viable alternative chemotype for advancement into further studies.</div><div class="NLM_p last">While we deemed it unnecessary to screen <b>14g</b>, <b>14k</b>–<b>l</b>, and <b>14p</b> against ALK1, ALK2 mutants, ALK3, or ALK6 based on the known pattern of activity for this class of compounds (see above), we did spot-check the activity of these compounds against ALK4. <b>14k</b>–<b>l</b> had an ALK4 IC<sub>50</sub> > 2000 nM, with only relatively marginal activity shown by <b>14g</b> (ALK4 IC<sub>50</sub> = 1131 nM) and <b>14p</b> (ALK4 IC<sub>50</sub> = 1363 nM) corresponding to 39-fold and 227-fold selectivity for ALK2, respectively. Although the reduced selectivity of <b>14g</b> over ALK4 was of some concern, we still felt that analysis of its absorption, distribution, metabolism, and excretion (ADME) and PK properties was warranted based on the compound’s relatively high cellular potency against ALK2, significant selectivity over ALK5, and lack of affinity for the hERG potassium channel. As an interesting, representative piperidine-containing inhibitor, we screened <b>14k</b> at 1 μM against the 374-member kinase panel, finding >50% inhibition against only 1.9% of the kinases (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Table S1</a>). All of the seven kinases inhibited (ABL1, BRK, DDR1, LYN, MINK, TNIK, and ZAK) had also been inhibited by <b>6a</b> and/or <b>11b</b>.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vitro</i> ADME</h3><div class="NLM_p">Presented with six compounds exhibiting the structural attributes of a potentially successful CNS drug while meeting our criteria for activity against ALK2, selectivity over ALK5, and binding to the hERG potassium channel, we moved to evaluate the <i>in vitro</i> stability, permeability, and plasma protein binding (PPB) of <b>6a</b>, <b>11b</b>, <b>14g</b>, <b>14k</b>–<b>l</b>, and <b>14p</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Phase I (CYP enzymes only) metabolic stability of the compounds was examined at 1 μM in both mouse and human liver microsomes (MLM and HLM) following a 60 min incubation period at 37 °C, permeability was assessed using a Caco-2 assay, and heparinized pooled human plasma coupled with a compound concentration of 5 μM and 4 h incubation period at 37 °C was used for PPB determination.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> ADME Parameters for <b>6a</b>, <b>11b</b>, <b>14g</b>, <b>14k</b>–<b>l</b>, and <b>14p</b><a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0012.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0013.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Stability classification: stable (>70%), moderately stable (20–70%), or unstable (<20%) compound remaining.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Permeability classification: low (<i>P</i><sub>app</sub> < 1), medium (<i>P</i><sub>app</sub> 1–3), or high (<i>P</i><sub>app</sub> > 3) × 10<sup>–6</sup> cm/s.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Efflux ratio (BA/AB) classification: negative (ratio < 2), minor/moderate (ratio 2–7), or high (ratio > 7).</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Average of duplicate measurements.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Poor post-assay recovery in A to B chambers possibly due to low aqueous solubility, high lipophilicity, nonspecific binding to plastics or cells, and/or poor intracellular stability of the test article.</p></div></div><div></div></div><div class="NLM_p">We were pleased to find that across both the MLM and HLM assays, all of the compounds could be classified as being at least moderately stable (20–70% remaining), with some showing higher degrees of stability (>70% remaining). Compound <b>14p</b> appeared to be the most labile, although it still demonstrated adequate stability to remain of interest. While it had been reported that the piperazine moiety of <b>LDN-193189</b> is a metabolic liability,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> the motif did not appear to present any significant issue in the context of our 3,5-diphenylpyridine class inhibitors with a half-life greater than 60 min apparent for all compounds.</div><div class="NLM_p">Caco-2 permeability values were also high, with <i>P</i><sub>app_AB</sub> ≥ 3 × 10<sup>–6</sup> cm/s for all compounds except for <b>11b</b>. Although the compound was found to be moderately permeable with a <i>P</i><sub>app_AB</sub> = 1.8 × 10<sup>–6</sup> cm/s, poor post-assay recovery (<15%) for this compound, possibly a function of its increased lipophilicity, rendered the value less accurate. It also appeared that compounds <b>6a</b>, <b>14g</b>, and <b>14k</b>–<b>l</b> were not subject to P-gp-mediated efflux, with <b>11b</b> and <b>14p</b> being only moderately so. These low efflux ratios, coupled with high <i>P</i><sub>app_AB</sub> values and microsomal stability, suggested that all compounds were suitable candidates for <i>in vivo</i> analysis.</div><div class="NLM_p last">Measurement of PPB for <b>6a</b> (cLog <i>P</i> = 3.29), <b>11b</b> (cLog <i>P</i> = 3.72), and <b>14k</b> (cLog <i>P</i> = 4.21) showed <b>6a</b> and <b>14k</b> to have comparable, “druglike” free fractions (5.7 and 5.0%, respectively) despite their difference in lipophilicity. Although the 0.4% free fraction of <b>11b</b> appears suboptimal in comparison, current understanding reveals that <i>in vitro</i> PPB does not determine the actual unbound concentration in plasma <i>in vivo</i>, and as such, optimizing for PPB in drug design is not recommended.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> For drugs targeting the CNS, it is suggested that efforts should focus on reducing drug efflux transport at the BBB to achieve a high unbound brain concentration and to use PPB and brain tissue binding to calculate the unbound brain to unbound plasma concentration ratio for brain distribution assessment.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>In Vivo</i> PK and ADME</h3><div class="NLM_p">Given the favorable <i>in vivo</i> PK properties, suitable brain penetration, and general tolerability of <b>LDN-214117</b> facilitating its successful use in orthotopic <i>in vivo</i> models of DIPG,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> we felt confident that our modified, yet structurally related compounds would exhibit comparable or superior characteristics. To that end, we initially chose to evaluate the <i>in vivo</i> PK profiles of <b>6a</b>, <b>11b</b>, <b>14g</b>, <b>14k–l</b>, and <b>14p</b> in female CB17 SCID mice following 2 mg/kg IV (<i>n</i> = 3) and 10 mg/kg PO (<i>n</i> = 3) dosing in a formulation of 5% dimethyl sulfoxide (DMSO), 47.5% poly(ethylene glycol) (PEG) 400, and 47.5% deionized water with 10% Tween80. The inhibitors were all well tolerated, with no adverse effects observed in any test group allowing for successful readout of all parameters (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vivo</i> PK and ADME Parameters for <b>6a</b>, <b>11b</b>, <b>14g</b>, <b>14k–l</b>, and <b>14p</b><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0014.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0015.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Italicized table entries.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Male CD-1 mice at 2 h.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Compound administered at 100 mg/kg PO.</p></div></div><div></div></div><div class="NLM_p">Assessment in the IV arm showed clearance (Cl) for all compounds well below our set 30 mL/(min kg) upper limit, with <b>11b</b> showing the highest rate at 17.1 mL/(min kg). The steady-state volume of distribution (<i>V</i><sub>ss</sub>) was uniformly favorable (<i>V</i><sub>ss</sub> = 1–3 L/kg), with the exception of <b>14g</b> (<i>V</i><sub>ss</sub> = 0.48 L/kg). With <b>14g</b> also registering a half-life (<i>t</i><sub>1/2</sub>) under an hour (<i>t</i><sub>1/2</sub> = 0.80 h), a peak serum concentration (<i>C</i><sub>max</sub>) barely above our set 1 μM lower limit (<i>C</i><sub>max</sub> = 1.43 μM), total exposure (area under curve, AUC<sub>inf</sub>) an order of magnitude lower than that of the other compounds (AUC<sub>inf</sub> = 2.97 h·μM), and bioavailability (<i>F</i>) that was grossly suboptimal (<i>F</i> = 7%), the compound was a distinct outlier. Despite its considerable stability in the MLM/HLM assays and high degree of permeability in the Caco-2 assay, <b>14g</b> performed so poorly <i>in vivo</i> that we opted to drop the compound from further consideration.</div><div class="NLM_p">To evaluate the viability of an alternate, DMSO-free vehicle for dosing and its effect on exposure, we opted to convert <b>6a</b> to both its hydrochloride (HCl) and mesylate (MsOH) salt forms by taking advantage of the 1-position piperazine nitrogen’s basicity. Subsequent administration of <b>6a</b>·<b>HCl</b> and <b>6a</b>·<b>MsOH</b> in a formulation of 0.5% aqueous methylcellulose at 25 mg/kg PO to NOD SCID mice showed that both increased exposure levels relative to the free base control <b>6a</b> at the 0.5, 1, 2, and 6 h time points studied. Although similar in their effect, <b>6a</b>·<b>HCl</b> proved marginally superior and, at the reference time point of 1 h, resulted in a 22% increase in plasma concentration <i>versus</i><b>6a</b> (<i>C</i><sub>plasma</sub> = 9.11 μM for <b>6a</b>·<b>HCl</b>, while <i>C</i><sub>plasma</sub> = 7.46 μM for <b>6a</b>). Subsequent preparation and screening of <b>11b</b>·<b>HCl</b> in the 0.5% aqueous methylcellulose vehicle produced a comparable improvement in exposure <i>versus</i> the free base <b>11b</b>.</div><div class="NLM_p">Compounds <b>6a</b>, <b>11b</b>, and <b>14p</b> were found to be significantly more bioavailable than <b>LDN-214117</b> (<i>F</i> = 75%),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> with <b>14k–l</b> showing more comparable values. The <i>t</i><sub>1/2</sub> of all compounds (other than <b>14g</b>) matched or exceeded that of <b>LDN-214117</b> (<i>t</i><sub>1/2</sub> = 3.91 h), but evaluation of relative <i>C</i><sub>max</sub> and AUC<sub>inf</sub> values is more difficult given the differential dosing across the two trials (5 mg/kg PO in BALB/c mice for <b>LDN-214117</b>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> With PK parameters aligned or superior to those of <b>LDN-214117</b>, it was imperative to determine how well these compounds could potentially function in the CNS.</div><div class="NLM_p">Determination of BBB penetration was conducted for <b>6a</b>, <b>11b</b>, and <b>14k–l</b>, opting to remove <b>14p</b> from the analysis given its broadly similar PK profile and extra HBA (the phenolic oxygen) we felt could be a liability. At a dose of 10 mg/kg PO in female CB17 SCID mice (<i>n</i> = 3), <b>6a</b>, <b>11b</b>, and <b>14k</b> showed exceptional brain-to-plasma ratios (<i>C</i><sub>brain</sub>/<i>C</i><sub>plasma</sub>, or <i>B</i>/<i>P</i>) of 0.90, 1.41, and 0.82, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Although not measured under comparable conditions and at the same time point, a <i>B</i>/<i>P</i> of 0.80 (<i>C</i><sub>brain</sub> = 10.94 μM) was reported for <b>LDN-214117</b> at 2 h after 25 mg/kg PO dosing,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> making <b>11b</b> a considerably more CNS-penetrant compound. Even <b>6a</b> appears to have a modest advantage in BBB penetration, with <b>14k</b> more akin to <b>LDN-214117</b>. A dose-dependency was observed for the <i>B</i>/<i>P</i> ratios of the two more lipophilic compounds, with increased values observed for both <b>11b</b> (<i>B</i>/<i>P</i> = 2.03 with a <i>C</i><sub>brain</sub> = 33 μM) and <b>14k</b> (<i>B</i>/<i>P</i> = 1.55 with a <i>C</i><sub>brain</sub> = 39 μM) following 100 mg/kg PO dosing in the same mouse strain (<i>n</i> = 3). While these values are exceptional, the efficiency of drug delivery across the BBB is better described by looking at the ratio of the unbound brain concentration (<i>C</i><sub>u,brain</sub>) to the unbound plasma concentration (<i>C</i><sub>u,plasma</sub>) at steady state, <i>K</i><sub>p,uu</sub>.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Measuring these concentrations at the 2 h time point following 1 mg/kg IV dosing of <b>6a</b> in male CD-1 mice (<i>n</i> = 3), we found <i>C</i><sub>u,brain</sub> = 3.7 nM (3% of <i>C</i><sub>brain</sub> = 123 nM because m-BTB = 97%) and <i>C</i><sub>u,plasma</sub> = 14 nM (9% of <i>C</i><sub>plasma</sub> = 156 nM because m-PPB = 91%), so <i>K</i><sub>p,uu</sub> = 0.3. Although a <i>K</i><sub>p,uu</sub> < 1 is indicative of active efflux at the BBB, <i>K</i><sub>p,uu</sub> = 0.3 is in-line with a significant number of approved CNS drugs<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and, as such, was quite acceptable.</div><div class="NLM_p">With compound <b>14l</b> showing relatively low BBB penetration (<i>B</i>/<i>P</i> = 0.43), we opted to evaluate the PK of only <b>6a</b>, <b>11b</b>, and <b>14k</b> in a second rodent species, dosing male SD rats at 2 mg/kg IV (<i>n</i> = 3) and 10 mg/kg PO (<i>n</i> = 3). Notably, <i>t</i><sub>1/2</sub> values were comparable to or improved (as with <b>11b</b>) <i>versus</i> those observed in mice, although <i>C</i><sub>max</sub>, AUC<sub>inf</sub>, and <i>F</i> metrics were uniformly diminished (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, italicized entries). Compound <b>6a</b> emerged as the best performer, retaining both a decent maximum concentration (<i>C</i><sub>max</sub> = 1.28 μM) and bioavailability (<i>F</i> = 96%).</div><div class="NLM_p last">The evident oral bioavailability across two rodent species prompted us to conduct dose escalation trials with <b>6a</b>, <b>11b</b>, and <b>14k</b> to establish the linearity of <i>C</i><sub>max</sub> and AUC<sub>inf</sub>, and administration of the compounds at 10, 25, 50, and 100 mg/kg PO in female CB17 SCID mice (<i>n</i> = 3 per treatment) showed a high degree of dose-dependent correlation (<i>r</i><sup>2</sup> > 0.95) across both parameters. The absence of any observable behavioral or physical abnormalities in the mice after 24 h at the highest dose of 100 mg/kg PO suggested we could test that limit in a prolonged maximum tolerated dose (MTD) study. As we were anticipating the use of <b>6a</b> for an <i>in vivo</i> C57BL/6 mouse FOP model to demonstrate ALK2<sup>R206H</sup> target engagement, we opted to conduct the MTD study in that strain. Oral dosing over 5 days at 25 mg/kg once a day (QD) and twice a day (BID), 50 mg/kg QD, and 100 mg/kg QD showed <b>6a</b> to be well tolerated with no deaths, body weight loss (<5%), or gross pathology observed. Plasma concentrations increased linearly with dose (<i>r</i><sup>2</sup> > 0.95), and significant brain exposure was also observed. As with <b>11b</b> and <b>14k</b>, an increase in <i>B</i>/<i>P</i> ratios was recorded at the 4 h time point following the increased doses, with <i>B</i>/<i>P</i> = 1.5, 1.8, and 1.1 for <b>6a</b> at 25, 50, and 100 mg/kg QD, respectively.</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>In Vitro</i> Biology and <i>In Vivo</i> Mouse Models</h3><div class="NLM_p last">Screening of the lead inhibitors <b>6a</b>, <b>11b</b>, and <b>14k</b> in a panel of patient-derived <i>ACVR1</i> mutant and WT cell lines showed particularly significant growth inhibition of SU-DIPG-XXI (<i>ACVR1</i><sup><i>G328W</i></sup>) and HSJD-DIPG-007 (<i>ACVR1</i><sup><i>R206H</i></sup>) cells, with a GI<sub>50</sub> < 250 nM across both lines for all compounds (except <b>14k</b> against HSJD-DIPG-007 with a GI<sub>50</sub> = 2.1 μM)<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> coupled to an observed decrease in <i>ID1</i> expression (>50%). These <i>in vitro</i> results, the aggregate properties of <b>6a</b>, <b>11b</b>, and <b>14k</b>, and their scalable syntheses (50 g quantities of each were prepared by GL Chemtec International Ltd. through an in-kind contribution) led us to select these compounds as suitable inhibitors for proof-of-concept <i>in vivo</i> studies in models of FOP and DIPG. Active against ALK2<sup>R206H</sup><i>in vitro</i>, we anticipated that explicit <i>in vivo</i> target engagement could be demonstrated with 14 day compound dosing in an injury-induced heterotopic ossification (HO) <i>Acvr1</i><sup><i>R206H/+</i></sup> mouse model of FOP.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Efficacy in this model would build confidence to dose compounds over 28–56 days in an orthotopic H3.1K27M, <i>ACVR1</i><sup><i>R206H</i></sup> (Cre, PDGFA infected),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> or patient-derived H3.3K27M, <i>ACVR1</i><sup><i>R206H</i></sup> HSJD-DIPG-007 tumor xenograft<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> mouse model of DIPG. Full disclosure of the <i>in vitro</i> biology and <i>in vivo</i> model outcomes is beyond the scope of this publication and will be done under separate cover (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Note S2</a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">With the recent identification of ALK2 as a suitable target for therapeutic intervention in the treatment of DIPG, inhibitors from several chemical classes have been reported (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). One of the most well characterized, <b>LDN-214117</b>, demonstrated significant efficacy in an orthotopic mouse model of the disease and provided the basis for the further development of related inhibitors.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In this work, using <b>LDN-214117</b> as a lead compound, we expanded the SAR around the 3,5-diphenylpyridine inhibitor class to optimize potency against ALK2, increase selectivity over important off-targets such as ALK5, and produce a set of preclinical compounds with superior ADME and PK properties characteristic of a viable CNS drug. With the development of compound <b>6a</b>, we found that incorporation of a C-4 position methyl group on the pyridine core allowed for greater potency against ALK2 in both biochemical and cell-based assays while simultaneously conferring increased selectivity over ALK5. The compound also exhibited remarkable kinome-wide selectivity, little activity against other (receptor) off-targets, no significant CYP inhibition, and a manageable degree of activity against the hERG potassium channel. Subsequent structural modifications at the C-3 and C-5 positions gave rise to compounds <b>11b</b> and <b>14k</b>, which not only possessed the favorable PK characteristics evident in <b>6a</b> but also demonstrated the superior levels of BBB penetration required of a CNS drug candidate. The aggregate properties of <b>6a</b>, <b>11b</b>, and <b>14k</b> prompted us to select these compounds for further preclinical development as advanced candidates <b>M4K2009</b>, <b>M4K2163</b>, and <b>M4K2117</b>, respectively. All three inhibitors satisfied the criteria of our target product profile (TPP), with only hERG potassium channel inhibition being the exception (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Alignment of <b>M4K2009</b>, <b>M4K2117</b>, and <b>M4K2163</b> with the Target Product Profile</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0016.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Low post-assay recovery.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">2C9 IC<sub>50</sub> = 7.3 μM and 2C19 IC<sub>50</sub> = 7.7 μM.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">2 mg/kg IV and 10 mg/kg PO dosing.</p></div></div><div></div></div><div class="NLM_p last">Employing an open science model, we were able to compress the development timeline for these analogs by bringing together chemistry and biological screening capacity. Extensive evaluation of <b>M4K2009</b>, <b>M4K2117</b>, and <b>M4K2163</b><i>in vitro</i> against patient-derived DIPG cell lines and <i>in vivo</i> proof-of-concept studies in orthotopic mouse models of DIPG will be conducted in an equally open manner, with complete results to be reported at a later date.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p">All reagents were purchased from commercial vendors and used without further purification. Volatiles were removed under reduced pressure by rotary evaporation or using the V-10 solvent evaporator system from Biotage. Very high boiling point (6000 rpm, 0 mbar, 56 °C), mixed volatile (7000 rpm, 30 mbar, 36 °C), and volatile (6000 rpm, 30 mbar, 36 °C) methods were used to evaporate solvents. The yields given refer to chromatographically purified and spectroscopically pure compounds, unless stated otherwise. Compounds were purified using a Biotage Isolera One system by normal phase chromatography using Biotage SNAP KP-Sil or Sfär Silica D columns (part no. FSKO-1107/FSRD-0445) or by reverse-phase chromatography using Biotage SNAP KP-C18-HS or Sfär C18 D columns (part no. FSLO-1118/FSUD-040). If additional purification was required, compounds were purified by solid-phase extraction (SPE) using Biotage Isolute Flash SCX-2 cation exchange cartridges (part nos. 532-0050-C and 456-0200-D). Products were washed with two cartridge volumes of MeOH and eluted with a solution of MeOH and NH<sub>4</sub>OH (9:1 v/v). Preparative chromatography was carried out using a Waters 2767 injector with a collector attached to PDA UV–vis and SQD mass detectors. An XSelect CSH Prep C18 5 μm OBD 19 mm × 100 mm (part no. 186005421) or an Xselect CSH Prep C18 5 μm 10 mm × 100 mm (part no. 186005415) column was used for purification. Final compounds were dried using the Labconco Benchtop FreeZoneTM Freeze-Dry System (4.5 L model). <sup>1</sup>H NMRs were recorded on a Bruker Avance-III 500 MHz spectrometer at ambient temperature. Residual protons of CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, and CD<sub>3</sub>OD solvents were used as internal references. Spectral data are reported as follows: chemical shift (δ in ppm), multiplicity (br, broad; s, singlet; d, doublet; dd, doublet of doublets; m, multiplet), coupling constants (<i>J</i> in Hz), and proton integration. Compound purity was determined by UV absorbance at 254 nm during tandem liquid chromatography/mass spectrometry (LCMS) using a Waters Acquity separation module. All final compounds had a purity of ≥95% as determined using this method. Low-resolution mass spectrometry was conducted in the positive ion mode using a Waters Acquity SQD mass spectrometer (electrospray ionization source) fitted with a PDA detector. Mobile phase A consisted of 0.1% formic acid in water, while mobile phase B consisted of 0.1% formic acid in acetonitrile. One of three types of columns were used; column 1: Acquity UPLC CSH C18 (2.1 mm × 50 mm, 130 Å, 1.7 μm. part no. 186005296); column 2: Acquity UPLC BEH C8 (2.1 mm × 50 mm, 130 Å, 1.7 μm. part no. 186002877); or column 3: Acquity UPLC HSS T3 (2.1 mm × 50 mm, 100 Å, 1.8 μm. part no. 186003538). For columns 1 and 2, the gradient went from 90 to 5% mobile phase A over 1.8 min, maintained at 5% for 0.5 min, then increased to 90% over 0.2 min for a total run time of 3 min. For column 3, the gradient went from 98 to 5% mobile phase A over 1.8 min, maintained at 5% for 0.5 min, then increased to 98% over 0.2 min for a total run time of 3 min. The flow rate was 0.4 mL/min throughout both runs. All columns were used with the temperature maintained at 25 °C. High-resolution mass spectrometry was conducted using a Waters Synapt G2-S quadrupole-time-of-flight (Q-TOF) hybrid mass spectrometer system coupled with an Acquity ultraperformance liquid chromatography (UPLC) I-Class system. Chromatographic separations were carried out on an Acquity UPLC HSS T3 (2.1 mm × 100 mm, 100 Å, 1.8 μm, part no. 186003539). The mobile phases were 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). Leucine Enkephalin was used as the lock-mass. MassLynx 4.1 was used for data analysis.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure A for the Synthesis of Intermediates <b>3a</b>, <b>3d–e</b>, <b>and 3g–i</b></h4><div class="NLM_p last">To a solution of 3-bromo-5-chloro-pyridine <b>1a</b>, <b>1d–e</b>, or <b>1g–i</b> (0.484 mmol), 3,4,5-trimethoxyphenylboronic acid (<b>2</b>) (103 mg, 0.484 mmol), and Na<sub>2</sub>CO<sub>3</sub> (205 mg, 1.94 mmol) in DMF (2.2 mL) and water (0.6 mL) at room temperature was added [1,12-bis(diphenylphosphino)ferrocene]dichloropalladium(II)·DCM complex (20 mg, 0.024 mmol). After heating the resulting mixture at 100 °C for 16 h, it was cooled down to room temperature and diluted with water (40 mL) and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. This crude material was purified by chromatography on silica (10<b>–</b>100% EtOAc in hexanes) to afford intermediate <b>3a</b>, <b>3e</b>, <b>3h–i</b> (all in >70% yield), <b>3d</b>, or <b>3g</b> (both in ∼50% yield) as a powder. The identity of all products was confirmed by low-resolution mass spectrometry (LRMS) before use in the subsequent synthetic step.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedure B for the Synthesis of Intermediates <b>3b–c</b> and <b>3f</b></h4><div class="NLM_p last">To a solution of 3,5-dichloropyridine <b>1b–c</b> or <b>1f</b> (0.484 mmol), 3,4,5-trimethoxyphenylboronic acid (<b>2</b>) (103 mg, 0.484 mmol), and XPhos Pd G2 (19 mg, 0.024 mmol) in butanol (3 mL) at room temperature was added K<sub>3</sub>PO<sub>4</sub> (1.3 M solution in water) (0.748 mL, 0.973 mmol). After heating the resulting mixture at 100 °C for 4 h, it was cooled down to room temperature and diluted with water (40 mL) and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. This crude material was purified by chromatography on silica (10<b>–</b>100% EtOAc in hexanes) to afford intermediate <b>3b–c</b> or <b>3f</b> (all in ∼50% yield) as a powder. The identity of all products was confirmed by LRMS before use in the subsequent synthetic step.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Procedure for the Synthesis of Intermediates <b>5a–i</b></h4><div class="NLM_p last">General procedure B, with <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (<b>4</b>) replacing 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), was used to synthesize intermediates <b>5a–i</b> (all in >70% yield) as a powder from intermediates <b>3a–i</b>. The identity of all products was confirmed by LRMS before use in the subsequent synthetic step.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure C for the Synthesis of Compounds <b>6a–i</b></h4><div class="NLM_p">To a solution of intermediates <b>5a–i</b> (0.230 mmol) in methanol (MeOH) (4 mL) at room temperature was added hydrogen chloride solution (4.0 M in dioxane) (0.29 mL, 1.16 mmol). The resulting mixture was stirred for 30 min prior to removal of all solvents under reduced pressure, dissolution of the residue in a minimal amount of MeOH, and purification by SPE to afford compounds <b>6a–i</b> (all in >95% yield) as a powder.</div><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 1-(4-(4-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6a</b>) (M4K2009)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.32 (s, 1H), 8.31 (s, 1H), 7.33 (d, <i>J</i> = 8.9 Hz, 2H), 7.12 (d, <i>J</i> = 8.8 Hz, 2H), 6.70 (s, 2H), 3.90 (s, 6H), 3.86 (s, 3H), 3.28–3.24 (m, 4H), 3.07–3.03 (m, 4H), 2.26 (s, 3H). HRMS (ESI) for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 420.2287; found, 420.2279.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 1-(4-(4-Ethyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.29 (s, 1H), 8.25 (s, 1H), 7.31 (d, <i>J</i> = 8.5 Hz, 2H), 7.14 (d, <i>J</i> = 8.5 Hz, 2H), 6.68 (s, 2H), 3.88 (s, 6H), 3.84 (s, 3H), 3.40–3.36 (m, 4H), 3.25–3.21 (m, 4H), 2.75–2.68 (m, 2H), 0.82 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (ESI) for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 434.2444; found, 434.2436.</div></div><div id="sec4_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 1-(4-(4-Cyclopropyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.44 (s, 1H), 8.42 (s, 1H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.19 (d, <i>J</i> = 8.5 Hz, 2H), 6.89 (s, 2H), 3.98 (s, 6H), 3.93 (s, 3H), 3.37 (d, <i>J</i> = 4.9 Hz, 4H), 3.21–3.14 (m, 4H), 2.32–2.20 (m, 1H), 0.63–0.58 (br m, 2H), 0.05–0.00 (br m, 2H). HRMS (ESI) for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 446.2444; found, 446.2437.</div></div><div id="sec4_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(4-(4-Methoxy-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.49 (s, 1H), 8.46 (s, 1H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.02 (d, <i>J</i> = 8.8 Hz, 2H), 6.79 (s, 2H), 3.94–3.88 (m, 9H), 3.39 (s, 3H), 3.28–3.21 (m, 4H), 3.12–3.04 (m, 4H). HRMS (ESI) for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 436.2236; found, 436.2234.</div></div><div id="sec4_1_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 3-(4-(Piperazin-1-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridin-4-amine (<b>6e</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 7.85 (s, 1H), 7.82 (s, 1H), 7.25 (d, <i>J</i> = 8.7 Hz, 2H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 6.64 (s, 2H), 3.78 (s, 6H), 3.72 (s, 3H), 3.15–3.08 (m, 4H), 2.94–2.87 (m, 4H). HRMS (ESI) for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 421.2240; found, 421.2235.</div></div><div id="sec4_1_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 1-(4-(4-Fluoro-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6f</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.59 (d, <i>J</i> = 5.4 Hz, 1H), 8.57 (d, <i>J</i> = 5.4 Hz, 1H), 7.57 (d, <i>J</i> = 7.8 Hz, 2H), 7.14 (d, <i>J</i> = 8.8 Hz, 2H), 6.91 (s, 2H), 3.91 (s, 6H), 3.85 (s, 3H), 3.40–3.36 (m, 4H), 3.22–3.16 (m, 4H). HRMS (ESI) for C<sub>24</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 424.2036; found, 424.2025.</div></div><div id="sec4_1_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 1-(4-(4-Chloro-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6g</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.52 (s, 1H), 8.48 (s, 1H), 7.39 (d, <i>J</i> = 8.2 Hz, 2H), 7.03 (d, <i>J</i> = 8.3 Hz, 2H), 6.82 (s, 2H), 3.82 (s, 6H), 3.72 (s, 3H), 3.14 (br s, 4H), 2.85 (br s, 4H). HRMS (ESI) for C<sub>24</sub>H<sub>27</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 440.1741; found, 440.1728.</div></div><div id="sec4_1_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 1-(4-(4-(Trifluoromethyl)-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>6h</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.60 (s, 1H), 8.56 (s, 1H), 7.33 (d, <i>J</i> = 8.7 Hz, 2H), 7.09 (d, <i>J</i> = 8.8 Hz, 2H), 6.74 (s, 2H), 3.89 (s, 6H), 3.85 (s, 3H), 3.28–3.24 (m. 4H), 3.05–3.01 (m, 4H). HRMS (ESI) for C<sub>25</sub>H<sub>27</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 474.2005; found, 474.2000.</div></div><div id="sec4_1_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-(4-(Piperazin-1-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)isonicotinonitrile (<b>6i</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.76 (s, 1H), 8.75 (s, 1H), 7.62 (d, <i>J</i> = 8.7 Hz, 2H), 7.16 (d, <i>J</i> = 8.7 Hz, 2H), 7.00 (s, 2H), 3.95 (s, 6H), 3.88 (s, 3H), 3.35–331 (m, 4H), 3.07–3.03 (m, 4H). HRMS (ESI) for C<sub>25</sub>H<sub>27</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 431.2083; found, 431.2074.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Procedure for the Synthesis of Intermediates <b>7a</b>–<b>b</b></h4><div class="NLM_p last">General procedure A, with <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (<b>4</b>) replacing 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), was used to synthesize intermediates <b>7a</b>–<b>b</b> (both in >70% yield) as a powder from 3-bromo-5-chloro-pyridine <b>1a</b> or <b>1i</b>. The identity of both products was confirmed by LRMS before use in the subsequent synthetic step.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Procedure for the Synthesis of Intermediates <b>10a</b>–<b>c</b></h4><div class="NLM_p last">General procedure B, with either 3,5-dimethoxyphenylboronic acid (<b>8</b>) or (4-fluoro-3,5-dimethoxyphenyl)boronic acid (<b>9</b>) replacing 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), was used to synthesize intermediates <b>10a</b>–<b>c</b> (all in >70% yield) as a powder from intermediates <b>7a</b>–<b>b</b>. The identity of all products was confirmed by LRMS before use in the subsequent synthetic step.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Procedure for the Synthesis of Compounds <b>11a</b>–<b>c</b></h4><div class="NLM_p">General procedure C, with intermediates <b>10a</b>–<b>c</b> replacing intermediates <b>5a</b>–<b>i</b>, was used to synthesize compounds <b>11a</b>–<b>c</b> (all in >95% yield) as a powder.</div><div id="sec4_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 1-(4-(5-(3,5-Dimethoxyphenyl)-4-methylpyridin-3-yl)phenyl)piperazine (<b>11a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.18 (s, 1H), 8.16 (s, 1H), 7.20 (d, <i>J</i> = 8.7 Hz, 2H), 6.99 (d, <i>J</i> = 8.7 Hz, 2H), 6.45 (t, <i>J</i> = 2.1 Hz, 1H), 6.41 (d, <i>J</i> = 2.2 Hz, 2H), 3.72 (s, 6H), 3.20–3.15 (m, 4H), 3.04–2.93 (m, 4H), 2.10 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 390.2182; found, 390.2171.</div></div><div id="sec4_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 1-(4-(5-(4-Fluoro-3,5-dimethoxyphenyl)-4-methylpyridin-3-yl)phenyl)piperazine (<b>11b</b>) (M4K2163)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.32 (s, 2H), 7.32 (d, <i>J</i> = 8.8 Hz, 2H), 7.12 (d, <i>J</i> = 8.8 Hz, 2H), 6.75 (d, <i>J</i> = 7.0 Hz, 2H), 3.92 (s, 6H), 3.28–3.23 (m, 4H), 3.07–3.02 (m, 4H), 2.25 (s, 3H). HRMS (ESI) for C<sub>24</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 408.2087; found, 408.2075.</div></div><div id="sec4_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 3-(4-Fluoro-3,5-dimethoxyphenyl)-5-(4-(piperazin-1-yl)phenyl)isonicotinonitrile (<b>11c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.65 (s, 1H), 8.63 (s, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 2H), 7.06 (s, 1H), 7.04 (s, 1H), 6.93 (d, <i>J</i> = 6.9 Hz, 2H), 3.84 (s, 6H), 3.26–3.21 (m, 4H), 3.01–2.96 (m, 4H). HRMS (ESI) for C<sub>24</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 419.1883; found, 419.1874.</div></div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Procedure for the Synthesis of Intermediates <b>13c</b>, <b>13j</b>, <b>13l</b>, <b>13n</b>, and <b>13p</b> and Compounds <b>14a</b>–<b>b</b>, <b>14h</b>–<b>i</b>, <b>14k</b>, <b>14m</b>, <b>14o</b>, <b>and 14q</b></h4><div class="NLM_p last">General procedure B, with a 4-(R<sub>1</sub>)phenylboronic acid/pinacol ester <b>12a</b>–<b>c</b> or <b>12h</b>–<b>q</b> replacing 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), was used to synthesize intermediates <b>13c</b>, <b>13j</b>, <b>13l</b>, <b>13n</b>, or <b>13p</b> and compound <b>14a</b>–<b>b, 14h</b>–<b>i, 14k, 14m, 14o</b>, or <b>14q</b> (all in >70% yield) as a powder from intermediate <b>3a</b>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Procedure for the Synthesis of Compounds <b>14c</b>, <b>14j</b>, <b>14l</b>, <b>14n</b>, and <b>14p</b></h4><div class="NLM_p last">General procedure C, with intermediate <b>13c</b>, <b>13j</b>, <b>13l</b>, <b>13n</b>, or <b>13p</b> replacing intermediates <b>5a</b>–<b>i</b>, was used to synthesize compound <b>14c</b>, <b>14j</b>, <b>14l</b>, <b>14n</b>, or <b>14p</b> (all in >95% yield) as a powder.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Procedure for the Synthesis of Compound <b>14d</b></h4><div class="NLM_p last">To a solution of compound <b>6a</b> (<b>M4K2009</b>) (40 mg, 0.095 mmol) and 2-fluoroethyl tosylate (25 mg, 0.114 mmol) in acetonitrile (1 mL) at room temperature was added TEA (19 mg, 0.190 mmol). After heating the resulting mixture at 100 °C for 16 h, it was cooled down to room temperature and diluted with water (30 mL) and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. This crude material was purified by chromatography on silica (0–20% MeOH in EtOAc) to afford compound <b>14d</b> (65% yield) as a powder.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> General Procedure for the Synthesis of Compounds <b>14e</b>–<b>g</b></h4><div class="NLM_p">To a solution of compound <b>6a</b> (<b>M4K2009</b>) (40 mg, 0.095 mmol) in THF (4 mL) at room temperature was added acetyl chloride (for <b>14e</b>), dimethylcarbamyl chloride (for <b>14f</b>), or methanesulfonyl chloride (for <b>14g</b>) (0.114 mmol) and DIPEA (25 mg, 0.190 mmol). After stirring the resulting mixture for 1 h, it was diluted with water (30 mL) and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. This crude material was purified by chromatography on silica (0–100% EtOAc in hexanes) to afford compounds <b>14e</b>–<b>g</b> (all in >80% yield) as a powder.</div><div id="sec4_1_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 1-Methyl-4-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>14a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.30 (d, <i>J</i> = 2.7 Hz, 2H), 7.31 (t, <i>J</i> = 5.7 Hz, 2H), 7.11 (d, <i>J</i> = 8.8 Hz, 2H), 6.69 (s, 2H), 3.89 (s, 6H), 3.84 (s, 3H), 3.33–3.29 (m, 4H), 2.72–2.67 (m, 4H), 2.41 (s, 3H), 2.24 (s, 3H). HRMS (ESI) for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 434.2444; found, 434.2432.</div></div><div id="sec4_1_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 1-Isopropyl-4-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>14b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.31 (s, 2H), 7.32 (d, <i>J</i> = 8.7 Hz, 2H), 7.11 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (s, 2H), 3.89 (s, 6H), 3.84 (s, 3H), 3.33–3.29 (m, 4H), 2.84–2.68 (m, 5H), 2.25 (s, 3H), 1.17 (d, <i>J</i> = 6.5 Hz, 6H). HRMS (ESI) for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 462.2757; found, 462.2746.</div></div><div id="sec4_1_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (3<i>S</i>,5<i>R</i>)-3,5-Dimethyl-1-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>14c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 8.32 (s, 1H), 7.28 (br d, <i>J</i> = 8.6 Hz, 2H), 7.02 (br d, <i>J</i> = 8.7 Hz, 2H), 6.72 (s, 2H), 3.81 (s, 6H), 3.72 (s, 3H), 3.61 (br d, <i>J</i> = 10.8 Hz, 2H), 2.80–2.90 (m, 2H), 2.10–2.20 (m, 6H), 1.04 (d, <i>J</i> = 6.2 Hz, 6H). HRMS (ESI) for C<sub>27</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 448.2600; found, 448.2591.</div></div><div id="sec4_1_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 1-(2-Fluoroethyl)-4-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine (<b>14d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.18 (s, 2H), 7.19 (d, <i>J</i> = 8.6 Hz, 2H), 6.99 (d, <i>J</i> = 8.6 Hz, 2H), 6.57 (s, 2H), 4.58 (t, <i>J</i> = 4.7 Hz, 1H), 4.49 (t, <i>J</i> = 4.9 Hz, 1H), 3.77 (s, 6H), 3.72 (s, 3H), 3.21–3.17 (m, 4H), 2.75–2.69 (m, 1H), 2.69–2.62 (m, 5H), 2.13 (s, 3H). HRMS (ESI) for C<sub>27</sub>H<sub>33</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 466.2506; found, 466.2495.</div></div><div id="sec4_1_11_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 1-(4-(4-(4-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazin-1-yl)ethan-1-one (<b>14e</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 8.34 (s, 1H), 7.33 (br d, <i>J</i> = 8.3 Hz, 2H), 7.07 (br d, <i>J</i> = 8.6 Hz, 2H), 6.73 (s, 2H), 3.82 (s, 6H), 3.72 (s, 3H), 3.60 (br s, 4H), 3.25 (br s, 2H), 3.18 (br s, 2H), 2.19 (s, 3H), 2.06 (s, 3H). HRMS (ESI) for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 462.2393; found, 462.2391.</div></div><div id="sec4_1_11_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>N</i>,<i>N</i>-Dimethyl-4-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine-1-carboxamide (<b>14f</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 8.34 (s, 1H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.08 (d, <i>J</i> = 8.7 Hz, 2H), 6.73 (s, 2H), 3.82 (s, 6H), 3.72 (s, 3H), 3.28 (br d, <i>J</i> = 6.1 Hz, 4H), 3.23 (br d, <i>J</i> = 5.7 Hz, 4H), 2.80 (s, 6H), 2.19 (s, 3H). HRMS (ESI) for C<sub>28</sub>H<sub>35</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 491.2658; found, 491.2652.</div></div><div id="sec4_1_11_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 1-(4-(4-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)-4-(methylsulfonyl)piperazine (<b>14g</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.32 (s, 1H), 8.30 (s, 1H), 7.34 (d, <i>J</i> = 8.7 Hz, 2H), 7.15 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (s, 2H), 3.89 (s, 6H), 3.84 (s, 3H), 3.44–3.37 (m, 8H), 2.92 (s, 3H), 2.44 (s, 3H). HRMS (ESI) for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 498.2063; found, 498.2049.</div></div><div id="sec4_1_11_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 4-(4-(4-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)morpholine (<b>14h</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 8.33 (s, 1H), 7.32 (br d, <i>J</i> = 8.1 Hz, 2H), 7.06 (br d, <i>J</i> = 8.2 Hz, 2H), 6.73 (s, 2H), 3.82 (s, 6H), 3.76 (br d, <i>J</i> = 4.0 Hz, 4H), 3.72 (s, 3H), 3.18 (br d, <i>J</i> = 4.2 Hz, 4H), 2.19 (s, 3H). HRMS (ESI) for C<sub>25</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 421.2127; found, 421.2123.</div></div><div id="sec4_1_11_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 4-(4-(4-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)thiomorpholine 1,1-Dioxide (<b>14i</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 8.34 (s, 1H), 7.35 (br d, <i>J</i> = 8.6 Hz, 2H), 7.15 (br d, <i>J</i> = 8.7 Hz, 2H), 6.73 (s, 2H), 3.85 (br s, 4H), 3.82 (s, 6H), 3.72 (s, 3H), 3.16 (br s, 4H), 2.20 (s, 3H). HRMS (ESI) for C<sub>25</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 469.1797; found, 469.1793.</div></div><div id="sec4_1_11_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 4-Methyl-3-(4-(piperidin-4-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine (<b>14j</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.36 (s, 1H), 8.30 (s, 1H), 7.42 (q, <i>J</i> = 8.3 Hz, 4H), 6.70 (s, 2H), 3.89 (s, 6H), 3.84 (s, 3H), 3.45 (d, <i>J</i> = 12.8 Hz, 2H), 3.08 (td, <i>J</i> = 12.7, 2.3 Hz, 2H), 2.96 (ddd, <i>J</i> = 12.1, 8.8, 3.5 Hz, 1H), 2.23 (s, 3H), 2.10 (d, <i>J</i> = 13.8 Hz, 2H), 1.92 (qd, <i>J</i> = 13.5, 3.8 Hz, 2H). HRMS (ESI) for C<sub>26</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 419.2335; found, 419.2330.</div></div><div id="sec4_1_11_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 4-Methyl-3-(4-(1-methylpiperidin-4-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine (<b>14k</b>) (M4K2117)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.35 (s, 1H), 8.31 (s, 1H), 7.42 (d, <i>J</i> = 8.2 Hz, 2H), 7.37 (d, <i>J</i> = 8.2 Hz, 2H), 6.70 (s, 2H), 3.90 (s, 6H), 3.85 (s, 3H), 3.08 (d, <i>J</i> = 11.7 Hz, 2H), 2.72–2.63 (m, 1H), 2.40 (s, 3H), 2.30–2.23 (m, 2H), 2.23 (br s, 3H), 1.95–1.86 (m, 4H). HRMS (ESI) for C<sub>27</sub>H<sub>33</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 433.2491; found, 433.2485.</div></div><div id="sec4_1_11_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 4-Methyl-3-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine (<b>14l</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.23 (s, 1H), 8.20 (s, 1H), 7.47 (d, <i>J</i> = 8.3 Hz, 2H), 7.28 (d, <i>J</i> = 8.3 Hz, 2H), 6.58 (s, 2H), 6.20–6.13 (m, 1H), 3.77 (s, 6H), 3.72 (s, 3H), 3.46 (dd, <i>J</i> = 5.6, 2.6 Hz, 2H), 3.05 (t, <i>J</i> = 5.8 Hz, 2H), 2.54–2.46 (m, 2H), 2.12 (s, 3H). HRMS (ESI) for C<sub>26</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 417.2178; found, 417.2172.</div></div><div id="sec4_1_11_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 4-Methyl-3-(4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine (<b>14m</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.35 (s, 1H), 8.33 (s, 1H), 7.60 (d, <i>J</i> = 8.2 Hz, 2H), 7.41 (d, <i>J</i> = 8.2 Hz, 2H), 6.70 (s, 2H), 6.26 (s, 1H), 3.89 (s, 6H), 3.84 (s, 3H), 3.28 (d, <i>J</i> = 2.0 Hz, 2H), 2.86 (t, <i>J</i> = 5.7 Hz, 2H), 2.73 (s, 2H), 2.50 (s, 3H), 2.24 (s, 3H). HRMS (ESI) for C<sub>27</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 431.2335; found, 431.2328.</div></div><div id="sec4_1_11_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 1-(4-(4-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)-1,4-diazepane (<b>14n</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.33 (s, 2H), 7.24 (d, <i>J</i> = 8.7 Hz, 2H), 6.80 (d, <i>J</i> = 8.8 Hz, 2H), 6.73 (s, 2H), 3.81 (s, 6H), 3.72 (s, 3H), 3.57 (t, <i>J</i> = 6.0 Hz, 2H), 3.54–3.49 (m, 2H), 2.95–2.87 (m, 2H), 2.73–2.66 (m, 2H), 2.21 (s, 3H), 1.86–1.78 (m, 2H). HRMS (ESI) for C<sub>26</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 434.2444; found, 434.2433.</div></div><div id="sec4_1_11_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 1-Methyl-4-(4-(4-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)benzyl)piperazine (<b>14o</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.35 (s, 1H), 8.31 (s, 1H), 7.50 (d, <i>J</i> = 7.9 Hz, 2H), 7.40 (d, <i>J</i> = 8.0 Hz, 2H), 6.70 (s, 2H), 3.89 (s, 6H), 3.84 (s, 3H), 3.65 (s, 2H), 2.83–2.43 (br s, 8H), 2.36 (s, 3H), 2.23 (s, 3H). HRMS (ESI) for C<sub>27</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 448.2600; found, 448.2592.</div></div><div id="sec4_1_11_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 4-Methyl-3-(4-(piperidin-4-yloxy)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine (<b>14p</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.34 (s, 1H), 8.31 (s, 1H), 7.37 (d, <i>J</i> = 8.7 Hz, 2H), 7.13 (d, <i>J</i> = 8.7 Hz, 2H), 6.70 (s, 2H), 4.72–4.66 (m, 1H), 3.90 (s, 6H), 3.85 (s, 3H), 3.32–3.26 (m, 2H), 3.04–2.98 (m, 2H), 2.24 (s, 3H), 2.19–2.12 (m, 2H), 1.95–1.87 (m, 2H). HRMS (ESI) for C<sub>26</sub>H<sub>31</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 435.2284; found, 435.2273.</div></div><div id="sec4_1_11_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 4-Methyl-3-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-5-(3,4,5-trimethoxyphenyl)pyridine (<b>14q</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.21 (s, 1H), 8.19 (s, 1H), 7.23 (d, <i>J</i> = 8.7 Hz, 2H), 6.97 (d, <i>J</i> = 8.7 Hz, 2H), 6.58 (s, 2H), 4.46–4.37 (br m, 1H), 3.77 (s, 6H), 3.72 (s, 3H), 2.74–2.62 (br m, 2H), 2.41–2.30 (br m, 2H), 2.25 (s, 3H), 2.12 (s, 3H), 2.02–1.92 (br m, 2H), 1.81–1.72 (br m, 2H). HRMS (ESI) for C<sub>27</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>: calcd, 449.2440; found, 449.2429.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Kinase Assay</h3><div class="NLM_p last">The biochemical potencies of all compounds were measured by Reaction Biology Corporation (Malvern, Pennsylvania). Compounds were tested against ALK1/ACVRL1, ALK2/ACVR1, ALK3/BMPR1α, ALK4/ACVR1β, ALK5/TGFβ-R1, and ALK6/BMPR1β in a 10-dose IC<sub>50</sub> mode with a twofold serial dilution starting at 1 or 5 μM. Reactions were conducted at an ATP concentration of 10 μM and Casein concentration of 1 mg/mL. <b>LDN-193189</b> was tested as a control in a 10-dose IC<sub>50</sub> mode with a threefold serial dilution starting at 10 μM. Reductions in enzymatic activity were determined relative to dimethyl sulfoxide (DMSO) controls.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Cell Culture and Transfection</h3><div class="NLM_p last">HEK-293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher) and penicillin/streptomycin (Thermo Fisher). HEK-293 cells were transfected with the protein expression or reporter constructs using FuGENE HD (Promega) according to the manufacturer’s instructions. Briefly, DNA was diluted into phenol red-free Opti-MEM (Gibco) at a concentration of 10 μg/mL. Without coming in contact with the sides of the container, 3 μL of FuGENE HD was added for each microgram of DNA used. After thorough mixing by inversion, FuGENE HD/DNA complexes were allowed to form by incubation at room temperature for 20 min. The transfection mixture (1 part) was added to 20 parts of the HEK-293 cell suspension with a density of 200 000 cells per mL (volume/volume). HEK-293 cells were incubated in a humidified, 37 °C incubator with 5% CO<sub>2</sub> for 24 h before they were used in the NanoBRET target engagement assay or dual luciferase reporter assay.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> NanoBRET Target Engagement Assay</h3><div class="NLM_p last">ALK2-C-terminal nanoluciferase fusion with a GSSG linker was encoded by the pFC32K vector (Promega). ALK2-nanoluciferase fusion construct (1 part) was mixed with 9 parts of Transfection Carrier DNA (mass/mass) (Promega). Transfected cells were trypsinized and resuspended in Opti-MEM at a density of 200 000 cells per mL. Cells (17 μL) were dispensed into each well of a 384-well flat-bottom polypropylene plate (Greiner). Working solution (20×) of the target engagement tracer PBI-6908 (Promega) was prepared by diluting DMSO stock in tracer dilution buffer (12.5 mM HEPES pH 7.5, 31.25% PEG-400). Stocks (1000×) of test compounds in DMSO (Cell Signaling Technology) were diluted further in Opti-MEM for 10× working solutions. After the addition of 1 μL of 20× target engagement tracer and 2 μL of 10× working solutions, contents of the wells were thoroughly mixed by agitating the plate at 500 rpm for 1 min. Cells were incubated in a humidified, 37 °C incubator with 5% CO<sub>2</sub> for 2 h prior to bioluminescence resonance energy transfer (BRET) measurement. For BRET measurement, the NanoBRET NanoGlo Substrate and the Extracellular NanoLuc Inhibitor (Promega) were diluted 166× and 500×, respectively, in Opti-MEM to produce 3× working stock. A PHERAstar FSX microplate reader (BMG Labtech) with the LUM 610-LP 460-80 optical module was used to measure the intensity of dual emission. A measurement interval of 1 s and gain settings of 3600 and 1879 for 610 and 460 nm, respectively, were used. Milli-BRET units (mBU) were calculated by dividing the signal measured at 610 nm with the signal measured at 460 nm and multiplying by 1000. The apparent EC<sub>50</sub> values of test compounds were estimated using the [Inhibitor] <i>versus</i> response (three-parameter) nonlinear regression curve fitting function of GraphPad Prism 7.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Dual Luciferase Reporter Assay</h3><div class="NLM_p last">CAGA-Luc and Renilla-luciferase constructs (a gift from Dr. Petra Knaus, Free University of Berlin) were used as reporters for ALK5 signaling and loading control, respectively. The CAGA-Luc construct (4 parts) was mixed with 1 part of Renilla-luciferase construct (mass/mass). Ten thousand transfected cells were seeded into each well of a 96-well plate (Corning). Some 24 h after transfection, the cells were incubated with 10 ng/mL TGFβ1 (Peprotech, 100-21-10) and test compounds simultaneously at the concentrations indicated in a humidified, 37 °C incubator with 5% CO<sub>2</sub>. Another 24 h later, the cells were harvested, lysed, and processed for the measurement of luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer’s instructions. Briefly, the culture medium was aspirated completely, and cells were lysed in 50 μL of 1× PLB with 300 rpm agitation for 30 min. The cell lysate (10 μL) was dispensed into each well of a 384-well flat-bottom polypropylene plate (Greiner). The luminescent signal of firefly- and Renilla-luciferase activity was measured sequentially using a PHERAstar FS microplate reader (BMG Labtech) after the addition of 25 μL of LARII and Stop & Glo, respectively. A measurement interval of 2 s and gain setting of 3600 were used. The firefly-luciferase signal was normalized to the cell number by division with the Renilla-luciferase signal. The relative luciferase unit (RLU) was obtained by further division with the signal from cells without TGFβ stimulation. The apparent EC<sub>50</sub> values of test compounds were estimated using the [Inhibitor] <i>versus</i> response (three-parameter) nonlinear regression curve fitting function of GraphPad Prism 7.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Caco-2 Permeability Assay</h3><div class="NLM_p">Caco-2 cells (C2BBe1) were purchased from American Type Culture Collection (ATCC). Caco-2 cell cultures were routinely maintained in T-75 tissue culture flasks in DMEM containing 20% FBS, 0.1 mg/mL normocin, and 0.05 mg/mL gentamicin. These cells were seeded at a density of 40 000 cells per well on the 24-well poly(ethylene terephthalate) (PET) membrane (1.0 μm pore size, 0.3 cm<sup>2</sup> surface area) insert plates. Cell monolayers were grown for 21 or 22 days at 37 °C with 5% CO<sub>2</sub> in a humidified incubator. The cell culture medium was replaced twice weekly during the cell growth period. Prior to beginning the permeability assay, cell monolayers were rinsed with Hank’s balanced salt solution (HBSS) twice to remove the residual cell culture medium. The assay buffer comprised HBSS containing 10 mM HEPES and 15 mM glucose at pH 7.4. The dosing buffer contained 5 μM metoprolol (positive control), 5 μM atenolol (negative control), and 100 μM Lucifer yellow in the assay buffer. The receiving buffer contained 1% bovine serum albumin (BSA) in the assay buffer. The concentration of the test compound was 5 μM in the dosing buffer (final DMSO concentration was 0.1%). Digoxin at 10 μM was utilized as a P-gp substrate control. For the apical to basolateral (A to B) permeability experiment, 0.25 mL of the dosing buffer was added to the apical chambers, and 1.0 mL of the receiving buffer was added to the basolateral chambers of the assay plate. For the basolateral to apical (B to A) permeability experiment, 0.25 mL of the receiving buffer was added to the apical chambers, and 1.0 mL of dosing buffer was added to the basolateral chambers of the assay plates. The assay plates were then incubated at 37 °C for 2 h on an orbital shaker at 65 rpm. Sample solutions were taken from the donor chambers (10 μL) and receiver chambers (100 μL) after the incubation period. For each sample, there were two technical replicates. The sample solutions from donor chambers were diluted 10× with the receiving buffer. To extract test compounds and precipitate BSA from sample solutions, three volumes of acetonitrile (containing 0.5% formic acid and an internal standard) were added, and the plate was vigorously mixed. Sample solutions were then centrifuged at 4000 rpm for 10 min to remove debris and precipitated BSA. Approximately 150 μL of the supernatant was subsequently transferred to a new 96-well microplate for LC/MS analysis. Narrow-window mass extraction LC/MS analysis was performed for all samples using a Waters Acquity UPLC system with a Waters Xevo quadrupole-time-of-flight (Q-TOF) mass spectrometer to determine relative peak areas of the parent compounds. Chromatographic separations were performed on a Waters Acquity UPLC HSS T3 column (2.1 mm × 100 mm, 100 Å, 1.8 μm, part no. 186003539) at 30 °C. Mobile phases A and B were 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. The sample temperature was kept at 10 °C. The typical injection volume was 0.3 μL. Chromatographic gradients used are shown in the table below.</div><div class="NLM_array scrollable-table-wrap"><table class="table"><tbody><row>Time (min)Flow Rate (μL/min)%A%B</row><row>0.00.4001000</row><row>0.50.4001000</row><row>4.50.400595</row><row>5.00.400595</row><row>5.50.4001000</row><row>6.50.4001000</row></tbody></table></div><div class="NLM_p last">Data acquisition was performed in the electrospray (ES) positive ion mode in the mass range of 100–1000 <i>m</i>/<i>z</i>. The following source parameters were used: capillary voltage, 0.8 kV; cone voltage, 25 V; source temperature, 150 °C; desolvation temperature, 500 °C; cone gas flow, 150 L/h; desolvation gas flow, 600 L/h. Accurate masses were measured in the lock-spray automated exact mass measurement mode. The fragment ions of leucine-enkephalin were used as reference substances (lock-mass) in the acquisition mode. The following lock-spray configuration was used: frequency, 10 s; cone voltage, 25 V; collision energy, 22 V. Data processing was performed using MassLynx 4.1 software (Waters). The co-dosed positive and negative controls were also measured for each well to monitor integrity of cell monolayers and well-to-well variability. The apparent permeability coefficient (<i>P</i><sub>app</sub>) and post-assay recovery are calculated using the following equations<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_m001.gif" alt="" id="_i73" /></img></span><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_m002.gif" alt="" id="_i74" /></img></span>where d<i>C</i>/d<i>t</i> is the slope of cumulative concentration in the receiver compartment <i>versus</i> time, <i>V</i><sub>r</sub> is the volume of the receiver compartment, <i>V</i><sub>d</sub> is the volume of the donor compartment, <i>A</i> is the membrane surface area, <i>C</i><sub>0</sub> is the initial compound concentration in the donor chamber, <i>C</i><sub>r</sub><sup>final</sup> is the cumulative receiver concentration at the end of the incubation period, and <i>C</i><sub>d</sub><sup>final</sup> is the concentration of the donor at the end of the incubation period. The efflux ratio (ER) is defined as <i>P</i><sub>app</sub> (B-to-A)/<i>P</i><sub>app</sub> (A-to-B).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Liver Microsomal Metabolic Stability Assay</h3><div class="NLM_p">For this assay, stock solutions of test compounds in DMSO (1 mM) were initially diluted to a concentration of 40.0 μM using 0.1 M potassium phosphate buffer (pH 7.4). Test compounds were then added to reaction wells at a final concentration of 1 μM, which was assumed to be well below <i>K</i><sub>m</sub> values to ensure linear reaction conditions (<i>i.e</i>., avoid saturation). The final DMSO concentration was kept constant at 0.1%. Each compound was tested in duplicate for both time points (0 and 60 min). CD-1 mouse (male) or pooled human liver microsomes (Corning Gentest) were added to the reaction wells at a final concentration of 0.5 mg/mL (protein). The final volume for each reaction was 100 μL, which included the NADPH-regeneration solution (NRS) mix (Corning Gentest). This NRS mix comprised glucose 6-phosphate dehydrogenase, NADP<sup>+</sup>, MgCl<sub>2</sub>, and glucose 6-phosphate. Reactions were carried out at 37 °C in an orbital shaker at 175 rpm. Upon completion of the 60 min time point, reactions were terminated by the addition of 2 V (200 μL) of ice-cold acetonitrile containing 0.5% formic acid and an internal standard. Samples were then centrifuged at 4000 rpm for 10 min to remove debris and precipitated proteins. Approximately 150 μL of supernatant was subsequently transferred to a new 96-well microplate for LC/MS analysis. Narrow-window mass extraction LC/MS analysis was performed for all samples using a Waters Acquity UPLC system with a Waters Xevo quadrupole-time-of-flight (Q-TOF) mass spectrometer to determine relative peak areas of the parent compounds. Chromatographic separations were performed on a Waters Acquity UPLC HSS T3 column (2.1 mm × 100 mm, 100 Å, 1.8 μm, part no. 186003539) at 30 °C. Mobile phased A and B were 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. The sample temperature was kept at 10 °C. The typical injection volume was 0.3 μL. Chromatographic gradients used are shown in the table below.</div><div class="NLM_array scrollable-table-wrap"><table class="table"><tbody><row>Time (min)Flow Rate (μL/min)%A%B</row><row>0.00.4501000</row><row>2.50.450595</row><row>3.00.450595</row><row>3.50.4501000</row><row>4.50.4501000</row></tbody></table></div><div class="NLM_p last">Data acquisition was performed in the electrospray (ES) positive ion mode in the mass range of 100–1000 <i>m</i>/<i>z</i>. The following source parameters were used: capillary voltage, 0.8 kV; cone voltage, 25 V; source temperature, 150 °C; desolvation temperature, 500 °C; cone gas flow, 150 L/h; desolvation gas flow, 600 L/h. Accurate masses were measured in the lock-spray automated exact mass measurement mode. The fragment ions of leucine-enkephalin were used as reference substances (lock-mass) in the acquisition mode. The following lock-spray configuration was used: frequency, 10 s; cone voltage, 25 V; collision energy, 22 V. Data processing was performed using MassLynx 4.1 software (Waters). The percentage remaining values were calculated using the following equation:<span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_m003.gif" alt="" id="_i76" /></img></span>where <i>A</i> is area response after incubation and <i>A</i><sub>0</sub> is area response at the initial time point.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Plasma Protein Binding Assay</h3><div class="NLM_p">A 48-well format rapid equilibrium dialysis (RED) device from Thermo Fisher Scientific was used for the plasma protein binding assay. Each RED device insert contained a buffer and a plasma compartment separated by a semipermeable membrane with a molecular weight cutoff of approximately 8 kDa. Stock solutions of test compounds in DMSO (1 mM) were spiked into heparinized pooled human plasma from Innovative Research (Novi, Michigan) at the final compound concentration of 5 μM (final DMSO concentration was 0.5%). The prepared plasma sample (300 μL) was added to a plasma chamber, and 500 μL of Dulbecco’s phosphate-buffered saline (DPBS) was added to a buffer chamber. The RED plate was incubated in an orbital shaker at 37 °C and 200 rpm for 4 h. After the incubation, 50 μL aliquots of postdialysis samples from the buffer and the plasma chambers were transferred to a 96-well deep well plate. Samples were matrix-matched for the analysis by the addition of 50 μL of plasma to the buffer samples and 50 μL of buffer to the plasma samples. Ice-cold acetonitrile (300 μL) containing 0.5% formic acid and an internal standard was added to each well to precipitate plasma proteins. The deep well plate was tightly sealed with a plastic mat, mixed vigorously for 5 min, and placed on ice for 30 min. After the extraction step, the deep well plate was centrifuged for 10 min at 4000 rpm. Approximately 150 μL of supernatant was subsequently transferred to a new 96-well microplate for LC/MS analysis. Narrow-window mass extraction LC/MS analysis was performed for all samples using a Waters Acquity UPLC system with a Waters Xevo quadrupole-time-of-flight (Q-TOF) mass spectrometer to determine relative peak areas of the parent compounds. Chromatographic separations were performed on a Waters Acquity UPLC HSS T3 column (2.1 mm × 100 mm, 100 Å, 1.8 μm, part no. 186003539) at 30 °C. Mobile phases A and B were 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. The sample temperature was kept at 10 °C. The typical injection volume was 0.3 μL. Chromatographic gradients used are shown in the table below.</div><div class="NLM_array scrollable-table-wrap"><table class="table"><tbody><row>Time (min)Flow Rate (μL/min)%A%B</row><row>0.00.4001000</row><row>4.50.400595</row><row>5.00.400595</row><row>5.50.4001000</row><row>6.50.4001000</row></tbody></table></div><div class="NLM_p last">Data acquisition was performed in the electrospray (ES) positive ion mode in the mass range of 100–1000 <i>m</i>/<i>z</i>. The following source parameters were used: capillary voltage, 0.8 kV; cone voltage, 25 V; source temperature, 150 °C; desolvation temperature, 500 °C; cone gas flow, 150 L/h; desolvation gas flow, 600 L/h. Accurate masses were measured in the lock-spray automated exact mass measurement mode. The fragment ions of leucine-enkephalin were used as reference substances (lock-mass) in the acquisition mode. The following lock-spray configuration was used: frequency, 10 s; cone voltage, 25 V; collision energy, 22 V. Data processing was performed using MassLynx 4.1 software (Waters). Each determination was performed in triplicate. The percentage of the bound test compound was calculated using the following equation:<span class="NLM_disp-formula" id="ueq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_m004.gif" alt="" id="_i78" /></img></span>where <i>A</i><sub>buffer</sub> is area response of the buffer chamber and <i>A</i><sub>plasma</sub> is area response of the plasma chamber.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> hERG Potassium Channel Inhibition Assay</h3><div class="NLM_p last">hERG IC<sub>50</sub> values were generated by Charles River Laboratories (Cleveland, Ohio). Compounds were tested against cloned hERG potassium channels expressed in HEK-293 cells. Chemicals used in solution preparation were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted and were of ACS reagent-grade purity or higher. Stock solutions of test articles and the positive control were prepared in dimethyl sulfoxide (DMSO) and stored frozen. Reference compound concentrations were prepared fresh daily by diluting stock solutions into a Charles River proprietary HEPES-buffered physiological saline (HB-PS) solution, which was prepared weekly and refrigerated until use. Because previous results have shown that ≤0.3% DMSO did not affect channel currents, all test and control solutions contained 0.3% DMSO. Each test article formulation was sonicated (model 2510/5510, Branson Ultrasonics, Danbury, CT) at ambient room temperature for 20 min to facilitate dissolution. Cells were cultured in DMEM/nutrient mixture F-12 (D-MEM/F-12) supplemented with 10% FBS, 100 U/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, and 500 μg/mL G418. Before testing, cells in culture dishes were washed twice with HBSS and detached with accutase. Immediately before use in the IonWorks Barracuda system, the cells were washed twice in HB-PS to remove the accutase and resuspended in 5 mL of HB-PS. The test article effects were evaluated using IonWorks Barracuda systems (Molecular Devices Corporation, Union City, CA). HEPES-buffered intracellular solution (Charles River proprietary) for whole-cell recordings was loaded into the intracellular compartment of the Population Patch Clamp (PPC) planar electrode. Extracellular buffer (HB-PS) was loaded into PPC planar electrode plate wells (11 μL per well). The cell suspension was pipetted into the wells of the PPC planar electrode (9 μL per well). After establishment of a whole-cell configuration (the perforated patch), membrane currents were recorded using a patch clamp amplifier in the IonWorks Barracuda system. The current recordings were performed one time before test article application to the cells (baseline) and one time after application of the test article. Test article concentrations were applied to naive cells (<i>n</i> = 4, where <i>n</i> = replicates per concentration). Each application consisted of addition of 20 μL of 2× concentrated test article solution to the total 40 μL of the final volume of the extracellular well of the PPC plate. The duration of exposure to each compound concentration was 5 min. The hERG current was measured using a pulse pattern with fixed amplitudes (conditioning prepulse: −80 mV for 25 ms; test pulse: +40 mV for 80 ms) from a holding potential of 0 mV (“zero holding” procedure). The hERG current was measured as a difference between the peak current at 1 ms after the test step to +40 mV and the steady-state current at the end of the step to +40 mV.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> CYP Inhibition Assay</h3><div class="NLM_p last">CYP IC<sub>50</sub> values were generated by Pharmaron (Beijing, China). Multiple concentrations (1 μL) of the test compound or positive control compound (CYP1A2, furafylline; CYP2B6, ketoconazole; CYP2C8, quercetin; CYP2C9, sulfaphenazole; CYP2C19, <i>N</i>-3-benzylnirvanol; CYP2D6, quinidine; and CYP3A4, ketoconazole) were transferred to the “compound plate”. The concentrations of test compounds and positive control compounds were 0, 0.2, 1, 2, 10, 50, 200, 2000, and 10 000 μM. The master solution was prepared with MgCl<sub>2</sub> solution (20 μL of 50 mM solution), phosphate buffer (100 μL of 200 mM solution), ultrapure water (56 μL), human liver microsomes [2 μL of 20 mg/mL stock concentration (Corning 1328 UltraPool HLM 150, Mixed Gender, cat. no. 452117)], and 1 μL of substrate [CYP1A2, phenacetin (8 mM stock concentration); CYP2B6, bupropion (10 mM stock concentration); CYP2C8, paclitaxel (1 mM stock concentration); CYP2C9, tolbutamide (40 mM stock concentration); CYP2C19, mephenytoin (10 mM stock concentration); CYP2D6, dextromethorphan (2 mM stock concentration); and CYP3A4, midazolam (1 mM stock concentration), and testosterone (10 mM stock concentration)]. The master solution was prewarmed in a water bath at 37 °C for 5 min. The incubated master solution (179 μL) was transferred to the compound plate. In the mixed system, the final concentrations of the test compounds and positive control compounds were 0, 0.001, 0.005, 0.01, 0.05, 0.25, 1, 10, and 50 μM. All experiments were performed in duplicate. The reaction was started with the addition of 20 μL of 10 mM NADPH solution at the final concentration of 1 mM. The reaction was stopped by the addition of 1.5 V of methanol with IS (100 nM alprazolam, 200 nM imipramine, 200 nM labetalol, and 2 μM ketoprofen) to the “incubation plate” at the designated time points (20 min for CYP1A2, 2B6, 2C9, 2C19, and 2D6, 5 min for midazolam-mediated 3A4, and 10 min for testosterone-mediated 3A4). The incubation plate was centrifuged at 3220<i>g</i> for 40 min to precipitate the protein. An aliquot of 100 μL of the supernatant was diluted using 100 μL ultrapure water, and the mixture was used for LC/MS/MS analysis. The formation of metabolites was analyzed using LC/MS/MS. A decrease in the formation of the metabolites in the peak area to vehicle control was used to calculate the IC<sub>50</sub> value (test compound concentration that produces 50% inhibition) using Excel Xlfit.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>In Vivo</i> Pharmacokinetic Studies</h3><div class="NLM_p">The pharmacokinetic profiles of <b>6a</b>, <b>11b</b>, <b>14g</b>, <b>14k</b>–<b>l</b>, and <b>14p</b> were assessed by Pharmaron (Louisville, Kentucky), and all animal studies were performed in accordance with institutional guidelines as defined by the Institutional Animal Care and Use Committee. Test compounds were dissolved first in DMSO and then mixed with 47.5% PEG-400 and 47.5% deionized water with 10% Tween80. The solutions were thoroughly vortexed after each step and stored at room temperature. Solutions were freshly prepared on the day of dosing. Female CB17 SCID mice (<i>n</i> = 3) (6–8 weeks old, 17–20 g weight) were orally administered a 10 mg/kg dose (10 mL/kg dose volume, 1 mg/mL concentration) of the test compound. Blood samples were taken <i>via</i> the dorsal metatarsal vein at 0.25, 0.5, 1, 2, 4, 8, and 24 h postdosage. Blood samples were transferred into plastic microcentrifuge tubes containing the anticoagulant Heparin-Na and centrifuged at 4000<i>g</i> for 5 min at 4 °C to obtain plasma. The samples were stored in a freezer at −75 ± 15 °C prior to analysis.</div><div class="NLM_p">To determine brain concentrations, female CB17 SCID mice (<i>n</i> = 3) (6–8 weeks old, 17–20 g weight) were orally administered a 100 mg/kg dose (10 mL/kg dose volume, 10 mg/mL concentration) of the test compound. At 4 h postdose, the animals were terminally anesthetized by an increasing concentration of CO<sub>2</sub>. Their chest cavities were opened to expose the heart, and an incision at the right auricle using surgical scissors was done. A syringe full of gentle saline was pushed into the heart slowly <i>via</i> the left ventricle (saline volume ∼10 mL). The animal was placed head down at a 45° angle to facilitate blood removal. Brain samples were collected and kept frozen at −75 ± 15 °C. All brain samples were weighed and homogenized with phosphate-buffered saline by a brain weight (g)-to-buffer volume (mL) ratio of 1:3 before analysis. The actual concentrations were the detected value multiplied using the dilution factor.</div><div class="NLM_p last">Concentrations of the test compound in the plasma samples were analyzed using an LC/MS/MS method. WinNonlin (Phoenix, version 8.0) or other similar software was used for pharmacokinetic calculations. The following pharmacokinetic parameters were calculated, whenever possible, from the plasma concentration <i>versus</i> time data following PO administration: <i>t</i><sub>1/2</sub>, <i>C</i><sub>max</sub>, <i>T</i><sub>max</sub>, AUC<sub>last</sub>, AUC<sub>inf</sub>, and <i>F</i>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Cocrystallization of ALK2 with M4K2009</h3><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Protein Expression and Purification</h4><div class="NLM_p last">Constructs were prepared by ligation-independent cloning. The kinase domain of ALK2 (residues 201–499; Uniprot ID, <a href="https://Q04771" class="ext-link">Q04771</a>) was cloned into pFB-LIC-Bse for the baculoviral expression. The construct was verified by sequencing. ALK2 was expressed in Sf9 insect cells grown at 27 °C. Some 72 h postinfection, cells were harvested and lysed using ultrasonication. ALK2 was initially purified by nickel affinity chromatography before subsequent purification by size exclusion chromatography (Superdex 200 16/600). The eluted protein was stored in 50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM DTT. The hexahistidine tag of ALK2 was cleaved using tobacco etch virus protease after initial nickel purification.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Crystallization</h4><div class="NLM_p last">Crystallization was achieved at 4 °C using the sitting-drop vapor diffusion method. ALK2 was preincubated with 1 mM <b>M4K2009</b> at a protein concentration of 11 mg/mL and crystallized using a precipitant containing 0.1 M citrate pH 4.9, 1 M ammonium sulfate, and 0.2 M sodium/potassium tartrate. Viable crystals were obtained when the protein solution was mixed with the reservoir solution at a 2:1 volume ratio. Crystals were cryoprotected with mother liquor plus 25% ethylene glycol prior to vitrification in liquid nitrogen.</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Data Collection</h4><div class="NLM_p last">Diffraction data were collected at the Diamond Light Source, station I03 using monochromatic radiation at a wavelength of 0.9686 Å.</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Phasing, Model Building, Refinement, and Validation</h4><div class="NLM_p last">Data were processed with Xia2 and subsequently scaled using the program AIMLESS from the CCP4 suite.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> Initial phases were obtained by molecular replacement using the program PHASER and the structure of ALK2 (Protein Data Bank code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM">6SZM</a>) as a search model.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The resulting structure solution was refined using Phenix Refine and manually rebuilt with COOT.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> The complete structure was verified for geometric correctness with MolProbity.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Data collection and refinement statistics can be found in the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">Table S3</a>. Cocrystal images in the article were processed using Molsoft MolBrowser 3.8, and the 2D ligand interaction plot was generated using Maestro (Schrödinger Release 2019-4, Schrödinger, LLC, New York).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01199" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01199?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01199</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Kinase selectivity panel, safety screen panel, ALK2·<b>M4K2009</b> cocrystal data collection and refinement statistics, <sup>1</sup>H spectra and HPLC traces of select compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf">jm0c01199_si_001.pdf (585.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_002.csv">jm0c01199_si_002.csv (1.85 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PBD ID codes: ALK2·<b>M4K2009</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM">6SZM</a>; ALK2·<b>LDN-213844</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01199" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Smil</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6232-6087" title="Orcid link">http://orcid.org/0000-0002-6232-6087</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#83e7e2f5eae7adf0eeeaefc3eceae0f1adecedade0e2"><span class="__cf_email__" data-cfemail="553134233c317b26383c39153a3c36277b3a3b7b3634">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Methvin B. Isaac</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d6bbb3a2bea0bfb8f8bfa5b7b7b596b9bfb5a4f8b9b8f8b5b7"><span class="__cf_email__" data-cfemail="0b666e7f637d62652562786a6a684b6462687925646525686a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jong Fu Wong</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eleanor P. Williams</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roslin J. Adamson</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alison Howarth</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. McLeod</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmed Mamai</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soyoung Kim</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian J. Wilson</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taira Kiyota</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmed Aman</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Leslie
Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Owen</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gennady Poda</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Leslie
Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kurumi Y. Horiuchi</span> - <span class="hlFld-Affiliation affiliation">Reaction
Biology Corp., Suite
2, 1 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ekaterina Kuznetsova</span> - <span class="hlFld-Affiliation affiliation">Reaction
Biology Corp., Suite
2, 1 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiching Ma</span> - <span class="hlFld-Affiliation affiliation">Reaction
Biology Corp., Suite
2, 1 Great Valley Parkway, Malvern, Pennsylvania 19355, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Nicole Hamblin</span> - <span class="hlFld-Affiliation affiliation">Charles
River Discovery, Chesterford
Research Park, Saffron Waldon, Essex CB10 1XL, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sue Cramp</span> - <span class="hlFld-Affiliation affiliation">Charles
River Discovery, 8-9
Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Owen G. Roberts</span> - <span class="hlFld-Affiliation affiliation">M4K
Pharma, 101 College Street,
MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aled M. Edwards</span> - <span class="hlFld-Affiliation affiliation">M4K
Pharma, 101 College Street,
MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Toronto, 101 College Street, MaRS Centre,
South Tower, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4782-6016" title="Orcid link">http://orcid.org/0000-0002-4782-6016</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Uehling</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rima Al-awar</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Toxicology, University
of Toronto, Medical Sciences
Building, Room 4207, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4185-055X" title="Orcid link">http://orcid.org/0000-0002-4185-055X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alex N. Bullock</span> - <span class="hlFld-Affiliation affiliation">Structural
Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6757-0436" title="Orcid link">http://orcid.org/0000-0001-6757-0436</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff A. O’Meara</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">M4K
Pharma, 101 College Street,
MaRS Centre, South Tower, Toronto, Ontario M5G 1L7, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Compounds were designed and their syntheses were devised by D.S., D.A.M., and B.J.W. Compounds were synthesized by D.S., D.A.M., and S.K. In vitro kinase screening data was generated by K.Y.H., E.K., and H.M. NanoBRET and DLA data were generated by J.F.W. and A.H. Crystallography experiments were performed by E.P.W. and R.J.A. Caco-2, microsomal stability, and PPB studies were conducted by T.K. HRMS data were generated by T.K. J.O. created the cocrystal structure graphics. G.P. generated the Oracle database where compound data were stored. A.M., A.A., J.N.H, S.C., D.U., R.A.-a., A.N.B., J.A.O., and M.B.I. were involved in experimental design, interpretation of data, and monitored project progress. O.G.R. and A.M.E. initiated the project, monitored project progress, and edited the paper. The manuscript was written by D.S. and revised by A.M.E., R.A.-a., A.N.B., and M.B.I.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">The authors will release the atomic coordinates and experimental data upon article publication.</p></div></li></ul></div><div class="ack" id="ACK-d7e6135-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M4K Pharma Inc., functioning as a virtual biotech, serves as a <i>de facto</i> hub for gathering and aligning the cooperation and contributions of academic and industry partners into a drug development program that operates free of restrictions on data disclosure (<i>i.e</i>., no patents are filed). Work was performed by nonprofit organizations, the Ontario Institute for Cancer Research (OICR), and the Structural Genomics Consortium (SGC), with additional biological evaluation of compounds made possible through the in-kind contributions of collaborators at Reaction Biology Corporation and Charles River Laboratories. This work was funded by the Cancer Therapeutics Innovation Pipeline program at the OICR, which receives financial support from the Government of Ontario through the Ministry of Training, Colleges, and Universities. Funding from The Brain Tumour Charity was used to support the cellular and crystallographic research conducted at the University of Oxford. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through the Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z]. The authors thank the Reaction Biology Corporation kinase assay group for their <i>pro bono</i> contribution to the <i>in vitro</i> kinase screening and Charles River Laboratories Cleveland for all hERG activity screening. The authors also thank Mehakpreet Saini for contributing to the writing and editing of ADME protocols.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ALK2</td><td class="NLM_def"><p class="first last">activin receptor-like kinase-2</p></td></tr><tr><td class="NLM_term">BMP</td><td class="NLM_def"><p class="first last">bone morphogenetic protein</p></td></tr><tr><td class="NLM_term"><i>B</i>/<i>P</i></td><td class="NLM_def"><p class="first last">total brain-to-plasma ratio</p></td></tr><tr><td class="NLM_term">BRET</td><td class="NLM_def"><p class="first last">bioluminescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">BTB</td><td class="NLM_def"><p class="first last">brain tissue binding</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">DIPG</td><td class="NLM_def"><p class="first last">diffuse intrinsic pontine glioma</p></td></tr><tr><td class="NLM_term">DLA</td><td class="NLM_def"><p class="first last">dual luciferase assay</p></td></tr><tr><td class="NLM_term">EDG</td><td class="NLM_def"><p class="first last">electron donating group</p></td></tr><tr><td class="NLM_term">EWG</td><td class="NLM_def"><p class="first last">electron withdrawing group</p></td></tr><tr><td class="NLM_term">FOP</td><td class="NLM_def"><p class="first last">fibrodysplasia ossificans progressiva</p></td></tr><tr><td class="NLM_term">GS</td><td class="NLM_def"><p class="first last">glycine–serine</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">TGFβ</td><td class="NLM_def"><p class="first last">transforming growth factor β</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 69 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allemani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M. P.</span></span> <span> </span><span class="NLM_article-title">Worldwide trends in survival from common childhood brain tumors: a systematic review</span>. <i>J. Global Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1200/JGO.19.00140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1200%2FJGO.19.00140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3MjkslChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=1-25&author=F.+Girardiauthor=C.+Allemaniauthor=M.+P.+Coleman&title=Worldwide+trends+in+survival+from+common+childhood+brain+tumors%3A+a+systematic+review&doi=10.1200%2FJGO.19.00140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review</span></div><div class="casAuthors">Girardi Fabio; Allemani Claudia; Coleman Michel P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of global oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The histology of brain tumors determines treatment and predicts outcome.  Population-based survival reflects the effectiveness of a health care system in managing cancer.  No systematic review of worldwide variation and time trends in survival from brain tumors in children is currently available.  PATIENTS AND METHODS:  We considered longitudinal, observational studies comprising children diagnosed with intracranial astrocytic or embryonal tumors.  We searched six electronic databases from database inception to September 30, 2018, using complex search strategies.  The outcome measure was 5-year survival, estimated through a time-to-event analysis.  This study is registered with PROSPERO, number CRD42018111981.  RESULTS:  Among 5,244 studies, we identified 47 eligible articles that provided 228 survival estimates.  Only five studies were entirely or partially conducted in low-income or middle-income countries.  Five-year survival from embryonal tumors increased from 37% in 1980 to approximately 60% in 2009.  Although survival for medulloblastoma improved substantially (from 29% to 73% during 1959-2009), survival for primitive neuroectodermal tumors wavered over time (1973-2009) and between countries.  Five-year survival from astrocytoma changed very little over the 27 years between 1982 and 2009 (from 78% to 89%).  Interpretation of the literature was made difficult by the heterogeneity of study designs.  CONCLUSION:  Survival has improved for embryonal tumors, but little change has been observed for astrocytic tumors.  We found a striking gap in knowledge about survival from childhood brain tumor subtypes in middle-income and low-income countries, where half of these tumors are diagnosed.  Larger studies are needed, including in under-represented countries and based on standardized data collection, to provide up-to-date survival estimates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS06p2BKJnqagWRJ3OJdH_qfW6udTcc2eZAsXQS09ywhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjkslChtw%253D%253D&md5=d66faeb7beecf7c31894d49ff552b677</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJGO.19.00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJGO.19.00140%26sid%3Dliteratum%253Aachs%26aulast%3DGirardi%26aufirst%3DF.%26aulast%3DAllemani%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DM.%2BP.%26atitle%3DWorldwide%2520trends%2520in%2520survival%2520from%2520common%2520childhood%2520brain%2520tumors%253A%2520a%2520systematic%2520review%26jtitle%3DJ.%2520Global%2520Oncol.%26date%3D2019%26volume%3D5%26spage%3D1%26epage%3D25%26doi%3D10.1200%2FJGO.19.00140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacifici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.cytogfr.2015.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26776312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=93-104&author=M.+Pacificiauthor=E.+M.+Shore&title=Common+mutations+in+ALK2%2FACVR1%2C+a+multi-faceted+receptor%2C+have+roles+in+distinct+pediatric+musculoskeletal+and+neural+orphan+disorders&doi=10.1016%2Fj.cytogfr.2015.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span></div><div class="casAuthors">Pacifici, Maurizio; Shore, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-104</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activin receptor-like kinase-2 (ALK2), the product of ACVR1, is a member of the type I bone morphogenetic protein (BMP) receptor family.  ALK2 exerts key and non-redundant roles in numerous developmental processes, including the specification, growth and morphogenesis of endochondral skeletal elements.  There is also strong evidence that BMP signaling plays important roles in detn., differentiation and function of neural cells and tissues.  Here we focus on the intriguing discovery that common activating mutations in ALK2 occur in Fibrodysplasia Ossificans Progressiva (FOP) and Diffuse Intrinsic Pontine Gliomas (DIPGs), distinct pediatric disorders of significant severity that are assocd. with premature death.  Pathogenesis and treatment remain elusive for both.  We consider recent studies on the nature of the ACVR1 mutations, possible modes of action and targets, and plausible therapeutic measures.  Comparisons of the diverse - but genetically interrelated - pathologies of FOP and DIPG will continue to be of major mutual benefit with broad biomedical and clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwM08RQn6m7LVg90H21EOLACvtfcHk0liHrht9TBQvTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D&md5=1b6f732518596d155f46178c2743d841</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DPacifici%26aufirst%3DM.%26aulast%3DShore%26aufirst%3DE.%2BM.%26atitle%3DCommon%2520mutations%2520in%2520ALK2%252FACVR1%252C%2520a%2520multi-faceted%2520receptor%252C%2520have%2520roles%2520in%2520distinct%2520pediatric%2520musculoskeletal%2520and%2520neural%2520orphan%2520disorders%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2016%26volume%3D27%26spage%3D93%26epage%3D104%26doi%3D10.1016%2Fj.cytogfr.2015.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truffaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span> <span> </span><span class="NLM_article-title">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1038/ng.2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fng.2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=24705252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=457-461&author=K.+R.+Taylorauthor=A.+Mackayauthor=N.+Truffauxauthor=Y.+S.+Butterfieldauthor=O.+Morozovaauthor=C.+Philippeauthor=D.+Castelauthor=C.+S.+Grassoauthor=M.+Vinciauthor=D.+Carvalhoauthor=A.+M.+Carcabosoauthor=C.+de+Torresauthor=O.+Cruzauthor=J.+Moraauthor=N.+Entz-Werleauthor=W.+J.+Ingramauthor=M.+Monjeauthor=D.+Hargraveauthor=A.+N.+Bullockauthor=S.+Pugetauthor=S.+Yipauthor=C.+Jonesauthor=J.+Grill&title=Recurrent+activating+ACVR1+mutations+in+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fng.2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Taylor, Kathryn R.; Mackay, Alan; Truffaux, Nathalene; Butterfield, Yaron S.; Morozova, Olena; Philippe, Cathy; Castel, David; Grasso, Catherine S.; Vinci, Maria; Carvalho, Diana; Carcaboso, Angel M.; de Torres, Carmen; Cruz, Ofelia; Mora, Jaume; Entz-Werle, Natacha; Ingram, Wendy J.; Monje, Michelle; Hargrave, Darren; Bullock, Alex N.; Puget, Stephanie; Yip, Stephen; Jones, Chris; Grill, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-461</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clin. outcome.  The median survival time is 9-12 mo, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clin. trials in children with these tumors.  We report the identification of recurrent activating mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG samples.  Strikingly, these somatic mutations (encoding p.Arg206His, p.Arg258Gly, p.Gly328Glu, p.Gly328Val, p.Gly328Trp and p.Gly356Asp substitutions) have not been reported previously in cancer but are identical to mutations found in the germ line of individuals with the congenital childhood developmental disorder fibrodysplasia ossificans progressiva (FOP) and have been shown to constitutively activate the BMP-TGF-β signaling pathway.  These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMRfkuGtWYWLVg90H21EOLACvtfcHk0ljY16KfaPtkMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D&md5=69fb86fc99975a0f0dbaa060141788a4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fng.2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2925%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DTruffaux%26aufirst%3DN.%26aulast%3DButterfield%26aufirst%3DY.%2BS.%26aulast%3DMorozova%26aufirst%3DO.%26aulast%3DPhilippe%26aufirst%3DC.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DGrasso%26aufirst%3DC.%2BS.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3Dde%2BTorres%26aufirst%3DC.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DEntz-Werle%26aufirst%3DN.%26aulast%3DIngram%26aufirst%3DW.%2BJ.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DGrill%26aufirst%3DJ.%26atitle%3DRecurrent%2520activating%2520ACVR1%2520mutations%2520in%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D457%26epage%3D461%26doi%3D10.1038%2Fng.2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutka, J. T.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: clinical features, molecular genetics, and novel targeted therapeutics</span>. <i>J. Korean Neurosurg. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.3340/jkns.2018.0008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.3340%2Fjkns.2018.0008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=29742880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=343-351&author=R.+K.+Mathewauthor=J.+T.+Rutka&title=Diffuse+intrinsic+pontine+glioma%3A+clinical+features%2C+molecular+genetics%2C+and+novel+targeted+therapeutics&doi=10.3340%2Fjkns.2018.0008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma : clinical features, molecular genetics, and novel targeted therapeutics</span></div><div class="casAuthors">Mathew, Ryan K.; Rutka, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Neurosurgical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-351</span>CODEN:
                <span class="NLM_cas:coden">JKNSAI</span>;
        ISSN:<span class="NLM_cas:issn">1598-7876</span>.
    
            (<span class="NLM_cas:orgname">Korean Neurosurgical Society</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a deadly paediatric brain cancer.  Transient response to radiation, ineffective chemotherapeutic agents and aggressive biol. result in rapid progression of symptoms and a dismal prognosis.  Increased availability of tumor tissue has enabled the identification of histone gene aberrations, genetic driver mutations and methylation changes, which have resulted in mol. and phenotypic subgrouping.  However, many of the underlying mechanisms of DIPG oncogenesis remain unexplained.  It is hoped that more representative in vitro and preclin. models-using both xenografted material and genetically engineered mice-will enable the development of novel chemotherapeutic agents and strategies for targeted drug delivery.  This review provides a clin. overview of DIPG, the barriers to progress in developing effective treatment, updates on drug development and preclin. models, and an introduction to new technologies aimed at enhancing drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohREcp3C8kCLVg90H21EOLACvtfcHk0ljY16KfaPtkMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ&md5=0f37c4371f752f813af3014085c0dca3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3340%2Fjkns.2018.0008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3340%252Fjkns.2018.0008%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DR.%2BK.%26aulast%3DRutka%26aufirst%3DJ.%2BT.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520clinical%2520features%252C%2520molecular%2520genetics%252C%2520and%2520novel%2520targeted%2520therapeutics%26jtitle%3DJ.%2520Korean%2520Neurosurg.%2520Soc.%26date%3D2018%26volume%3D61%26spage%3D343%26epage%3D351%26doi%3D10.3340%2Fjkns.2018.0008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldhuijzen van Zanten, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colditz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartels, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouffet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minturn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chintagumpala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carret, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escorza, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dholaria, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doughman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drissi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddaert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varlet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulleman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giagnacovo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bueren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanki, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadrijevic Cvrlje, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandertop, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biassoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massimino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calmon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth-Metz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vuurden, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramm, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouladi, M.</span></span> <span> </span><span class="NLM_article-title">Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and european society for pediatric oncology DIPG registries</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1972</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.75.9308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1200%2FJCO.2017.75.9308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=29746225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1963-1972&author=L.+M.+Hoffmanauthor=S.+E.+M.+Veldhuijzen+van+Zantenauthor=N.+Colditzauthor=J.+Baughauthor=B.+Chaneyauthor=M.+Hoffmannauthor=A.+Laneauthor=C.+Fullerauthor=L.+Milesauthor=C.+Hawkinsauthor=U.+Bartelsauthor=E.+Bouffetauthor=S.+Goldmanauthor=S.+Learyauthor=N.+K.+Foremanauthor=R.+Packerauthor=K.+E.+Warrenauthor=A.+Broniscerauthor=M.+W.+Kieranauthor=J.+Minturnauthor=M.+Comitoauthor=E.+Broxsonauthor=C.+S.+Shihauthor=S.+Khatuaauthor=M.+Chintagumpalaauthor=A.+S.+Carretauthor=N.+Y.+Escorzaauthor=T.+Hassallauthor=D.+S.+Zieglerauthor=N.+Gottardoauthor=H.+Dholariaauthor=R.+Doughmanauthor=M.+Beneschauthor=R.+Drissiauthor=J.+Nazarianauthor=N.+Jabadoauthor=N.+Boddaertauthor=P.+Varletauthor=G.+Giraudauthor=D.+Castelauthor=S.+Pugetauthor=C.+Jonesauthor=E.+Hullemanauthor=P.+Modenaauthor=M.+Giagnacovoauthor=M.+Antonelliauthor=T.+Pietschauthor=G.+H.+Gielenauthor=D.+T.+W.+Jonesauthor=D.+Sturmauthor=S.+M.+Pfisterauthor=N.+U.+Gerberauthor=M.+A.+Grotzerauthor=E.+Pfaffauthor=A.+O.+von+Buerenauthor=D.+Hargraveauthor=G.+A.+Solankiauthor=F.+Jadrijevic+Cvrljeauthor=G.+J.+L.+Kaspersauthor=W.+P.+Vandertopauthor=J.+Grillauthor=S.+Baileyauthor=V.+Biassoniauthor=M.+Massiminoauthor=R.+Calmonauthor=E.+Sanchezauthor=B.+Bisonauthor=M.+Warmuth-Metzauthor=J.+Leachauthor=B.+Jonesauthor=D.+G.+van+Vuurdenauthor=C.+M.+Krammauthor=M.+Fouladi&title=Clinical%2C+radiologic%2C+pathologic%2C+and+molecular+characteristics+of+long-term+survivors+of+diffuse+intrinsic+pontine+glioma+%28DIPG%29%3A+a+collaborative+report+from+the+international+and+european+society+for+pediatric+oncology+DIPG+registries&doi=10.1200%2FJCO.2017.75.9308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of Diffuse Intrinsic Pontine Glioma (DIPG): a collaborative report from the international and european society for pediatric oncology DIPG registries</span></div><div class="casAuthors">Hoffman, Lindsey M.; Veldhuijzen van Zanten, Sophie E. M.; Colditz, Niclas; Baugh, Joshua; Chaney, Brooklyn; Hoffmann, Marion; Lane, Adam; Fuller, Christine; Miles, Lili; Hawkins, Cynthia; Bartels, Ute; Bouffet, Eric; Goldman, Stewart; Leary, Sarah; Foreman, Nicholas K.; Packer, Roger; Warren, Katherine E.; Broniscer, Alberto; Kieran, Mark W.; Minturn, Jane; Comito, Melanie; Broxson, Emmett; Shih, Chie-Schin; Khatua, Soumen; Chintagumpala, Murali; Carret, Anne Sophie; Escorza, Nancy Yanez; Hassall, Timothy; Ziegler, David S.; Gottardo, Nicholas; Dholaria, Hetal; Doughman, Renee; Benesch, Martin; Drissi, Rachid; Nazarian, Javad; Jabado, Nada; Boddaert, Nathalie; Varlet, Pascale; Giraud, Geraldine; Castel, David; Puget, Stephanie; Jones, Chris; Hulleman, Esther; Modena, Piergiorgio; Giagnacovo, Marzia; Antonelli, Manila; Pietsch, Torsten; Gielen, Gerrit H.; Jones, David T. W.; Sturm, Dominik; Pfister, Stefan M.; Gerber, Nicolas U.; Grotzer, Michael A.; Pfaff, Elke; von Bueren, Andre O.; Hargrave, Darren; Solanki, Guirish A.; Cvrlje, Filip Jadrijevic; Kaspers, Gertjan J. L.; Vandertop, William P.; Grill, Jacques; Bailey, Simon; Biassoni, Veronica; Massimino, Maura; Calmon, Raphael; Sanchez, Esther; Bison, Brigitte; Warmuth-Metz, Monika; Leach, James; Jones, Blaise; van Vuurden, Dannis G.; Kramm, Christof M.; Fouladi, Maryam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1963-1978</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of > 1 yr.  The International and European Society for Pediatric Oncol. DIPG Registries collaborated to compare clin., radiol., and histomol. characteristics between short-term survivors (STSs) and long-term survivors (LTSs).  Materials and Methods Data abstracted from registry databases included patients from North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia.  Results Among 1,130 pediatric and young adults with radiog. confirmed DIPG, 122 (11%) were excluded.  Of the 1,008 remaining patients, 101 (10%) were LTSs (survival ≥ 2 years).  Median survival time was 11 mo (interquartile range, 7.5 to 16 mo), and 1-, 2-, 3-, 4-, and 5-yr survival rates were 42.3%(95%CI, 38.1%to 44.1%), 9.6%(95% CI, 7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI, 2.4%to 4.6%), and 2.2% (95%CI, 1.4%to 3.4%), resp.  LTSs, compared with STSs, more commonly presented at age < 3 or ≥ 10 years (11% v 3% and 33% v 23%, resp.; P < .001) and with longer symptom duration (P < .001).  STSs, compared with LTSs, more commonly presented with cranial nerve palsy (83% v 73%, resp.; P = .008), ring enhancement (38% v23%, resp.; P = .007), necrosis (42% v 26%, resp.; P = .009), and extrapontine extension (92% v 86%, resp.; P = .04).  LTSs more commonly received systemic therapy at diagnosis (88% v 75% for STSs; P = .005).  Biopsies and autopsies were performed in 299 patients (30%) and 77 patients (10%), resp.; 181 tumors (48%) were molecularly characterized.  LTSs were more likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002).  Conclusion We report clin., radiol., and mol. factors that correlate with survival in children and young adults with DIPG, which are important for risk stratification in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkAtaHt1q_Q7Vg90H21EOLACvtfcHk0lhX4lnKe-ZNjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyltLg%253D&md5=9744cca319e4a00924584c69586826ac</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.75.9308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.75.9308%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DL.%2BM.%26aulast%3DVeldhuijzen%2Bvan%2BZanten%26aufirst%3DS.%2BE.%2BM.%26aulast%3DColditz%26aufirst%3DN.%26aulast%3DBaugh%26aufirst%3DJ.%26aulast%3DChaney%26aufirst%3DB.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DA.%26aulast%3DFuller%26aufirst%3DC.%26aulast%3DMiles%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DBartels%26aufirst%3DU.%26aulast%3DBouffet%26aufirst%3DE.%26aulast%3DGoldman%26aufirst%3DS.%26aulast%3DLeary%26aufirst%3DS.%26aulast%3DForeman%26aufirst%3DN.%2BK.%26aulast%3DPacker%26aufirst%3DR.%26aulast%3DWarren%26aufirst%3DK.%2BE.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DMinturn%26aufirst%3DJ.%26aulast%3DComito%26aufirst%3DM.%26aulast%3DBroxson%26aufirst%3DE.%26aulast%3DShih%26aufirst%3DC.%2BS.%26aulast%3DKhatua%26aufirst%3DS.%26aulast%3DChintagumpala%26aufirst%3DM.%26aulast%3DCarret%26aufirst%3DA.%2BS.%26aulast%3DEscorza%26aufirst%3DN.%2BY.%26aulast%3DHassall%26aufirst%3DT.%26aulast%3DZiegler%26aufirst%3DD.%2BS.%26aulast%3DGottardo%26aufirst%3DN.%26aulast%3DDholaria%26aufirst%3DH.%26aulast%3DDoughman%26aufirst%3DR.%26aulast%3DBenesch%26aufirst%3DM.%26aulast%3DDrissi%26aufirst%3DR.%26aulast%3DNazarian%26aufirst%3DJ.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DBoddaert%26aufirst%3DN.%26aulast%3DVarlet%26aufirst%3DP.%26aulast%3DGiraud%26aufirst%3DG.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DHulleman%26aufirst%3DE.%26aulast%3DModena%26aufirst%3DP.%26aulast%3DGiagnacovo%26aufirst%3DM.%26aulast%3DAntonelli%26aufirst%3DM.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DGielen%26aufirst%3DG.%2BH.%26aulast%3DJones%26aufirst%3DD.%2BT.%2BW.%26aulast%3DSturm%26aufirst%3DD.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DGerber%26aufirst%3DN.%2BU.%26aulast%3DGrotzer%26aufirst%3DM.%2BA.%26aulast%3DPfaff%26aufirst%3DE.%26aulast%3Dvon%2BBueren%26aufirst%3DA.%2BO.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DSolanki%26aufirst%3DG.%2BA.%26aulast%3DJadrijevic%2BCvrlje%26aufirst%3DF.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DVandertop%26aufirst%3DW.%2BP.%26aulast%3DGrill%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBiassoni%26aufirst%3DV.%26aulast%3DMassimino%26aufirst%3DM.%26aulast%3DCalmon%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DBison%26aufirst%3DB.%26aulast%3DWarmuth-Metz%26aufirst%3DM.%26aulast%3DLeach%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DB.%26aulast%3Dvan%2BVuurden%26aufirst%3DD.%2BG.%26aulast%3DKramm%26aufirst%3DC.%2BM.%26aulast%3DFouladi%26aufirst%3DM.%26atitle%3DClinical%252C%2520radiologic%252C%2520pathologic%252C%2520and%2520molecular%2520characteristics%2520of%2520long-term%2520survivors%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520%2528DIPG%2529%253A%2520a%2520collaborative%2520report%2520from%2520the%2520international%2520and%2520european%2520society%2520for%2520pediatric%2520oncology%2520DIPG%2520registries%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1963%26epage%3D1972%26doi%3D10.1200%2FJCO.2017.75.9308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: poised for progress</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fonc.2012.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.3389%2Ffonc.2012.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=23293772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=205&author=K.+E.+Warren&title=Diffuse+intrinsic+pontine+glioma%3A+poised+for+progress&doi=10.3389%2Ffonc.2012.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma: poised for progress</span></div><div class="casAuthors">Warren Katherine E</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are amongst the most challenging tumors to treat.  Surgery is not an option, the effects of radiation therapy are temporary, and no chemotherapeutic agent has demonstrated significant efficacy.  Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, yet without success.  The diagnosis of DIPG is based on radiographic findings in the setting of a typical clinical presentation, and tissue is not routinely obtained as the standard of care.  The paradigm for treating children with these tumors has been based on that for supratentorial high-grade gliomas in adults as the biology of these lesions were presumed to be similar.  However, recent pivotal studies demonstrate that DIPGs appear to be their own entity.  Simply identifying this fact releases a number of constraints and opens opportunities for biologic investigation of these lesions, setting the stage to move forward in identifying DIPG-specific treatments.  This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREW6_X20GCz7YtC3U5jeOifW6udTcc2ebxRsmQw0Sx2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D&md5=d51f614b4d5e8bfa9b7bb755cdf736e6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2012.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2012.00205%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DK.%2BE.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520poised%2520for%2520progress%26jtitle%3DFront.%2520Oncol.%26date%3D2012%26volume%3D2%26spage%3D205%26doi%3D10.3389%2Ffonc.2012.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandeville, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Albiac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Beek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benghiat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeben, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales La Madrid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortmann, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biassoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bueren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vuurden, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massimino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramm, C. M.</span></span> <span> </span><span class="NLM_article-title">Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.ejca.2016.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28161497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jtFertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=38-47&author=G.+O.+Janssensauthor=L.+Gandolaauthor=S.+Bolleauthor=H.+Mandevilleauthor=M.+Ramos-Albiacauthor=K.+van+Beekauthor=H.+Benghiatauthor=B.+Hoebenauthor=A.+Morales+La+Madridauthor=R.+D.+Kortmannauthor=D.+Hargraveauthor=J.+Mentenauthor=E.+Pecoriauthor=V.+Biassoniauthor=A.+O.+von+Buerenauthor=D.+G.+van+Vuurdenauthor=M.+Massiminoauthor=D.+Sturmauthor=M.+Petersauthor=C.+M.+Kramm&title=Survival+benefit+for+patients+with+diffuse+intrinsic+pontine+glioma+%28DIPG%29+undergoing+re-irradiation+at+first+progression%3A+a+matched-cohort+analysis+on+behalf+of+the+SIOP-E-HGG%2FDIPG+working+group&doi=10.1016%2Fj.ejca.2016.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group</span></div><div class="casAuthors">Janssens Geert O; Gandola Lorenza; Pecori Emilia; Bolle Stephanie; Mandeville Henry; Ramos-Albiac Monica; van Beek Karen; Menten Johan; Benghiat Helen; Hoeben Bianca; Morales La Madrid Andres; Kortmann Rolf-Dieter; Hargrave Darren; Biassoni Veronica; Massimino Maura; von Bueren Andre O; van Vuurden Dannis G; Sturm Dominik; Peters Max; Kramm Christof M</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer (Oxford, England : 1990)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor.  The purpose of this study is to analyse benefit and toxicity of re-irradiation at first progression.  METHODS:  At first progression, 31 children with DIPG, aged 2-16 years, underwent re-irradiation (dose 19.8-30.0 Gy) alone (n = 16) or combined with systemic therapy (n = 15).  At initial presentation, all patients had typical symptoms and characteristic MRI features of DIPG, or biopsy-proven high-grade glioma.  An interval of ≥3 months after upfront radiotherapy was required before re-irradiation.  Thirty-nine patients fulfilling the same criteria receiving radiotherapy at diagnosis, followed by best supportive care (n = 20) or systemic therapy (n = 19) at progression but no re-irradiation, were eligible for a matched-cohort analysis.  RESULTS:  Median OS for patients undergoing re-irradiation was 13.7 months.  For a similar median progression-free survival after upfront radiotherapy (8.2 versus 7.7 months; P = .58), a significant benefit in median OS (13.7 versus 10.3 months; P = .04) was observed in favour of patients undergoing re-irradiation.  Survival benefit of re-irradiation increased with a longer interval between end-of-radiotherapy and first progression (3-6 months: 4.0 versus 2.7; P < .01; 6-12 months: 6.4 versus 3.3; P = .04).  Clinical improvement with re-irradiation was observed in 24/31 (77%) patients.  No grade 4-5 toxicity was recorded.  On multivariable analysis, interval to progression (corrected hazard ratio = .27-.54; P < .01) and re-irradiation (corrected hazard ratio = .18-.22; P < .01) remained prognostic for survival.  A risk score (RS), comprising 5 categories, was developed to predict survival from first progression (ROC: .79).  Median survival ranges from 1.0 month (RS-1) to 6.7 months (RS-5).  CONCLUSIONS:  The majority of patients with DIPG, responding to upfront radiotherapy, do benefit of re-irradiation with acceptable tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZk0zDEn-1Uf69nzq6467DfW6udTcc2ebxRsmQw0Sx2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jtFertA%253D%253D&md5=4ef043a14eda06a11b8a27c874f6f01b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DG.%2BO.%26aulast%3DGandola%26aufirst%3DL.%26aulast%3DBolle%26aufirst%3DS.%26aulast%3DMandeville%26aufirst%3DH.%26aulast%3DRamos-Albiac%26aufirst%3DM.%26aulast%3Dvan%2BBeek%26aufirst%3DK.%26aulast%3DBenghiat%26aufirst%3DH.%26aulast%3DHoeben%26aufirst%3DB.%26aulast%3DMorales%2BLa%2BMadrid%26aufirst%3DA.%26aulast%3DKortmann%26aufirst%3DR.%2BD.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DMenten%26aufirst%3DJ.%26aulast%3DPecori%26aufirst%3DE.%26aulast%3DBiassoni%26aufirst%3DV.%26aulast%3Dvon%2BBueren%26aufirst%3DA.%2BO.%26aulast%3Dvan%2BVuurden%26aufirst%3DD.%2BG.%26aulast%3DMassimino%26aufirst%3DM.%26aulast%3DSturm%26aufirst%3DD.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DKramm%26aufirst%3DC.%2BM.%26atitle%3DSurvival%2520benefit%2520for%2520patients%2520with%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520%2528DIPG%2529%2520undergoing%2520re-irradiation%2520at%2520first%2520progression%253A%2520a%2520matched-cohort%2520analysis%2520on%2520behalf%2520of%2520the%2520SIOP-E-HGG%252FDIPG%2520working%2520group%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D73%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.ejca.2016.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lg7IYMyLTRcdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heideman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavey, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouffet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, I. F.</span></span> <span> </span><span class="NLM_article-title">Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1093/neuonc/noq205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1093%2Fneuonc%2Fnoq205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21345842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ovF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=410-416&author=K.+J.+Cohenauthor=R.+L.+Heidemanauthor=T.+Zhouauthor=E.+J.+Holmesauthor=R.+S.+Laveyauthor=E.+Bouffetauthor=I.+F.+Pollack&title=Temozolomide+in+the+treatment+of+children+with+newly+diagnosed+diffuse+intrinsic+pontine+gliomas%3A+a+report+from+the+Children%E2%80%99s+Oncology+Group&doi=10.1093%2Fneuonc%2Fnoq205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group</span></div><div class="casAuthors">Cohen Kenneth J; Heideman Richard L; Zhou Tianni; Holmes Emiko J; Lavey Robert S; Bouffet Eric; Pollack Ian F</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">410-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group.  During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study.  All patients received TMZ at a dosage of 90 mg/m(2)/day for 42 days to a dose of 59.4 Gy.  Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m(2)/day for 5 days every 28 days, for a total of 10 cycles.  The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941.  The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941.  The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96.  There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%.  The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941.  The median time to death was 9.6 months.  Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRWqSAwVzDshpyrDyM_m9cfW6udTcc2eZRxH29YLt2Qbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ovF2rtg%253D%253D&md5=75a91c9fa553be1474104a0798215671</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnoq205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnoq205%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DK.%2BJ.%26aulast%3DHeideman%26aufirst%3DR.%2BL.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DE.%2BJ.%26aulast%3DLavey%26aufirst%3DR.%2BS.%26aulast%3DBouffet%26aufirst%3DE.%26aulast%3DPollack%26aufirst%3DI.%2BF.%26atitle%3DTemozolomide%2520in%2520the%2520treatment%2520of%2520children%2520with%2520newly%2520diagnosed%2520diffuse%2520intrinsic%2520pontine%2520gliomas%253A%2520a%2520report%2520from%2520the%2520Children%25E2%2580%2599s%2520Oncology%2520Group%26jtitle%3DNeuro-Oncol.%26date%3D2011%26volume%3D13%26spage%3D410%26epage%3D416%26doi%3D10.1093%2Fneuonc%2Fnoq205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korones, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, C.</span></span> <span> </span><span class="NLM_article-title">Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a children’s oncology group phase II study</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1002/pbc.21154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fpbc.21154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17278121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjsFWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2008&pages=227-230&author=D.+N.+Koronesauthor=P.+G.+Fisherauthor=C.+Kretschmarauthor=T.+Zhouauthor=Z.+Chenauthor=J.+Kepnerauthor=C.+Freeman&title=Treatment+of+children+with+diffuse+intrinsic+brain+stem+glioma+with+radiotherapy%2C+vincristine+and+oral+VP-16%3A+a+children%E2%80%99s+oncology+group+phase+II+study&doi=10.1002%2Fpbc.21154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study</span></div><div class="casAuthors">Korones David N; Fisher Paul G; Kretschmar Cynthia; Zhou Tianni; Chen Zhengjia; Kepner James; Freeman Carolyn</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">227-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The prognosis for children with brain stem glioma remains grim.  Based on studies suggesting efficacy of vincristine and oral VP-16, The Pediatric Oncology Group (POG, now part of the Children's Oncology Group) conducted a study using these agents in combination with standard external beam radiation for children with newly diagnosed brain stem glioma.  METHODS:  Children were eligible for the study if they 3-21 years of age, had MRI-evidence of a diffuse intrinsic pontine glioma, and had neurologic deficits of <6 months duration.  Patients received local radiotherapy to a dosage of 54 Gy.  Chemotherapy consisted of two 28-day cycles of vincristine, 1.5 mg/m(2), days 1, 8, and 15 and oral VP-16, 50 mg/m(2), days 1-21, starting concurrent with radiation, and continuing for ten cycles following radiation.  RESULTS:  Of the 31 children enrolled, 30 were eligible and evaluable for survival and toxicity.  Their median age was 8 years (range 3-14 years).  Seven patients (23%) had a partial response following radiation, 18 (60%) had stable disease, 2 (7%) had progressive disease, and response in 3 patients (10%) was not measured.  All 30 children have died.  Overall survival at 1 year was 27 +/- 7% and at 2 years, 3 +/- 2%.  The median survival was 9 months (range 3-36 months).  Hematologic toxicity was significant; other toxicities included constipation, mucositis, emesis, and infection.  CONCLUSION:  The addition of vincristine and oral VP-16 to standard external beam radiation causes moderate toxicity and does not improve survival of children with diffuse intrinsic brain stem glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDnWJ92eNBALP3FVUi_gf8fW6udTcc2eZRxH29YLt2Qbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjsFWktA%253D%253D&md5=48b57f6c9060981dfc29f71e8f2cef77</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpbc.21154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.21154%26sid%3Dliteratum%253Aachs%26aulast%3DKorones%26aufirst%3DD.%2BN.%26aulast%3DFisher%26aufirst%3DP.%2BG.%26aulast%3DKretschmar%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DKepner%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DC.%26atitle%3DTreatment%2520of%2520children%2520with%2520diffuse%2520intrinsic%2520brain%2520stem%2520glioma%2520with%2520radiotherapy%252C%2520vincristine%2520and%2520oral%2520VP-16%253A%2520a%2520children%25E2%2580%2599s%2520oncology%2520group%2520phase%2520II%2520study%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2008%26volume%3D50%26spage%3D227%26epage%3D230%26doi%3D10.1002%2Fpbc.21154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roujeau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miquel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoerger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddaert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Rocco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainte-Rose, C.</span></span> <span> </span><span class="NLM_article-title">Stereotactic biopsy of diffuse pontine lesions in children</span>. <i>J. Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.3171/PED-07/07/001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.3171%2FPED-07%2F07%2F001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17647306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD2svislyhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=1-4&author=T.+Roujeauauthor=G.+Machadoauthor=M.+R.+Garnettauthor=C.+Miquelauthor=S.+Pugetauthor=B.+Geoergerauthor=J.+Grillauthor=N.+Boddaertauthor=F.+Di+Roccoauthor=M.+Zerahauthor=C.+Sainte-Rose&title=Stereotactic+biopsy+of+diffuse+pontine+lesions+in+children&doi=10.3171%2FPED-07%2F07%2F001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Stereotactic biopsy of diffuse pontine lesions in children</span></div><div class="casAuthors">Roujeau Thomas; Machado Guilherme; Garnett Matthew R; Miquel Catherine; Puget Stephanie; Geoerger Birgit; Grill Jacques; Boddaert Nathalie; Di Rocco Federico; Zerah Michel; Sainte-Rose Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurosurgery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1 Suppl</span>),
    <span class="NLM_cas:pages">1-4</span>
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    </div><div class="casAbstract">OBJECT:  Empirical radiotherapy is the current treatment for children with diffuse pontine lesions that have imaging characteristics of an infiltrative malignant astrocytoma.  The use of chemotherapeutic agents is, however, currently under investigation in the treatment of these tumors.  To be included into a trial, patients need a definitive histological diagnosis.  The authors present their prospective study of the stereotactic biopsy of these lesions during a 4-year period.  METHODS:  A suboccipital, transcerebellar approach was used to obtain biopsy samples in 24 children.  RESULTS:  Two patients suffered deficits.  Both had a transient (< 2 months) new cranial nerve palsy; one of these patients also experienced an exacerbation of a preoperative hemiparesis.  No patient died during the perioperative period.  A histological diagnosis was made in all 24 patients as follows: 22 had a malignant infiltrative astrocytoma, one had a low-grade astrocytoma, and one had a pilocytic astrocytoma.  The diagnosis of the latter two patients affected the initial treatment after the biopsy.  CONCLUSIONS:  The findings of this study imply that stereotactic biopsy sampling of a diffuse pontine tumor is a safe procedure, is associated with minimal morbidity, and has a high diagnostic yield.  A nonmalignant tumor was identified in two of the 24 patients in whom the imaging findings were characteristic of a malignant infiltrative astrocytoma.  With the advent of new treatment protocols, stereotactic biopsy sampling, which would allow specific tumor characterization of diffuse pontine lesions, may become standard.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk63zbO0tbyO-MdeMhXAHkfW6udTcc2eaySKsaKsp-wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svislyhtA%253D%253D&md5=30b48b8c59adccd8f211acbd214fccdb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3171%2FPED-07%2F07%2F001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252FPED-07%252F07%252F001%26sid%3Dliteratum%253Aachs%26aulast%3DRoujeau%26aufirst%3DT.%26aulast%3DMachado%26aufirst%3DG.%26aulast%3DGarnett%26aufirst%3DM.%2BR.%26aulast%3DMiquel%26aufirst%3DC.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DGeoerger%26aufirst%3DB.%26aulast%3DGrill%26aufirst%3DJ.%26aulast%3DBoddaert%26aufirst%3DN.%26aulast%3DDi%2BRocco%26aufirst%3DF.%26aulast%3DZerah%26aufirst%3DM.%26aulast%3DSainte-Rose%26aufirst%3DC.%26atitle%3DStereotactic%2520biopsy%2520of%2520diffuse%2520pontine%2520lesions%2520in%2520children%26jtitle%3DJ.%2520Neurosurg.%26date%3D2007%26volume%3D107%26spage%3D1%26epage%3D4%26doi%3D10.3171%2FPED-07%2F07%2F001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karajannis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas-Kogan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaides, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonds, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span> <span> </span><span class="NLM_article-title">Pediatric high-grade glioma: biologically and clinically in need of new thinking</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1093/neuonc/now101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1093%2Fneuonc%2Fnow101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27282398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSntr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=153-161&author=C.+Jonesauthor=M.+A.+Karajannisauthor=D.+T.+W.+Jonesauthor=M.+W.+Kieranauthor=M.+Monjeauthor=S.+J.+Bakerauthor=O.+J.+Becherauthor=Y.+J.+Choauthor=N.+Guptaauthor=C.+Hawkinsauthor=D.+Hargraveauthor=D.+A.+Haas-Koganauthor=N.+Jabadoauthor=X.+N.+Liauthor=S.+Muellerauthor=T.+Nicolaidesauthor=R.+J.+Packerauthor=A.+I.+Perssonauthor=J.+J.+Phillipsauthor=E.+F.+Simondsauthor=J.+M.+Staffordauthor=Y.+Tangauthor=S.+M.+Pfisterauthor=W.+A.+Weiss&title=Pediatric+high-grade+glioma%3A+biologically+and+clinically+in+need+of+new+thinking&doi=10.1093%2Fneuonc%2Fnow101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pediatric high-grade glioma: biologically and clinically in need of new thinking</span></div><div class="casAuthors">Jones, Chris; Karajannis, Matthias A.; Jones, David T. W.; Kieran, Mark W.; Monje, Michelle; Baker, Suzanne J.; Becher, Oren J.; Cho, Yoon-Jae; Gupta, Nalin; Hawkins, Cynthia; Hargrave, Darren; Haas-Kogan, Daphne A.; Jabado, Nada; Li, Xiao-Nan; Mueller, Sabine; Nicolaides, Theo; Packer, Roger J.; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Stafford, James M.; Tang, Yujie; Pfister, Stefan M.; Weiss, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-161</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">High-grade gliomas in children are different from those that arise in adults.  Recent collaborative mol. analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis.  As we begin to unravel the unique developmental origins and distinct biol. drivers of this heterogeneous group of tumors, clin. trials need to keep pace.  It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma.  This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clin. outcome.  The authors of this perspective, comprising biol. and clin. expertise in the disease, recently convened to discuss the most effective ways to translate the emerging mol. insights into patient benefit.  This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clin. management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovI4tjqPTy6rVg90H21EOLACvtfcHk0ljCu2YP1gIrNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSntr%252FM&md5=79288507fd1bd4373e5fb70048583add</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnow101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnow101%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKarajannis%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DD.%2BT.%2BW.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBecher%26aufirst%3DO.%2BJ.%26aulast%3DCho%26aufirst%3DY.%2BJ.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DHaas-Kogan%26aufirst%3DD.%2BA.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DMueller%26aufirst%3DS.%26aulast%3DNicolaides%26aufirst%3DT.%26aulast%3DPacker%26aufirst%3DR.%2BJ.%26aulast%3DPersson%26aufirst%3DA.%2BI.%26aulast%3DPhillips%26aufirst%3DJ.%2BJ.%26aulast%3DSimonds%26aufirst%3DE.%2BF.%26aulast%3DStafford%26aufirst%3DJ.%2BM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DPediatric%2520high-grade%2520glioma%253A%2520biologically%2520and%2520clinically%2520in%2520need%2520of%2520new%2520thinking%26jtitle%3DNeuro-Oncol.%26date%3D2017%26volume%3D19%26spage%3D153%26epage%3D161%26doi%3D10.1093%2Fneuonc%2Fnow101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal-Salom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjerke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandhabalan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temelso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waanders, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharoulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandeville, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Sarraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabelsi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisljakov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konovalov, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shats, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavale, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidinotto, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crimmins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pears, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debily, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikbakht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouladi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bueren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">520</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2017.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.ccell.2017.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28966033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=520-537&author=A.+Mackayauthor=A.+Burfordauthor=D.+Carvalhoauthor=E.+Izquierdoauthor=J.+Fazal-Salomauthor=K.+R.+Taylorauthor=L.+Bjerkeauthor=M.+Clarkeauthor=M.+Vinciauthor=M.+Nandhabalanauthor=S.+Temelsoauthor=S.+Popovauthor=V.+Molinariauthor=P.+Ramanauthor=A.+J.+Waandersauthor=H.+J.+Hanauthor=S.+Guptaauthor=L.+Marshallauthor=S.+Zacharoulisauthor=S.+Vaidyaauthor=H.+C.+Mandevilleauthor=L.+R.+Bridgesauthor=A.+J.+Martinauthor=S.+Al-Sarrajauthor=C.+Chandlerauthor=H.+K.+Ngauthor=X.+Liauthor=K.+Muauthor=S.+Trabelsiauthor=D.+H.+Brahimauthor=A.+N.+Kisljakovauthor=D.+M.+Konovalovauthor=A.+S.+Mooreauthor=A.+M.+Carcabosoauthor=M.+Sunolauthor=C.+de+Torresauthor=O.+Cruzauthor=J.+Moraauthor=L.+I.+Shatsauthor=J.+N.+Stavaleauthor=L.+T.+Bidinottoauthor=R.+M.+Reisauthor=N.+Entz-Werleauthor=M.+Farrellauthor=J.+Cryanauthor=D.+Crimminsauthor=J.+Cairdauthor=J.+Pearsauthor=M.+Monjeauthor=M.+A.+Debilyauthor=D.+Castelauthor=J.+Grillauthor=C.+Hawkinsauthor=H.+Nikbakhtauthor=N.+Jabadoauthor=S.+J.+Bakerauthor=S.+M.+Pfisterauthor=D.+T.+W.+Jonesauthor=M.+Fouladiauthor=A.+O.+von+Buerenauthor=M.+Baudisauthor=A.+Resnickauthor=C.+Jones&title=Integrated+molecular+meta-analysis+of+1%2C000+pediatric+high-grade+and+diffuse+intrinsic+pontine+glioma&doi=10.1016%2Fj.ccell.2017.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma</span></div><div class="casAuthors">MacKay, Alan; Burford, Anna; Carvalho, Diana; Izquierdo, Elisa; Fazal-Salom, Janat; Taylor, Kathryn R.; Bjerke, Lynn; Clarke, Matthew; Vinci, Mara; Nandhabalan, Meera; Temelso, Sara; Popov, Sergey; Molinari, Valeria; Raman, Pichai; Waanders, Angela J.; Han, Harry J.; Gupta, Saumya; Marshall, Lynley; Zacharoulis, Stergios; Vaidya, Sucheta; Mandeville, Henry C.; Bridges, Leslie R.; Martin, Andrew J.; Al-Sarraj, Safa; Chandler, Christopher; Ng, Ho-Keung; Li, Xingang; Mu, Kun; Trabelsi, Saoussen; H'mida-Ben Brahim, Dorra; Kisljakov, Alexei N.; Konovalov, Dmitry M.; Moore, Andrew S.; Carcaboso, Angel Montero; Sunol, Mariona; de Torres, Carmen; Cruz, Ofelia; Mora, Jaume; Shats, Ludmila I.; Stavale, Joao N.; Bidinotto, Lucas T.; Reis, Rui M.; Entz-Werle, Natacha; Farrell, Michael; Cryan, Jane; Crimmins, Darach; Caird, John; Pears, Jane; Monje, Michelle; Debily, Marie-Anne; Castel, David; Grill, Jacques; Hawkins, Cynthia; Nikbakht, Hamid; Jabado, Nada; Baker, Suzanne J.; Pfister, Stefan M.; Jones, David T. W.; Fouladi, Maryam; von Bueren, Andre O.; Baudis, Michael; Resnick, Adam; Jones, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">520-537.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated anal. of >1,000 cases.  We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M.  Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors.  Genomic aberrations increase with age, highlighting the infant population as biol. and clin. distinct.  Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the mol. diversity of the disease, opening up avenues for biol. study and providing a basis for functionally defined future treatment stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwsnPkJGgJWrVg90H21EOLACvtfcHk0ljCu2YP1gIrNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrjL&md5=aa10ce3347bfc85a694bee343d9e7533</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DBurford%26aufirst%3DA.%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DIzquierdo%26aufirst%3DE.%26aulast%3DFazal-Salom%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DNandhabalan%26aufirst%3DM.%26aulast%3DTemelso%26aufirst%3DS.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DMolinari%26aufirst%3DV.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DWaanders%26aufirst%3DA.%2BJ.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DMarshall%26aufirst%3DL.%26aulast%3DZacharoulis%26aufirst%3DS.%26aulast%3DVaidya%26aufirst%3DS.%26aulast%3DMandeville%26aufirst%3DH.%2BC.%26aulast%3DBridges%26aufirst%3DL.%2BR.%26aulast%3DMartin%26aufirst%3DA.%2BJ.%26aulast%3DAl-Sarraj%26aufirst%3DS.%26aulast%3DChandler%26aufirst%3DC.%26aulast%3DNg%26aufirst%3DH.%2BK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMu%26aufirst%3DK.%26aulast%3DTrabelsi%26aufirst%3DS.%26aulast%3DBrahim%26aufirst%3DD.%2BH.%26aulast%3DKisljakov%26aufirst%3DA.%2BN.%26aulast%3DKonovalov%26aufirst%3DD.%2BM.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3DSunol%26aufirst%3DM.%26aulast%3Dde%2BTorres%26aufirst%3DC.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DShats%26aufirst%3DL.%2BI.%26aulast%3DStavale%26aufirst%3DJ.%2BN.%26aulast%3DBidinotto%26aufirst%3DL.%2BT.%26aulast%3DReis%26aufirst%3DR.%2BM.%26aulast%3DEntz-Werle%26aufirst%3DN.%26aulast%3DFarrell%26aufirst%3DM.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DCrimmins%26aufirst%3DD.%26aulast%3DCaird%26aufirst%3DJ.%26aulast%3DPears%26aufirst%3DJ.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DDebily%26aufirst%3DM.%2BA.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DGrill%26aufirst%3DJ.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DNikbakht%26aufirst%3DH.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DJones%26aufirst%3DD.%2BT.%2BW.%26aulast%3DFouladi%26aufirst%3DM.%26aulast%3Dvon%2BBueren%26aufirst%3DA.%2BO.%26aulast%3DBaudis%26aufirst%3DM.%26aulast%3DResnick%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DIntegrated%2520molecular%2520meta-analysis%2520of%25201%252C000%2520pediatric%2520high-grade%2520and%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D32%26spage%3D520%26epage%3D537%26doi%3D10.1016%2Fj.ccell.2017.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1038/nrc3811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnrc3811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=651-661&author=C.+Jonesauthor=S.+J.+Baker&title=Unique+genetic+and+epigenetic+mechanisms+driving+paediatric+diffuse+high-grade+glioma&doi=10.1038%2Fnrc3811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma</span></div><div class="casAuthors">Jones, Chris; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">651-661</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse high-grade gliomas (HGGs) of childhood are a devastating spectrum of disease with no effective cures.  The two-year survival for paediatric HGG ranges from 30%, for tumors arising in the cerebral cortex, to less than 10% for diffuse intrinsic pontine gliomas (DIPGs), which arise in the brainstem.  Recent genome-wide studies provided abundant evidence that unique selective pressures drive HGG in children compared to adults, identifying novel oncogenic mutations connecting tumorigenesis and chromatin regulation, as well as developmental signalling pathways.  These new genetic findings give insights into disease pathogenesis and the challenges and opportunities for improving patient survival in these mostly incurable childhood brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVGWSwXk98SbVg90H21EOLACvtfcHk0liZzyUFK0URcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlu7rO&md5=86613a1f2bd8e9afebcfe1067371284a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc3811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3811%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DUnique%2520genetic%2520and%2520epigenetic%2520mechanisms%2520driving%2520paediatric%2520diffuse%2520high-grade%2520glioma%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D651%26epage%3D661%26doi%3D10.1038%2Fnrc3811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLuca, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monlong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sammeth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pervouchine, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segrè, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djebali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niarchou, A.</span></span>; <span class="NLM_contrib-group">The GTEx Consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappalainen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dermitzakis, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigó, R.</span></span> <span> </span><span class="NLM_article-title">The human transcriptome across tissues and individuals</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1126/science.aaa0355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1126%2Fscience.aaa0355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=25954002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslGjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=660-665&author=M.+Mel%C3%A9author=P.+G.+Ferreiraauthor=F.+Reverterauthor=D.+S.+DeLucaauthor=J.+Monlongauthor=M.+Sammethauthor=T.+R.+Youngauthor=J.+M.+Goldmannauthor=D.+D.+Pervouchineauthor=T.+J.+Sullivanauthor=R.+Johnsonauthor=A.+V.+Segr%C3%A8author=S.+Djebaliauthor=A.+Niarchouauthor=The+GTEx+Consortiumauthor=F.+A.+Wrightauthor=T.+Lappalainenauthor=M.+Calvoauthor=G.+Getzauthor=E.+T.+Dermitzakisauthor=K.+G.+Ardlieauthor=R.+Guig%C3%B3&title=The+human+transcriptome+across+tissues+and+individuals&doi=10.1126%2Fscience.aaa0355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The human transcriptome across tissues and individuals</span></div><div class="casAuthors">Mele, Marta; Ferreira, Pedro G.; Reverter, Ferran; De Luca, David S.; Monlong, Jean; Sammeth, Michael; Young, Taylor R.; Goldmann, Jakob M.; Pervouchine, Dmitri D.; Sullivan, Timothy J.; Johnson, Rory; Segre, Ayellet V.; Djebali, Sarah; Niarchou, Anastasia; Wright, Fred A.; Lappalainen, Tuuli; Calvo, Miquel; Getz, Gad; Dermitzakis, Emmanouil T.; Ardlie, Kristin G.; Guigo, Roderic</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6235</span>),
    <span class="NLM_cas:pages">660-665</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Transcriptional regulation and posttranscriptional processing underlie many cellular and organismal phenotypes.  We used RNA sequence data generated by Genotype-Tissue Expression (GTEx) project to investigate the patterns of transcriptome variation across individuals and tissues.  Tissues exhibit characteristic transcriptional signatures that show stability in postmortem samples.  These signatures are dominated by a relatively small no. of genes-which is most clearly seen in blood-though few are exclusive to a particular tissue and vary more across tissues than individuals.  Genes exhibiting high interindividual expression variation include disease candidates assocd. with sex, ethnicity, and age.  Primary transcription is the major driver of cellular specificity, with splicing playing mostly a complementary role; except for the brain, which exhibits a more divergent splicing program.  Variation in splicing, despite its stochasticity, may play in contrast a comparatively greater role in defining individual phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp69NDKxbHrt7Vg90H21EOLACvtfcHk0liZzyUFK0URcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslGjsbY%253D&md5=e0461ad2426d9cbb0a26cb537bda7251</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa0355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa0355%26sid%3Dliteratum%253Aachs%26aulast%3DMel%25C3%25A9%26aufirst%3DM.%26aulast%3DFerreira%26aufirst%3DP.%2BG.%26aulast%3DReverter%26aufirst%3DF.%26aulast%3DDeLuca%26aufirst%3DD.%2BS.%26aulast%3DMonlong%26aufirst%3DJ.%26aulast%3DSammeth%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DT.%2BR.%26aulast%3DGoldmann%26aufirst%3DJ.%2BM.%26aulast%3DPervouchine%26aufirst%3DD.%2BD.%26aulast%3DSullivan%26aufirst%3DT.%2BJ.%26aulast%3DJohnson%26aufirst%3DR.%26aulast%3DSegr%25C3%25A8%26aufirst%3DA.%2BV.%26aulast%3DDjebali%26aufirst%3DS.%26aulast%3DNiarchou%26aufirst%3DA.%26aulast%3D%26aulast%3DWright%26aufirst%3DF.%2BA.%26aulast%3DLappalainen%26aufirst%3DT.%26aulast%3DCalvo%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DDermitzakis%26aufirst%3DE.%2BT.%26aulast%3DArdlie%26aufirst%3DK.%2BG.%26aulast%3DGuig%25C3%25B3%26aufirst%3DR.%26atitle%3DThe%2520human%2520transcriptome%2520across%2520tissues%2520and%2520individuals%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D660%26epage%3D665%26doi%3D10.1126%2Fscience.aaa0355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ACVR1 mutations in DIPG: lessons learned from FOP</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4565</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1158%2F0008-5472.CAN-14-1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=25136070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=4565-4570&author=K.+R.+Taylorauthor=M.+Vinciauthor=A.+N.+Bullockauthor=C.+Jones&title=ACVR1+mutations+in+DIPG%3A+lessons+learned+from+FOP&doi=10.1158%2F0008-5472.CAN-14-1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">ACVR1 mutations in DIPG: Lessons learned from FOP</span></div><div class="casAuthors">Taylor, Kathryn R.; Vinci, Maria; Bullock, Alex N.; Jones, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4565-4570</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Whole-genome sequencing studies have recently identified a quarter of cases of the rare childhood brainstem tumor diffuse intrinsic pontine glioma to harbor somatic mutations in ACVR1.  This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone.  This unexpected link points toward the importance of developmental biol. processes in tumorigenesis and provides an extensive experience in mechanistic understanding and drug development hard-won by FOP researchers to pediatric neurooncol.  Here, we review the literature in both fields and identify potential areas for collaboration and rapid advancement for patients of both diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEL1hRMgcHVLVg90H21EOLACvtfcHk0liZzyUFK0URcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I&md5=6954694896e9f71ad21eec835247b1cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1298%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DACVR1%2520mutations%2520in%2520DIPG%253A%2520lessons%2520learned%2520from%2520FOP%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D4565%26epage%3D4570%26doi%3D10.1158%2F0008-5472.CAN-14-1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermacher, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeMerrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morhart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtizberea, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zasloff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, F. S.</span></span> <span> </span><span class="NLM_article-title">A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1038/ng1783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fng1783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=16642017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvVGktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2006&pages=525-527&author=E.+M.+Shoreauthor=M.+Xuauthor=G.+J.+Feldmanauthor=D.+A.+Fenstermacherauthor=T.+J.+Choauthor=I.+H.+Choiauthor=J.+M.+Connorauthor=P.+Delaiauthor=D.+L.+Glaserauthor=M.+LeMerrerauthor=R.+Morhartauthor=J.+G.+Rogersauthor=R.+Smithauthor=J.+T.+Triffittauthor=J.+A.+Urtizbereaauthor=M.+Zasloffauthor=M.+A.+Brownauthor=F.+S.+Kaplan&title=A+recurrent+mutation+in+the+BMP+type+I+receptor+ACVR1+causes+inherited+and+sporadic+fibrodysplasia+ossificans+progressiva&doi=10.1038%2Fng1783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</span></div><div class="casAuthors">Shore, Eileen M.; Xu, Meiqi; Feldman, George J.; Fenstermacher, David A.; Brown, Matthew A.; Kaplan, Frederick S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-527</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification.  We mapped FOP to chromosome 2q23-24 by linkage anal. and identified an identical heterozygous mutation (617G → A; R206H) in the glycine-serine (GS) activation domain of ACVR1, a BMP type I receptor, in all affected individuals examd.  Protein modeling predicts destabilization of the GS domain, consistent with constitutive activation of ACVR1 as the underlying cause of the ectopic chondrogenesis, osteogenesis and joint fusions seen in FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJCMFDulIw-LVg90H21EOLACvtfcHk0lgZHOCHmm2vRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvVGktrk%253D&md5=24f4dce60f3073f2c621326d3c146601</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fng1783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1783%26sid%3Dliteratum%253Aachs%26aulast%3DShore%26aufirst%3DE.%2BM.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DFeldman%26aufirst%3DG.%2BJ.%26aulast%3DFenstermacher%26aufirst%3DD.%2BA.%26aulast%3DCho%26aufirst%3DT.%2BJ.%26aulast%3DChoi%26aufirst%3DI.%2BH.%26aulast%3DConnor%26aufirst%3DJ.%2BM.%26aulast%3DDelai%26aufirst%3DP.%26aulast%3DGlaser%26aufirst%3DD.%2BL.%26aulast%3DLeMerrer%26aufirst%3DM.%26aulast%3DMorhart%26aufirst%3DR.%26aulast%3DRogers%26aufirst%3DJ.%2BG.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DUrtizberea%26aufirst%3DJ.%2BA.%26aulast%3DZasloff%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DKaplan%26aufirst%3DF.%2BS.%26atitle%3DA%2520recurrent%2520mutation%2520in%2520the%2520BMP%2520type%2520I%2520receptor%2520ACVR1%2520causes%2520inherited%2520and%2520sporadic%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DNat.%2520Genet.%26date%3D2006%26volume%3D38%26spage%3D525%26epage%3D527%26doi%3D10.1038%2Fng1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fastnacht-Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillessen-Kaesbach, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoover-Fong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zasloff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morhart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundlos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groppe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1002/humu.20868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fhumu.20868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=19085907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFCms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=379-390&author=F.+S.+Kaplanauthor=M.+Xuauthor=P.+Seemannauthor=J.+M.+Connorauthor=D.+L.+Glaserauthor=L.+Carrollauthor=P.+Delaiauthor=E.+Fastnacht-Urbanauthor=S.+J.+Formanauthor=G.+Gillessen-Kaesbachauthor=J.+Hoover-Fongauthor=B.+Kosterauthor=R.+M.+Pauliauthor=W.+Reardonauthor=S.+A.+Zaidiauthor=M.+Zasloffauthor=R.+Morhartauthor=S.+Mundlosauthor=J.+Groppeauthor=E.+M.+Shore&title=Classic+and+atypical+fibrodysplasia+ossificans+progressiva+%28FOP%29+phenotypes+are+caused+by+mutations+in+the+bone+morphogenetic+protein+%28BMP%29+type+I+receptor+ACVR1&doi=10.1002%2Fhumu.20868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1</span></div><div class="casAuthors">Kaplan, Frederick S.; Xu, Meiqi; Seemann, Petra; Connor, J. Michael; Glaser, David L.; Carroll, Liam; Delai, Patricia; Fastnacht-Urban, Elisabeth; Forman, Stephen J.; Gillessen-Kaesbach, Gabriele; Hoover-Fong, Julie; Koster, Bernhard; Pauli, Richard M.; Reardon, William; Zaidi, Syed-Adeel; Zasloff, Michael; Morhart, Rolf; Mundlos, Stefan; Groppe, Jay; Shore, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-390</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant human disorder of bone formation that causes developmental skeletal defects and extensive debilitating bone formation within soft connective tissues (heterotopic ossification) during childhood.  All patients with classic clin. features of FOP (great toe malformations and progressive heterotopic ossification) have previously been found to carry the same heterozygous mutation (c.617G > A; p.R206H) in the glycine and serine residue (GS) activation domain of activin A type I receptor/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor.  Among patients with FOP-like heterotopic ossification and/or toe malformations, we identified patients with clin. features unusual for FOP.  These atypical FOP patients form two classes: FOP-plus (classic defining features of FOP plus one or more atypical features) and FOP variants (major variations in one or both of the two classic defining features of FOP).  All patients examd. have heterozygous ACVR1 mis-sense mutations in conserved amino acids.  While the recurrent c.617G > A; p.R206H mutation was found in all cases of classic FOP and most cases of FOP-plus, novel ACVR1 mutations occur in the FOP variants and two cases of FOP-plus.  Protein structure homol. modeling predicts that each of the amino acid substitutions activates the ACVR1 protein to enhance receptor signaling.  We obsd. genotype-phenotype correlation between some ACVR1 mutations and the age of onset of heterotopic ossification or on embryonic skeletal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjtZIaoHwVy7Vg90H21EOLACvtfcHk0lgZHOCHmm2vRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFCms7w%253D&md5=ea8c6bd96082f0290fc54b62cb1fa0c9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fhumu.20868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.20868%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DF.%2BS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DSeemann%26aufirst%3DP.%26aulast%3DConnor%26aufirst%3DJ.%2BM.%26aulast%3DGlaser%26aufirst%3DD.%2BL.%26aulast%3DCarroll%26aufirst%3DL.%26aulast%3DDelai%26aufirst%3DP.%26aulast%3DFastnacht-Urban%26aufirst%3DE.%26aulast%3DForman%26aufirst%3DS.%2BJ.%26aulast%3DGillessen-Kaesbach%26aufirst%3DG.%26aulast%3DHoover-Fong%26aufirst%3DJ.%26aulast%3DKoster%26aufirst%3DB.%26aulast%3DPauli%26aufirst%3DR.%2BM.%26aulast%3DReardon%26aufirst%3DW.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DZasloff%26aufirst%3DM.%26aulast%3DMorhart%26aufirst%3DR.%26aulast%3DMundlos%26aufirst%3DS.%26aulast%3DGroppe%26aufirst%3DJ.%26aulast%3DShore%26aufirst%3DE.%2BM.%26atitle%3DClassic%2520and%2520atypical%2520fibrodysplasia%2520ossificans%2520progressiva%2520%2528FOP%2529%2520phenotypes%2520are%2520caused%2520by%2520mutations%2520in%2520the%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520type%2520I%2520receptor%2520ACVR1%26jtitle%3DHum.%2520Mutat.%26date%3D2009%26volume%3D30%26spage%3D379%26epage%3D390%26doi%3D10.1002%2Fhumu.20868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikbakht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panditharatna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikael, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gayden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osmond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambhampati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papillon-Cavanagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellezam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamchandani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, J.</span></span> <span> </span><span class="NLM_article-title">Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">11185</span> <span class="refDoi"> DOI: 10.1038/ncomms11185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fncomms11185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27048880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Kgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=H.+Nikbakhtauthor=E.+Panditharatnaauthor=L.+G.+Mikaelauthor=R.+Liauthor=T.+Gaydenauthor=M.+Osmondauthor=C.+Y.+Hoauthor=M.+Kambhampatiauthor=E.+I.+Hwangauthor=D.+Fauryauthor=A.+Siuauthor=S.+Papillon-Cavanaghauthor=D.+Bechetauthor=K.+L.+Ligonauthor=B.+Ellezamauthor=W.+J.+Ingramauthor=C.+Stinsonauthor=A.+S.+Mooreauthor=K.+E.+Warrenauthor=J.+Karamchandaniauthor=R.+J.+Packerauthor=N.+Jabadoauthor=J.+Majewskiauthor=J.+Nazarian&title=Spatial+and+temporal+homogeneity+of+driver+mutations+in+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fncomms11185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Nikbakht, Hamid; Panditharatna, Eshini; Mikael, Leonie G.; Li, Rui; Gayden, Tenzin; Osmond, Matthew; Ho, Cheng-Ying; Kambhampati, Madhuri; Hwang, Eugene I.; Faury, Damien; Siu, Alan; Papillon-Cavanagh, Simon; Bechet, Denise; Ligon, Keith L.; Ellezam, Benjamin; Ingram, Wendy J.; Stinson, Caedyn; Moore, Andrew S.; Warren, Katherine E.; Karamchandani, Jason; Packer, Roger J.; Jabado, Nada; Majewski, Jacek; Nazarian, Javad</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11185</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse Intrinsic Pontine Gliomas (DIPGs) are deadly pediatric brain tumors where needle biopsies help guide diagnosis and targeted therapies.  To address spatial heterogeneity, here we analyze 134 specimens from various neuroanatomical structures of whole autopsy brains from nine DIPG patients.  Evolutionary reconstruction indicates histone 3 (H3) K27M-including H3.2K27M-mutations potentially arise first and are invariably assocd. with specific, high-fidelity obligate partners throughout the tumor and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis.  These H3K27M ubiquitously-assocd. mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1).  Later oncogenic alterations arise in sub-clones and often affect the PI3K pathway.  Our findings are consistent with early tumor spread outside the brainstem including the cerebrum.  The spatial and temporal homogeneity of main driver mutations in DIPG implies they will be captured by limited biopsies and emphasizes the need to develop therapies specifically targeting obligate oncohistone partnerships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0xu1GtUyNrVg90H21EOLACvtfcHk0lgZHOCHmm2vRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Kgtbg%253D&md5=fd267da3e8fee87ed6c76ece59efe2bd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms11185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11185%26sid%3Dliteratum%253Aachs%26aulast%3DNikbakht%26aufirst%3DH.%26aulast%3DPanditharatna%26aufirst%3DE.%26aulast%3DMikael%26aufirst%3DL.%2BG.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DGayden%26aufirst%3DT.%26aulast%3DOsmond%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DKambhampati%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DE.%2BI.%26aulast%3DFaury%26aufirst%3DD.%26aulast%3DSiu%26aufirst%3DA.%26aulast%3DPapillon-Cavanagh%26aufirst%3DS.%26aulast%3DBechet%26aufirst%3DD.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DEllezam%26aufirst%3DB.%26aulast%3DIngram%26aufirst%3DW.%2BJ.%26aulast%3DStinson%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DWarren%26aufirst%3DK.%2BE.%26aulast%3DKaramchandani%26aufirst%3DJ.%26aulast%3DPacker%26aufirst%3DR.%2BJ.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DMajewski%26aufirst%3DJ.%26aulast%3DNazarian%26aufirst%3DJ.%26atitle%3DSpatial%2520and%2520temporal%2520homogeneity%2520of%2520driver%2520mutations%2520in%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms11185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ten
Dijke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichijo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoshima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldin, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, K.</span></span> <span> </span><span class="NLM_article-title">Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2879</span>– <span class="NLM_lpage">2887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=8397373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADyaK3szptV2ltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1993&pages=2879-2887&author=P.+ten%0ADijkeauthor=H.+Ichijoauthor=P.+Franzenauthor=P.+Schulzauthor=J.+Sarasauthor=H.+Toyoshimaauthor=C.+H.+Heldinauthor=K.+Miyazono&title=Activin+receptor-like+kinases%3A+a+novel+subclass+of+cell-surface+receptors+with+predicted+serine%2Fthreonine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity</span></div><div class="casAuthors">ten Dijke P; Ichijo H; Franzen P; Schulz P; Saras J; Toyoshima H; Heldin C H; Miyazono K</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2879-87</span>
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">Human cDNA clones encoding four novel putative transmembrane protein serine/threonine kinases, denoted activin receptor-like kinase (ALK) -1, -2, -3 and -4, were obtained using a polymerase chain reaction (PCR)-based strategy.  The PCR primers were designed based upon the sequence similarity between the activin receptor type II and Daf-1.  The cDNA clones for ALK-1, -2 and -3 encode complete proteins of 503, 509 and 532 amino acids respectively.  The ALK-4 cDNA is incomplete and the predicted protein of 383 amino acids has a truncated extracellular domain.  The ALKs share similar domain structures, comprising predicted signal sequences at the N-terminals, followed by hydrophilic cysteine-rich ligand-binding domains, single hydrophobic transmembrane regions and C-terminal intracellular portions that consist almost entirely of putative serine/threonine kinase domains.  The ALKs have approximately 40% sequence identity to activin receptors type II and IIB, transforming growth factor-beta (TGF-beta) type II receptor and Daf-1 in the kinase domains.  However, the sequence identities are higher (60-79%) between ALK-1, -2, -3 and -4, suggesting that they form a subfamily among the putative receptor serine/threonine kinases.  The extracellular domains of ALKs show only little sequence identity to other putative receptor serine/threonine kinases, but the cysteine residues are conserved.  Their structural properties suggest that ALK-1 to -4 are receptors that may bind ligands that are members of the TGF-beta superfamily.  The expression of mRNA in human tissues varied for the different ALKs; ALK-2 and ALK-4 showed ubiquitous tissue expression patterns, whereas the distribution of ALK-1 and ALK-3 varied strongly between different tissues with more restricted expression patterns.  These results suggest that each ALK may have different in vivo functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrdSBxdXQSDoMcDoIzZtNkfW6udTcc2eYy-CO4LqVY47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptV2ltQ%253D%253D&md5=d6daa31d855593d6106600531251f835</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dten%2BDijke%26aufirst%3DP.%26aulast%3DIchijo%26aufirst%3DH.%26aulast%3DFranzen%26aufirst%3DP.%26aulast%3DSchulz%26aufirst%3DP.%26aulast%3DSaras%26aufirst%3DJ.%26aulast%3DToyoshima%26aufirst%3DH.%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26aulast%3DMiyazono%26aufirst%3DK.%26atitle%3DActivin%2520receptor-like%2520kinases%253A%2520a%2520novel%2520subclass%2520of%2520cell-surface%2520receptors%2520with%2520predicted%2520serine%252Fthreonine%2520kinase%2520activity%26jtitle%3DOncogene%26date%3D1993%26volume%3D8%26spage%3D2879%26epage%3D2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macias-Silva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoodless, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrana, J. L.</span></span> <span> </span><span class="NLM_article-title">Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">25628</span>– <span class="NLM_lpage">25636</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.40.25628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1074%2Fjbc.273.40.25628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=9748228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADyaK1cXms1egs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=25628-25636&author=M.+Macias-Silvaauthor=P.+A.+Hoodlessauthor=S.+J.+Tangauthor=M.+Buchwaldauthor=J.+L.+Wrana&title=Specific+activation+of+Smad1+signaling+pathways+by+the+BMP7+type+I+receptor%2C+ALK2&doi=10.1074%2Fjbc.273.40.25628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2</span></div><div class="casAuthors">Macias-Silva, Marina; Hoodless, Pamela A.; Tang, Shao Jun; Buchwald, Manuel; Wrana, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">25628-25636</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">BMP7 and activin are members of the transforming growth factor β superfamily.  Here we characterize endogenous activin and BMP7 signaling pathways in P19 embryonic carcinoma cells.  We show that BMP7 and activin bind to the same type II receptors, ActRII and IIB, but recruit distinct type I receptors into heteromeric receptor complexes.  The major BMP7 type I receptor obsd. was ALK2, while activin bound exclusively to ALK4 (ActRIB).  BMP7 and activin elicited distinct biol. responses and activated different Smad pathways.  BMP7 stimulated phosphorylation of endogenous Smad1 and 5, formation of complexes with Smad4 and induced the promoter for the homeobox gene, Tlx2.  In contrast, activin induced phosphorylation of Smad2, assocn. with Smad4, and induction of the activin response element from the Xenopus Mix.2 gene.  Biochem. anal. revealed that constitutively active ALK2 assocd. with and phosphorylated Smad1 on the COOH-terminal SSXS motif, and also regulated Smad5 and Smad8 phosphorylation.  Activated ALK2 also induced the Tlx2 promoter in the absence of BMP7.  Furthermore, we show that ALK1 (TSRI), an orphan receptor that is closely related to ALK2 also mediates Smad1 signaling.  Thus, ALK1 and ALK2 induce Smad1-dependent pathways and ALK2 functions to mediate BMP7 but not activin signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2cQzZTWUPGbVg90H21EOLACvtfcHk0lhJDHC4k4jmtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1egs7c%253D&md5=920ec4d2851366586faae52ff9c0dc74</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.40.25628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.40.25628%26sid%3Dliteratum%253Aachs%26aulast%3DMacias-Silva%26aufirst%3DM.%26aulast%3DHoodless%26aufirst%3DP.%2BA.%26aulast%3DTang%26aufirst%3DS.%2BJ.%26aulast%3DBuchwald%26aufirst%3DM.%26aulast%3DWrana%26aufirst%3DJ.%2BL.%26atitle%3DSpecific%2520activation%2520of%2520Smad1%2520signaling%2520pathways%2520by%2520the%2520BMP7%2520type%2520I%2520receptor%252C%2520ALK2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D25628%26epage%3D25636%26doi%3D10.1074%2Fjbc.273.40.25628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">López-Rovira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, F.</span></span> <span> </span><span class="NLM_article-title">Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">3176</span>– <span class="NLM_lpage">3185</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106826200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1074%2Fjbc.M106826200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=11700304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtVaks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=3176-3185&author=T.+L%C3%B3pez-Roviraauthor=E.+Chalauxauthor=J.+Massagueauthor=J.+L.+Rosaauthor=F.+Ventura&title=Direct+binding+of+Smad1+and+Smad4+to+two+distinct+motifs+mediates+bone+morphogenetic+protein-specific+transcriptional+activation+of+Id1+gene&doi=10.1074%2Fjbc.M106826200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene</span></div><div class="casAuthors">Lopez-Rovira, Teresa; Chalaux, Elisabet; Massague, Joan; Rosa, Jose Luis; Ventura, Francesc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3176-3185</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bone morphogenetic proteins (BMPs) are potent inhibitors of myoblast differentiation and inducers of bone formation both in vivo and in vitro.  Expression of Id1, a neg. regulator of basic helix-loop-helix transcription factors, is up-regulated by BMPs and contributes to the antimyogenic effects of this family of cytokines.  In this report, the authors have identified a specific BMP-2 immediate early response enhancer in the human Id1 gene.  Transcriptional activation of the enhancer was increased by overexpression of BMP-responsive Smads, and Smad4 and was completely abrogated in Smad4-deficient cells.  Deletion anal. demonstrates that the responsive region is composed of two sep. DNA binding elements, a set of overlapping GC boxes, which bind BMP-regulated Smads upon BMP stimulation, and three repeats of CAGAC boxes.  Gel shift and oligonucleotide pull-down assays demonstrated that these two types of motifs were capable of binding their corresponding Smads.  However, deletion or mutation of either DNA binding element was nonadditive, since disruption of either GC or CAGAC boxes resulted in complete or severe loss of BMP-2 responsiveness.  These data suggest the simultaneous requirement of two independent DNA binding elements to allow functional co-operativity of BMP-regulated Smads and Smad4 in BMP-activated gene promoters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6ELFR5aBxLVg90H21EOLACvtfcHk0lhJDHC4k4jmtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtVaks70%253D&md5=58d3624c36703561cae928da94556da8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106826200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106826200%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-Rovira%26aufirst%3DT.%26aulast%3DChalaux%26aufirst%3DE.%26aulast%3DMassague%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DJ.%2BL.%26aulast%3DVentura%26aufirst%3DF.%26atitle%3DDirect%2520binding%2520of%2520Smad1%2520and%2520Smad4%2520to%2520two%2520distinct%2520motifs%2520mediates%2520bone%2520morphogenetic%2520protein-specific%2520transcriptional%2520activation%2520of%2520Id1%2520gene%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D3176%26epage%3D3185%26doi%3D10.1074%2Fjbc.M106826200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korchynskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4891</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111023200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1074%2Fjbc.M111023200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=11729207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFeqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=4883-4891&author=O.+Korchynskyiauthor=P.+ten+Dijke&title=Identification+and+functional+characterization+of+distinct+critically+important+bone+morphogenetic+protein-specific+response+elements+in+the+Id1+promoter&doi=10.1074%2Fjbc.M111023200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter</span></div><div class="casAuthors">Korchynskyi, Olexander; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4883-4891</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Transforming growth factor-β (TGF-β) family members, which include bone morphogenetic proteins (BMPs) and TGF-βs, elicit their cellular effects by activating specific Smad proteins, which control the transcription of target genes.  BMPs and TGF-βs have overlapping as well as specific effects on mesenchymal cell differentiation for which the mechanisms are incompletely understood.  Here we report that Id1, a dominant neg. inhibitor of basic helix-loop-helix proteins, is a direct target gene for BMP.  BMP, but not TGF-β, strongly activates the Id1 promoter in an Smad-dependent manner.  We identified two BMP-responsive regions in the mouse Id1 promoter, which contain three distinct sequence elements; one region contains two Smad binding elements (SBEs), and the other region contains a GGCGCC palindromic sequence flanked by two CAGC and two CGCC motifs.  Whereas SBEs and GGCGCC sequence are critically important, the CAGC and CGCC motifs are needed for efficient BMP-induced Id1 promoter activation.  Smads are part of nuclear transcription factor complexes that specifically bind to SBEs and GGCGCC sequence in response to BMP but not TGF-β.  Multimerization of the all three distinct sequence motifs is needed to generate a highly sensitive and BMP/Smad-dependent specific enhancer.  Our results provide important new insights into how the BMP/Smad pathway can specifically activate target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp15NKd4FagVrVg90H21EOLACvtfcHk0lh7aAaIhIIRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFeqtbo%253D&md5=5c9e9524342c1a9f9ea246fb4ba4c247</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111023200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111023200%26sid%3Dliteratum%253Aachs%26aulast%3DKorchynskyi%26aufirst%3DO.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520distinct%2520critically%2520important%2520bone%2520morphogenetic%2520protein-specific%2520response%2520elements%2520in%2520the%2520Id1%2520promoter%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D4883%26epage%3D4891%26doi%3D10.1074%2Fjbc.M111023200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horigome, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebise, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toguchida, J.</span></span> <span> </span><span class="NLM_article-title">Neofunction of ACVR1 in fibrodysplasia ossificans progressiva</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">15438</span>– <span class="NLM_lpage">15443</span>, <span class="refDoi"> DOI: 10.1073/pnas.1510540112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1073%2Fpnas.1510540112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26621707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWqur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15438-15443&author=K.+Hinoauthor=M.+Ikeyaauthor=K.+Horigomeauthor=Y.+Matsumotoauthor=H.+Ebiseauthor=M.+Nishioauthor=K.+Sekiguchiauthor=M.+Shibataauthor=S.+Nagataauthor=S.+Matsudaauthor=J.+Toguchida&title=Neofunction+of+ACVR1+in+fibrodysplasia+ossificans+progressiva&doi=10.1073%2Fpnas.1510540112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Neofunction of ACVR1 in fibrodysplasia ossificans progressiva</span></div><div class="casAuthors">Hino, Kyosuke; Ikeya, Makoto; Horigome, Kazuhiko; Matsumoto, Yoshihisa; Ebise, Hayao; Nishio, Megumi; Sekiguchi, Kazuya; Shibata, Mitsuaki; Nagata, Sanae; Matsuda, Shuichi; Toguchida, Junya</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">15438-15443</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by extraskeletal bone formation through endochondral ossification.  FOP patients harbor point mutations in ACVR1 (also known as ALK2), a type I receptor for bone morphogenetic protein (BMP).  Two mechanisms of mutated ACVR1 (FOP-ACVR1) have been proposed: ligand-independent constitutive activity and ligand-dependent hyperactivity in BMP signaling.  Here, by using FOP patient-derived induced pluripotent stem cells (FOP-iPSCs), we report a third mechanism, where FOP-ACVR1 abnormally transduces BMP signaling in response to Activin-A, a mol. that normally transduces TGF-β signaling but not BMP signaling.  Activin-A enhanced the chondrogenesis of induced mesenchymal stromal cells derived from FOP-iPSCs (FOP-iMSCs) via aberrant activation of BMP signaling in addn. to the normal activation of TGF-β signaling in vitro, and induced endochondral ossification of FOP-iMSCs in vivo.  These results uncover a novel mechanism of extraskeletal bone formation in FOP and provide a potential new therapeutic strategy for FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_N0VtcCNm97Vg90H21EOLACvtfcHk0lh7aAaIhIIRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWqur%252FL&md5=21363365af31167197b87b246845e01f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1510540112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1510540112%26sid%3Dliteratum%253Aachs%26aulast%3DHino%26aufirst%3DK.%26aulast%3DIkeya%26aufirst%3DM.%26aulast%3DHorigome%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DEbise%26aufirst%3DH.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DM.%26aulast%3DNagata%26aufirst%3DS.%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DToguchida%26aufirst%3DJ.%26atitle%3DNeofunction%2520of%2520ACVR1%2520in%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D15438%26epage%3D15443%26doi%3D10.1073%2Fpnas.1510540112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatsell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolken, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannuru, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhoul, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernomorsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corpina, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Economides, A. N.</span></span> <span> </span><span class="NLM_article-title">ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">303ra137</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aac4358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1126%2Fscitranslmed.aac4358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26333933" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=S.+J.+Hatsellauthor=V.+Idoneauthor=D.+M.+Wolkenauthor=L.+Huangauthor=H.+J.+Kimauthor=L.+Wangauthor=X.+Wenauthor=K.+C.+Nannuruauthor=J.+Jimenezauthor=L.+Xieauthor=N.+Dasauthor=G.+Makhoulauthor=R.+Chernomorskyauthor=D.+D%E2%80%99Ambrosioauthor=R.+A.+Corpinaauthor=C.+J.+Schoenherrauthor=K.+Feeleyauthor=P.+B.+Yuauthor=G.+D.+Yancopoulosauthor=A.+J.+Murphyauthor=A.+N.+Economides&title=ACVR1R206H+receptor+mutation+causes+fibrodysplasia+ossificans+progressiva+by+imparting+responsiveness+to+activin+A&doi=10.1126%2Fscitranslmed.aac4358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac4358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac4358%26sid%3Dliteratum%253Aachs%26aulast%3DHatsell%26aufirst%3DS.%2BJ.%26aulast%3DIdone%26aufirst%3DV.%26aulast%3DWolken%26aufirst%3DD.%2BM.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DNannuru%26aufirst%3DK.%2BC.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DN.%26aulast%3DMakhoul%26aufirst%3DG.%26aulast%3DChernomorsky%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DD.%26aulast%3DCorpina%26aufirst%3DR.%2BA.%26aulast%3DSchoenherr%26aufirst%3DC.%2BJ.%26aulast%3DFeeley%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DMurphy%26aufirst%3DA.%2BJ.%26aulast%3DEconomides%26aufirst%3DA.%2BN.%26atitle%3DACVR1R206H%2520receptor%2520mutation%2520causes%2520fibrodysplasia%2520ossificans%2520progressiva%2520by%2520imparting%2520responsiveness%2520to%2520activin%2520A%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26doi%3D10.1126%2Fscitranslmed.aac4358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paugh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahawatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onar-Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becksfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadodaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yergeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boop, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0lhe0CitX0ncPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misuraca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procissi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, O. J.</span></span> <span> </span><span class="NLM_article-title">ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">1023</span> <span class="refDoi"> DOI: 10.1038/s41467-019-08823-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fs41467-019-08823-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30833574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=C.+M.+Hoemanauthor=F.+J.+Corderoauthor=G.+Huauthor=K.+Misuracaauthor=M.+M.+Romeroauthor=H.+J.+Cardonaauthor=J.+Nazarianauthor=R.+Hashizumeauthor=R.+McLendonauthor=P.+Yuauthor=D.+Procissiauthor=S.+Gaddauthor=O.+J.+Becher&title=ACVR1+R206H+cooperates+with+H3.1K27M+in+promoting+diffuse+intrinsic+pontine+glioma+pathogenesis&doi=10.1038%2Fs41467-019-08823-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis</span></div><div class="casAuthors">Hoeman Christine M; Romero Megan M; Cardona Herminio J; Becher Oren J; Cordero Francisco J; Hu Guo; Misuraca Katie; Nazarian Javad; Hashizume Rintaro; Hashizume Rintaro; Becher Oren J; Hashizume Rintaro; Becher Oren J; McLendon Roger; McLendon Roger; Yu Paul; Procissi Daniele; Gadd Samantha; Becher Oren J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1023</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brain tumor, with approximately 25% of DIPGs harboring activating ACVR1 mutations that commonly co-associate with H3.1K27M mutations.  Here we show that in vitro expression of ACVR1 R206H with and without H3.1K27M upregulates mesenchymal markers and activates Stat3 signaling.  In vivo expression of ACVR1 R206H or G328V with H3.1K27M and p53 deletion induces glioma-like lesions but is not sufficient for full gliomagenesis.  However, in combination with PDGFA signaling, ACVR1 R206H and H3.1K27M significantly decrease survival and increase tumor incidence.  Treatment of ACVR1 R206H mutant DIPGs with exogenous Noggin or the ACVR1 inhibitor LDN212854 significantly prolongs survival, with human ACVR1 mutant DIPG cell lines also being sensitive to LDN212854 treatment.  Together, our results demonstrate that ACVR1 R206H and H3.1K27M promote tumor initiation, accelerate gliomagenesis, promote a mesenchymal profile partly due to Stat3 activation, and identify LDN212854 as a promising compound to treat DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKDjpfXAfQCT0O18WR3iAofW6udTcc2eZpzd9g3DN9nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtA%253D%253D&md5=6329143062096abbcef61d0dd08f1982</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-08823-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-08823-9%26sid%3Dliteratum%253Aachs%26aulast%3DHoeman%26aufirst%3DC.%2BM.%26aulast%3DCordero%26aufirst%3DF.%2BJ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DMisuraca%26aufirst%3DK.%26aulast%3DRomero%26aufirst%3DM.%2BM.%26aulast%3DCardona%26aufirst%3DH.%2BJ.%26aulast%3DNazarian%26aufirst%3DJ.%26aulast%3DHashizume%26aufirst%3DR.%26aulast%3DMcLendon%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DProcissi%26aufirst%3DD.%26aulast%3DGadd%26aufirst%3DS.%26aulast%3DBecher%26aufirst%3DO.%2BJ.%26atitle%3DACVR1%2520R206H%2520cooperates%2520with%2520H3.1K27M%2520in%2520promoting%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520pathogenesis%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-019-08823-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babitt, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyng, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2007.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnchembio.2007.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=18026094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVegtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=33-41&author=P.+B.+Yuauthor=C.+C.+Hongauthor=C.+Sachidanandanauthor=J.+L.+Babittauthor=D.+Y.+Dengauthor=S.+A.+Hoyngauthor=H.+Y.+Linauthor=K.+D.+Blochauthor=R.+T.+Peterson&title=Dorsomorphin+inhibits+BMP+signals+required+for+embryogenesis+and+iron+metabolism&doi=10.1038%2Fnchembio.2007.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism</span></div><div class="casAuthors">Yu, Paul B.; Hong, Charles C.; Sachidanandan, Chetana; Babitt, Jodie L.; Deng, Donna Y.; Hoyng, Stefan A.; Lin, Herbert Y.; Bloch, Kenneth D.; Peterson, Randall T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bone morphogenetic protein (BMP) signals coordinate developmental patterning and have essential physiol. roles in mature organisms.  Here we describe the first known small-mol. inhibitor of BMP signaling-dorsomorphin, which we identified in a screen for compds. that perturb dorsoventral axis formation in zebrafish.  We found that dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation.  Using dorsomorphin, we examd. the role of BMP signaling in iron homeostasis.  In vitro, dorsomorphin inhibited BMP-, hemojuvelin- and interleukin 6-stimulated expression of the systemic iron regulator hepcidin, which suggests that BMP receptors regulate hepcidin induction by all of these stimuli.  In vivo, systemic challenge with iron rapidly induced SMAD1/5/8 phosphorylation and hepcidin expression in the liver, whereas treatment with dorsomorphin blocked SMAD1/5/8 phosphorylation, normalized hepcidin expression and increased serum iron levels.  These findings suggest an essential physiol. role for hepatic BMP signaling in iron-hepcidin homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Ot0o1uk6ErVg90H21EOLACvtfcHk0lhe0CitX0ncPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVegtbnF&md5=fb064fa0f1d036b790a8635a913dc0fc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2007.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2007.54%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DBabitt%26aufirst%3DJ.%2BL.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DHoyng%26aufirst%3DS.%2BA.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26atitle%3DDorsomorphin%2520inhibits%2520BMP%2520signals%2520required%2520for%2520embryogenesis%2520and%2520iron%2520metabolism%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D33%26epage%3D41%26doi%3D10.1038%2Fnchembio.2007.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1080/13543776.2016.1217330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1080%2F13543776.2016.1217330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27476794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1115-1128&author=C.+R.+Hopkins&title=Inhibitors+of+the+bone+morphogenetic+protein+%28BMP%29+signaling+pathway%3A+a+patent+review+%282008-2015%29&doi=10.1080%2F13543776.2016.1217330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span></div><div class="casAuthors">Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1128</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The bone morphogenetic protein (BMP) is a crit. signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others.  Areas covered: This review covers small mol. inhibitors/antagonists of BMP in patent applications between 2008 - 2015, along with brief synopses of the disclosed inhibitors in the primary literature.  Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile.  Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP).  Recently, however, there has been increased interest in their use in a no. of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few.  Although the primary participants in the early work were from academic labs., recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications.  Due to this, expect a no. of new approaches such as repurposing of other kinase inhibitors to be brought into clin. trials in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShe2EZoRM8LVg90H21EOLACvtfcHk0ljLL_Nz7saGIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO&md5=e71e2ed75369d31a3835aaed4cf65de6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1217330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1217330%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DInhibitors%2520of%2520the%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520pathway%253A%2520a%2520patent%2520review%2520%25282008-2015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D1115%26epage%3D1128%26doi%3D10.1080%2F13543776.2016.1217330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laha, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.bmcl.2008.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=18621530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4388-4392&author=G.+D.+Cunyauthor=P.+B.+Yuauthor=J.+K.+Lahaauthor=X.+Xingauthor=J.-F.+Liuauthor=C.+S.+Laiauthor=D.+Y.+Dengauthor=C.+Sachidanandanauthor=K.+D.+Blochauthor=R.+T.+Peterson&title=Structure-activity+relationship+study+of+bone+morphogenetic+protein+%28BMP%29+signaling+inhibitors&doi=10.1016%2Fj.bmcl.2008.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span></div><div class="casAuthors">Cuny, Gregory D.; Yu, Paul B.; Laha, Joydev K.; Xing, Xuechao; Liu, Ji-Feng; Lai, Carol S.; Deng, Donna Y.; Sachidanandan, Chetana; Bloch, Kenneth D.; Peterson, Randall T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4388-4392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline.  The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examd. by prepg. and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivs.  In addn., increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent Ph ring with piperazine.  Finally, an optimized compd. 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t 1/2 = 1.6 h) following i.p. administration in mice.  These studies provide useful mol. probes for examg. the in vivo pharmacol. of BMP signaling inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxlj03oLBHLVg90H21EOLACvtfcHk0ljLL_Nz7saGIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D&md5=227395181629474e47aee6163492c4bc</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DLaha%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DLai%26aufirst%3DC.%2BS.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4388%26epage%3D4392%26doi%3D10.1016%2Fj.bmcl.2008.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">Development of an ALK2-biased BMP type I receptor kinase inhibitor</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1021/cb300655w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300655w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1291-1302&author=A.+H.+Mohedasauthor=X.+Xingauthor=K.+A.+Armstrongauthor=A.+N.+Bullockauthor=G.+D.+Cunyauthor=P.+B.+Yu&title=Development+of+an+ALK2-biased+BMP+type+I+receptor+kinase+inhibitor&doi=10.1021%2Fcb300655w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor</span></div><div class="casAuthors">Mohedas, Agustin H.; Xing, Xuechao; Armstrong, Kelli A.; Bullock, Alex N.; Cuny, Gregory D.; Yu, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1291-1302</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bone morphogenetic protein (BMP) signaling pathway has essential functions in development, homeostasis, and the normal and pathophysiol. remodeling of tissues.  Small mol. inhibitors of the BMP receptor kinase family have been useful for probing physiol. functions of BMP signaling in vitro and in vivo and may have roles in the treatment of BMP-mediated diseases.  Here we describe the development of a selective and potent inhibitor of the BMP type I receptor kinases, LDN-212854, which in contrast to previously described BMP receptor kinase inhibitors exhibits nearly 4 orders of selectivity for BMP vs. the closely related TGF-β and Activin type I receptors.  In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity, and function.  LDN-212854 potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.  These findings represent a significant step toward developing selective inhibitors targeting individual members of the highly homologous BMP type I receptor family.  Such inhibitors would provide greater resoln. as probes of physiol. function and improved selectivity against therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHih4D1koDbrVg90H21EOLACvtfcHk0ljLL_Nz7saGIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCksrY%253D&md5=0f151ea0674207160616b8a2b093c463</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fcb300655w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300655w%26sid%3Dliteratum%253Aachs%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DArmstrong%26aufirst%3DK.%2BA.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DDevelopment%2520of%2520an%2520ALK2-biased%2520BMP%2520type%2520I%2520receptor%2520kinase%2520inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1291%26epage%3D1302%26doi%3D10.1021%2Fcb300655w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the potent and selective binding of LDN-212854 to the BMP rceptor kinase ALK2</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2017.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.bone.2017.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28918311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWit77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=251-258&author=E.+Williamsauthor=A.+N.+Bullock&title=Structural+basis+for+the+potent+and+selective+binding+of+LDN-212854+to+the+BMP+rceptor+kinase+ALK2&doi=10.1016%2Fj.bone.2017.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2</span></div><div class="casAuthors">Williams, Eleanor; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-258</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">1873-2763</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Individuals with the rare developmental disorder fibrodysplasia ossificans progressiva (FOP) experience disabling heterotopic ossification caused by a gain of function mutation in the intracellular region of the BMP type I receptor kinase ALK2, encoded by the gene ACVR1.  Small mol. BMP type I receptor inhibitors that block this ossification in FOP mouse models have been derived from the pyrazolo[1,5-a]pyrimidine scaffold of dorsomorphin.  While the first deriv. LDN-193189 exhibited pan inhibition of BMP receptors, the more recent compd. LDN-212854 has shown increased selectivity for ALK2.  Here we solved the crystal structure of ALK2 in complex with LDN-212854 to define how its binding interactions compare to previously reported BMP and TGFβ receptor inhibitors.  LDN-212854 bound to the kinase hinge region as a typical type I ATP-competitive inhibitor with a single hydrogen bond to ALK2 His286.  Specificity arising from the 5-quinoline moiety was assocd. with a distinct pattern of water-mediated hydrogen bonds involving Lys235 and Glu248 in the inactive conformation favored by ALK2.  The structure of this complex provides a template for the design of future ALK2 inhibitors under development for the treatment of FOP and other related conditions of heterotopic ossification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1vfj50E7qHbVg90H21EOLACvtfcHk0ljstJBI-3XqoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWit77N&md5=b3b28a6fe7675c9a3b23e90758827699</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2017.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2017.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DStructural%2520basis%2520for%2520the%2520potent%2520and%2520selective%2520binding%2520of%2520LDN-212854%2520to%2520the%2520BMP%2520rceptor%2520kinase%2520ALK2%26jtitle%3DBone%26date%3D2018%26volume%3D109%26spage%3D251%26epage%3D258%26doi%3D10.1016%2Fj.bone.2017.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouxsein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katagiri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span> <span> </span><span class="NLM_article-title">BMP type I receptor inhibition reduces heterotopic [corrected] ossification</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1038/nm.1888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnm.1888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=19029982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1363-1369&author=P.+B.+Yuauthor=D.+Y.+Dengauthor=C.+S.+Laiauthor=C.+C.+Hongauthor=G.+D.+Cunyauthor=M.+L.+Bouxseinauthor=D.+W.+Hongauthor=P.+M.+McManusauthor=T.+Katagiriauthor=C.+Sachidanandanauthor=N.+Kamiyaauthor=T.+Fukudaauthor=Y.+Mishinaauthor=R.+T.+Petersonauthor=K.+D.+Bloch&title=BMP+type+I+receptor+inhibition+reduces+heterotopic+%5Bcorrected%5D+ossification&doi=10.1038%2Fnm.1888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">BMP type I receptor inhibition reduces heterotopic ossification</span></div><div class="casAuthors">Yu, Paul B.; Deng, Donna Y.; Lai, Carol S.; Hong, Charles C.; Cuny, Gregory D.; Bouxsein, Mary L.; Hong, Deborah W.; McManus, Patrick M.; Katagiri, Takenobu; Sachidanandan, Chetana; Kamiya, Nobuhiro; Fukuda, Tomokazu; Mishina, Yuji; Peterson, Randall T.; Bloch, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1363-1369</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive and widespread postnatal ossification of soft tissues and is without known effective treatments.  Affected individuals harbor conserved mutations in the ACVR1 gene that are thought to cause constitutive activation of the bone morphogenetic protein (BMP) type I receptor, activin receptor-like kinase-2 (ALK2).  Here we show that i.m. expression in the mouse of an inducible transgene encoding constitutively active ALK2 (caALK2), resulting from a glutamine to aspartic acid change at amino acid position 207, leads to ectopic endochondral bone formation, joint fusion and functional impairment, thus phenocopying key aspects of human FOP.  A selective inhibitor of BMP type I receptor kinases, LDN-193189, inhibits activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in tissues expressing caALK2 via adenovirus expressing, reducing ectopic ossification and functional impairment.  In contrast to induced expression of caALK2 via adenovirus expressing Cre (Ad.Cre), global postnatal expression of caALK2 by itself does not lead to ectopic ossification; however, in combination with infection by a control adenovirus ectopic bone formation was induced.  Corticosteroid treatment inhibits ossification in Ad.Cre-injected mutant mice, suggesting caALK2 expression and an inflammatory milieu are both required for the development of ectopic ossification in this model.  These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and suggest that small mol. inhibition of BMP type I receptor activity may be useful in treating FOP and heterotopic ossification syndromes assocd. with excessive BMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt63Bkmo9HuLVg90H21EOLACvtfcHk0ljstJBI-3XqoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7nM&md5=f5743345aec7ae55fc948ccf41fcd782</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnm.1888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1888%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DLai%26aufirst%3DC.%2BS.%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DBouxsein%26aufirst%3DM.%2BL.%26aulast%3DHong%26aufirst%3DD.%2BW.%26aulast%3DMcManus%26aufirst%3DP.%2BM.%26aulast%3DKatagiri%26aufirst%3DT.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DKamiya%26aufirst%3DN.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26atitle%3DBMP%2520type%2520I%2520receptor%2520inhibition%2520reduces%2520heterotopic%2520%255Bcorrected%255D%2520ossification%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D1363%26epage%3D1369%26doi%3D10.1038%2Fnm.1888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, G. P.</span></span> <span> </span><span class="NLM_article-title">The specificities of small molecule inhibitors of the TGFβ and BMP pathways</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1831</span>– <span class="NLM_lpage">1842</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2011.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.cellsig.2011.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21740966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVCntr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=1831-1842&author=J.+Vogtauthor=R.+Traynorauthor=G.+P.+Sapkota&title=The+specificities+of+small+molecule+inhibitors+of+the+TGF%CE%B2+and+BMP+pathways&doi=10.1016%2Fj.cellsig.2011.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The specificities of small molecule inhibitors of the TGFss and BMP pathways</span></div><div class="casAuthors">Vogt, Janis; Traynor, Ryan; Sapkota, Gopal P.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1831-1842</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small mol. inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGFss and BMP signals, have been employed extensively to assess their physiol. roles in cells and organisms.  While all of these inhibitors have been reported as "selective" inhibitors of specific ALKs, extensive specificity tests against a wide array of protein kinases have not been performed.  In this study, we examine the specificities and potencies of the most frequently used small mol. inhibitors of the TGFss pathway (SB-431542, SB-505124, LY-364947 and A-83-01) and the BMP pathway (Dorsomorphin and LDN-193189) against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome.  We demonstrate that the inhibitors of the TGFss pathway are relatively more selective than the inhibitors of the BMP pathway.  Based on our specificity and potency profile and published data, we recommend SB-505124 as the most suitable mol. for use as an inhibitor of ALKs 4, 5 and 7 and the TGFss pathway.  We do not recommend Dorsomorphin, also called Compd. C, for use as an inhibitor of the BMP pathway.  Although LDN-193189, a Dorsomorphin deriv., is a very potent inhibitor of ALK2/3 and the BMP-pathway, we found that it potently inhibited a no. of other protein kinases at concns. sufficient to inhibit ALK2/3 and its use as a selective BMP-pathway inhibitor has to be considered cautiously.  Our observations have highlighted the need for caution when using these small mol. inhibitors to assess the physiol. roles of BMP and TGFss pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY5EQkxMmiQ7Vg90H21EOLACvtfcHk0ljstJBI-3XqoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVCntr7L&md5=f5529bfbd3732efec9eb6887a5f6c304</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2011.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2011.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DVogt%26aufirst%3DJ.%26aulast%3DTraynor%26aufirst%3DR.%26aulast%3DSapkota%26aufirst%3DG.%2BP.%26atitle%3DThe%2520specificities%2520of%2520small%2520molecule%2520inhibitors%2520of%2520the%2520TGF%25CE%25B2%2520and%2520BMP%2520pathways%26jtitle%3DCell.%2520Signalling%26date%3D2011%26volume%3D23%26spage%3D1831%26epage%3D1842%26doi%3D10.1016%2Fj.cellsig.2011.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechtold, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgariglia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billings, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacific, M.</span></span> <span> </span><span class="NLM_article-title">Unsuspected osteochondroma-like outgrowths in the crania base of hereditary multiple exostoses patients and modeling and treatment with a BMP antagonist in mice</span>. <i>PloS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e1006742</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1006742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1371%2Fjournal.pgen.1006742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28445472" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&author=S.+Sinhaauthor=C.+Mundyauthor=T.+Bechtoldauthor=F.+Sgarigliaauthor=M.+M.+Ibrahimauthor=P.+C.+Billingsauthor=K.+Carrollauthor=E.+Koyamaauthor=K.+B.+Jonesauthor=M.+Pacific&title=Unsuspected+osteochondroma-like+outgrowths+in+the+crania+base+of+hereditary+multiple+exostoses+patients+and+modeling+and+treatment+with+a+BMP+antagonist+in+mice&doi=10.1371%2Fjournal.pgen.1006742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1006742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1006742%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DMundy%26aufirst%3DC.%26aulast%3DBechtold%26aufirst%3DT.%26aulast%3DSgariglia%26aufirst%3DF.%26aulast%3DIbrahim%26aufirst%3DM.%2BM.%26aulast%3DBillings%26aufirst%3DP.%2BC.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DKoyama%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DK.%2BB.%26aulast%3DPacific%26aufirst%3DM.%26atitle%3DUnsuspected%2520osteochondroma-like%2520outgrowths%2520in%2520the%2520crania%2520base%2520of%2520hereditary%2520multiple%2520exostoses%2520patients%2520and%2520modeling%2520and%2520treatment%2520with%2520a%2520BMP%2520antagonist%2520in%2520mice%26jtitle%3DPloS%2520Genet.%26date%3D2017%26volume%3D13%26doi%3D10.1371%2Fjournal.pgen.1006742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">A new class of small molecule inhibitor of BMP signaling</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e62721</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0062721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1371%2Fjournal.pone.0062721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=23646137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=C.+E.+Sanvitaleauthor=G.+Kerrauthor=A.+Chaikuadauthor=M.+C.+Ramelauthor=A.+H.+Mohedasauthor=S.+Reichertauthor=Y.+Wangauthor=J.+T.+Triffittauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=C.+S.+Hillauthor=A.+N.+Bullock&title=A+new+class+of+small+molecule+inhibitor+of+BMP+signaling&doi=10.1371%2Fjournal.pone.0062721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of small molecule inhibitor of BMP signaling</span></div><div class="casAuthors">Sanvitale, Caroline E.; Kerr, Georgina; Chaikuad, Apirat; Ramel, Marie-Christine; Mohedas, Agustin H.; Reichert, Sabine; Wang, You; Triffitt, James T.; Cuny, Gregory D.; Yu, Paul B.; Hill, Caroline S.; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e62721</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Growth factor signaling pathways are tightly regulated by phosphorylation and include many important kinase targets of interest for drug discovery.  Small mol. inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP).  Dorsomorphin analogs, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date.  By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concns. similar to the current lead compd. LDN-193189.  K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-β signaling and induced dorsalization of zebrafish embryos.  Comparison of the crystal structures of ALK2 with K02288 and LDN-193189 revealed addnl. contacts in the K02288 complex affording improved shape complementarity and identified the exposed phenol group for further optimization of pharmacokinetics.  The discovery of a new chem. series provides an independent pharmacol. tool to investigate BMP signaling and offers multiple opportunities for pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomMygI9eYjlbVg90H21EOLACvtfcHk0lh25JqE1Dm7uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D&md5=d00f0fddc871eb1a92fa90f36c7d54dc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0062721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0062721%26sid%3Dliteratum%253Aachs%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DRamel%26aufirst%3DM.%2BC.%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DReichert%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DHill%26aufirst%3DC.%2BS.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DA%2520new%2520class%2520of%2520small%2520molecule%2520inhibitor%2520of%2520BMP%2520signaling%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0062721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7900</span>– <span class="NLM_lpage">7915</span>, <span class="refDoi"> DOI: 10.1021/jm501177w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501177w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7900-7915&author=A.+H.+Mohedasauthor=Y.+Wangauthor=C.+E.+Sanvitaleauthor=P.+Canningauthor=S.+Choiauthor=X.+Xingauthor=A.+N.+Bullockauthor=G.+D.+Cunyauthor=P.+B.+Yu&title=Structure-activity+relationship+of+3%2C5-diaryl-2-aminopyridine+ALK2+inhibitors+reveals+unaltered+binding+affinity+for+fibrodysplasia+ossificans+progressiva+causing+mutants&doi=10.1021%2Fjm501177w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants</span></div><div class="casAuthors">Mohedas, Agustin H.; Wang, You; Sanvitale, Caroline E.; Canning, Peter; Choi, Sungwoon; Xing, Xuechao; Bullock, Alex N.; Cuny, Gregory D.; Yu, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7900-7915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2.  Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors.  Here the authors describe the structure-activity relationship for a series of novel ALK2 inhibitors based on the 2-aminopyridine compd. K02288.  Several modifications increased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as well as selectivity for ALK2 vs. closely related BMP and TGF-β type I receptor kinases.  Compds. in this series exhibited a wide range of in vitro cytotoxicity that was not correlated with potency or selectivity, suggesting mechanisms independent of BMP or TGF-β inhibition.  The study also highlights a potent 2-methylpyridine deriv. I (LDN-214117) with a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclin. development.  Contrary to the notion that activating mutations of ALK2 might alter inhibitor efficacy due to potential conformational changes in the ATP-binding site, the compds. demonstrated consistent binding to a panel of mutant and wild-type ALK2 proteins.  Thus, BMP inhibitors identified via activity against wild-type ALK2 signaling are likely to be of clin. relevance for the diverse ALK2 mutant proteins assocd. with FOP and DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBKhBWuwrqjLVg90H21EOLACvtfcHk0lh25JqE1Dm7uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP&md5=c5efce9b3d06bbb126aa8a197d3d2b40</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm501177w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501177w%26sid%3Dliteratum%253Aachs%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DStructure-activity%2520relationship%2520of%25203%252C5-diaryl-2-aminopyridine%2520ALK2%2520inhibitors%2520reveals%2520unaltered%2520binding%2520affinity%2520for%2520fibrodysplasia%2520ossificans%2520progressiva%2520causing%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7900%26epage%3D7915%26doi%3D10.1021%2Fjm501177w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3356</span>– <span class="NLM_lpage">3362</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.bmcl.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30227946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3356-3362&author=J.-k.+Jiangauthor=X.+Huangauthor=K.+Shamimauthor=P.+R.+Patelauthor=A.+Leeauthor=A.+Q.+Wangauthor=K.+Nguyenauthor=G.+Tawaauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=W.+Zhengauthor=X.+Xuauthor=P.+Sandersonauthor=W.+Huang&title=Discovery+of+3-%284-sulfamoylnaphthyl%29pyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+and+selective+ALK2+inhibitors&doi=10.1016%2Fj.bmcl.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span></div><div class="casAuthors">Jiang, Jian-kang; Huang, Xiuli; Shamim, Khalida; Patel, Paresma R.; Lee, Arthur; Wang, Amy Q.; Nguyen, Kimloan; Tawa, Gregory; Cuny, Gregory D.; Yu, Paul B.; Zheng, Wei; Xu, Xin; Sanderson, Philip; Huang, Wenwei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3356-3362</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity.  Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination vs. ALK3 but also high kinome selectivity.  In addn., the optimized compd. 23 demonstrates good ADME and in vivo pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotGqzp6yONDLVg90H21EOLACvtfcHk0lj_M2uhOODTJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP&md5=c612015c66df5b0bebaaf43b67f55970</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.-k.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShamim%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSanderson%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25203-%25284-sulfamoylnaphthyl%2529pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520and%2520selective%2520ALK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3356%26epage%3D3362%26doi%3D10.1016%2Fj.bmcl.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span> <span> </span><span class="NLM_article-title">Novel quinazolinone inhibitors of ALK2 flip between alternate binding modes: structure-activity relationship, structural characterization, kinase profiling, and cellular proof of concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7261</span>– <span class="NLM_lpage">7272</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00782</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00782" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVClurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7261-7272&author=L.+Hudsonauthor=J.+Muiauthor=S.+Vazquezauthor=D.+M.+Carvalhoauthor=E.+Williamsauthor=C.+Jonesauthor=A.+N.+Bullockauthor=S.+Hoelder&title=Novel+quinazolinone+inhibitors+of+ALK2+flip+between+alternate+binding+modes%3A+structure-activity+relationship%2C+structural+characterization%2C+kinase+profiling%2C+and+cellular+proof+of+concept&doi=10.1021%2Facs.jmedchem.8b00782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept</span></div><div class="casAuthors">Hudson, Liam; Mui, James; Vazquez, Santiago; Carvalho, Diana M.; Williams, Eleanor; Jones, Chris; Bullock, Alex N.; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7261-7272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationship and crystallog. data revealed that quinazolinone-contg. fragments flip between two distinct modes of binding to activin receptor-like kinase-2 (ALK2).  We explored both binding modes to discover potent inhibitors and characterized the chem. modifications that triggered the flip in binding mode.  We report kinase selectivity and demonstrate that compds. of this series modulate ALK2 in cancer cells.  These inhibitors are attractive starting points for the discovery of more advanced ALK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqae6Cwj4ijKbVg90H21EOLACvtfcHk0lj_M2uhOODTJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVClurjE&md5=a3a04f969265895f79f720d4a312ba57</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00782%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DL.%26aulast%3DMui%26aufirst%3DJ.%26aulast%3DVazquez%26aufirst%3DS.%26aulast%3DCarvalho%26aufirst%3DD.%2BM.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DNovel%2520quinazolinone%2520inhibitors%2520of%2520ALK2%2520flip%2520between%2520alternate%2520binding%2520modes%253A%2520structure-activity%2520relationship%252C%2520structural%2520characterization%252C%2520kinase%2520profiling%252C%2520and%2520cellular%2520proof%2520of%2520concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7261%26epage%3D7272%26doi%3D10.1021%2Facs.jmedchem.8b00782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekimata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima-Tsumagari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)</span>. <i>Chem. Pharm. Bull. (Tokyo)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1248/cpb.c18-00598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1248%2Fcpb.c18-00598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30828000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3cfpvVekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=224-235&author=K.+Sekimataauthor=T.+Satoauthor=N.+Sakaiauthor=H.+Watanabeauthor=C.+Mishima-Tsumagariauthor=T.+Taguriauthor=T.+Matsumotoauthor=Y.+Fujiiauthor=N.+Handaauthor=T.+Honmaauthor=A.+Tanakaauthor=M.+Shirouzuauthor=S.+Yokoyamaauthor=K.+Miyazonoauthor=Y.+Hashizumeauthor=H.+Koyama&title=Bis-heteroaryl+pyrazoles%3A+identification+of+orally+bioavailable+inhibitors+of+activin+receptor-like+kinase-2+%28R206H%29&doi=10.1248%2Fcpb.c18-00598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H)</span></div><div class="casAuthors">Sekimata Katsuhiko; Taguri Tomonori; Koyama Hiroo; Sato Tomohiro; Honma Teruki; Sakai Naoki; Watanabe Hisami; Mishima-Tsumagari Chiemi; Matsumoto Takehisa; Tanaka Akiko; Shirouzu Mikako; Fujii Yoshifumi; Handa Noriko; Yokoyama Shigeyuki; Miyazono Kohei; Hashizume Yoshinobu</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & pharmaceutical bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-235</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutant activin receptor-like kinase-2 (ALK2) was reported to be closely associated with the pathogenesis of fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG), and therefore presents an attractive target for therapeutic intervention.  Through in silico virtual screenings and structure-activity relationship studies assisted by X-ray crystallographic analyses, a novel series of bis-heteroaryl pyrazole was identified as potent inhibitors of ALK2 (R206H).  Derived from in silico hit compound RK-59638 (6a), compound 18p was identified as a potent inhibitor of ALK2 (R206H) with good aqueous solubility, liver microsomal stability, and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa63P45f1-gUmhnSqMnvzDfW6udTcc2ebTGFANoVHvn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfpvVekug%253D%253D&md5=529c9d5fbc686147fdb7044a053515ca</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c18-00598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c18-00598%26sid%3Dliteratum%253Aachs%26aulast%3DSekimata%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMishima-Tsumagari%26aufirst%3DC.%26aulast%3DTaguri%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DMiyazono%26aufirst%3DK.%26aulast%3DHashizume%26aufirst%3DY.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DBis-heteroaryl%2520pyrazoles%253A%2520identification%2520of%2520orally%2520bioavailable%2520inhibitors%2520of%2520activin%2520receptor-like%2520kinase-2%2520%2528R206H%2529%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2019%26volume%3D67%26spage%3D224%26epage%3D235%26doi%3D10.1248%2Fcpb.c18-00598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Duffhues, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benderitter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Wijhe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia de Vinuesa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caradec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goumans, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eekhoff, E. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Piga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachiller-Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoflack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">Development of macrocycle kinase inhibitors for ALK2 using fibrodysplasia ossificans progressiva-derived endothelial cells</span>. <i>JBMR Plus</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e10230</span> <span class="refDoi"> DOI: 10.1002/jbm4.10230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fjbm4.10230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=31768489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&author=G.+S%C3%A1nchez-Duffhuesauthor=E.+Williamsauthor=P.+Benderitterauthor=V.+Orlovaauthor=M.+van+Wijheauthor=A.+Garcia+de+Vinuesaauthor=G.+Kerrauthor=J.+Caradecauthor=K.+Lodderauthor=H.+C.+de+Boerauthor=M.-J.+Goumansauthor=E.+M.+W.+Eekhoffauthor=A.+Morales-Pigaauthor=J.+Bachiller-Corralauthor=P.+Koolwijkauthor=A.+N.+Bullockauthor=J.+Hoflackauthor=P.+ten+Dijke&title=Development+of+macrocycle+kinase+inhibitors+for+ALK2+using+fibrodysplasia+ossificans+progressiva-derived+endothelial+cells&doi=10.1002%2Fjbm4.10230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells</span></div><div class="casAuthors">Sanchez-Duffhues, Gonzalo; Williams, Eleanor; Benderitter, Pascal; Orlova, Valeria; van Wijhe, Michiel; Garcia de Vinuesa, Amaya; Kerr, Georgina; Caradec, Josselin; Lodder, Kirsten; de Boer, Hetty C.; Goumans, Marie-Jose; Eekhoff, Elisabeth M. W.; Morales-Piga, Antonio; Bachiller-Corral, Javier; Koolwijk, Pieter; Bullock, Alex N.; Hoflack, Jan; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">JBMR Plus</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e10230</span>CODEN:
                <span class="NLM_cas:coden">JPBLA6</span>;
        ISSN:<span class="NLM_cas:issn">2473-4039</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous mutations in the activin A type I receptor (ACVR1), that encodes the bone morphogenetic protein (BMP) type I receptor ALK2.  These mutations enable ALK2 to induce downstream signaling in response to activins, thereby turning them into bone-inducing agents.  To date, there is no cure for FOP.  The further development of FOP patient-derived models may contribute to the discovery of novel biomarkers and therapeutic approaches.  Nevertheless, this has traditionally been a challenge, as biopsy sampling often triggers HO.  We have characterized peripheral blood-derived endothelial colony-forming cells (ECFCs) from three independent FOP donors as a new model for FOP.  FOP ECFCs are prone to undergo endothelial-to-mesenchymal transition and exhibit increased ALK2 downstream signaling and subsequent osteogenic differentiation upon stimulation with activin A. Moreover, we have identified a new class of small mol. macrocycles with potential activity against ALK2 kinase.  Finally, using FOP ECFCs, we have selected OD36 and OD52 as potent inhibitors with excellent kinase selectivity profiles that potently antagonize mutant ALK2 signaling and osteogenic differentiation.  We expect that these results will contribute to the development of novel ALK2 clin. candidates for the treatment of FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdMImAbYILErVg90H21EOLACvtfcHk0liTo4mC_qtKQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE&md5=19b74fb9ff4bc6c0cbc7a5071b876f87</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjbm4.10230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbm4.10230%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Duffhues%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBenderitter%26aufirst%3DP.%26aulast%3DOrlova%26aufirst%3DV.%26aulast%3Dvan%2BWijhe%26aufirst%3DM.%26aulast%3DGarcia%2Bde%2BVinuesa%26aufirst%3DA.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DCaradec%26aufirst%3DJ.%26aulast%3DLodder%26aufirst%3DK.%26aulast%3Dde%2BBoer%26aufirst%3DH.%2BC.%26aulast%3DGoumans%26aufirst%3DM.-J.%26aulast%3DEekhoff%26aufirst%3DE.%2BM.%2BW.%26aulast%3DMorales-Piga%26aufirst%3DA.%26aulast%3DBachiller-Corral%26aufirst%3DJ.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DHoflack%26aufirst%3DJ.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520macrocycle%2520kinase%2520inhibitors%2520for%2520ALK2%2520using%2520fibrodysplasia%2520ossificans%2520progressiva-derived%2520endothelial%2520cells%26jtitle%3DJBMR%2520Plus%26date%3D2019%26volume%3D3%26doi%3D10.1002%2Fjbm4.10230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wentworth, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masharani, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, E. C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1111/bcp.13823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1111%2Fbcp.13823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30501012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3crnt1Cisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2019&pages=1180-1187&author=K.+L.+Wentworthauthor=U.+Masharaniauthor=E.+C.+Hsiao&title=Therapeutic+advances+for+blocking+heterotopic+ossification+in+fibrodysplasia+ossificans+progressiva&doi=10.1111%2Fbcp.13823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva</span></div><div class="casAuthors">Wentworth Kelly L; Masharani Umesh; Hsiao Edward C; Wentworth Kelly L; Hsiao Edward C</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1180-1187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease in which heterotopic bone forms in muscle and soft tissue, leading to joint dysfunction and significant disability.  FOP is progressive and many patients are wheelchair-bound by the 3rd decade of life.  FOP is caused by an activating mutation in the ACVR1 gene, which encodes the activin A Type 1 receptor.  Aberrant signalling through this receptor leads to abnormal activation of the pSMAD 1/5/8 pathway and triggers the formation of bone outside of the skeleton.  There is no curative therapy for FOP; however, exciting advances in novel therapies have developed recently.  Here, we review the clinical and translational pharmacology of three drugs that are currently in clinical trials (palovarotene, REGN 2477 and rapamycin) as well as other emerging treatment strategies for FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBrTeTGtNRpZNiNltV31zlfW6udTcc2ea5QWB9dEXwrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnt1Cisg%253D%253D&md5=fba969a5ffe82bc12e535b50d018c8bd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13823%26sid%3Dliteratum%253Aachs%26aulast%3DWentworth%26aufirst%3DK.%2BL.%26aulast%3DMasharani%26aufirst%3DU.%26aulast%3DHsiao%26aufirst%3DE.%2BC.%26atitle%3DTherapeutic%2520advances%2520for%2520blocking%2520heterotopic%2520ossification%2520in%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D85%26spage%3D1180%26epage%3D1187%26doi%3D10.1111%2Fbcp.13823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaciregui, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span>. <i>Commun. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">156</span> <span class="refDoi"> DOI: 10.1038/s42003-019-0420-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fs42003-019-0420-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=31098401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=D.+Carvalhoauthor=K.+R.+Taylorauthor=N.+G.+Olacireguiauthor=V.+Molinariauthor=M.+Clarkeauthor=A.+Mackayauthor=R.+Ruddleauthor=A.+Henleyauthor=M.+Valentiauthor=A.+Hayesauthor=A.+H.+Brandonauthor=S.+A.+Ecclesauthor=F.+Raynaudauthor=A.+Boudharauthor=M.+Monjeauthor=S.+Popovauthor=A.+S.+Mooreauthor=J.+Moraauthor=O.+Cruzauthor=M.+Vinciauthor=P.+E.+Brennanauthor=A.+N.+Bullockauthor=A.+M.+Carcabosoauthor=C.+Jones&title=ALK2+inhibitors+display+beneficial+effects+in+preclinical+models+of+ACVR1+mutant+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fs42003-019-0420-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Popov Sergey; Vinci Mara; Jones Chris; Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Ruddle Ruth; Henley Alan; Valenti Melanie; Hayes Angela; Brandon Alexis De Haven; Eccles Suzanne A; Raynaud Florence; Popov Sergey; Vinci Mara; Jones Chris; Taylor Kathryn R; Monje Michelle; Olaciregui Nagore Gene; Mora Jaume; Cruz Ofelia; Carcaboso Angel Montero; Boudhar Aicha; Brennan Paul E; Bullock Alex N; Boudhar Aicha; Brennan Paul E; Popov Sergey; Moore Andrew S; Moore Andrew S; Vinci Mara</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2.  Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-derived tumour models.  Here we show the dependence of DIPG cells on the mutant receptor, and the preclinical efficacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo.  We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to be orally bioavailable and well-tolerated, with good brain penetration.  Treatment of immunodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-DIPG-007 cells with 25 mg/kg LDN-193189 or LDN-214117 for 28 days extended survival compared with vehicle controls.  Development of ALK2 inhibitors with improved potency, selectivity and advantageous pharmacokinetic properties may play an important role in therapy for DIPG patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZQ93BSEDMxWZyxfu64m4ffW6udTcc2ea5QWB9dEXwrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D&md5=bc5f88aabf7d4d758e1288df1e70d5cd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fs42003-019-0420-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-019-0420-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DOlaciregui%26aufirst%3DN.%2BG.%26aulast%3DMolinari%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DBrandon%26aufirst%3DA.%2BH.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DBoudhar%26aufirst%3DA.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DALK2%2520inhibitors%2520display%2520beneficial%2520effects%2520in%2520preclinical%2520models%2520of%2520ACVR1%2520mutant%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DCommun.%2520Biol.%26date%3D2019%26volume%3D2%26doi%3D10.1038%2Fs42003-019-0420-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span> <span> </span><span class="NLM_article-title">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span>. <i>Wellcome Open Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">154</span>, <span class="refDoi"> DOI: 10.12688/wellcomeopenres.14947.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.12688%2Fwellcomeopenres.14947.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30705971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=154&author=M.+R.+Morganauthor=O.+G.+Robertsauthor=A.+M.+Edwards&title=Ideation+and+implementation+of+an+open+science+drug+discovery+business+model+-+M4K+Pharma&doi=10.12688%2Fwellcomeopenres.14947.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span></div><div class="casAuthors">Morgan Maxwell Robert; Edwards Aled Morgan; Morgan Maxwell Robert; Roberts Owen Gwilym; Edwards Aled Morgan; Morgan Maxwell Robert; Edwards Aled Morgan</div><div class="citationInfo"><span class="NLM_cas:title">Wellcome open research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154</span>
        ISSN:<span class="NLM_cas:issn">2398-502X</span>.
    </div><div class="casAbstract">M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science.  The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5e8MVHlijOLZpSb_XWfMrfW6udTcc2ebR6XEFSpN_urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D&md5=375dea208c308eb3199d178e4b1977a3</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.12688%2Fwellcomeopenres.14947.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Fwellcomeopenres.14947.1%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DM.%2BR.%26aulast%3DRoberts%26aufirst%3DO.%2BG.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26atitle%3DIdeation%2520and%2520implementation%2520of%2520an%2520open%2520science%2520drug%2520discovery%2520business%2520model%2520-%2520M4K%2520Pharma%26jtitle%3DWellcome%2520Open%2520Res.%26date%3D2018%26volume%3D3%26spage%3D154%26doi%3D10.12688%2Fwellcomeopenres.14947.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Fostering open collaboration in drug development for paediatric brain tumours</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1042/BST20190315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1042%2FBST20190315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=31551357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCntrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=1471-1479&author=J.+F.+Wongauthor=E.+J.+Brownauthor=E.+Williamsauthor=A.+N.+Bullock&title=Fostering+open+collaboration+in+drug+development+for+paediatric+brain+tumours&doi=10.1042%2FBST20190315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Fostering open collaboration in drug development for paediatric brain tumours</span></div><div class="casAuthors">Wong, Jong Fu; Brown, Elizabeth J.; Williams, Eleanor; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1471-1479</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Brain tumors have become the leading cause of child mortality from cancer.  Indeed, aggressive brainstem tumors, such as diffuse intrinsic pontine glioma (DIPG), are nearly uniformly fatal.  These tumors display a unique set of driver mutations that distinguish them from adult gliomas and define new opportunity for the development of precision medicines.  The specific assocn. of ACVR1 mutations with DIPG tumors suggests a direct link to neurodevelopment and highlights the encoded bone morphogenetic protein receptor kinase ALK2 as a promising drug target.  Beneficial effects of ALK2 inhibition have now been obsd. in two different in vivo models of DIPG.  Nonetheless, such tumors present a huge challenge for traditional economic models of drug development due to their small market size, high failure rate, tumor location and paediatric population.  Moreover, a toolkit of different investigational drugs may be needed to fully address the heterogeneity of these tumors in clin. trials.  One new business model is suggested by M4K Pharma, a recent virtual start up that aims to align diffuse academic and industry research into a collaborative open science drug discovery program.  Fostering scientific collaboration may offer hope in rare conditions of dire unmet clin. need and provide an alternative route to affordable medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPjWKLvTZkN7Vg90H21EOLACvtfcHk0lgQ7Lt4QzWXpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCntrjF&md5=124c6674324227d7d9e0a1acfe893e43</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1042%2FBST20190315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20190315%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DJ.%2BF.%26aulast%3DBrown%26aufirst%3DE.%2BJ.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DFostering%2520open%2520collaboration%2520in%2520drug%2520development%2520for%2520paediatric%2520brain%2520tumours%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2019%26volume%3D47%26spage%3D1471%26epage%3D1479%26doi%3D10.1042%2FBST20190315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrem, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleverly, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaiah, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slapak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahn, M. M.</span></span> <span> </span><span class="NLM_article-title">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4479</span>– <span class="NLM_lpage">4499</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S86621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.2147%2FDDDT.S86621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26309397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4479-4499&author=S.+Herbertzauthor=J.+S.+Sawyerauthor=A.+J.+Stauberauthor=I.+Gueorguievaauthor=K.+E.+Driscollauthor=S.+T.+Estremauthor=A.+L.+Cleverlyauthor=D.+Desaiahauthor=S.+C.+Gubaauthor=K.+A.+Benhadjiauthor=C.+A.+Slapakauthor=M.+M.+Lahn&title=Clinical+development+of+galunisertib+%28LY2157299+monohydrate%29%2C+a+small+molecule+inhibitor+of+transforming+growth+factor-beta+signaling+pathway&doi=10.2147%2FDDDT.S86621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span></div><div class="casAuthors">Herbertz, Stephan; Sawyer, J. Scott; Stauber, Anja J.; Gueorguieva, Ivelina; Driscoll, Kyla E.; Estrem, Shawn T.; Cleverly, Ann L.; Desaiah, Durisala; Guba, Susan C.; Benhadji, Karim A.; Slapak, Christopher A.; Lahn, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4479-4499</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biol. processes.  TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance.  There are several pharmacol. approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small mol. inhibitors.  Galunisertib (LY2157299 monohydrate) is an oral small mol. inhibitor of the TGF-β receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway.  Furthermore, galunisertib has antitumor activity in tumor-bearing animal models such as breast, colon, lung cancers, and hepatocellular carcinoma.  Continuous long-term exposure to galunisertib caused cardiac toxicities in animals requiring adoption of a pharmacokinetic/pharmacodynamic-based dosing strategy to allow further development.  The use of such a pharmacokinetic/pharmacodynamic model defined a therapeutic window with an appropriate safety profile that enabled the clin. investigation of galunisertib.  These efforts resulted in an intermittent dosing regimen (14 days on/14 days off, on a 28-day cycle) of galunisertib for all ongoing trials.  Galunisertib is being investigated either as monotherapy or in combination with std. antitumor regimens (including nivolumab) in patients with cancer with high unmet medical needs such as glioblastoma, pancreatic cancer, and hepatocellular carcinoma.  The present review summarizes the past and current experiences with different pharmacol. treatments that enabled galunisertib to be investigated in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYOwgVYb7M2bVg90H21EOLACvtfcHk0lgQ7Lt4QzWXpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D&md5=f896505ddcd4dbc54bd59863588c4268</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S86621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S86621%26sid%3Dliteratum%253Aachs%26aulast%3DHerbertz%26aufirst%3DS.%26aulast%3DSawyer%26aufirst%3DJ.%2BS.%26aulast%3DStauber%26aufirst%3DA.%2BJ.%26aulast%3DGueorguieva%26aufirst%3DI.%26aulast%3DDriscoll%26aufirst%3DK.%2BE.%26aulast%3DEstrem%26aufirst%3DS.%2BT.%26aulast%3DCleverly%26aufirst%3DA.%2BL.%26aulast%3DDesaiah%26aufirst%3DD.%26aulast%3DGuba%26aufirst%3DS.%2BC.%26aulast%3DBenhadji%26aufirst%3DK.%2BA.%26aulast%3DSlapak%26aufirst%3DC.%2BA.%26aulast%3DLahn%26aufirst%3DM.%2BM.%26atitle%3DClinical%2520development%2520of%2520galunisertib%2520%2528LY2157299%2520monohydrate%2529%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520transforming%2520growth%2520factor-beta%2520signaling%2520pathway%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4479%26epage%3D4499%26doi%3D10.2147%2FDDDT.S86621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasteuning-Vuhman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boertje-van der Meulen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Putten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overzier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiełbasa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arindrarto, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolterbeek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezhnina, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliper, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogaars, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aartsma-Rus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomans, C. J. M.</span></span> <span> </span><span class="NLM_article-title">New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1096/fj.201600675r</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1096%2Ffj.201600675r" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27733450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivV2rtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=238-255&author=S.+Pasteuning-Vuhmanauthor=J.+W.+Boertje-van+der+Meulenauthor=M.+van+Puttenauthor=M.+Overzierauthor=P.+ten+Dijkeauthor=S.+M.+Kie%C5%82basaauthor=W.+Arindrartoauthor=R.+Wolterbeekauthor=K.+V.+Lezhninaauthor=I.+V.+Ozerovauthor=A.+M.+Aliperauthor=W.+M.+Hoogaarsauthor=A.+Aartsma-Rusauthor=C.+J.+M.+Loomans&title=New+function+of+the+myostatin%2Factivin+type+I+receptor+%28ALK4%29+as+a+mediator+of+muscle+atrophy+and+muscle+regeneration&doi=10.1096%2Ffj.201600675r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration</span></div><div class="casAuthors">Pasteuning-Vuhman, Svitlana; Boertje-van der Meulen, Johanna; van Putten, Maaike; Overzier, Maurice; ten Dijke, Peter; Kielbasa, Szymon M.; Arindarto, Wibowo; Wolterbeek, Ron; Lezhnina, Ksenia V.; Ozerov, Ivan V.; Aliper, Aleksandr M.; Hoogaars, Willem M.; Aartsma-Rus, Annemieke; Loomans, Cindy J. M.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-256</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Skeletal muscle fibrosis and impaired muscle regeneration are major contributors to muscle wasting in Duchenne muscular dystrophy (DMD).  Muscle growth is neg. regulated by myostatin (MSTN) and activins.  Blockage of these pathways may improve muscle quality and function in DMD.  Antisense oligonucleotides (AONs) were designed specifically to block the function of ALK4, a key receptor for the MSTN/activin pathway in skeletal muscle.  AON-induced exon skipping resulted in specific Alk4 down-regulation, inhibition of MSTN activity, and increased myoblast differentiation in vitro.  Unexpectedly, a marked decrease in muscle mass (10%) was found after Alk4 AON treatment in mdx mice.  In line with in vitro results,muscle regeneration was stimulated, and muscle fiber size decreased markedly.  Notably, when Alk4 was down-regulated in adult wild-type mice, muscle mass decreased even more.  RNA sequence anal. revealed dysregulated metabolic functions and signs of muscle atrophy.  We conclude that ALK4 inhibition increases myogenesis but also regulates the tight balance of protein synthesis and degrdn.  Therefore, caution must be used when developing therapies that interfere with MSTN/activin pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXMHq5IysQDLVg90H21EOLACvtfcHk0lj_u7Umtw3RlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivV2rtrY%253D&md5=5e353a06b36c0a0d1d3344b667cf9e17</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600675r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600675r%26sid%3Dliteratum%253Aachs%26aulast%3DPasteuning-Vuhman%26aufirst%3DS.%26aulast%3DBoertje-van%2Bder%2BMeulen%26aufirst%3DJ.%2BW.%26aulast%3Dvan%2BPutten%26aufirst%3DM.%26aulast%3DOverzier%26aufirst%3DM.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26aulast%3DKie%25C5%2582basa%26aufirst%3DS.%2BM.%26aulast%3DArindrarto%26aufirst%3DW.%26aulast%3DWolterbeek%26aufirst%3DR.%26aulast%3DLezhnina%26aufirst%3DK.%2BV.%26aulast%3DOzerov%26aufirst%3DI.%2BV.%26aulast%3DAliper%26aufirst%3DA.%2BM.%26aulast%3DHoogaars%26aufirst%3DW.%2BM.%26aulast%3DAartsma-Rus%26aufirst%3DA.%26aulast%3DLoomans%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DNew%2520function%2520of%2520the%2520myostatin%252Factivin%2520type%2520I%2520receptor%2520%2528ALK4%2529%2520as%2520a%2520mediator%2520of%2520muscle%2520atrophy%2520and%2520muscle%2520regeneration%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D238%26epage%3D255%26doi%3D10.1096%2Ffj.201600675r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roman, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinck, A. P.</span></span> <span> </span><span class="NLM_article-title">ALK1 signaling in development and disease: new paradigms</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4560</span>, <span class="refDoi"> DOI: 10.1007/s00018-017-2636-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1007%2Fs00018-017-2636-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28871312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGjtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=4539-4560&author=B.+L.+Romanauthor=A.+P.+Hinck&title=ALK1+signaling+in+development+and+disease%3A+new+paradigms&doi=10.1007%2Fs00018-017-2636-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">ALK1 signaling in development and disease: new paradigms</span></div><div class="casAuthors">Roman, Beth L.; Hinck, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4539-4560</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Activin A receptor like type 1 (ALK1) is a transmembrane serine/threonine receptor kinase in the transforming growth factor-beta receptor family that is expressed on endothelial cells.  Defects in ALK1 signaling cause the autosomal dominant vascular disorder, hereditary hemorrhagic telangiectasia (HHT), which is characterized by development of direct connections between arteries and veins, or arteriovenous malformations (AVMs).  Although previous studies have implicated ALK1 in various aspects of sprouting angiogenesis, including tip/stalk cell selection, migration, and proliferation, recent work suggests an intriguing role for ALK1 in transducing a flow-based signal that governs directed endothelial cell migration within patent, perfused vessels.  In this review, we present an updated view of the mechanism of ALK1 signaling, put forth a unified hypothesis to explain the cellular missteps that lead to AVMs assocd. with ALK1 deficiency, and discuss emerging roles for ALK1 signaling in diseases beyond HHT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE3O14HSFxhrVg90H21EOLACvtfcHk0lj_u7Umtw3RlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGjtrfK&md5=838c08a79918a1c4d7114e71dad88188</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs00018-017-2636-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-017-2636-4%26sid%3Dliteratum%253Aachs%26aulast%3DRoman%26aufirst%3DB.%2BL.%26aulast%3DHinck%26aufirst%3DA.%2BP.%26atitle%3DALK1%2520signaling%2520in%2520development%2520and%2520disease%253A%2520new%2520paradigms%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D4539%26epage%3D4560%26doi%3D10.1007%2Fs00018-017-2636-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbicker, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartnikas, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmeyer, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span> <span> </span><span class="NLM_article-title">Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4224</span>– <span class="NLM_lpage">4230</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-03-339952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1182%2Fblood-2011-03-339952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21841161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlKgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=4224-4230&author=A.+U.+Steinbickerauthor=T.+B.+Bartnikasauthor=L.+K.+Lohmeyerauthor=P.+Leytonauthor=C.+Mayeurauthor=S.+M.+Kaoauthor=A.+E.+Pappasauthor=R.+T.+Petersonauthor=D.+B.+Blochauthor=P.+B.+Yuauthor=M.+D.+Flemingauthor=K.+D.+Bloch&title=Perturbation+of+hepcidin+expression+by+BMP+type+I+receptor+deletion+induces+iron+overload+in+mice&doi=10.1182%2Fblood-2011-03-339952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice</span></div><div class="casAuthors">Steinbicker, Andrea U.; Bartnikas, Thomas B.; Lohmeyer, Lisa K.; Leyton, Patricio; Mayeur, Claire; Kao, Sonya M.; Pappas, Alexandra E.; Peterson, Randall T.; Bloch, Donald B.; Yu, Paul B.; Fleming, Mark D.; Bloch, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4224-4230</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Bone morphogenetic protein (BMP) signaling induces hepatic expression of the peptide hormone hepcidin.  Hepcidin reduces serum iron levels by promoting degrdn. of the iron exporter ferroportin.  A relative deficiency of hepcidin underlies the pathophysiol. of many of the genetically distinct iron overload disorders, collectively termed hereditary hemochromatosis.  Conversely, chronic inflammatory conditions and neoplastic diseases can induce high hepcidin levels, leading to impaired mobilization of iron stores and the anemia of chronic disease.  Two BMP type I receptors, Alk2 (Acvr1) and Alk3 (Bmpr1a), are expressed in murine hepatocytes.  We report that liver-specific deletion of either Alk2 or Alk3 causes iron overload in mice.  The iron overload phenotype was more marked in Alk3- than in Alk2-deficient mice, and Alk3 deficiency was assocd. with a nearly complete ablation of basal BMP signaling and hepcidin expression.  Both Alk2 and Alk3 were required for induction of hepcidin gene expression by BMP2 in cultured hepatocytes or by iron challenge in vivo.  These observations demonstrate that one type I BMP receptor, Alk3, is critically responsible for basal hepcidin expression, whereas 2 type I BMP receptors, Alk2 and Alk3, are required for regulation of hepcidin gene expression in response to iron and BMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrhUIYdi5xUrVg90H21EOLACvtfcHk0lj_u7Umtw3RlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlKgtA%253D%253D&md5=7bcb4074bdc4b03c5dcc22403852af04</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-03-339952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-03-339952%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbicker%26aufirst%3DA.%2BU.%26aulast%3DBartnikas%26aufirst%3DT.%2BB.%26aulast%3DLohmeyer%26aufirst%3DL.%2BK.%26aulast%3DLeyton%26aufirst%3DP.%26aulast%3DMayeur%26aufirst%3DC.%26aulast%3DKao%26aufirst%3DS.%2BM.%26aulast%3DPappas%26aufirst%3DA.%2BE.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26aulast%3DBloch%26aufirst%3DD.%2BB.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DFleming%26aufirst%3DM.%2BD.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26atitle%3DPerturbation%2520of%2520hepcidin%2520expression%2520by%2520BMP%2520type%2520I%2520receptor%2520deletion%2520induces%2520iron%2520overload%2520in%2520mice%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D4224%26epage%3D4230%26doi%3D10.1182%2Fblood-2011-03-339952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goff, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyshchik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberasco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stampino, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span> <span> </span><span class="NLM_article-title">A Phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2154</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1158%2F1078-0432.CCR-15-1622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26655846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlOrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=2146-2154&author=L.+W.+Goffauthor=R.+B.+Cohenauthor=J.+D.+Berlinauthor=F.+G.+de+Braudauthor=A.+Lyshchikauthor=C.+Noberascoauthor=F.+Bertoliniauthor=M.+Carpentieriauthor=C.+G.+Stampinoauthor=A.+Abbattistaauthor=E.+Wangauthor=H.+Borghaei&title=A+Phase+I+study+of+the+anti-activin+receptor-like+kinase+1+%28ALK-1%29+monoclonal+antibody+PF-03446962+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-15-1622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Goff, Laura W.; Cohen, Roger B.; Berlin, Jordan D.; de Braud, Filippo G.; Lyshchik, Andrej; Noberasco, Cristina; Bertolini, Francesco; Carpentieri, Marina; Stampino, Corrado Gallo; Abbattista, Antonello; Wang, Erjan; Borghaei, Hossein</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2146-2154</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Objectives of this dose-finding study were to det. the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity in patients with advanced solid tumors.  Exptl. Design: This open-label, multicenter study was based on a 3+3 design.  PF-03446962 was administered biweekly by i.v. infusion, at doses ranging from 0.5 to 15 mg/kg.  Results: Forty-four patients received treatment with PF-03446962.  Dose-limiting toxicities obsd. during dose escalation included grade 3 increased amylase, grade 3/4 increased lipase, and grade 3/4 thrombocytopenia.  The MTD was detd. to be 10 mg/kg.  The RP2D was set at 7 mg/kg for patients with advanced solid tumors, based on the obsd. safety, pharmacokinetics, and antitumor activity.  The most-frequent treatment-related, all-grade adverse events included thrombocytopenia (20.5%), fatigue (15.9%), and nausea, increased amylase, and increased lipase (each 11.4%).  Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway.  None of the deaths was deemed to be treatment-related.  Three (6.8%) patients with advanced hepatocellular carcinoma, renal cell carcinoma, or non-small cell lung cancer achieved a partial response, and 12 (27.3%) patients had stable disease, across dose levels.  Contrast-enhanced ultrasound anal. of tumor vascularity showed redn. in tumor perfusion in 2 patients with stable disease following treatment with PF-03446962.  Conclusions: The clin. activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.  Clin Cancer Res; 22(9); 2146-54. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCU3F6ZAiwyrVg90H21EOLACvtfcHk0lgVvdr_FX5llg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlOrsLc%253D&md5=3e31a8c14d25fefd58830f62a2b7c74c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1622%26sid%3Dliteratum%253Aachs%26aulast%3DGoff%26aufirst%3DL.%2BW.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DBerlin%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DLyshchik%26aufirst%3DA.%26aulast%3DNoberasco%26aufirst%3DC.%26aulast%3DBertolini%26aufirst%3DF.%26aulast%3DCarpentieri%26aufirst%3DM.%26aulast%3DStampino%26aufirst%3DC.%2BG.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DBorghaei%26aufirst%3DH.%26atitle%3DA%2520Phase%2520I%2520study%2520of%2520the%2520anti-activin%2520receptor-like%2520kinase%25201%2520%2528ALK-1%2529%2520monoclonal%2520antibody%2520PF-03446962%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D2146%26epage%3D2154%26doi%3D10.1158%2F1078-0432.CCR-15-1622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pajouhesh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G. R.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry properties of successful central nervous system drugs</span>. <i>NeuroRx</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1602/neurorx.2.4.541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1602%2Fneurorx.2.4.541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=16489364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=541-553&author=H.+Pajouheshauthor=G.+R.+Lenz&title=Medicinal+chemistry+properties+of+successful+central+nervous+system+drugs&doi=10.1602%2Fneurorx.2.4.541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemical properties of successful central nervous system drugs</span></div><div class="casAuthors">Pajouhesh Hassan; Lenz George R</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-53</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity.  Factors relevant to the success of CNS drugs are reviewed.  CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics.  Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent.  The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters.  The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems.  This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_ncsy3yuEinl8icjszYl0fW6udTcc2ebtQat1Wz20R7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D&md5=0815084e2d107b9243b785d0782dfc3a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.4.541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.4.541%26sid%3Dliteratum%253Aachs%26aulast%3DPajouhesh%26aufirst%3DH.%26aulast%3DLenz%26aufirst%3DG.%2BR.%26atitle%3DMedicinal%2520chemistry%2520properties%2520of%2520successful%2520central%2520nervous%2520system%2520drugs%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D541%26epage%3D553%26doi%3D10.1602%2Fneurorx.2.4.541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS drug design: balancing physicochemical properties for optimal brain exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0lgVvdr_FX5llg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitors for the treatment of brain cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10030</span>– <span class="NLM_lpage">10066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10030-10066&author=T.+P.+Heffron&title=Small+molecule+kinase+inhibitors+for+the+treatment+of+brain+cancer&doi=10.1021%2Facs.jmedchem.6b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</span></div><div class="casAuthors">Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10030-10066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to each of the factors that govern the identification of a successful oncol. drug candidate, drug discovery aimed at treating neurol. cancer must also consider the presence of the blood-brain barrier (BBB).  The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small mols. from freely reaching the brain, where neurooncol. malignancies reside.  Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable.  This Perspective discusses the unmet need for neurooncol. treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clin. inhibitors of kinases that are of interest for the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqij86WIpk16LVg90H21EOLACvtfcHk0lhwCHlRYSPZiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E&md5=7e184f17a60658174cb44a9fbadc8dfd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10030%26epage%3D10066%26doi%3D10.1021%2Facs.jmedchem.6b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanguinetti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tristani-Firouzi, M.</span></span> <span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>440</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1038/nature04710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia&doi=10.1038%2Fnature04710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0lhwCHlRYSPZiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469%26doi%3D10.1038%2Fnature04710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. R.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1007/s40264-013-0047-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1007%2Fs40264-013-0047-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=23620167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=295-316&author=R.+R.+Shahauthor=J.+Morganrothauthor=D.+R.+Shah&title=Cardiovascular+safety+of+tyrosine+kinase+inhibitors%3A+with+a+special+focus+on+cardiac+repolarisation+%28QT+interval%29&doi=10.1007%2Fs40264-013-0047-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)</span></div><div class="casAuthors">Shah, Rashmi R.; Morganroth, Joel; Shah, Devron R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">295-316</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The development of tyrosine kinase inhibitors (TKI) represents a major milestone in oncol.  However, their use has been found to be assocd. with serious toxicities that impinge on various vital organs including the heart.  Sixteen TKIs have been approved for use in oncol. as of 30 Sept. 2012, and a large no. of others are in development or under regulatory review.  Cardiovascular safety of medicinal products is a major public health issue that has concerned all the stakeholders.  This review focuses on three specific cardiovascular safety aspects of TKIs, namely their propensity to induce QT interval prolongation, left ventricular (LV) dysfunction and hypertension (both systemic and pulmonary).  Analyses of information in drug labels, the data submitted to the regulatory authorities and the published literature show that a no. of TKIs are assocd. with these undesirable effects.  Whereas LV dysfunction and systemic hypertension are on-target effects related to the inhibition of ligand-related signalling pathways, QT interval prolongation appears to be an off-target class III electrophysiol. effect, possibly related to the presence of a fluorine-based pharmacophore.  If not adequately managed, these cardiovascular effects significantly increase the morbidity and mortality in a population already at high risk.  Hitherto, the QT effect of most QT-prolonging TKIs (except lapatinib, nilotinib, sunitinib and vandetanib) is relatively mild at clin. doses and has not led to appreciable morbidity clin.  In contrast, LV dysfunction and untreated hypertension have resulted in significant morbidity.  Inevitably, dilemmas arise in detg. the risk/benefit of a TKI therapy in an individual patient who develops any of these effects following the treatment of the TKI-sensitive cancer.  QT interval prolongation, hypertension and LV dysfunction can be managed effectively by using reliable methods of measurement and careful monitoring of patients whose clin. management requires optimization by a close collaboration between an oncologist and a cardiologist, an evolving subspecialty referred to as cardio-oncol.  Despite their potential adverse clin. impact, the effects of TKIs on hypertension and LV function are generally inadequately characterised during their development.  As has been the case with QT liability of drugs, there is now a persuasive case for a regulatory requirement to study TKIs systematically for these effects.  Furthermore, since most of these novel drugs are studied in trials with relatively small sample sizes and approved on an expedited basis, there is also a compelling case for their effective pharmacovigilance and on-going reassessment of their risk/benefit after approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgTIlxLItaUbVg90H21EOLACvtfcHk0lhVJw5FufDdhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsL3L&md5=7e24ea72e614d9b85a87dbc88a973c58</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs40264-013-0047-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-013-0047-5%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%2BR.%26aulast%3DMorganroth%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DD.%2BR.%26atitle%3DCardiovascular%2520safety%2520of%2520tyrosine%2520kinase%2520inhibitors%253A%2520with%2520a%2520special%2520focus%2520on%2520cardiac%2520repolarisation%2520%2528QT%2520interval%2529%26jtitle%3DDrug%2520Saf.%26date%3D2013%26volume%3D36%26spage%3D295%26epage%3D316%26doi%3D10.1007%2Fs40264-013-0047-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smil, D.</span>; <span class="NLM_string-name">McLeod, D. A.</span>; <span class="NLM_string-name">O’Meara, J. A.</span>; <span class="NLM_string-name">Isaac, M. B.</span></span> Unpublished results. Data can be viewed in presentations archived at <a href="https://m4kpharma.com/blog/" class="extLink">https://m4kpharma.com/blog/</a> (accessed Jul 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Smil%2C+D.%3B+McLeod%2C+D.+A.%3B+O%E2%80%99Meara%2C+J.+A.%3B+Isaac%2C+M.+B.+Unpublished+results.+Data+can+be+viewed+in+presentations+archived+at+https%3A%2F%2Fm4kpharma.com%2Fblog%2F+%28accessed+Jul+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DSmil%26aufirst%3DD." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ensan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zepeda-Velázquez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panagopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4978</span>– <span class="NLM_lpage">4996</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVCms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4978-4996&author=D.+Ensanauthor=D.+Smilauthor=C.+A.+Zepeda-Vel%C3%A1zquezauthor=D.+Panagopoulosauthor=J.+F.+Wongauthor=E.+P.+Williamsauthor=R.+Adamsonauthor=A.+N.+Bullockauthor=T.+Kiyotaauthor=A.+Amanauthor=O.+G.+Robertsauthor=A.+M.+Edwardsauthor=J.+A.+O%E2%80%99Mearaauthor=M.+B.+Isaacauthor=R.+Al-awar&title=Targeting+ALK2%3A+an+open+science+approach+to+developing+therapeutics+for+the+treatment+of+diffuse+intrinsic+pontine+glioma&doi=10.1021%2Facs.jmedchem.0c00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma</span></div><div class="casAuthors">Ensan, Deeba; Smil, David; Zepeda-Velazquez, Carlos A.; Panagopoulos, Dimitrios; Wong, Jong Fu; Williams, Eleanor P.; Adamson, Roslin; Bullock, Alex N.; Kiyota, Taira; Aman, Ahmed; Roberts, Owen G.; Edwards, Aled M.; O'Meara, Jeff A.; Isaac, Methvin B.; Al-awar, Rima</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4978-4996</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist.  Anal. of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention.  In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant.  Initial efforts resulted in the discovery of M4K2009 (I), an analog of the previously reported ALK2 inhibitor LDN-214117.  Although highly selective for ALK2 over the TGF-βR1 receptor ALK5, M4K2009 is also moderately active against the hERG potassium channel.  Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analog M4K2149 (II) with reduced off-target affinity for the ion channel.  Addnl. modifications yielded 2-fluoro-6-methoxybenzamide derivs. (26a(III)-c), which possess high inhibitory activity against ALK2, excellent selectivity, and superior pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi_5prjgzaG7Vg90H21EOLACvtfcHk0lhVJw5FufDdhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVCms7Y%253D&md5=6213b81cf89f37b0b8157e0e799ed5d6</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00395%26sid%3Dliteratum%253Aachs%26aulast%3DEnsan%26aufirst%3DD.%26aulast%3DSmil%26aufirst%3DD.%26aulast%3DZepeda-Vel%25C3%25A1zquez%26aufirst%3DC.%2BA.%26aulast%3DPanagopoulos%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DJ.%2BF.%26aulast%3DWilliams%26aufirst%3DE.%2BP.%26aulast%3DAdamson%26aufirst%3DR.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DKiyota%26aufirst%3DT.%26aulast%3DAman%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DO.%2BG.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DJ.%2BA.%26aulast%3DIsaac%26aufirst%3DM.%2BB.%26aulast%3DAl-awar%26aufirst%3DR.%26atitle%3DTargeting%2520ALK2%253A%2520an%2520open%2520science%2520approach%2520to%2520developing%2520therapeutics%2520for%2520the%2520treatment%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4978%26epage%3D4996%26doi%3D10.1021%2Facs.jmedchem.0c00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span>Predicted
cLogP, pKa, and tPSA values were calculated using ChemDraw Professional
17.1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Predicted%0AcLogP%2C+pKa%2C+and+tPSA+values+were+calculated+using+ChemDraw+Professional%0A17.1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poluzzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span> <span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3844</span>– <span class="NLM_lpage">3853</span>, <span class="refDoi"> DOI: 10.1021/jm0208875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers&doi=10.1021%2Fjm0208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0lg2lnwn6jrtDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853%26doi%3D10.1021%2Fjm0208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lg2lnwn6jrtDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Röder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lg2lnwn6jrtDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span> <span> </span><span class="NLM_article-title">Rational use of plasma protein and tissue binding data in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8238</span>– <span class="NLM_lpage">8248</span>, <span class="refDoi"> DOI: 10.1021/jm5007935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+use+of+plasma+protein+and+tissue+binding+data+in+drug+design&doi=10.1021%2Fjm5007935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0lg2lnwn6jrtDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520use%2520of%2520plasma%2520protein%2520and%2520tissue%2520binding%2520data%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248%26doi%3D10.1021%2Fjm5007935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakkalakal, S. A.</span>; <span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva</span>. In  <i>Bone Morphogenetic Proteins: Methods and Protocols (Methods in Molecular Biology)</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. B.</span></span>, Ed.; <span class="NLM_publisher-name">Springer Nature</span>: <span class="NLM_publisher-loc">Berlin</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">1891</span>, pp  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">255</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1007%2F978-1-4939-8904-1_18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=247-255&author=S.+A.+Chakkalakal&author=E.+M.+Shoreauthor=M.+B.+Rogers&title=Bone+Morphogenetic+Proteins%3A+Methods+and+Protocols+%28Methods+in+Molecular+Biology%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-8904-1_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-8904-1_18%26sid%3Dliteratum%253Aachs%26aulast%3DChakkalakal%26aufirst%3DS.%2BA.%26atitle%3DHeterotopic%2520Ossification%2520in%2520Mouse%2520Models%2520of%2520Fibrodysplasia%2520Ossificans%2520Progressiva%26btitle%3DBone%2520Morphogenetic%2520Proteins%253A%2520Methods%2520and%2520Protocols%2520%2528Methods%2520in%2520Molecular%2520Biology%2529%26aulast%3DRogers%26aufirst%3DM.%2BB.%26pub%3DSpringer%2520Nature%26date%3D2019%26volume%3D1891%26spage%3D247%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">xia2: an expert system for macromolecular crystallography data reduction</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1107/S0021889809045701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0021889809045701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=186-190&author=G.+Winter&title=xia2%3A+an+expert+system+for+macromolecular+crystallography+data+reduction&doi=10.1107%2FS0021889809045701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">xia2: An expert system for macromolecular crystallography data reduction</span></div><div class="casAuthors">Winter, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-190, S186/1-S186/5</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An expert system for macromol. crystallog. data redn. is presented, which builds on existing software to automate the complete data redn. process from images to merged structure factor amplitudes.  This can automatically identify multi-wedge, multi-pass and multiwavelength data sets and includes explicit procedures to test for crystallog. special cases.  With the push towards high-throughput crystallog. at synchrotron beamlines and automation of structure soln., the ability to reduce data with no user input fills an important gap in the pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOi3u0ydXbSrVg90H21EOLACvtfcHk0liqyt_gR8dNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D&md5=27771caa813f3e828abdf2a331ae55e3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1107%2FS0021889809045701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889809045701%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%26atitle%3Dxia2%253A%2520an%2520expert%2520system%2520for%2520macromolecular%2520crystallography%2520data%2520reduction%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2010%26volume%3D43%26spage%3D186%26epage%3D190%26doi%3D10.1107%2FS0021889809045701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0liqyt_gR8dNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0liqyt_gR8dNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lirPEFKeoyO3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lirPEFKeoyO3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaver-Fay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeyink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">W375</span>– <span class="NLM_lpage">W383</span>, <span class="refDoi"> DOI: 10.1093/nar/gkm216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1093%2Fnar%2Fgkm216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17452350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=W375-W383&author=I.+W.+Davisauthor=A.+Leaver-Fayauthor=V.+B.+Chenauthor=J.+N.+Blockauthor=G.+J.+Kapralauthor=X.+Wangauthor=L.+W.+Murrayauthor=W.+B.+Arendallauthor=J.+Snoeyinkauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+contacts+and+structure+validation+for+proteins+and+nucleic+acids&doi=10.1093%2Fnar%2Fgkm216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span></div><div class="casAuthors">Davis Ian W; Leaver-Fay Andrew; Chen Vincent B; Block Jeremy N; Kapral Gary J; Wang Xueyi; Murray Laura W; Arendall W Bryan 3rd; Snoeyink Jack; Richardson Jane S; Richardson David C</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">Web Server issue</span>),
    <span class="NLM_cas:pages">W375-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MolProbity is a general-purpose web server offering quality validation for 3D structures of proteins, nucleic acids and complexes.  It provides detailed all-atom contact analysis of any steric problems within the molecules as well as updated dihedral-angle diagnostics, and it can calculate and display the H-bond and van der Waals contacts in the interfaces between components.  An integral step in the process is the addition and full optimization of all hydrogen atoms, both polar and nonpolar.  New analysis functions have been added for RNA, for interfaces, and for NMR ensembles.  Additionally, both the web site and major component programs have been rewritten to improve speed, convenience, clarity and integration with other resources.  MolProbity results are reported in multiple forms: as overall numeric scores, as lists or charts of local problems, as downloadable PDB and graphics files, and most notably as informative, manipulable 3D kinemage graphics shown online in the KiNG viewer.  This service is available free to all users at http://molprobity.biochem.duke.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuyhuetoNS59bHMBt0mMIXfW6udTcc2eZhjOnyh2TgPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D&md5=726ca1e7e162ab2a4a05048f493731fb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm216%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DLeaver-Fay%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DBlock%26aufirst%3DJ.%2BN.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DSnoeyink%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520contacts%2520and%2520structure%2520validation%2520for%2520proteins%2520and%2520nucleic%2520acids%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2007%26volume%3D35%26spage%3DW375%26epage%3DW383%26doi%3D10.1093%2Fnar%2Fgkm216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Emily Murrell, Junchao Tong, David Smil, Taira Kiyota, Ahmed M. Aman, Methvin B. Isaac, Iain D. G. Watson, <span class="NLM_string-name hlFld-ContribAuthor">Neil Vasdev</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 846-850. <a href="https://doi.org/10.1021/acsmedchemlett.1c00127" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00127%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLeveraging%252BOpen%252BScience%252BDrug%252BDevelopment%252Bfor%252BPET%25253A%252BPreliminary%252BNeuroimaging%252Bof%252B11C-Labeled%252BALK2%252BInhibitors%26aulast%3DMurrell%26aufirst%3DEmily%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02032021%26date%3D21042021%26date%3D23042021%26volume%3D12%26issue%3D5%26spage%3D846%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugene N.  Muratov</span>, <span class="hlFld-ContribAuthor ">Rommie  Amaro</span>, <span class="hlFld-ContribAuthor ">Carolina H.  Andrade</span>, <span class="hlFld-ContribAuthor ">Nathan  Brown</span>, <span class="hlFld-ContribAuthor ">Sean  Ekins</span>, <span class="hlFld-ContribAuthor ">Denis  Fourches</span>, <span class="hlFld-ContribAuthor ">Olexandr  Isayev</span>, <span class="hlFld-ContribAuthor ">Dima  Kozakov</span>, <span class="hlFld-ContribAuthor ">José L.  Medina-Franco</span>, <span class="hlFld-ContribAuthor ">Kenneth M.  Merz</span>, <span class="hlFld-ContribAuthor ">Tudor I.  Oprea</span>, <span class="hlFld-ContribAuthor ">Vladimir  Poroikov</span>, <span class="hlFld-ContribAuthor ">Gisbert  Schneider</span>, <span class="hlFld-ContribAuthor ">Matthew H.  Todd</span>, <span class="hlFld-ContribAuthor ">Alexandre  Varnek</span>, <span class="hlFld-ContribAuthor ">David A.  Winkler</span>, <span class="hlFld-ContribAuthor ">Alexey V.  Zakharov</span>, <span class="hlFld-ContribAuthor ">Artem  Cherkasov</span>, <span class="hlFld-ContribAuthor ">Alexander  Tropsha</span>. </span><span class="cited-content_cbyCitation_article-title">A critical overview of computational approaches employed for COVID-19 drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>581 </em><a href="https://doi.org/10.1039/D0CS01065K" title="DOI URL">https://doi.org/10.1039/D0CS01065K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS01065K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS01065K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DA%252Bcritical%252Boverview%252Bof%252Bcomputational%252Bapproaches%252Bemployed%252Bfor%252BCOVID-19%252Bdrug%252Bdiscovery%26aulast%3DMuratov%26aufirst%3DEugene%2BN.%26date%3D2021%26date%3D2021%26volume%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Reported ALK2 inhibitors based on pyrazolo[1,5-<i>a</i>]pyrimidine (blue), 3,5-diphenylpyridine (black), bis-heteroaryl pyrazole (red), quinazolinone (magenta), and macrocyclic (green) scaffolds. (B) Cocrystal structure of prototypic 3,5-diphenylpyridine inhibitor <b>LDN-213844</b> (yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>6a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), Pd(dppf)Cl<sub>2</sub>·dichloromethane (DCM), Na<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF)/H<sub>2</sub>O, 100 °C, 16 h for <b>1a</b>, <b>1d–e</b>, <b>1g</b>, <b>1i</b> and XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h for <b>1b–c</b>, <b>1f</b>, <b>1h</b>; (b) <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (<b>4</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h; (c) 4 M HCl in dioxane, MeOH, room temperature (rt), 30 min.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystal structure of <b>6a</b> (yellow) with ALK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM">6SZM</a>). Hydrogen bonds are established with H286 and K235. The 3,4,5-trimethoxyphenyl moiety of <b>6a</b> occupies a hydrophobic pocket (green) of ALK2 and is flanked by several hydrogen bond-donating (blue; K235) and hydrogen bond-accepting residues (red; D354 and E248). The protonated piperazine motif is in close proximity to D293, indicative of an electrostatic interaction. (B) Plot detailing the interactions of <b>6a</b> (black) within the ALK2 pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>11a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (<b>4</b>), Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O, 100 °C, 16 h; (b) 3,5-dimethoxyphenylboronic acid (<b>8</b>) or (4-fluoro-3,5-dimethoxyphenyl)boronic acid (<b>9</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h; (c) 4 M HCl in dioxane, MeOH, rt, 30 min.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/medium/jm0c01199_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>14a</b>–<b>q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01199&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3,4,5-trimethoxyphenylboronic acid (<b>2</b>), Pd(dppf)Cl<sub>2</sub>·DCM, Na<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O, 100 °C, 16 h; (b) 4-(R<sub>1</sub>)phenylboronic acid or pinacol ester (<b>12a</b>–<b>c</b> and <b>12h</b>–<b>q</b>), XPhos Pd G2, K<sub>3</sub>PO<sub>4</sub>, butanol/H<sub>2</sub>O, 100 °C, 4 h; (c) [<b>13c</b>, <b>13j</b>, <b>13l</b>, <b>13n</b>, <b>13p</b>], 4 M HCl in dioxane, MeOH, rt, 30 min; (d) <b>R</b><sub><b>2</b></sub><b>OTs</b>, triethylamine (TEA), acetonitrile, 100 °C, 16 h for <b>14d</b>; (e) <b>R</b><sub><b>2</b></sub><b>Cl</b>, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), tetrahydrofuran (THF), rt, 1 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 69 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allemani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M. P.</span></span> <span> </span><span class="NLM_article-title">Worldwide trends in survival from common childhood brain tumors: a systematic review</span>. <i>J. Global Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1200/JGO.19.00140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1200%2FJGO.19.00140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3MjkslChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=1-25&author=F.+Girardiauthor=C.+Allemaniauthor=M.+P.+Coleman&title=Worldwide+trends+in+survival+from+common+childhood+brain+tumors%3A+a+systematic+review&doi=10.1200%2FJGO.19.00140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review</span></div><div class="casAuthors">Girardi Fabio; Allemani Claudia; Coleman Michel P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of global oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The histology of brain tumors determines treatment and predicts outcome.  Population-based survival reflects the effectiveness of a health care system in managing cancer.  No systematic review of worldwide variation and time trends in survival from brain tumors in children is currently available.  PATIENTS AND METHODS:  We considered longitudinal, observational studies comprising children diagnosed with intracranial astrocytic or embryonal tumors.  We searched six electronic databases from database inception to September 30, 2018, using complex search strategies.  The outcome measure was 5-year survival, estimated through a time-to-event analysis.  This study is registered with PROSPERO, number CRD42018111981.  RESULTS:  Among 5,244 studies, we identified 47 eligible articles that provided 228 survival estimates.  Only five studies were entirely or partially conducted in low-income or middle-income countries.  Five-year survival from embryonal tumors increased from 37% in 1980 to approximately 60% in 2009.  Although survival for medulloblastoma improved substantially (from 29% to 73% during 1959-2009), survival for primitive neuroectodermal tumors wavered over time (1973-2009) and between countries.  Five-year survival from astrocytoma changed very little over the 27 years between 1982 and 2009 (from 78% to 89%).  Interpretation of the literature was made difficult by the heterogeneity of study designs.  CONCLUSION:  Survival has improved for embryonal tumors, but little change has been observed for astrocytic tumors.  We found a striking gap in knowledge about survival from childhood brain tumor subtypes in middle-income and low-income countries, where half of these tumors are diagnosed.  Larger studies are needed, including in under-represented countries and based on standardized data collection, to provide up-to-date survival estimates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS06p2BKJnqagWRJ3OJdH_qfW6udTcc2ebrtBe5NCHg6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjkslChtw%253D%253D&md5=d66faeb7beecf7c31894d49ff552b677</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJGO.19.00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJGO.19.00140%26sid%3Dliteratum%253Aachs%26aulast%3DGirardi%26aufirst%3DF.%26aulast%3DAllemani%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DM.%2BP.%26atitle%3DWorldwide%2520trends%2520in%2520survival%2520from%2520common%2520childhood%2520brain%2520tumors%253A%2520a%2520systematic%2520review%26jtitle%3DJ.%2520Global%2520Oncol.%26date%3D2019%26volume%3D5%26spage%3D1%26epage%3D25%26doi%3D10.1200%2FJGO.19.00140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacifici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.cytogfr.2015.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26776312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=93-104&author=M.+Pacificiauthor=E.+M.+Shore&title=Common+mutations+in+ALK2%2FACVR1%2C+a+multi-faceted+receptor%2C+have+roles+in+distinct+pediatric+musculoskeletal+and+neural+orphan+disorders&doi=10.1016%2Fj.cytogfr.2015.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders</span></div><div class="casAuthors">Pacifici, Maurizio; Shore, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-104</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activin receptor-like kinase-2 (ALK2), the product of ACVR1, is a member of the type I bone morphogenetic protein (BMP) receptor family.  ALK2 exerts key and non-redundant roles in numerous developmental processes, including the specification, growth and morphogenesis of endochondral skeletal elements.  There is also strong evidence that BMP signaling plays important roles in detn., differentiation and function of neural cells and tissues.  Here we focus on the intriguing discovery that common activating mutations in ALK2 occur in Fibrodysplasia Ossificans Progressiva (FOP) and Diffuse Intrinsic Pontine Gliomas (DIPGs), distinct pediatric disorders of significant severity that are assocd. with premature death.  Pathogenesis and treatment remain elusive for both.  We consider recent studies on the nature of the ACVR1 mutations, possible modes of action and targets, and plausible therapeutic measures.  Comparisons of the diverse - but genetically interrelated - pathologies of FOP and DIPG will continue to be of major mutual benefit with broad biomedical and clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwM08RQn6m7LVg90H21EOLACvtfcHk0lje_mWrIejgtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCktQ%253D%253D&md5=1b6f732518596d155f46178c2743d841</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DPacifici%26aufirst%3DM.%26aulast%3DShore%26aufirst%3DE.%2BM.%26atitle%3DCommon%2520mutations%2520in%2520ALK2%252FACVR1%252C%2520a%2520multi-faceted%2520receptor%252C%2520have%2520roles%2520in%2520distinct%2520pediatric%2520musculoskeletal%2520and%2520neural%2520orphan%2520disorders%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2016%26volume%3D27%26spage%3D93%26epage%3D104%26doi%3D10.1016%2Fj.cytogfr.2015.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truffaux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span> <span> </span><span class="NLM_article-title">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1038/ng.2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fng.2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=24705252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=457-461&author=K.+R.+Taylorauthor=A.+Mackayauthor=N.+Truffauxauthor=Y.+S.+Butterfieldauthor=O.+Morozovaauthor=C.+Philippeauthor=D.+Castelauthor=C.+S.+Grassoauthor=M.+Vinciauthor=D.+Carvalhoauthor=A.+M.+Carcabosoauthor=C.+de+Torresauthor=O.+Cruzauthor=J.+Moraauthor=N.+Entz-Werleauthor=W.+J.+Ingramauthor=M.+Monjeauthor=D.+Hargraveauthor=A.+N.+Bullockauthor=S.+Pugetauthor=S.+Yipauthor=C.+Jonesauthor=J.+Grill&title=Recurrent+activating+ACVR1+mutations+in+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fng.2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Taylor, Kathryn R.; Mackay, Alan; Truffaux, Nathalene; Butterfield, Yaron S.; Morozova, Olena; Philippe, Cathy; Castel, David; Grasso, Catherine S.; Vinci, Maria; Carvalho, Diana; Carcaboso, Angel M.; de Torres, Carmen; Cruz, Ofelia; Mora, Jaume; Entz-Werle, Natacha; Ingram, Wendy J.; Monje, Michelle; Hargrave, Darren; Bullock, Alex N.; Puget, Stephanie; Yip, Stephen; Jones, Chris; Grill, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-461</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clin. outcome.  The median survival time is 9-12 mo, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clin. trials in children with these tumors.  We report the identification of recurrent activating mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG samples.  Strikingly, these somatic mutations (encoding p.Arg206His, p.Arg258Gly, p.Gly328Glu, p.Gly328Val, p.Gly328Trp and p.Gly356Asp substitutions) have not been reported previously in cancer but are identical to mutations found in the germ line of individuals with the congenital childhood developmental disorder fibrodysplasia ossificans progressiva (FOP) and have been shown to constitutively activate the BMP-TGF-β signaling pathway.  These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMRfkuGtWYWLVg90H21EOLACvtfcHk0lieiGanCzHafg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Kgtbw%253D&md5=69fb86fc99975a0f0dbaa060141788a4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fng.2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2925%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DTruffaux%26aufirst%3DN.%26aulast%3DButterfield%26aufirst%3DY.%2BS.%26aulast%3DMorozova%26aufirst%3DO.%26aulast%3DPhilippe%26aufirst%3DC.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DGrasso%26aufirst%3DC.%2BS.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3Dde%2BTorres%26aufirst%3DC.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DEntz-Werle%26aufirst%3DN.%26aulast%3DIngram%26aufirst%3DW.%2BJ.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DGrill%26aufirst%3DJ.%26atitle%3DRecurrent%2520activating%2520ACVR1%2520mutations%2520in%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D457%26epage%3D461%26doi%3D10.1038%2Fng.2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutka, J. T.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: clinical features, molecular genetics, and novel targeted therapeutics</span>. <i>J. Korean Neurosurg. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.3340/jkns.2018.0008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.3340%2Fjkns.2018.0008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=29742880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=343-351&author=R.+K.+Mathewauthor=J.+T.+Rutka&title=Diffuse+intrinsic+pontine+glioma%3A+clinical+features%2C+molecular+genetics%2C+and+novel+targeted+therapeutics&doi=10.3340%2Fjkns.2018.0008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma : clinical features, molecular genetics, and novel targeted therapeutics</span></div><div class="casAuthors">Mathew, Ryan K.; Rutka, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Neurosurgical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-351</span>CODEN:
                <span class="NLM_cas:coden">JKNSAI</span>;
        ISSN:<span class="NLM_cas:issn">1598-7876</span>.
    
            (<span class="NLM_cas:orgname">Korean Neurosurgical Society</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a deadly paediatric brain cancer.  Transient response to radiation, ineffective chemotherapeutic agents and aggressive biol. result in rapid progression of symptoms and a dismal prognosis.  Increased availability of tumor tissue has enabled the identification of histone gene aberrations, genetic driver mutations and methylation changes, which have resulted in mol. and phenotypic subgrouping.  However, many of the underlying mechanisms of DIPG oncogenesis remain unexplained.  It is hoped that more representative in vitro and preclin. models-using both xenografted material and genetically engineered mice-will enable the development of novel chemotherapeutic agents and strategies for targeted drug delivery.  This review provides a clin. overview of DIPG, the barriers to progress in developing effective treatment, updates on drug development and preclin. models, and an introduction to new technologies aimed at enhancing drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohREcp3C8kCLVg90H21EOLACvtfcHk0lieiGanCzHafg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVenurfJ&md5=0f37c4371f752f813af3014085c0dca3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3340%2Fjkns.2018.0008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3340%252Fjkns.2018.0008%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DR.%2BK.%26aulast%3DRutka%26aufirst%3DJ.%2BT.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520clinical%2520features%252C%2520molecular%2520genetics%252C%2520and%2520novel%2520targeted%2520therapeutics%26jtitle%3DJ.%2520Korean%2520Neurosurg.%2520Soc.%26date%3D2018%26volume%3D61%26spage%3D343%26epage%3D351%26doi%3D10.3340%2Fjkns.2018.0008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldhuijzen van Zanten, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colditz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartels, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouffet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minturn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chintagumpala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carret, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escorza, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dholaria, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doughman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drissi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddaert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varlet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulleman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giagnacovo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bueren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanki, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadrijevic Cvrlje, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandertop, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biassoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massimino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calmon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bison, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth-Metz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vuurden, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramm, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouladi, M.</span></span> <span> </span><span class="NLM_article-title">Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and european society for pediatric oncology DIPG registries</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1972</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.75.9308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1200%2FJCO.2017.75.9308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=29746225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1963-1972&author=L.+M.+Hoffmanauthor=S.+E.+M.+Veldhuijzen+van+Zantenauthor=N.+Colditzauthor=J.+Baughauthor=B.+Chaneyauthor=M.+Hoffmannauthor=A.+Laneauthor=C.+Fullerauthor=L.+Milesauthor=C.+Hawkinsauthor=U.+Bartelsauthor=E.+Bouffetauthor=S.+Goldmanauthor=S.+Learyauthor=N.+K.+Foremanauthor=R.+Packerauthor=K.+E.+Warrenauthor=A.+Broniscerauthor=M.+W.+Kieranauthor=J.+Minturnauthor=M.+Comitoauthor=E.+Broxsonauthor=C.+S.+Shihauthor=S.+Khatuaauthor=M.+Chintagumpalaauthor=A.+S.+Carretauthor=N.+Y.+Escorzaauthor=T.+Hassallauthor=D.+S.+Zieglerauthor=N.+Gottardoauthor=H.+Dholariaauthor=R.+Doughmanauthor=M.+Beneschauthor=R.+Drissiauthor=J.+Nazarianauthor=N.+Jabadoauthor=N.+Boddaertauthor=P.+Varletauthor=G.+Giraudauthor=D.+Castelauthor=S.+Pugetauthor=C.+Jonesauthor=E.+Hullemanauthor=P.+Modenaauthor=M.+Giagnacovoauthor=M.+Antonelliauthor=T.+Pietschauthor=G.+H.+Gielenauthor=D.+T.+W.+Jonesauthor=D.+Sturmauthor=S.+M.+Pfisterauthor=N.+U.+Gerberauthor=M.+A.+Grotzerauthor=E.+Pfaffauthor=A.+O.+von+Buerenauthor=D.+Hargraveauthor=G.+A.+Solankiauthor=F.+Jadrijevic+Cvrljeauthor=G.+J.+L.+Kaspersauthor=W.+P.+Vandertopauthor=J.+Grillauthor=S.+Baileyauthor=V.+Biassoniauthor=M.+Massiminoauthor=R.+Calmonauthor=E.+Sanchezauthor=B.+Bisonauthor=M.+Warmuth-Metzauthor=J.+Leachauthor=B.+Jonesauthor=D.+G.+van+Vuurdenauthor=C.+M.+Krammauthor=M.+Fouladi&title=Clinical%2C+radiologic%2C+pathologic%2C+and+molecular+characteristics+of+long-term+survivors+of+diffuse+intrinsic+pontine+glioma+%28DIPG%29%3A+a+collaborative+report+from+the+international+and+european+society+for+pediatric+oncology+DIPG+registries&doi=10.1200%2FJCO.2017.75.9308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of Diffuse Intrinsic Pontine Glioma (DIPG): a collaborative report from the international and european society for pediatric oncology DIPG registries</span></div><div class="casAuthors">Hoffman, Lindsey M.; Veldhuijzen van Zanten, Sophie E. M.; Colditz, Niclas; Baugh, Joshua; Chaney, Brooklyn; Hoffmann, Marion; Lane, Adam; Fuller, Christine; Miles, Lili; Hawkins, Cynthia; Bartels, Ute; Bouffet, Eric; Goldman, Stewart; Leary, Sarah; Foreman, Nicholas K.; Packer, Roger; Warren, Katherine E.; Broniscer, Alberto; Kieran, Mark W.; Minturn, Jane; Comito, Melanie; Broxson, Emmett; Shih, Chie-Schin; Khatua, Soumen; Chintagumpala, Murali; Carret, Anne Sophie; Escorza, Nancy Yanez; Hassall, Timothy; Ziegler, David S.; Gottardo, Nicholas; Dholaria, Hetal; Doughman, Renee; Benesch, Martin; Drissi, Rachid; Nazarian, Javad; Jabado, Nada; Boddaert, Nathalie; Varlet, Pascale; Giraud, Geraldine; Castel, David; Puget, Stephanie; Jones, Chris; Hulleman, Esther; Modena, Piergiorgio; Giagnacovo, Marzia; Antonelli, Manila; Pietsch, Torsten; Gielen, Gerrit H.; Jones, David T. W.; Sturm, Dominik; Pfister, Stefan M.; Gerber, Nicolas U.; Grotzer, Michael A.; Pfaff, Elke; von Bueren, Andre O.; Hargrave, Darren; Solanki, Guirish A.; Cvrlje, Filip Jadrijevic; Kaspers, Gertjan J. L.; Vandertop, William P.; Grill, Jacques; Bailey, Simon; Biassoni, Veronica; Massimino, Maura; Calmon, Raphael; Sanchez, Esther; Bison, Brigitte; Warmuth-Metz, Monika; Leach, James; Jones, Blaise; van Vuurden, Dannis G.; Kramm, Christof M.; Fouladi, Maryam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1963-1978</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of > 1 yr.  The International and European Society for Pediatric Oncol. DIPG Registries collaborated to compare clin., radiol., and histomol. characteristics between short-term survivors (STSs) and long-term survivors (LTSs).  Materials and Methods Data abstracted from registry databases included patients from North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia.  Results Among 1,130 pediatric and young adults with radiog. confirmed DIPG, 122 (11%) were excluded.  Of the 1,008 remaining patients, 101 (10%) were LTSs (survival ≥ 2 years).  Median survival time was 11 mo (interquartile range, 7.5 to 16 mo), and 1-, 2-, 3-, 4-, and 5-yr survival rates were 42.3%(95%CI, 38.1%to 44.1%), 9.6%(95% CI, 7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI, 2.4%to 4.6%), and 2.2% (95%CI, 1.4%to 3.4%), resp.  LTSs, compared with STSs, more commonly presented at age < 3 or ≥ 10 years (11% v 3% and 33% v 23%, resp.; P < .001) and with longer symptom duration (P < .001).  STSs, compared with LTSs, more commonly presented with cranial nerve palsy (83% v 73%, resp.; P = .008), ring enhancement (38% v23%, resp.; P = .007), necrosis (42% v 26%, resp.; P = .009), and extrapontine extension (92% v 86%, resp.; P = .04).  LTSs more commonly received systemic therapy at diagnosis (88% v 75% for STSs; P = .005).  Biopsies and autopsies were performed in 299 patients (30%) and 77 patients (10%), resp.; 181 tumors (48%) were molecularly characterized.  LTSs were more likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002).  Conclusion We report clin., radiol., and mol. factors that correlate with survival in children and young adults with DIPG, which are important for risk stratification in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkAtaHt1q_Q7Vg90H21EOLACvtfcHk0lj43qztlRzGcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyltLg%253D&md5=9744cca319e4a00924584c69586826ac</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.75.9308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.75.9308%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DL.%2BM.%26aulast%3DVeldhuijzen%2Bvan%2BZanten%26aufirst%3DS.%2BE.%2BM.%26aulast%3DColditz%26aufirst%3DN.%26aulast%3DBaugh%26aufirst%3DJ.%26aulast%3DChaney%26aufirst%3DB.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DA.%26aulast%3DFuller%26aufirst%3DC.%26aulast%3DMiles%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DBartels%26aufirst%3DU.%26aulast%3DBouffet%26aufirst%3DE.%26aulast%3DGoldman%26aufirst%3DS.%26aulast%3DLeary%26aufirst%3DS.%26aulast%3DForeman%26aufirst%3DN.%2BK.%26aulast%3DPacker%26aufirst%3DR.%26aulast%3DWarren%26aufirst%3DK.%2BE.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DMinturn%26aufirst%3DJ.%26aulast%3DComito%26aufirst%3DM.%26aulast%3DBroxson%26aufirst%3DE.%26aulast%3DShih%26aufirst%3DC.%2BS.%26aulast%3DKhatua%26aufirst%3DS.%26aulast%3DChintagumpala%26aufirst%3DM.%26aulast%3DCarret%26aufirst%3DA.%2BS.%26aulast%3DEscorza%26aufirst%3DN.%2BY.%26aulast%3DHassall%26aufirst%3DT.%26aulast%3DZiegler%26aufirst%3DD.%2BS.%26aulast%3DGottardo%26aufirst%3DN.%26aulast%3DDholaria%26aufirst%3DH.%26aulast%3DDoughman%26aufirst%3DR.%26aulast%3DBenesch%26aufirst%3DM.%26aulast%3DDrissi%26aufirst%3DR.%26aulast%3DNazarian%26aufirst%3DJ.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DBoddaert%26aufirst%3DN.%26aulast%3DVarlet%26aufirst%3DP.%26aulast%3DGiraud%26aufirst%3DG.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DHulleman%26aufirst%3DE.%26aulast%3DModena%26aufirst%3DP.%26aulast%3DGiagnacovo%26aufirst%3DM.%26aulast%3DAntonelli%26aufirst%3DM.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DGielen%26aufirst%3DG.%2BH.%26aulast%3DJones%26aufirst%3DD.%2BT.%2BW.%26aulast%3DSturm%26aufirst%3DD.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DGerber%26aufirst%3DN.%2BU.%26aulast%3DGrotzer%26aufirst%3DM.%2BA.%26aulast%3DPfaff%26aufirst%3DE.%26aulast%3Dvon%2BBueren%26aufirst%3DA.%2BO.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DSolanki%26aufirst%3DG.%2BA.%26aulast%3DJadrijevic%2BCvrlje%26aufirst%3DF.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DVandertop%26aufirst%3DW.%2BP.%26aulast%3DGrill%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBiassoni%26aufirst%3DV.%26aulast%3DMassimino%26aufirst%3DM.%26aulast%3DCalmon%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DBison%26aufirst%3DB.%26aulast%3DWarmuth-Metz%26aufirst%3DM.%26aulast%3DLeach%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DB.%26aulast%3Dvan%2BVuurden%26aufirst%3DD.%2BG.%26aulast%3DKramm%26aufirst%3DC.%2BM.%26aulast%3DFouladi%26aufirst%3DM.%26atitle%3DClinical%252C%2520radiologic%252C%2520pathologic%252C%2520and%2520molecular%2520characteristics%2520of%2520long-term%2520survivors%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520%2528DIPG%2529%253A%2520a%2520collaborative%2520report%2520from%2520the%2520international%2520and%2520european%2520society%2520for%2520pediatric%2520oncology%2520DIPG%2520registries%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1963%26epage%3D1972%26doi%3D10.1200%2FJCO.2017.75.9308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span> <span> </span><span class="NLM_article-title">Diffuse intrinsic pontine glioma: poised for progress</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fonc.2012.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.3389%2Ffonc.2012.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=23293772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=205&author=K.+E.+Warren&title=Diffuse+intrinsic+pontine+glioma%3A+poised+for+progress&doi=10.3389%2Ffonc.2012.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Diffuse intrinsic pontine glioma: poised for progress</span></div><div class="casAuthors">Warren Katherine E</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine gliomas (DIPGs) are amongst the most challenging tumors to treat.  Surgery is not an option, the effects of radiation therapy are temporary, and no chemotherapeutic agent has demonstrated significant efficacy.  Numerous clinical trials of new agents and novel therapeutic approaches have been performed over the course of several decades in efforts to improve the outcome of children with DIPG, yet without success.  The diagnosis of DIPG is based on radiographic findings in the setting of a typical clinical presentation, and tissue is not routinely obtained as the standard of care.  The paradigm for treating children with these tumors has been based on that for supratentorial high-grade gliomas in adults as the biology of these lesions were presumed to be similar.  However, recent pivotal studies demonstrate that DIPGs appear to be their own entity.  Simply identifying this fact releases a number of constraints and opens opportunities for biologic investigation of these lesions, setting the stage to move forward in identifying DIPG-specific treatments.  This review will summarize the current state of knowledge of DIPG, discuss obstacles to therapy, and summarize results of recent biologic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREW6_X20GCz7YtC3U5jeOifW6udTcc2eYBtSf-xTOvNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nt1SjsA%253D%253D&md5=d51f614b4d5e8bfa9b7bb755cdf736e6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2012.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2012.00205%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DK.%2BE.%26atitle%3DDiffuse%2520intrinsic%2520pontine%2520glioma%253A%2520poised%2520for%2520progress%26jtitle%3DFront.%2520Oncol.%26date%3D2012%26volume%3D2%26spage%3D205%26doi%3D10.3389%2Ffonc.2012.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandeville, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Albiac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Beek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benghiat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeben, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales La Madrid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortmann, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biassoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bueren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vuurden, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massimino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramm, C. M.</span></span> <span> </span><span class="NLM_article-title">Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.ejca.2016.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28161497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jtFertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=38-47&author=G.+O.+Janssensauthor=L.+Gandolaauthor=S.+Bolleauthor=H.+Mandevilleauthor=M.+Ramos-Albiacauthor=K.+van+Beekauthor=H.+Benghiatauthor=B.+Hoebenauthor=A.+Morales+La+Madridauthor=R.+D.+Kortmannauthor=D.+Hargraveauthor=J.+Mentenauthor=E.+Pecoriauthor=V.+Biassoniauthor=A.+O.+von+Buerenauthor=D.+G.+van+Vuurdenauthor=M.+Massiminoauthor=D.+Sturmauthor=M.+Petersauthor=C.+M.+Kramm&title=Survival+benefit+for+patients+with+diffuse+intrinsic+pontine+glioma+%28DIPG%29+undergoing+re-irradiation+at+first+progression%3A+a+matched-cohort+analysis+on+behalf+of+the+SIOP-E-HGG%2FDIPG+working+group&doi=10.1016%2Fj.ejca.2016.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group</span></div><div class="casAuthors">Janssens Geert O; Gandola Lorenza; Pecori Emilia; Bolle Stephanie; Mandeville Henry; Ramos-Albiac Monica; van Beek Karen; Menten Johan; Benghiat Helen; Hoeben Bianca; Morales La Madrid Andres; Kortmann Rolf-Dieter; Hargrave Darren; Biassoni Veronica; Massimino Maura; von Bueren Andre O; van Vuurden Dannis G; Sturm Dominik; Peters Max; Kramm Christof M</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer (Oxford, England : 1990)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor.  The purpose of this study is to analyse benefit and toxicity of re-irradiation at first progression.  METHODS:  At first progression, 31 children with DIPG, aged 2-16 years, underwent re-irradiation (dose 19.8-30.0 Gy) alone (n = 16) or combined with systemic therapy (n = 15).  At initial presentation, all patients had typical symptoms and characteristic MRI features of DIPG, or biopsy-proven high-grade glioma.  An interval of ≥3 months after upfront radiotherapy was required before re-irradiation.  Thirty-nine patients fulfilling the same criteria receiving radiotherapy at diagnosis, followed by best supportive care (n = 20) or systemic therapy (n = 19) at progression but no re-irradiation, were eligible for a matched-cohort analysis.  RESULTS:  Median OS for patients undergoing re-irradiation was 13.7 months.  For a similar median progression-free survival after upfront radiotherapy (8.2 versus 7.7 months; P = .58), a significant benefit in median OS (13.7 versus 10.3 months; P = .04) was observed in favour of patients undergoing re-irradiation.  Survival benefit of re-irradiation increased with a longer interval between end-of-radiotherapy and first progression (3-6 months: 4.0 versus 2.7; P < .01; 6-12 months: 6.4 versus 3.3; P = .04).  Clinical improvement with re-irradiation was observed in 24/31 (77%) patients.  No grade 4-5 toxicity was recorded.  On multivariable analysis, interval to progression (corrected hazard ratio = .27-.54; P < .01) and re-irradiation (corrected hazard ratio = .18-.22; P < .01) remained prognostic for survival.  A risk score (RS), comprising 5 categories, was developed to predict survival from first progression (ROC: .79).  Median survival ranges from 1.0 month (RS-1) to 6.7 months (RS-5).  CONCLUSIONS:  The majority of patients with DIPG, responding to upfront radiotherapy, do benefit of re-irradiation with acceptable tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZk0zDEn-1Uf69nzq6467DfW6udTcc2eZbltSjuU1OC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jtFertA%253D%253D&md5=4ef043a14eda06a11b8a27c874f6f01b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DG.%2BO.%26aulast%3DGandola%26aufirst%3DL.%26aulast%3DBolle%26aufirst%3DS.%26aulast%3DMandeville%26aufirst%3DH.%26aulast%3DRamos-Albiac%26aufirst%3DM.%26aulast%3Dvan%2BBeek%26aufirst%3DK.%26aulast%3DBenghiat%26aufirst%3DH.%26aulast%3DHoeben%26aufirst%3DB.%26aulast%3DMorales%2BLa%2BMadrid%26aufirst%3DA.%26aulast%3DKortmann%26aufirst%3DR.%2BD.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DMenten%26aufirst%3DJ.%26aulast%3DPecori%26aufirst%3DE.%26aulast%3DBiassoni%26aufirst%3DV.%26aulast%3Dvon%2BBueren%26aufirst%3DA.%2BO.%26aulast%3Dvan%2BVuurden%26aufirst%3DD.%2BG.%26aulast%3DMassimino%26aufirst%3DM.%26aulast%3DSturm%26aufirst%3DD.%26aulast%3DPeters%26aufirst%3DM.%26aulast%3DKramm%26aufirst%3DC.%2BM.%26atitle%3DSurvival%2520benefit%2520for%2520patients%2520with%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520%2528DIPG%2529%2520undergoing%2520re-irradiation%2520at%2520first%2520progression%253A%2520a%2520matched-cohort%2520analysis%2520on%2520behalf%2520of%2520the%2520SIOP-E-HGG%252FDIPG%2520working%2520group%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D73%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.ejca.2016.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lgVEN1u_6iHeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heideman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavey, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouffet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, I. F.</span></span> <span> </span><span class="NLM_article-title">Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1093/neuonc/noq205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1093%2Fneuonc%2Fnoq205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21345842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ovF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=410-416&author=K.+J.+Cohenauthor=R.+L.+Heidemanauthor=T.+Zhouauthor=E.+J.+Holmesauthor=R.+S.+Laveyauthor=E.+Bouffetauthor=I.+F.+Pollack&title=Temozolomide+in+the+treatment+of+children+with+newly+diagnosed+diffuse+intrinsic+pontine+gliomas%3A+a+report+from+the+Children%E2%80%99s+Oncology+Group&doi=10.1093%2Fneuonc%2Fnoq205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group</span></div><div class="casAuthors">Cohen Kenneth J; Heideman Richard L; Zhou Tianni; Holmes Emiko J; Lavey Robert S; Bouffet Eric; Pollack Ian F</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">410-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group.  During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study.  All patients received TMZ at a dosage of 90 mg/m(2)/day for 42 days to a dose of 59.4 Gy.  Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m(2)/day for 5 days every 28 days, for a total of 10 cycles.  The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941.  The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941.  The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96.  There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%.  The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941.  The median time to death was 9.6 months.  Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRWqSAwVzDshpyrDyM_m9cfW6udTcc2eZbltSjuU1OC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ovF2rtg%253D%253D&md5=75a91c9fa553be1474104a0798215671</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnoq205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnoq205%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DK.%2BJ.%26aulast%3DHeideman%26aufirst%3DR.%2BL.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DE.%2BJ.%26aulast%3DLavey%26aufirst%3DR.%2BS.%26aulast%3DBouffet%26aufirst%3DE.%26aulast%3DPollack%26aufirst%3DI.%2BF.%26atitle%3DTemozolomide%2520in%2520the%2520treatment%2520of%2520children%2520with%2520newly%2520diagnosed%2520diffuse%2520intrinsic%2520pontine%2520gliomas%253A%2520a%2520report%2520from%2520the%2520Children%25E2%2580%2599s%2520Oncology%2520Group%26jtitle%3DNeuro-Oncol.%26date%3D2011%26volume%3D13%26spage%3D410%26epage%3D416%26doi%3D10.1093%2Fneuonc%2Fnoq205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korones, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, C.</span></span> <span> </span><span class="NLM_article-title">Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a children’s oncology group phase II study</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1002/pbc.21154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fpbc.21154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17278121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjsFWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2008&pages=227-230&author=D.+N.+Koronesauthor=P.+G.+Fisherauthor=C.+Kretschmarauthor=T.+Zhouauthor=Z.+Chenauthor=J.+Kepnerauthor=C.+Freeman&title=Treatment+of+children+with+diffuse+intrinsic+brain+stem+glioma+with+radiotherapy%2C+vincristine+and+oral+VP-16%3A+a+children%E2%80%99s+oncology+group+phase+II+study&doi=10.1002%2Fpbc.21154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study</span></div><div class="casAuthors">Korones David N; Fisher Paul G; Kretschmar Cynthia; Zhou Tianni; Chen Zhengjia; Kepner James; Freeman Carolyn</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">227-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The prognosis for children with brain stem glioma remains grim.  Based on studies suggesting efficacy of vincristine and oral VP-16, The Pediatric Oncology Group (POG, now part of the Children's Oncology Group) conducted a study using these agents in combination with standard external beam radiation for children with newly diagnosed brain stem glioma.  METHODS:  Children were eligible for the study if they 3-21 years of age, had MRI-evidence of a diffuse intrinsic pontine glioma, and had neurologic deficits of <6 months duration.  Patients received local radiotherapy to a dosage of 54 Gy.  Chemotherapy consisted of two 28-day cycles of vincristine, 1.5 mg/m(2), days 1, 8, and 15 and oral VP-16, 50 mg/m(2), days 1-21, starting concurrent with radiation, and continuing for ten cycles following radiation.  RESULTS:  Of the 31 children enrolled, 30 were eligible and evaluable for survival and toxicity.  Their median age was 8 years (range 3-14 years).  Seven patients (23%) had a partial response following radiation, 18 (60%) had stable disease, 2 (7%) had progressive disease, and response in 3 patients (10%) was not measured.  All 30 children have died.  Overall survival at 1 year was 27 +/- 7% and at 2 years, 3 +/- 2%.  The median survival was 9 months (range 3-36 months).  Hematologic toxicity was significant; other toxicities included constipation, mucositis, emesis, and infection.  CONCLUSION:  The addition of vincristine and oral VP-16 to standard external beam radiation causes moderate toxicity and does not improve survival of children with diffuse intrinsic brain stem glioma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDnWJ92eNBALP3FVUi_gf8fW6udTcc2eY1p9z7O0bIh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjsFWktA%253D%253D&md5=48b57f6c9060981dfc29f71e8f2cef77</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpbc.21154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.21154%26sid%3Dliteratum%253Aachs%26aulast%3DKorones%26aufirst%3DD.%2BN.%26aulast%3DFisher%26aufirst%3DP.%2BG.%26aulast%3DKretschmar%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DKepner%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DC.%26atitle%3DTreatment%2520of%2520children%2520with%2520diffuse%2520intrinsic%2520brain%2520stem%2520glioma%2520with%2520radiotherapy%252C%2520vincristine%2520and%2520oral%2520VP-16%253A%2520a%2520children%25E2%2580%2599s%2520oncology%2520group%2520phase%2520II%2520study%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2008%26volume%3D50%26spage%3D227%26epage%3D230%26doi%3D10.1002%2Fpbc.21154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roujeau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miquel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puget, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoerger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddaert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Rocco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sainte-Rose, C.</span></span> <span> </span><span class="NLM_article-title">Stereotactic biopsy of diffuse pontine lesions in children</span>. <i>J. Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.3171/PED-07/07/001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.3171%2FPED-07%2F07%2F001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17647306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD2svislyhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2007&pages=1-4&author=T.+Roujeauauthor=G.+Machadoauthor=M.+R.+Garnettauthor=C.+Miquelauthor=S.+Pugetauthor=B.+Geoergerauthor=J.+Grillauthor=N.+Boddaertauthor=F.+Di+Roccoauthor=M.+Zerahauthor=C.+Sainte-Rose&title=Stereotactic+biopsy+of+diffuse+pontine+lesions+in+children&doi=10.3171%2FPED-07%2F07%2F001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Stereotactic biopsy of diffuse pontine lesions in children</span></div><div class="casAuthors">Roujeau Thomas; Machado Guilherme; Garnett Matthew R; Miquel Catherine; Puget Stephanie; Geoerger Birgit; Grill Jacques; Boddaert Nathalie; Di Rocco Federico; Zerah Michel; Sainte-Rose Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurosurgery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1 Suppl</span>),
    <span class="NLM_cas:pages">1-4</span>
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    </div><div class="casAbstract">OBJECT:  Empirical radiotherapy is the current treatment for children with diffuse pontine lesions that have imaging characteristics of an infiltrative malignant astrocytoma.  The use of chemotherapeutic agents is, however, currently under investigation in the treatment of these tumors.  To be included into a trial, patients need a definitive histological diagnosis.  The authors present their prospective study of the stereotactic biopsy of these lesions during a 4-year period.  METHODS:  A suboccipital, transcerebellar approach was used to obtain biopsy samples in 24 children.  RESULTS:  Two patients suffered deficits.  Both had a transient (< 2 months) new cranial nerve palsy; one of these patients also experienced an exacerbation of a preoperative hemiparesis.  No patient died during the perioperative period.  A histological diagnosis was made in all 24 patients as follows: 22 had a malignant infiltrative astrocytoma, one had a low-grade astrocytoma, and one had a pilocytic astrocytoma.  The diagnosis of the latter two patients affected the initial treatment after the biopsy.  CONCLUSIONS:  The findings of this study imply that stereotactic biopsy sampling of a diffuse pontine tumor is a safe procedure, is associated with minimal morbidity, and has a high diagnostic yield.  A nonmalignant tumor was identified in two of the 24 patients in whom the imaging findings were characteristic of a malignant infiltrative astrocytoma.  With the advent of new treatment protocols, stereotactic biopsy sampling, which would allow specific tumor characterization of diffuse pontine lesions, may become standard.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk63zbO0tbyO-MdeMhXAHkfW6udTcc2eY1p9z7O0bIh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svislyhtA%253D%253D&md5=30b48b8c59adccd8f211acbd214fccdb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3171%2FPED-07%2F07%2F001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252FPED-07%252F07%252F001%26sid%3Dliteratum%253Aachs%26aulast%3DRoujeau%26aufirst%3DT.%26aulast%3DMachado%26aufirst%3DG.%26aulast%3DGarnett%26aufirst%3DM.%2BR.%26aulast%3DMiquel%26aufirst%3DC.%26aulast%3DPuget%26aufirst%3DS.%26aulast%3DGeoerger%26aufirst%3DB.%26aulast%3DGrill%26aufirst%3DJ.%26aulast%3DBoddaert%26aufirst%3DN.%26aulast%3DDi%2BRocco%26aufirst%3DF.%26aulast%3DZerah%26aufirst%3DM.%26aulast%3DSainte-Rose%26aufirst%3DC.%26atitle%3DStereotactic%2520biopsy%2520of%2520diffuse%2520pontine%2520lesions%2520in%2520children%26jtitle%3DJ.%2520Neurosurg.%26date%3D2007%26volume%3D107%26spage%3D1%26epage%3D4%26doi%3D10.3171%2FPED-07%2F07%2F001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karajannis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas-Kogan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaides, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonds, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span> <span> </span><span class="NLM_article-title">Pediatric high-grade glioma: biologically and clinically in need of new thinking</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1093/neuonc/now101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1093%2Fneuonc%2Fnow101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27282398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSntr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=153-161&author=C.+Jonesauthor=M.+A.+Karajannisauthor=D.+T.+W.+Jonesauthor=M.+W.+Kieranauthor=M.+Monjeauthor=S.+J.+Bakerauthor=O.+J.+Becherauthor=Y.+J.+Choauthor=N.+Guptaauthor=C.+Hawkinsauthor=D.+Hargraveauthor=D.+A.+Haas-Koganauthor=N.+Jabadoauthor=X.+N.+Liauthor=S.+Muellerauthor=T.+Nicolaidesauthor=R.+J.+Packerauthor=A.+I.+Perssonauthor=J.+J.+Phillipsauthor=E.+F.+Simondsauthor=J.+M.+Staffordauthor=Y.+Tangauthor=S.+M.+Pfisterauthor=W.+A.+Weiss&title=Pediatric+high-grade+glioma%3A+biologically+and+clinically+in+need+of+new+thinking&doi=10.1093%2Fneuonc%2Fnow101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pediatric high-grade glioma: biologically and clinically in need of new thinking</span></div><div class="casAuthors">Jones, Chris; Karajannis, Matthias A.; Jones, David T. W.; Kieran, Mark W.; Monje, Michelle; Baker, Suzanne J.; Becher, Oren J.; Cho, Yoon-Jae; Gupta, Nalin; Hawkins, Cynthia; Hargrave, Darren; Haas-Kogan, Daphne A.; Jabado, Nada; Li, Xiao-Nan; Mueller, Sabine; Nicolaides, Theo; Packer, Roger J.; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Stafford, James M.; Tang, Yujie; Pfister, Stefan M.; Weiss, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-161</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">High-grade gliomas in children are different from those that arise in adults.  Recent collaborative mol. analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis.  As we begin to unravel the unique developmental origins and distinct biol. drivers of this heterogeneous group of tumors, clin. trials need to keep pace.  It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma.  This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clin. outcome.  The authors of this perspective, comprising biol. and clin. expertise in the disease, recently convened to discuss the most effective ways to translate the emerging mol. insights into patient benefit.  This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clin. management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovI4tjqPTy6rVg90H21EOLACvtfcHk0livmPxqb1bChw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSntr%252FM&md5=79288507fd1bd4373e5fb70048583add</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnow101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnow101%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKarajannis%26aufirst%3DM.%2BA.%26aulast%3DJones%26aufirst%3DD.%2BT.%2BW.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBecher%26aufirst%3DO.%2BJ.%26aulast%3DCho%26aufirst%3DY.%2BJ.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DHaas-Kogan%26aufirst%3DD.%2BA.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DMueller%26aufirst%3DS.%26aulast%3DNicolaides%26aufirst%3DT.%26aulast%3DPacker%26aufirst%3DR.%2BJ.%26aulast%3DPersson%26aufirst%3DA.%2BI.%26aulast%3DPhillips%26aufirst%3DJ.%2BJ.%26aulast%3DSimonds%26aufirst%3DE.%2BF.%26aulast%3DStafford%26aufirst%3DJ.%2BM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DPediatric%2520high-grade%2520glioma%253A%2520biologically%2520and%2520clinically%2520in%2520need%2520of%2520new%2520thinking%26jtitle%3DNeuro-Oncol.%26date%3D2017%26volume%3D19%26spage%3D153%26epage%3D161%26doi%3D10.1093%2Fneuonc%2Fnow101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal-Salom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjerke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandhabalan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temelso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waanders, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharoulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandeville, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Sarraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabelsi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisljakov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konovalov, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Torres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shats, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavale, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidinotto, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crimmins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pears, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debily, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikbakht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouladi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bueren, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">520</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2017.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.ccell.2017.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28966033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=520-537&author=A.+Mackayauthor=A.+Burfordauthor=D.+Carvalhoauthor=E.+Izquierdoauthor=J.+Fazal-Salomauthor=K.+R.+Taylorauthor=L.+Bjerkeauthor=M.+Clarkeauthor=M.+Vinciauthor=M.+Nandhabalanauthor=S.+Temelsoauthor=S.+Popovauthor=V.+Molinariauthor=P.+Ramanauthor=A.+J.+Waandersauthor=H.+J.+Hanauthor=S.+Guptaauthor=L.+Marshallauthor=S.+Zacharoulisauthor=S.+Vaidyaauthor=H.+C.+Mandevilleauthor=L.+R.+Bridgesauthor=A.+J.+Martinauthor=S.+Al-Sarrajauthor=C.+Chandlerauthor=H.+K.+Ngauthor=X.+Liauthor=K.+Muauthor=S.+Trabelsiauthor=D.+H.+Brahimauthor=A.+N.+Kisljakovauthor=D.+M.+Konovalovauthor=A.+S.+Mooreauthor=A.+M.+Carcabosoauthor=M.+Sunolauthor=C.+de+Torresauthor=O.+Cruzauthor=J.+Moraauthor=L.+I.+Shatsauthor=J.+N.+Stavaleauthor=L.+T.+Bidinottoauthor=R.+M.+Reisauthor=N.+Entz-Werleauthor=M.+Farrellauthor=J.+Cryanauthor=D.+Crimminsauthor=J.+Cairdauthor=J.+Pearsauthor=M.+Monjeauthor=M.+A.+Debilyauthor=D.+Castelauthor=J.+Grillauthor=C.+Hawkinsauthor=H.+Nikbakhtauthor=N.+Jabadoauthor=S.+J.+Bakerauthor=S.+M.+Pfisterauthor=D.+T.+W.+Jonesauthor=M.+Fouladiauthor=A.+O.+von+Buerenauthor=M.+Baudisauthor=A.+Resnickauthor=C.+Jones&title=Integrated+molecular+meta-analysis+of+1%2C000+pediatric+high-grade+and+diffuse+intrinsic+pontine+glioma&doi=10.1016%2Fj.ccell.2017.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma</span></div><div class="casAuthors">MacKay, Alan; Burford, Anna; Carvalho, Diana; Izquierdo, Elisa; Fazal-Salom, Janat; Taylor, Kathryn R.; Bjerke, Lynn; Clarke, Matthew; Vinci, Mara; Nandhabalan, Meera; Temelso, Sara; Popov, Sergey; Molinari, Valeria; Raman, Pichai; Waanders, Angela J.; Han, Harry J.; Gupta, Saumya; Marshall, Lynley; Zacharoulis, Stergios; Vaidya, Sucheta; Mandeville, Henry C.; Bridges, Leslie R.; Martin, Andrew J.; Al-Sarraj, Safa; Chandler, Christopher; Ng, Ho-Keung; Li, Xingang; Mu, Kun; Trabelsi, Saoussen; H'mida-Ben Brahim, Dorra; Kisljakov, Alexei N.; Konovalov, Dmitry M.; Moore, Andrew S.; Carcaboso, Angel Montero; Sunol, Mariona; de Torres, Carmen; Cruz, Ofelia; Mora, Jaume; Shats, Ludmila I.; Stavale, Joao N.; Bidinotto, Lucas T.; Reis, Rui M.; Entz-Werle, Natacha; Farrell, Michael; Cryan, Jane; Crimmins, Darach; Caird, John; Pears, Jane; Monje, Michelle; Debily, Marie-Anne; Castel, David; Grill, Jacques; Hawkins, Cynthia; Nikbakht, Hamid; Jabado, Nada; Baker, Suzanne J.; Pfister, Stefan M.; Jones, David T. W.; Fouladi, Maryam; von Bueren, Andre O.; Baudis, Michael; Resnick, Adam; Jones, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">520-537.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated anal. of >1,000 cases.  We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M.  Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors.  Genomic aberrations increase with age, highlighting the infant population as biol. and clin. distinct.  Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the mol. diversity of the disease, opening up avenues for biol. study and providing a basis for functionally defined future treatment stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwsnPkJGgJWrVg90H21EOLACvtfcHk0ljaXxDgvzb9IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOrtrjL&md5=aa10ce3347bfc85a694bee343d9e7533</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2017.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DBurford%26aufirst%3DA.%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DIzquierdo%26aufirst%3DE.%26aulast%3DFazal-Salom%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DNandhabalan%26aufirst%3DM.%26aulast%3DTemelso%26aufirst%3DS.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DMolinari%26aufirst%3DV.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DWaanders%26aufirst%3DA.%2BJ.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DMarshall%26aufirst%3DL.%26aulast%3DZacharoulis%26aufirst%3DS.%26aulast%3DVaidya%26aufirst%3DS.%26aulast%3DMandeville%26aufirst%3DH.%2BC.%26aulast%3DBridges%26aufirst%3DL.%2BR.%26aulast%3DMartin%26aufirst%3DA.%2BJ.%26aulast%3DAl-Sarraj%26aufirst%3DS.%26aulast%3DChandler%26aufirst%3DC.%26aulast%3DNg%26aufirst%3DH.%2BK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMu%26aufirst%3DK.%26aulast%3DTrabelsi%26aufirst%3DS.%26aulast%3DBrahim%26aufirst%3DD.%2BH.%26aulast%3DKisljakov%26aufirst%3DA.%2BN.%26aulast%3DKonovalov%26aufirst%3DD.%2BM.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3DSunol%26aufirst%3DM.%26aulast%3Dde%2BTorres%26aufirst%3DC.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DShats%26aufirst%3DL.%2BI.%26aulast%3DStavale%26aufirst%3DJ.%2BN.%26aulast%3DBidinotto%26aufirst%3DL.%2BT.%26aulast%3DReis%26aufirst%3DR.%2BM.%26aulast%3DEntz-Werle%26aufirst%3DN.%26aulast%3DFarrell%26aufirst%3DM.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DCrimmins%26aufirst%3DD.%26aulast%3DCaird%26aufirst%3DJ.%26aulast%3DPears%26aufirst%3DJ.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DDebily%26aufirst%3DM.%2BA.%26aulast%3DCastel%26aufirst%3DD.%26aulast%3DGrill%26aufirst%3DJ.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DNikbakht%26aufirst%3DH.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DJones%26aufirst%3DD.%2BT.%2BW.%26aulast%3DFouladi%26aufirst%3DM.%26aulast%3Dvon%2BBueren%26aufirst%3DA.%2BO.%26aulast%3DBaudis%26aufirst%3DM.%26aulast%3DResnick%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DIntegrated%2520molecular%2520meta-analysis%2520of%25201%252C000%2520pediatric%2520high-grade%2520and%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D32%26spage%3D520%26epage%3D537%26doi%3D10.1016%2Fj.ccell.2017.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1038/nrc3811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnrc3811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=651-661&author=C.+Jonesauthor=S.+J.+Baker&title=Unique+genetic+and+epigenetic+mechanisms+driving+paediatric+diffuse+high-grade+glioma&doi=10.1038%2Fnrc3811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma</span></div><div class="casAuthors">Jones, Chris; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">651-661</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse high-grade gliomas (HGGs) of childhood are a devastating spectrum of disease with no effective cures.  The two-year survival for paediatric HGG ranges from 30%, for tumors arising in the cerebral cortex, to less than 10% for diffuse intrinsic pontine gliomas (DIPGs), which arise in the brainstem.  Recent genome-wide studies provided abundant evidence that unique selective pressures drive HGG in children compared to adults, identifying novel oncogenic mutations connecting tumorigenesis and chromatin regulation, as well as developmental signalling pathways.  These new genetic findings give insights into disease pathogenesis and the challenges and opportunities for improving patient survival in these mostly incurable childhood brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVGWSwXk98SbVg90H21EOLACvtfcHk0ljaXxDgvzb9IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlu7rO&md5=86613a1f2bd8e9afebcfe1067371284a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc3811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3811%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DUnique%2520genetic%2520and%2520epigenetic%2520mechanisms%2520driving%2520paediatric%2520diffuse%2520high-grade%2520glioma%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D651%26epage%3D661%26doi%3D10.1038%2Fnrc3811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLuca, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monlong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sammeth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pervouchine, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segrè, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djebali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niarchou, A.</span></span>; <span class="NLM_contrib-group">The GTEx Consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappalainen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dermitzakis, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigó, R.</span></span> <span> </span><span class="NLM_article-title">The human transcriptome across tissues and individuals</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1126/science.aaa0355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1126%2Fscience.aaa0355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=25954002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslGjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=660-665&author=M.+Mel%C3%A9author=P.+G.+Ferreiraauthor=F.+Reverterauthor=D.+S.+DeLucaauthor=J.+Monlongauthor=M.+Sammethauthor=T.+R.+Youngauthor=J.+M.+Goldmannauthor=D.+D.+Pervouchineauthor=T.+J.+Sullivanauthor=R.+Johnsonauthor=A.+V.+Segr%C3%A8author=S.+Djebaliauthor=A.+Niarchouauthor=The+GTEx+Consortiumauthor=F.+A.+Wrightauthor=T.+Lappalainenauthor=M.+Calvoauthor=G.+Getzauthor=E.+T.+Dermitzakisauthor=K.+G.+Ardlieauthor=R.+Guig%C3%B3&title=The+human+transcriptome+across+tissues+and+individuals&doi=10.1126%2Fscience.aaa0355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The human transcriptome across tissues and individuals</span></div><div class="casAuthors">Mele, Marta; Ferreira, Pedro G.; Reverter, Ferran; De Luca, David S.; Monlong, Jean; Sammeth, Michael; Young, Taylor R.; Goldmann, Jakob M.; Pervouchine, Dmitri D.; Sullivan, Timothy J.; Johnson, Rory; Segre, Ayellet V.; Djebali, Sarah; Niarchou, Anastasia; Wright, Fred A.; Lappalainen, Tuuli; Calvo, Miquel; Getz, Gad; Dermitzakis, Emmanouil T.; Ardlie, Kristin G.; Guigo, Roderic</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6235</span>),
    <span class="NLM_cas:pages">660-665</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Transcriptional regulation and posttranscriptional processing underlie many cellular and organismal phenotypes.  We used RNA sequence data generated by Genotype-Tissue Expression (GTEx) project to investigate the patterns of transcriptome variation across individuals and tissues.  Tissues exhibit characteristic transcriptional signatures that show stability in postmortem samples.  These signatures are dominated by a relatively small no. of genes-which is most clearly seen in blood-though few are exclusive to a particular tissue and vary more across tissues than individuals.  Genes exhibiting high interindividual expression variation include disease candidates assocd. with sex, ethnicity, and age.  Primary transcription is the major driver of cellular specificity, with splicing playing mostly a complementary role; except for the brain, which exhibits a more divergent splicing program.  Variation in splicing, despite its stochasticity, may play in contrast a comparatively greater role in defining individual phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp69NDKxbHrt7Vg90H21EOLACvtfcHk0lhSBRSZSKyZ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslGjsbY%253D&md5=e0461ad2426d9cbb0a26cb537bda7251</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa0355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa0355%26sid%3Dliteratum%253Aachs%26aulast%3DMel%25C3%25A9%26aufirst%3DM.%26aulast%3DFerreira%26aufirst%3DP.%2BG.%26aulast%3DReverter%26aufirst%3DF.%26aulast%3DDeLuca%26aufirst%3DD.%2BS.%26aulast%3DMonlong%26aufirst%3DJ.%26aulast%3DSammeth%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DT.%2BR.%26aulast%3DGoldmann%26aufirst%3DJ.%2BM.%26aulast%3DPervouchine%26aufirst%3DD.%2BD.%26aulast%3DSullivan%26aufirst%3DT.%2BJ.%26aulast%3DJohnson%26aufirst%3DR.%26aulast%3DSegr%25C3%25A8%26aufirst%3DA.%2BV.%26aulast%3DDjebali%26aufirst%3DS.%26aulast%3DNiarchou%26aufirst%3DA.%26aulast%3D%26aulast%3DWright%26aufirst%3DF.%2BA.%26aulast%3DLappalainen%26aufirst%3DT.%26aulast%3DCalvo%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DDermitzakis%26aufirst%3DE.%2BT.%26aulast%3DArdlie%26aufirst%3DK.%2BG.%26aulast%3DGuig%25C3%25B3%26aufirst%3DR.%26atitle%3DThe%2520human%2520transcriptome%2520across%2520tissues%2520and%2520individuals%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D660%26epage%3D665%26doi%3D10.1126%2Fscience.aaa0355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ACVR1 mutations in DIPG: lessons learned from FOP</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4565</span>– <span class="NLM_lpage">4570</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1158%2F0008-5472.CAN-14-1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=25136070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=4565-4570&author=K.+R.+Taylorauthor=M.+Vinciauthor=A.+N.+Bullockauthor=C.+Jones&title=ACVR1+mutations+in+DIPG%3A+lessons+learned+from+FOP&doi=10.1158%2F0008-5472.CAN-14-1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">ACVR1 mutations in DIPG: Lessons learned from FOP</span></div><div class="casAuthors">Taylor, Kathryn R.; Vinci, Maria; Bullock, Alex N.; Jones, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4565-4570</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Whole-genome sequencing studies have recently identified a quarter of cases of the rare childhood brainstem tumor diffuse intrinsic pontine glioma to harbor somatic mutations in ACVR1.  This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone.  This unexpected link points toward the importance of developmental biol. processes in tumorigenesis and provides an extensive experience in mechanistic understanding and drug development hard-won by FOP researchers to pediatric neurooncol.  Here, we review the literature in both fields and identify potential areas for collaboration and rapid advancement for patients of both diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEL1hRMgcHVLVg90H21EOLACvtfcHk0lhSBRSZSKyZ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOisb7I&md5=6954694896e9f71ad21eec835247b1cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1298%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DACVR1%2520mutations%2520in%2520DIPG%253A%2520lessons%2520learned%2520from%2520FOP%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D4565%26epage%3D4570%26doi%3D10.1158%2F0008-5472.CAN-14-1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermacher, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeMerrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morhart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtizberea, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zasloff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, F. S.</span></span> <span> </span><span class="NLM_article-title">A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1038/ng1783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fng1783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=16642017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvVGktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2006&pages=525-527&author=E.+M.+Shoreauthor=M.+Xuauthor=G.+J.+Feldmanauthor=D.+A.+Fenstermacherauthor=T.+J.+Choauthor=I.+H.+Choiauthor=J.+M.+Connorauthor=P.+Delaiauthor=D.+L.+Glaserauthor=M.+LeMerrerauthor=R.+Morhartauthor=J.+G.+Rogersauthor=R.+Smithauthor=J.+T.+Triffittauthor=J.+A.+Urtizbereaauthor=M.+Zasloffauthor=M.+A.+Brownauthor=F.+S.+Kaplan&title=A+recurrent+mutation+in+the+BMP+type+I+receptor+ACVR1+causes+inherited+and+sporadic+fibrodysplasia+ossificans+progressiva&doi=10.1038%2Fng1783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</span></div><div class="casAuthors">Shore, Eileen M.; Xu, Meiqi; Feldman, George J.; Fenstermacher, David A.; Brown, Matthew A.; Kaplan, Frederick S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-527</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification.  We mapped FOP to chromosome 2q23-24 by linkage anal. and identified an identical heterozygous mutation (617G → A; R206H) in the glycine-serine (GS) activation domain of ACVR1, a BMP type I receptor, in all affected individuals examd.  Protein modeling predicts destabilization of the GS domain, consistent with constitutive activation of ACVR1 as the underlying cause of the ectopic chondrogenesis, osteogenesis and joint fusions seen in FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJCMFDulIw-LVg90H21EOLACvtfcHk0lhSBRSZSKyZ5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvVGktrk%253D&md5=24f4dce60f3073f2c621326d3c146601</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fng1783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1783%26sid%3Dliteratum%253Aachs%26aulast%3DShore%26aufirst%3DE.%2BM.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DFeldman%26aufirst%3DG.%2BJ.%26aulast%3DFenstermacher%26aufirst%3DD.%2BA.%26aulast%3DCho%26aufirst%3DT.%2BJ.%26aulast%3DChoi%26aufirst%3DI.%2BH.%26aulast%3DConnor%26aufirst%3DJ.%2BM.%26aulast%3DDelai%26aufirst%3DP.%26aulast%3DGlaser%26aufirst%3DD.%2BL.%26aulast%3DLeMerrer%26aufirst%3DM.%26aulast%3DMorhart%26aufirst%3DR.%26aulast%3DRogers%26aufirst%3DJ.%2BG.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DUrtizberea%26aufirst%3DJ.%2BA.%26aulast%3DZasloff%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DKaplan%26aufirst%3DF.%2BS.%26atitle%3DA%2520recurrent%2520mutation%2520in%2520the%2520BMP%2520type%2520I%2520receptor%2520ACVR1%2520causes%2520inherited%2520and%2520sporadic%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DNat.%2520Genet.%26date%3D2006%26volume%3D38%26spage%3D525%26epage%3D527%26doi%3D10.1038%2Fng1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fastnacht-Urban, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillessen-Kaesbach, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoover-Fong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zasloff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morhart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundlos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groppe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1002/humu.20868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fhumu.20868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=19085907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFCms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=379-390&author=F.+S.+Kaplanauthor=M.+Xuauthor=P.+Seemannauthor=J.+M.+Connorauthor=D.+L.+Glaserauthor=L.+Carrollauthor=P.+Delaiauthor=E.+Fastnacht-Urbanauthor=S.+J.+Formanauthor=G.+Gillessen-Kaesbachauthor=J.+Hoover-Fongauthor=B.+Kosterauthor=R.+M.+Pauliauthor=W.+Reardonauthor=S.+A.+Zaidiauthor=M.+Zasloffauthor=R.+Morhartauthor=S.+Mundlosauthor=J.+Groppeauthor=E.+M.+Shore&title=Classic+and+atypical+fibrodysplasia+ossificans+progressiva+%28FOP%29+phenotypes+are+caused+by+mutations+in+the+bone+morphogenetic+protein+%28BMP%29+type+I+receptor+ACVR1&doi=10.1002%2Fhumu.20868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1</span></div><div class="casAuthors">Kaplan, Frederick S.; Xu, Meiqi; Seemann, Petra; Connor, J. Michael; Glaser, David L.; Carroll, Liam; Delai, Patricia; Fastnacht-Urban, Elisabeth; Forman, Stephen J.; Gillessen-Kaesbach, Gabriele; Hoover-Fong, Julie; Koster, Bernhard; Pauli, Richard M.; Reardon, William; Zaidi, Syed-Adeel; Zasloff, Michael; Morhart, Rolf; Mundlos, Stefan; Groppe, Jay; Shore, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-390</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant human disorder of bone formation that causes developmental skeletal defects and extensive debilitating bone formation within soft connective tissues (heterotopic ossification) during childhood.  All patients with classic clin. features of FOP (great toe malformations and progressive heterotopic ossification) have previously been found to carry the same heterozygous mutation (c.617G > A; p.R206H) in the glycine and serine residue (GS) activation domain of activin A type I receptor/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor.  Among patients with FOP-like heterotopic ossification and/or toe malformations, we identified patients with clin. features unusual for FOP.  These atypical FOP patients form two classes: FOP-plus (classic defining features of FOP plus one or more atypical features) and FOP variants (major variations in one or both of the two classic defining features of FOP).  All patients examd. have heterozygous ACVR1 mis-sense mutations in conserved amino acids.  While the recurrent c.617G > A; p.R206H mutation was found in all cases of classic FOP and most cases of FOP-plus, novel ACVR1 mutations occur in the FOP variants and two cases of FOP-plus.  Protein structure homol. modeling predicts that each of the amino acid substitutions activates the ACVR1 protein to enhance receptor signaling.  We obsd. genotype-phenotype correlation between some ACVR1 mutations and the age of onset of heterotopic ossification or on embryonic skeletal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjtZIaoHwVy7Vg90H21EOLACvtfcHk0lieTnWIMUfupQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFCms7w%253D&md5=ea8c6bd96082f0290fc54b62cb1fa0c9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fhumu.20868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.20868%26sid%3Dliteratum%253Aachs%26aulast%3DKaplan%26aufirst%3DF.%2BS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DSeemann%26aufirst%3DP.%26aulast%3DConnor%26aufirst%3DJ.%2BM.%26aulast%3DGlaser%26aufirst%3DD.%2BL.%26aulast%3DCarroll%26aufirst%3DL.%26aulast%3DDelai%26aufirst%3DP.%26aulast%3DFastnacht-Urban%26aufirst%3DE.%26aulast%3DForman%26aufirst%3DS.%2BJ.%26aulast%3DGillessen-Kaesbach%26aufirst%3DG.%26aulast%3DHoover-Fong%26aufirst%3DJ.%26aulast%3DKoster%26aufirst%3DB.%26aulast%3DPauli%26aufirst%3DR.%2BM.%26aulast%3DReardon%26aufirst%3DW.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DZasloff%26aufirst%3DM.%26aulast%3DMorhart%26aufirst%3DR.%26aulast%3DMundlos%26aufirst%3DS.%26aulast%3DGroppe%26aufirst%3DJ.%26aulast%3DShore%26aufirst%3DE.%2BM.%26atitle%3DClassic%2520and%2520atypical%2520fibrodysplasia%2520ossificans%2520progressiva%2520%2528FOP%2529%2520phenotypes%2520are%2520caused%2520by%2520mutations%2520in%2520the%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520type%2520I%2520receptor%2520ACVR1%26jtitle%3DHum.%2520Mutat.%26date%3D2009%26volume%3D30%26spage%3D379%26epage%3D390%26doi%3D10.1002%2Fhumu.20868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikbakht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panditharatna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikael, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gayden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osmond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambhampati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papillon-Cavanagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellezam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamchandani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, J.</span></span> <span> </span><span class="NLM_article-title">Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">11185</span> <span class="refDoi"> DOI: 10.1038/ncomms11185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fncomms11185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27048880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Kgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=H.+Nikbakhtauthor=E.+Panditharatnaauthor=L.+G.+Mikaelauthor=R.+Liauthor=T.+Gaydenauthor=M.+Osmondauthor=C.+Y.+Hoauthor=M.+Kambhampatiauthor=E.+I.+Hwangauthor=D.+Fauryauthor=A.+Siuauthor=S.+Papillon-Cavanaghauthor=D.+Bechetauthor=K.+L.+Ligonauthor=B.+Ellezamauthor=W.+J.+Ingramauthor=C.+Stinsonauthor=A.+S.+Mooreauthor=K.+E.+Warrenauthor=J.+Karamchandaniauthor=R.+J.+Packerauthor=N.+Jabadoauthor=J.+Majewskiauthor=J.+Nazarian&title=Spatial+and+temporal+homogeneity+of+driver+mutations+in+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fncomms11185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Nikbakht, Hamid; Panditharatna, Eshini; Mikael, Leonie G.; Li, Rui; Gayden, Tenzin; Osmond, Matthew; Ho, Cheng-Ying; Kambhampati, Madhuri; Hwang, Eugene I.; Faury, Damien; Siu, Alan; Papillon-Cavanagh, Simon; Bechet, Denise; Ligon, Keith L.; Ellezam, Benjamin; Ingram, Wendy J.; Stinson, Caedyn; Moore, Andrew S.; Warren, Katherine E.; Karamchandani, Jason; Packer, Roger J.; Jabado, Nada; Majewski, Jacek; Nazarian, Javad</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11185</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diffuse Intrinsic Pontine Gliomas (DIPGs) are deadly pediatric brain tumors where needle biopsies help guide diagnosis and targeted therapies.  To address spatial heterogeneity, here we analyze 134 specimens from various neuroanatomical structures of whole autopsy brains from nine DIPG patients.  Evolutionary reconstruction indicates histone 3 (H3) K27M-including H3.2K27M-mutations potentially arise first and are invariably assocd. with specific, high-fidelity obligate partners throughout the tumor and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis.  These H3K27M ubiquitously-assocd. mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1).  Later oncogenic alterations arise in sub-clones and often affect the PI3K pathway.  Our findings are consistent with early tumor spread outside the brainstem including the cerebrum.  The spatial and temporal homogeneity of main driver mutations in DIPG implies they will be captured by limited biopsies and emphasizes the need to develop therapies specifically targeting obligate oncohistone partnerships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0xu1GtUyNrVg90H21EOLACvtfcHk0lieTnWIMUfupQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Kgtbg%253D&md5=fd267da3e8fee87ed6c76ece59efe2bd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms11185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11185%26sid%3Dliteratum%253Aachs%26aulast%3DNikbakht%26aufirst%3DH.%26aulast%3DPanditharatna%26aufirst%3DE.%26aulast%3DMikael%26aufirst%3DL.%2BG.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DGayden%26aufirst%3DT.%26aulast%3DOsmond%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DKambhampati%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DE.%2BI.%26aulast%3DFaury%26aufirst%3DD.%26aulast%3DSiu%26aufirst%3DA.%26aulast%3DPapillon-Cavanagh%26aufirst%3DS.%26aulast%3DBechet%26aufirst%3DD.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DEllezam%26aufirst%3DB.%26aulast%3DIngram%26aufirst%3DW.%2BJ.%26aulast%3DStinson%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DWarren%26aufirst%3DK.%2BE.%26aulast%3DKaramchandani%26aufirst%3DJ.%26aulast%3DPacker%26aufirst%3DR.%2BJ.%26aulast%3DJabado%26aufirst%3DN.%26aulast%3DMajewski%26aufirst%3DJ.%26aulast%3DNazarian%26aufirst%3DJ.%26atitle%3DSpatial%2520and%2520temporal%2520homogeneity%2520of%2520driver%2520mutations%2520in%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms11185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ten
Dijke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichijo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoshima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldin, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, K.</span></span> <span> </span><span class="NLM_article-title">Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2879</span>– <span class="NLM_lpage">2887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=8397373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADyaK3szptV2ltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1993&pages=2879-2887&author=P.+ten%0ADijkeauthor=H.+Ichijoauthor=P.+Franzenauthor=P.+Schulzauthor=J.+Sarasauthor=H.+Toyoshimaauthor=C.+H.+Heldinauthor=K.+Miyazono&title=Activin+receptor-like+kinases%3A+a+novel+subclass+of+cell-surface+receptors+with+predicted+serine%2Fthreonine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity</span></div><div class="casAuthors">ten Dijke P; Ichijo H; Franzen P; Schulz P; Saras J; Toyoshima H; Heldin C H; Miyazono K</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2879-87</span>
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">Human cDNA clones encoding four novel putative transmembrane protein serine/threonine kinases, denoted activin receptor-like kinase (ALK) -1, -2, -3 and -4, were obtained using a polymerase chain reaction (PCR)-based strategy.  The PCR primers were designed based upon the sequence similarity between the activin receptor type II and Daf-1.  The cDNA clones for ALK-1, -2 and -3 encode complete proteins of 503, 509 and 532 amino acids respectively.  The ALK-4 cDNA is incomplete and the predicted protein of 383 amino acids has a truncated extracellular domain.  The ALKs share similar domain structures, comprising predicted signal sequences at the N-terminals, followed by hydrophilic cysteine-rich ligand-binding domains, single hydrophobic transmembrane regions and C-terminal intracellular portions that consist almost entirely of putative serine/threonine kinase domains.  The ALKs have approximately 40% sequence identity to activin receptors type II and IIB, transforming growth factor-beta (TGF-beta) type II receptor and Daf-1 in the kinase domains.  However, the sequence identities are higher (60-79%) between ALK-1, -2, -3 and -4, suggesting that they form a subfamily among the putative receptor serine/threonine kinases.  The extracellular domains of ALKs show only little sequence identity to other putative receptor serine/threonine kinases, but the cysteine residues are conserved.  Their structural properties suggest that ALK-1 to -4 are receptors that may bind ligands that are members of the TGF-beta superfamily.  The expression of mRNA in human tissues varied for the different ALKs; ALK-2 and ALK-4 showed ubiquitous tissue expression patterns, whereas the distribution of ALK-1 and ALK-3 varied strongly between different tissues with more restricted expression patterns.  These results suggest that each ALK may have different in vivo functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrdSBxdXQSDoMcDoIzZtNkfW6udTcc2ebJhwMhHC5lPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptV2ltQ%253D%253D&md5=d6daa31d855593d6106600531251f835</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dten%2BDijke%26aufirst%3DP.%26aulast%3DIchijo%26aufirst%3DH.%26aulast%3DFranzen%26aufirst%3DP.%26aulast%3DSchulz%26aufirst%3DP.%26aulast%3DSaras%26aufirst%3DJ.%26aulast%3DToyoshima%26aufirst%3DH.%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26aulast%3DMiyazono%26aufirst%3DK.%26atitle%3DActivin%2520receptor-like%2520kinases%253A%2520a%2520novel%2520subclass%2520of%2520cell-surface%2520receptors%2520with%2520predicted%2520serine%252Fthreonine%2520kinase%2520activity%26jtitle%3DOncogene%26date%3D1993%26volume%3D8%26spage%3D2879%26epage%3D2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macias-Silva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoodless, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrana, J. L.</span></span> <span> </span><span class="NLM_article-title">Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">25628</span>– <span class="NLM_lpage">25636</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.40.25628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1074%2Fjbc.273.40.25628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=9748228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADyaK1cXms1egs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=25628-25636&author=M.+Macias-Silvaauthor=P.+A.+Hoodlessauthor=S.+J.+Tangauthor=M.+Buchwaldauthor=J.+L.+Wrana&title=Specific+activation+of+Smad1+signaling+pathways+by+the+BMP7+type+I+receptor%2C+ALK2&doi=10.1074%2Fjbc.273.40.25628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2</span></div><div class="casAuthors">Macias-Silva, Marina; Hoodless, Pamela A.; Tang, Shao Jun; Buchwald, Manuel; Wrana, Jeffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">25628-25636</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">BMP7 and activin are members of the transforming growth factor β superfamily.  Here we characterize endogenous activin and BMP7 signaling pathways in P19 embryonic carcinoma cells.  We show that BMP7 and activin bind to the same type II receptors, ActRII and IIB, but recruit distinct type I receptors into heteromeric receptor complexes.  The major BMP7 type I receptor obsd. was ALK2, while activin bound exclusively to ALK4 (ActRIB).  BMP7 and activin elicited distinct biol. responses and activated different Smad pathways.  BMP7 stimulated phosphorylation of endogenous Smad1 and 5, formation of complexes with Smad4 and induced the promoter for the homeobox gene, Tlx2.  In contrast, activin induced phosphorylation of Smad2, assocn. with Smad4, and induction of the activin response element from the Xenopus Mix.2 gene.  Biochem. anal. revealed that constitutively active ALK2 assocd. with and phosphorylated Smad1 on the COOH-terminal SSXS motif, and also regulated Smad5 and Smad8 phosphorylation.  Activated ALK2 also induced the Tlx2 promoter in the absence of BMP7.  Furthermore, we show that ALK1 (TSRI), an orphan receptor that is closely related to ALK2 also mediates Smad1 signaling.  Thus, ALK1 and ALK2 induce Smad1-dependent pathways and ALK2 functions to mediate BMP7 but not activin signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2cQzZTWUPGbVg90H21EOLACvtfcHk0ljAV2iT30X3mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1egs7c%253D&md5=920ec4d2851366586faae52ff9c0dc74</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.40.25628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.40.25628%26sid%3Dliteratum%253Aachs%26aulast%3DMacias-Silva%26aufirst%3DM.%26aulast%3DHoodless%26aufirst%3DP.%2BA.%26aulast%3DTang%26aufirst%3DS.%2BJ.%26aulast%3DBuchwald%26aufirst%3DM.%26aulast%3DWrana%26aufirst%3DJ.%2BL.%26atitle%3DSpecific%2520activation%2520of%2520Smad1%2520signaling%2520pathways%2520by%2520the%2520BMP7%2520type%2520I%2520receptor%252C%2520ALK2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D25628%26epage%3D25636%26doi%3D10.1074%2Fjbc.273.40.25628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">López-Rovira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, F.</span></span> <span> </span><span class="NLM_article-title">Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">3176</span>– <span class="NLM_lpage">3185</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106826200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1074%2Fjbc.M106826200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=11700304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtVaks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=3176-3185&author=T.+L%C3%B3pez-Roviraauthor=E.+Chalauxauthor=J.+Massagueauthor=J.+L.+Rosaauthor=F.+Ventura&title=Direct+binding+of+Smad1+and+Smad4+to+two+distinct+motifs+mediates+bone+morphogenetic+protein-specific+transcriptional+activation+of+Id1+gene&doi=10.1074%2Fjbc.M106826200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene</span></div><div class="casAuthors">Lopez-Rovira, Teresa; Chalaux, Elisabet; Massague, Joan; Rosa, Jose Luis; Ventura, Francesc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3176-3185</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bone morphogenetic proteins (BMPs) are potent inhibitors of myoblast differentiation and inducers of bone formation both in vivo and in vitro.  Expression of Id1, a neg. regulator of basic helix-loop-helix transcription factors, is up-regulated by BMPs and contributes to the antimyogenic effects of this family of cytokines.  In this report, the authors have identified a specific BMP-2 immediate early response enhancer in the human Id1 gene.  Transcriptional activation of the enhancer was increased by overexpression of BMP-responsive Smads, and Smad4 and was completely abrogated in Smad4-deficient cells.  Deletion anal. demonstrates that the responsive region is composed of two sep. DNA binding elements, a set of overlapping GC boxes, which bind BMP-regulated Smads upon BMP stimulation, and three repeats of CAGAC boxes.  Gel shift and oligonucleotide pull-down assays demonstrated that these two types of motifs were capable of binding their corresponding Smads.  However, deletion or mutation of either DNA binding element was nonadditive, since disruption of either GC or CAGAC boxes resulted in complete or severe loss of BMP-2 responsiveness.  These data suggest the simultaneous requirement of two independent DNA binding elements to allow functional co-operativity of BMP-regulated Smads and Smad4 in BMP-activated gene promoters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6ELFR5aBxLVg90H21EOLACvtfcHk0ljAV2iT30X3mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtVaks70%253D&md5=58d3624c36703561cae928da94556da8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106826200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106826200%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B3pez-Rovira%26aufirst%3DT.%26aulast%3DChalaux%26aufirst%3DE.%26aulast%3DMassague%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DJ.%2BL.%26aulast%3DVentura%26aufirst%3DF.%26atitle%3DDirect%2520binding%2520of%2520Smad1%2520and%2520Smad4%2520to%2520two%2520distinct%2520motifs%2520mediates%2520bone%2520morphogenetic%2520protein-specific%2520transcriptional%2520activation%2520of%2520Id1%2520gene%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D3176%26epage%3D3185%26doi%3D10.1074%2Fjbc.M106826200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korchynskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4891</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111023200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1074%2Fjbc.M111023200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=11729207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFeqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=4883-4891&author=O.+Korchynskyiauthor=P.+ten+Dijke&title=Identification+and+functional+characterization+of+distinct+critically+important+bone+morphogenetic+protein-specific+response+elements+in+the+Id1+promoter&doi=10.1074%2Fjbc.M111023200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter</span></div><div class="casAuthors">Korchynskyi, Olexander; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4883-4891</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Transforming growth factor-β (TGF-β) family members, which include bone morphogenetic proteins (BMPs) and TGF-βs, elicit their cellular effects by activating specific Smad proteins, which control the transcription of target genes.  BMPs and TGF-βs have overlapping as well as specific effects on mesenchymal cell differentiation for which the mechanisms are incompletely understood.  Here we report that Id1, a dominant neg. inhibitor of basic helix-loop-helix proteins, is a direct target gene for BMP.  BMP, but not TGF-β, strongly activates the Id1 promoter in an Smad-dependent manner.  We identified two BMP-responsive regions in the mouse Id1 promoter, which contain three distinct sequence elements; one region contains two Smad binding elements (SBEs), and the other region contains a GGCGCC palindromic sequence flanked by two CAGC and two CGCC motifs.  Whereas SBEs and GGCGCC sequence are critically important, the CAGC and CGCC motifs are needed for efficient BMP-induced Id1 promoter activation.  Smads are part of nuclear transcription factor complexes that specifically bind to SBEs and GGCGCC sequence in response to BMP but not TGF-β.  Multimerization of the all three distinct sequence motifs is needed to generate a highly sensitive and BMP/Smad-dependent specific enhancer.  Our results provide important new insights into how the BMP/Smad pathway can specifically activate target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp15NKd4FagVrVg90H21EOLACvtfcHk0lgOi0Vuai-ESQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFeqtbo%253D&md5=5c9e9524342c1a9f9ea246fb4ba4c247</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111023200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111023200%26sid%3Dliteratum%253Aachs%26aulast%3DKorchynskyi%26aufirst%3DO.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520distinct%2520critically%2520important%2520bone%2520morphogenetic%2520protein-specific%2520response%2520elements%2520in%2520the%2520Id1%2520promoter%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D4883%26epage%3D4891%26doi%3D10.1074%2Fjbc.M111023200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horigome, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebise, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toguchida, J.</span></span> <span> </span><span class="NLM_article-title">Neofunction of ACVR1 in fibrodysplasia ossificans progressiva</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">15438</span>– <span class="NLM_lpage">15443</span>, <span class="refDoi"> DOI: 10.1073/pnas.1510540112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1073%2Fpnas.1510540112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26621707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWqur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15438-15443&author=K.+Hinoauthor=M.+Ikeyaauthor=K.+Horigomeauthor=Y.+Matsumotoauthor=H.+Ebiseauthor=M.+Nishioauthor=K.+Sekiguchiauthor=M.+Shibataauthor=S.+Nagataauthor=S.+Matsudaauthor=J.+Toguchida&title=Neofunction+of+ACVR1+in+fibrodysplasia+ossificans+progressiva&doi=10.1073%2Fpnas.1510540112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Neofunction of ACVR1 in fibrodysplasia ossificans progressiva</span></div><div class="casAuthors">Hino, Kyosuke; Ikeya, Makoto; Horigome, Kazuhiko; Matsumoto, Yoshihisa; Ebise, Hayao; Nishio, Megumi; Sekiguchi, Kazuya; Shibata, Mitsuaki; Nagata, Sanae; Matsuda, Shuichi; Toguchida, Junya</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">15438-15443</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by extraskeletal bone formation through endochondral ossification.  FOP patients harbor point mutations in ACVR1 (also known as ALK2), a type I receptor for bone morphogenetic protein (BMP).  Two mechanisms of mutated ACVR1 (FOP-ACVR1) have been proposed: ligand-independent constitutive activity and ligand-dependent hyperactivity in BMP signaling.  Here, by using FOP patient-derived induced pluripotent stem cells (FOP-iPSCs), we report a third mechanism, where FOP-ACVR1 abnormally transduces BMP signaling in response to Activin-A, a mol. that normally transduces TGF-β signaling but not BMP signaling.  Activin-A enhanced the chondrogenesis of induced mesenchymal stromal cells derived from FOP-iPSCs (FOP-iMSCs) via aberrant activation of BMP signaling in addn. to the normal activation of TGF-β signaling in vitro, and induced endochondral ossification of FOP-iMSCs in vivo.  These results uncover a novel mechanism of extraskeletal bone formation in FOP and provide a potential new therapeutic strategy for FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_N0VtcCNm97Vg90H21EOLACvtfcHk0lgOi0Vuai-ESQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWqur%252FL&md5=21363365af31167197b87b246845e01f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1510540112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1510540112%26sid%3Dliteratum%253Aachs%26aulast%3DHino%26aufirst%3DK.%26aulast%3DIkeya%26aufirst%3DM.%26aulast%3DHorigome%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DEbise%26aufirst%3DH.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DM.%26aulast%3DNagata%26aufirst%3DS.%26aulast%3DMatsuda%26aufirst%3DS.%26aulast%3DToguchida%26aufirst%3DJ.%26atitle%3DNeofunction%2520of%2520ACVR1%2520in%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D15438%26epage%3D15443%26doi%3D10.1073%2Fpnas.1510540112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatsell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolken, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannuru, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhoul, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernomorsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corpina, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Economides, A. N.</span></span> <span> </span><span class="NLM_article-title">ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">303ra137</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aac4358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1126%2Fscitranslmed.aac4358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26333933" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=S.+J.+Hatsellauthor=V.+Idoneauthor=D.+M.+Wolkenauthor=L.+Huangauthor=H.+J.+Kimauthor=L.+Wangauthor=X.+Wenauthor=K.+C.+Nannuruauthor=J.+Jimenezauthor=L.+Xieauthor=N.+Dasauthor=G.+Makhoulauthor=R.+Chernomorskyauthor=D.+D%E2%80%99Ambrosioauthor=R.+A.+Corpinaauthor=C.+J.+Schoenherrauthor=K.+Feeleyauthor=P.+B.+Yuauthor=G.+D.+Yancopoulosauthor=A.+J.+Murphyauthor=A.+N.+Economides&title=ACVR1R206H+receptor+mutation+causes+fibrodysplasia+ossificans+progressiva+by+imparting+responsiveness+to+activin+A&doi=10.1126%2Fscitranslmed.aac4358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac4358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac4358%26sid%3Dliteratum%253Aachs%26aulast%3DHatsell%26aufirst%3DS.%2BJ.%26aulast%3DIdone%26aufirst%3DV.%26aulast%3DWolken%26aufirst%3DD.%2BM.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DNannuru%26aufirst%3DK.%2BC.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DN.%26aulast%3DMakhoul%26aufirst%3DG.%26aulast%3DChernomorsky%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DD.%26aulast%3DCorpina%26aufirst%3DR.%2BA.%26aulast%3DSchoenherr%26aufirst%3DC.%2BJ.%26aulast%3DFeeley%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DMurphy%26aufirst%3DA.%2BJ.%26aulast%3DEconomides%26aufirst%3DA.%2BN.%26atitle%3DACVR1R206H%2520receptor%2520mutation%2520causes%2520fibrodysplasia%2520ossificans%2520progressiva%2520by%2520imparting%2520responsiveness%2520to%2520activin%2520A%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26doi%3D10.1126%2Fscitranslmed.aac4358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paugh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahawatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pounds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onar-Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huether, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becksfort, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadodaria, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yergeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boop, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broniscer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span> <span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0lgcOVoKFtbFuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misuraca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazarian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procissi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, O. J.</span></span> <span> </span><span class="NLM_article-title">ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">1023</span> <span class="refDoi"> DOI: 10.1038/s41467-019-08823-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fs41467-019-08823-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30833574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=C.+M.+Hoemanauthor=F.+J.+Corderoauthor=G.+Huauthor=K.+Misuracaauthor=M.+M.+Romeroauthor=H.+J.+Cardonaauthor=J.+Nazarianauthor=R.+Hashizumeauthor=R.+McLendonauthor=P.+Yuauthor=D.+Procissiauthor=S.+Gaddauthor=O.+J.+Becher&title=ACVR1+R206H+cooperates+with+H3.1K27M+in+promoting+diffuse+intrinsic+pontine+glioma+pathogenesis&doi=10.1038%2Fs41467-019-08823-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis</span></div><div class="casAuthors">Hoeman Christine M; Romero Megan M; Cardona Herminio J; Becher Oren J; Cordero Francisco J; Hu Guo; Misuraca Katie; Nazarian Javad; Hashizume Rintaro; Hashizume Rintaro; Becher Oren J; Hashizume Rintaro; Becher Oren J; McLendon Roger; McLendon Roger; Yu Paul; Procissi Daniele; Gadd Samantha; Becher Oren J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1023</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brain tumor, with approximately 25% of DIPGs harboring activating ACVR1 mutations that commonly co-associate with H3.1K27M mutations.  Here we show that in vitro expression of ACVR1 R206H with and without H3.1K27M upregulates mesenchymal markers and activates Stat3 signaling.  In vivo expression of ACVR1 R206H or G328V with H3.1K27M and p53 deletion induces glioma-like lesions but is not sufficient for full gliomagenesis.  However, in combination with PDGFA signaling, ACVR1 R206H and H3.1K27M significantly decrease survival and increase tumor incidence.  Treatment of ACVR1 R206H mutant DIPGs with exogenous Noggin or the ACVR1 inhibitor LDN212854 significantly prolongs survival, with human ACVR1 mutant DIPG cell lines also being sensitive to LDN212854 treatment.  Together, our results demonstrate that ACVR1 R206H and H3.1K27M promote tumor initiation, accelerate gliomagenesis, promote a mesenchymal profile partly due to Stat3 activation, and identify LDN212854 as a promising compound to treat DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKDjpfXAfQCT0O18WR3iAofW6udTcc2eYdjY8EGZ_hObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtA%253D%253D&md5=6329143062096abbcef61d0dd08f1982</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-08823-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-08823-9%26sid%3Dliteratum%253Aachs%26aulast%3DHoeman%26aufirst%3DC.%2BM.%26aulast%3DCordero%26aufirst%3DF.%2BJ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DMisuraca%26aufirst%3DK.%26aulast%3DRomero%26aufirst%3DM.%2BM.%26aulast%3DCardona%26aufirst%3DH.%2BJ.%26aulast%3DNazarian%26aufirst%3DJ.%26aulast%3DHashizume%26aufirst%3DR.%26aulast%3DMcLendon%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DProcissi%26aufirst%3DD.%26aulast%3DGadd%26aufirst%3DS.%26aulast%3DBecher%26aufirst%3DO.%2BJ.%26atitle%3DACVR1%2520R206H%2520cooperates%2520with%2520H3.1K27M%2520in%2520promoting%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520pathogenesis%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-019-08823-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babitt, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyng, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2007.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnchembio.2007.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=18026094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVegtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=33-41&author=P.+B.+Yuauthor=C.+C.+Hongauthor=C.+Sachidanandanauthor=J.+L.+Babittauthor=D.+Y.+Dengauthor=S.+A.+Hoyngauthor=H.+Y.+Linauthor=K.+D.+Blochauthor=R.+T.+Peterson&title=Dorsomorphin+inhibits+BMP+signals+required+for+embryogenesis+and+iron+metabolism&doi=10.1038%2Fnchembio.2007.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism</span></div><div class="casAuthors">Yu, Paul B.; Hong, Charles C.; Sachidanandan, Chetana; Babitt, Jodie L.; Deng, Donna Y.; Hoyng, Stefan A.; Lin, Herbert Y.; Bloch, Kenneth D.; Peterson, Randall T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bone morphogenetic protein (BMP) signals coordinate developmental patterning and have essential physiol. roles in mature organisms.  Here we describe the first known small-mol. inhibitor of BMP signaling-dorsomorphin, which we identified in a screen for compds. that perturb dorsoventral axis formation in zebrafish.  We found that dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation.  Using dorsomorphin, we examd. the role of BMP signaling in iron homeostasis.  In vitro, dorsomorphin inhibited BMP-, hemojuvelin- and interleukin 6-stimulated expression of the systemic iron regulator hepcidin, which suggests that BMP receptors regulate hepcidin induction by all of these stimuli.  In vivo, systemic challenge with iron rapidly induced SMAD1/5/8 phosphorylation and hepcidin expression in the liver, whereas treatment with dorsomorphin blocked SMAD1/5/8 phosphorylation, normalized hepcidin expression and increased serum iron levels.  These findings suggest an essential physiol. role for hepatic BMP signaling in iron-hepcidin homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Ot0o1uk6ErVg90H21EOLACvtfcHk0lgcOVoKFtbFuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVegtbnF&md5=fb064fa0f1d036b790a8635a913dc0fc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2007.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2007.54%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DBabitt%26aufirst%3DJ.%2BL.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DHoyng%26aufirst%3DS.%2BA.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26atitle%3DDorsomorphin%2520inhibits%2520BMP%2520signals%2520required%2520for%2520embryogenesis%2520and%2520iron%2520metabolism%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D33%26epage%3D41%26doi%3D10.1038%2Fnchembio.2007.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1115</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1080/13543776.2016.1217330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1080%2F13543776.2016.1217330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27476794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1115-1128&author=C.+R.+Hopkins&title=Inhibitors+of+the+bone+morphogenetic+protein+%28BMP%29+signaling+pathway%3A+a+patent+review+%282008-2015%29&doi=10.1080%2F13543776.2016.1217330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)</span></div><div class="casAuthors">Hopkins, Corey R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1128</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: The bone morphogenetic protein (BMP) is a crit. signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others.  Areas covered: This review covers small mol. inhibitors/antagonists of BMP in patent applications between 2008 - 2015, along with brief synopses of the disclosed inhibitors in the primary literature.  Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile.  Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP).  Recently, however, there has been increased interest in their use in a no. of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few.  Although the primary participants in the early work were from academic labs., recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications.  Due to this, expect a no. of new approaches such as repurposing of other kinase inhibitors to be brought into clin. trials in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShe2EZoRM8LVg90H21EOLACvtfcHk0lgelJskLhSIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12ntbjO&md5=e71e2ed75369d31a3835aaed4cf65de6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1217330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1217330%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26atitle%3DInhibitors%2520of%2520the%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520pathway%253A%2520a%2520patent%2520review%2520%25282008-2015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D1115%26epage%3D1128%26doi%3D10.1080%2F13543776.2016.1217330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laha, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4392</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.bmcl.2008.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=18621530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4388-4392&author=G.+D.+Cunyauthor=P.+B.+Yuauthor=J.+K.+Lahaauthor=X.+Xingauthor=J.-F.+Liuauthor=C.+S.+Laiauthor=D.+Y.+Dengauthor=C.+Sachidanandanauthor=K.+D.+Blochauthor=R.+T.+Peterson&title=Structure-activity+relationship+study+of+bone+morphogenetic+protein+%28BMP%29+signaling+inhibitors&doi=10.1016%2Fj.bmcl.2008.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</span></div><div class="casAuthors">Cuny, Gregory D.; Yu, Paul B.; Laha, Joydev K.; Xing, Xuechao; Liu, Ji-Feng; Lai, Carol S.; Deng, Donna Y.; Sachidanandan, Chetana; Bloch, Kenneth D.; Peterson, Randall T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4388-4392</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline.  The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examd. by prepg. and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivs.  In addn., increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent Ph ring with piperazine.  Finally, an optimized compd. 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t 1/2 = 1.6 h) following i.p. administration in mice.  These studies provide useful mol. probes for examg. the in vivo pharmacol. of BMP signaling inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxlj03oLBHLVg90H21EOLACvtfcHk0lgelJskLhSIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVequrc%253D&md5=227395181629474e47aee6163492c4bc</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DLaha%26aufirst%3DJ.%2BK.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DLai%26aufirst%3DC.%2BS.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520bone%2520morphogenetic%2520protein%2520%2528BMP%2529%2520signaling%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4388%26epage%3D4392%26doi%3D10.1016%2Fj.bmcl.2008.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">Development of an ALK2-biased BMP type I receptor kinase inhibitor</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1021/cb300655w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300655w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1291-1302&author=A.+H.+Mohedasauthor=X.+Xingauthor=K.+A.+Armstrongauthor=A.+N.+Bullockauthor=G.+D.+Cunyauthor=P.+B.+Yu&title=Development+of+an+ALK2-biased+BMP+type+I+receptor+kinase+inhibitor&doi=10.1021%2Fcb300655w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor</span></div><div class="casAuthors">Mohedas, Agustin H.; Xing, Xuechao; Armstrong, Kelli A.; Bullock, Alex N.; Cuny, Gregory D.; Yu, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1291-1302</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bone morphogenetic protein (BMP) signaling pathway has essential functions in development, homeostasis, and the normal and pathophysiol. remodeling of tissues.  Small mol. inhibitors of the BMP receptor kinase family have been useful for probing physiol. functions of BMP signaling in vitro and in vivo and may have roles in the treatment of BMP-mediated diseases.  Here we describe the development of a selective and potent inhibitor of the BMP type I receptor kinases, LDN-212854, which in contrast to previously described BMP receptor kinase inhibitors exhibits nearly 4 orders of selectivity for BMP vs. the closely related TGF-β and Activin type I receptors.  In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity, and function.  LDN-212854 potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.  These findings represent a significant step toward developing selective inhibitors targeting individual members of the highly homologous BMP type I receptor family.  Such inhibitors would provide greater resoln. as probes of physiol. function and improved selectivity against therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHih4D1koDbrVg90H21EOLACvtfcHk0lgelJskLhSIAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCksrY%253D&md5=0f151ea0674207160616b8a2b093c463</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fcb300655w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300655w%26sid%3Dliteratum%253Aachs%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DArmstrong%26aufirst%3DK.%2BA.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DDevelopment%2520of%2520an%2520ALK2-biased%2520BMP%2520type%2520I%2520receptor%2520kinase%2520inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1291%26epage%3D1302%26doi%3D10.1021%2Fcb300655w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the potent and selective binding of LDN-212854 to the BMP rceptor kinase ALK2</span>. <i>Bone</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2017.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.bone.2017.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28918311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWit77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=251-258&author=E.+Williamsauthor=A.+N.+Bullock&title=Structural+basis+for+the+potent+and+selective+binding+of+LDN-212854+to+the+BMP+rceptor+kinase+ALK2&doi=10.1016%2Fj.bone.2017.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2</span></div><div class="casAuthors">Williams, Eleanor; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-258</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">1873-2763</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Individuals with the rare developmental disorder fibrodysplasia ossificans progressiva (FOP) experience disabling heterotopic ossification caused by a gain of function mutation in the intracellular region of the BMP type I receptor kinase ALK2, encoded by the gene ACVR1.  Small mol. BMP type I receptor inhibitors that block this ossification in FOP mouse models have been derived from the pyrazolo[1,5-a]pyrimidine scaffold of dorsomorphin.  While the first deriv. LDN-193189 exhibited pan inhibition of BMP receptors, the more recent compd. LDN-212854 has shown increased selectivity for ALK2.  Here we solved the crystal structure of ALK2 in complex with LDN-212854 to define how its binding interactions compare to previously reported BMP and TGFβ receptor inhibitors.  LDN-212854 bound to the kinase hinge region as a typical type I ATP-competitive inhibitor with a single hydrogen bond to ALK2 His286.  Specificity arising from the 5-quinoline moiety was assocd. with a distinct pattern of water-mediated hydrogen bonds involving Lys235 and Glu248 in the inactive conformation favored by ALK2.  The structure of this complex provides a template for the design of future ALK2 inhibitors under development for the treatment of FOP and other related conditions of heterotopic ossification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1vfj50E7qHbVg90H21EOLACvtfcHk0liq76uIInp43w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWit77N&md5=b3b28a6fe7675c9a3b23e90758827699</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2017.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2017.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DStructural%2520basis%2520for%2520the%2520potent%2520and%2520selective%2520binding%2520of%2520LDN-212854%2520to%2520the%2520BMP%2520rceptor%2520kinase%2520ALK2%26jtitle%3DBone%26date%3D2018%26volume%3D109%26spage%3D251%26epage%3D258%26doi%3D10.1016%2Fj.bone.2017.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouxsein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katagiri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachidanandan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span> <span> </span><span class="NLM_article-title">BMP type I receptor inhibition reduces heterotopic [corrected] ossification</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1038/nm.1888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnm.1888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=19029982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1363-1369&author=P.+B.+Yuauthor=D.+Y.+Dengauthor=C.+S.+Laiauthor=C.+C.+Hongauthor=G.+D.+Cunyauthor=M.+L.+Bouxseinauthor=D.+W.+Hongauthor=P.+M.+McManusauthor=T.+Katagiriauthor=C.+Sachidanandanauthor=N.+Kamiyaauthor=T.+Fukudaauthor=Y.+Mishinaauthor=R.+T.+Petersonauthor=K.+D.+Bloch&title=BMP+type+I+receptor+inhibition+reduces+heterotopic+%5Bcorrected%5D+ossification&doi=10.1038%2Fnm.1888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">BMP type I receptor inhibition reduces heterotopic ossification</span></div><div class="casAuthors">Yu, Paul B.; Deng, Donna Y.; Lai, Carol S.; Hong, Charles C.; Cuny, Gregory D.; Bouxsein, Mary L.; Hong, Deborah W.; McManus, Patrick M.; Katagiri, Takenobu; Sachidanandan, Chetana; Kamiya, Nobuhiro; Fukuda, Tomokazu; Mishina, Yuji; Peterson, Randall T.; Bloch, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1363-1369</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive and widespread postnatal ossification of soft tissues and is without known effective treatments.  Affected individuals harbor conserved mutations in the ACVR1 gene that are thought to cause constitutive activation of the bone morphogenetic protein (BMP) type I receptor, activin receptor-like kinase-2 (ALK2).  Here we show that i.m. expression in the mouse of an inducible transgene encoding constitutively active ALK2 (caALK2), resulting from a glutamine to aspartic acid change at amino acid position 207, leads to ectopic endochondral bone formation, joint fusion and functional impairment, thus phenocopying key aspects of human FOP.  A selective inhibitor of BMP type I receptor kinases, LDN-193189, inhibits activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in tissues expressing caALK2 via adenovirus expressing, reducing ectopic ossification and functional impairment.  In contrast to induced expression of caALK2 via adenovirus expressing Cre (Ad.Cre), global postnatal expression of caALK2 by itself does not lead to ectopic ossification; however, in combination with infection by a control adenovirus ectopic bone formation was induced.  Corticosteroid treatment inhibits ossification in Ad.Cre-injected mutant mice, suggesting caALK2 expression and an inflammatory milieu are both required for the development of ectopic ossification in this model.  These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and suggest that small mol. inhibition of BMP type I receptor activity may be useful in treating FOP and heterotopic ossification syndromes assocd. with excessive BMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt63Bkmo9HuLVg90H21EOLACvtfcHk0liq76uIInp43w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7nM&md5=f5743345aec7ae55fc948ccf41fcd782</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnm.1888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1888%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DDeng%26aufirst%3DD.%2BY.%26aulast%3DLai%26aufirst%3DC.%2BS.%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DBouxsein%26aufirst%3DM.%2BL.%26aulast%3DHong%26aufirst%3DD.%2BW.%26aulast%3DMcManus%26aufirst%3DP.%2BM.%26aulast%3DKatagiri%26aufirst%3DT.%26aulast%3DSachidanandan%26aufirst%3DC.%26aulast%3DKamiya%26aufirst%3DN.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26atitle%3DBMP%2520type%2520I%2520receptor%2520inhibition%2520reduces%2520heterotopic%2520%255Bcorrected%255D%2520ossification%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D1363%26epage%3D1369%26doi%3D10.1038%2Fnm.1888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, G. P.</span></span> <span> </span><span class="NLM_article-title">The specificities of small molecule inhibitors of the TGFβ and BMP pathways</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1831</span>– <span class="NLM_lpage">1842</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2011.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.cellsig.2011.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21740966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVCntr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2011&pages=1831-1842&author=J.+Vogtauthor=R.+Traynorauthor=G.+P.+Sapkota&title=The+specificities+of+small+molecule+inhibitors+of+the+TGF%CE%B2+and+BMP+pathways&doi=10.1016%2Fj.cellsig.2011.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The specificities of small molecule inhibitors of the TGFss and BMP pathways</span></div><div class="casAuthors">Vogt, Janis; Traynor, Ryan; Sapkota, Gopal P.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1831-1842</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small mol. inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGFss and BMP signals, have been employed extensively to assess their physiol. roles in cells and organisms.  While all of these inhibitors have been reported as "selective" inhibitors of specific ALKs, extensive specificity tests against a wide array of protein kinases have not been performed.  In this study, we examine the specificities and potencies of the most frequently used small mol. inhibitors of the TGFss pathway (SB-431542, SB-505124, LY-364947 and A-83-01) and the BMP pathway (Dorsomorphin and LDN-193189) against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome.  We demonstrate that the inhibitors of the TGFss pathway are relatively more selective than the inhibitors of the BMP pathway.  Based on our specificity and potency profile and published data, we recommend SB-505124 as the most suitable mol. for use as an inhibitor of ALKs 4, 5 and 7 and the TGFss pathway.  We do not recommend Dorsomorphin, also called Compd. C, for use as an inhibitor of the BMP pathway.  Although LDN-193189, a Dorsomorphin deriv., is a very potent inhibitor of ALK2/3 and the BMP-pathway, we found that it potently inhibited a no. of other protein kinases at concns. sufficient to inhibit ALK2/3 and its use as a selective BMP-pathway inhibitor has to be considered cautiously.  Our observations have highlighted the need for caution when using these small mol. inhibitors to assess the physiol. roles of BMP and TGFss pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY5EQkxMmiQ7Vg90H21EOLACvtfcHk0liq76uIInp43w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVCntr7L&md5=f5529bfbd3732efec9eb6887a5f6c304</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2011.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2011.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DVogt%26aufirst%3DJ.%26aulast%3DTraynor%26aufirst%3DR.%26aulast%3DSapkota%26aufirst%3DG.%2BP.%26atitle%3DThe%2520specificities%2520of%2520small%2520molecule%2520inhibitors%2520of%2520the%2520TGF%25CE%25B2%2520and%2520BMP%2520pathways%26jtitle%3DCell.%2520Signalling%26date%3D2011%26volume%3D23%26spage%3D1831%26epage%3D1842%26doi%3D10.1016%2Fj.cellsig.2011.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechtold, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgariglia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billings, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacific, M.</span></span> <span> </span><span class="NLM_article-title">Unsuspected osteochondroma-like outgrowths in the crania base of hereditary multiple exostoses patients and modeling and treatment with a BMP antagonist in mice</span>. <i>PloS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e1006742</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1006742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1371%2Fjournal.pgen.1006742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28445472" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&author=S.+Sinhaauthor=C.+Mundyauthor=T.+Bechtoldauthor=F.+Sgarigliaauthor=M.+M.+Ibrahimauthor=P.+C.+Billingsauthor=K.+Carrollauthor=E.+Koyamaauthor=K.+B.+Jonesauthor=M.+Pacific&title=Unsuspected+osteochondroma-like+outgrowths+in+the+crania+base+of+hereditary+multiple+exostoses+patients+and+modeling+and+treatment+with+a+BMP+antagonist+in+mice&doi=10.1371%2Fjournal.pgen.1006742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1006742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1006742%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DMundy%26aufirst%3DC.%26aulast%3DBechtold%26aufirst%3DT.%26aulast%3DSgariglia%26aufirst%3DF.%26aulast%3DIbrahim%26aufirst%3DM.%2BM.%26aulast%3DBillings%26aufirst%3DP.%2BC.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DKoyama%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DK.%2BB.%26aulast%3DPacific%26aufirst%3DM.%26atitle%3DUnsuspected%2520osteochondroma-like%2520outgrowths%2520in%2520the%2520crania%2520base%2520of%2520hereditary%2520multiple%2520exostoses%2520patients%2520and%2520modeling%2520and%2520treatment%2520with%2520a%2520BMP%2520antagonist%2520in%2520mice%26jtitle%3DPloS%2520Genet.%26date%3D2017%26volume%3D13%26doi%3D10.1371%2Fjournal.pgen.1006742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triffitt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">A new class of small molecule inhibitor of BMP signaling</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e62721</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0062721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1371%2Fjournal.pone.0062721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=23646137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=C.+E.+Sanvitaleauthor=G.+Kerrauthor=A.+Chaikuadauthor=M.+C.+Ramelauthor=A.+H.+Mohedasauthor=S.+Reichertauthor=Y.+Wangauthor=J.+T.+Triffittauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=C.+S.+Hillauthor=A.+N.+Bullock&title=A+new+class+of+small+molecule+inhibitor+of+BMP+signaling&doi=10.1371%2Fjournal.pone.0062721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of small molecule inhibitor of BMP signaling</span></div><div class="casAuthors">Sanvitale, Caroline E.; Kerr, Georgina; Chaikuad, Apirat; Ramel, Marie-Christine; Mohedas, Agustin H.; Reichert, Sabine; Wang, You; Triffitt, James T.; Cuny, Gregory D.; Yu, Paul B.; Hill, Caroline S.; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e62721</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Growth factor signaling pathways are tightly regulated by phosphorylation and include many important kinase targets of interest for drug discovery.  Small mol. inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP).  Dorsomorphin analogs, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date.  By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concns. similar to the current lead compd. LDN-193189.  K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-β signaling and induced dorsalization of zebrafish embryos.  Comparison of the crystal structures of ALK2 with K02288 and LDN-193189 revealed addnl. contacts in the K02288 complex affording improved shape complementarity and identified the exposed phenol group for further optimization of pharmacokinetics.  The discovery of a new chem. series provides an independent pharmacol. tool to investigate BMP signaling and offers multiple opportunities for pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomMygI9eYjlbVg90H21EOLACvtfcHk0ljeXSlImZsn-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVKhtrg%253D&md5=d00f0fddc871eb1a92fa90f36c7d54dc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0062721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0062721%26sid%3Dliteratum%253Aachs%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DRamel%26aufirst%3DM.%2BC.%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DReichert%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTriffitt%26aufirst%3DJ.%2BT.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DHill%26aufirst%3DC.%2BS.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DA%2520new%2520class%2520of%2520small%2520molecule%2520inhibitor%2520of%2520BMP%2520signaling%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0062721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohedas, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvitale, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7900</span>– <span class="NLM_lpage">7915</span>, <span class="refDoi"> DOI: 10.1021/jm501177w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501177w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7900-7915&author=A.+H.+Mohedasauthor=Y.+Wangauthor=C.+E.+Sanvitaleauthor=P.+Canningauthor=S.+Choiauthor=X.+Xingauthor=A.+N.+Bullockauthor=G.+D.+Cunyauthor=P.+B.+Yu&title=Structure-activity+relationship+of+3%2C5-diaryl-2-aminopyridine+ALK2+inhibitors+reveals+unaltered+binding+affinity+for+fibrodysplasia+ossificans+progressiva+causing+mutants&doi=10.1021%2Fjm501177w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants</span></div><div class="casAuthors">Mohedas, Agustin H.; Wang, You; Sanvitale, Caroline E.; Canning, Peter; Choi, Sungwoon; Xing, Xuechao; Bullock, Alex N.; Cuny, Gregory D.; Yu, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7900-7915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2.  Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors.  Here the authors describe the structure-activity relationship for a series of novel ALK2 inhibitors based on the 2-aminopyridine compd. K02288.  Several modifications increased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as well as selectivity for ALK2 vs. closely related BMP and TGF-β type I receptor kinases.  Compds. in this series exhibited a wide range of in vitro cytotoxicity that was not correlated with potency or selectivity, suggesting mechanisms independent of BMP or TGF-β inhibition.  The study also highlights a potent 2-methylpyridine deriv. I (LDN-214117) with a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclin. development.  Contrary to the notion that activating mutations of ALK2 might alter inhibitor efficacy due to potential conformational changes in the ATP-binding site, the compds. demonstrated consistent binding to a panel of mutant and wild-type ALK2 proteins.  Thus, BMP inhibitors identified via activity against wild-type ALK2 signaling are likely to be of clin. relevance for the diverse ALK2 mutant proteins assocd. with FOP and DIPG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBKhBWuwrqjLVg90H21EOLACvtfcHk0ljeXSlImZsn-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12gu7fP&md5=c5efce9b3d06bbb126aa8a197d3d2b40</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm501177w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501177w%26sid%3Dliteratum%253Aachs%26aulast%3DMohedas%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSanvitale%26aufirst%3DC.%2BE.%26aulast%3DCanning%26aufirst%3DP.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DStructure-activity%2520relationship%2520of%25203%252C5-diaryl-2-aminopyridine%2520ALK2%2520inhibitors%2520reveals%2520unaltered%2520binding%2520affinity%2520for%2520fibrodysplasia%2520ossificans%2520progressiva%2520causing%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7900%26epage%3D7915%26doi%3D10.1021%2Fjm501177w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3356</span>– <span class="NLM_lpage">3362</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1016%2Fj.bmcl.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30227946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3356-3362&author=J.-k.+Jiangauthor=X.+Huangauthor=K.+Shamimauthor=P.+R.+Patelauthor=A.+Leeauthor=A.+Q.+Wangauthor=K.+Nguyenauthor=G.+Tawaauthor=G.+D.+Cunyauthor=P.+B.+Yuauthor=W.+Zhengauthor=X.+Xuauthor=P.+Sandersonauthor=W.+Huang&title=Discovery+of+3-%284-sulfamoylnaphthyl%29pyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+and+selective+ALK2+inhibitors&doi=10.1016%2Fj.bmcl.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors</span></div><div class="casAuthors">Jiang, Jian-kang; Huang, Xiuli; Shamim, Khalida; Patel, Paresma R.; Lee, Arthur; Wang, Amy Q.; Nguyen, Kimloan; Tawa, Gregory; Cuny, Gregory D.; Yu, Paul B.; Zheng, Wei; Xu, Xin; Sanderson, Philip; Huang, Wenwei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3356-3362</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pyrazolo[1,5-a]pyrimidine LDN-193189 is a potent inhibitor of activin receptor-like kinase 2 (ALK2) but is nonselective for highly homologous ALK3 and shows only modest kinome selectivity.  Herein, we describe the discovery of a novel series of potent and selective ALK2 inhibitors by replacing the quinolinyl with a 4-(sulfamoyl)naphthyl, yielding ALK2 inhibitors that exhibit not only excellent discrimination vs. ALK3 but also high kinome selectivity.  In addn., the optimized compd. 23 demonstrates good ADME and in vivo pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotGqzp6yONDLVg90H21EOLACvtfcHk0lg23yoqMU7GUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslejsLjP&md5=c612015c66df5b0bebaaf43b67f55970</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.-k.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShamim%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DCuny%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSanderson%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25203-%25284-sulfamoylnaphthyl%2529pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520and%2520selective%2520ALK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3356%26epage%3D3362%26doi%3D10.1016%2Fj.bmcl.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span> <span> </span><span class="NLM_article-title">Novel quinazolinone inhibitors of ALK2 flip between alternate binding modes: structure-activity relationship, structural characterization, kinase profiling, and cellular proof of concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7261</span>– <span class="NLM_lpage">7272</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00782</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00782" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVClurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7261-7272&author=L.+Hudsonauthor=J.+Muiauthor=S.+Vazquezauthor=D.+M.+Carvalhoauthor=E.+Williamsauthor=C.+Jonesauthor=A.+N.+Bullockauthor=S.+Hoelder&title=Novel+quinazolinone+inhibitors+of+ALK2+flip+between+alternate+binding+modes%3A+structure-activity+relationship%2C+structural+characterization%2C+kinase+profiling%2C+and+cellular+proof+of+concept&doi=10.1021%2Facs.jmedchem.8b00782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept</span></div><div class="casAuthors">Hudson, Liam; Mui, James; Vazquez, Santiago; Carvalho, Diana M.; Williams, Eleanor; Jones, Chris; Bullock, Alex N.; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7261-7272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationship and crystallog. data revealed that quinazolinone-contg. fragments flip between two distinct modes of binding to activin receptor-like kinase-2 (ALK2).  We explored both binding modes to discover potent inhibitors and characterized the chem. modifications that triggered the flip in binding mode.  We report kinase selectivity and demonstrate that compds. of this series modulate ALK2 in cancer cells.  These inhibitors are attractive starting points for the discovery of more advanced ALK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqae6Cwj4ijKbVg90H21EOLACvtfcHk0lg23yoqMU7GUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVClurjE&md5=a3a04f969265895f79f720d4a312ba57</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00782%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DL.%26aulast%3DMui%26aufirst%3DJ.%26aulast%3DVazquez%26aufirst%3DS.%26aulast%3DCarvalho%26aufirst%3DD.%2BM.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DNovel%2520quinazolinone%2520inhibitors%2520of%2520ALK2%2520flip%2520between%2520alternate%2520binding%2520modes%253A%2520structure-activity%2520relationship%252C%2520structural%2520characterization%252C%2520kinase%2520profiling%252C%2520and%2520cellular%2520proof%2520of%2520concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7261%26epage%3D7272%26doi%3D10.1021%2Facs.jmedchem.8b00782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekimata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima-Tsumagari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)</span>. <i>Chem. Pharm. Bull. (Tokyo)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1248/cpb.c18-00598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1248%2Fcpb.c18-00598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30828000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3cfpvVekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=224-235&author=K.+Sekimataauthor=T.+Satoauthor=N.+Sakaiauthor=H.+Watanabeauthor=C.+Mishima-Tsumagariauthor=T.+Taguriauthor=T.+Matsumotoauthor=Y.+Fujiiauthor=N.+Handaauthor=T.+Honmaauthor=A.+Tanakaauthor=M.+Shirouzuauthor=S.+Yokoyamaauthor=K.+Miyazonoauthor=Y.+Hashizumeauthor=H.+Koyama&title=Bis-heteroaryl+pyrazoles%3A+identification+of+orally+bioavailable+inhibitors+of+activin+receptor-like+kinase-2+%28R206H%29&doi=10.1248%2Fcpb.c18-00598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H)</span></div><div class="casAuthors">Sekimata Katsuhiko; Taguri Tomonori; Koyama Hiroo; Sato Tomohiro; Honma Teruki; Sakai Naoki; Watanabe Hisami; Mishima-Tsumagari Chiemi; Matsumoto Takehisa; Tanaka Akiko; Shirouzu Mikako; Fujii Yoshifumi; Handa Noriko; Yokoyama Shigeyuki; Miyazono Kohei; Hashizume Yoshinobu</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & pharmaceutical bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-235</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutant activin receptor-like kinase-2 (ALK2) was reported to be closely associated with the pathogenesis of fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG), and therefore presents an attractive target for therapeutic intervention.  Through in silico virtual screenings and structure-activity relationship studies assisted by X-ray crystallographic analyses, a novel series of bis-heteroaryl pyrazole was identified as potent inhibitors of ALK2 (R206H).  Derived from in silico hit compound RK-59638 (6a), compound 18p was identified as a potent inhibitor of ALK2 (R206H) with good aqueous solubility, liver microsomal stability, and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa63P45f1-gUmhnSqMnvzDfW6udTcc2eZpd2OwgOkWFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfpvVekug%253D%253D&md5=529c9d5fbc686147fdb7044a053515ca</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c18-00598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c18-00598%26sid%3Dliteratum%253Aachs%26aulast%3DSekimata%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMishima-Tsumagari%26aufirst%3DC.%26aulast%3DTaguri%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DMiyazono%26aufirst%3DK.%26aulast%3DHashizume%26aufirst%3DY.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DBis-heteroaryl%2520pyrazoles%253A%2520identification%2520of%2520orally%2520bioavailable%2520inhibitors%2520of%2520activin%2520receptor-like%2520kinase-2%2520%2528R206H%2529%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2019%26volume%3D67%26spage%3D224%26epage%3D235%26doi%3D10.1248%2Fcpb.c18-00598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Duffhues, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benderitter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Wijhe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia de Vinuesa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caradec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goumans, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eekhoff, E. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Piga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachiller-Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoflack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">Development of macrocycle kinase inhibitors for ALK2 using fibrodysplasia ossificans progressiva-derived endothelial cells</span>. <i>JBMR Plus</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e10230</span> <span class="refDoi"> DOI: 10.1002/jbm4.10230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fjbm4.10230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=31768489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&author=G.+S%C3%A1nchez-Duffhuesauthor=E.+Williamsauthor=P.+Benderitterauthor=V.+Orlovaauthor=M.+van+Wijheauthor=A.+Garcia+de+Vinuesaauthor=G.+Kerrauthor=J.+Caradecauthor=K.+Lodderauthor=H.+C.+de+Boerauthor=M.-J.+Goumansauthor=E.+M.+W.+Eekhoffauthor=A.+Morales-Pigaauthor=J.+Bachiller-Corralauthor=P.+Koolwijkauthor=A.+N.+Bullockauthor=J.+Hoflackauthor=P.+ten+Dijke&title=Development+of+macrocycle+kinase+inhibitors+for+ALK2+using+fibrodysplasia+ossificans+progressiva-derived+endothelial+cells&doi=10.1002%2Fjbm4.10230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells</span></div><div class="casAuthors">Sanchez-Duffhues, Gonzalo; Williams, Eleanor; Benderitter, Pascal; Orlova, Valeria; van Wijhe, Michiel; Garcia de Vinuesa, Amaya; Kerr, Georgina; Caradec, Josselin; Lodder, Kirsten; de Boer, Hetty C.; Goumans, Marie-Jose; Eekhoff, Elisabeth M. W.; Morales-Piga, Antonio; Bachiller-Corral, Javier; Koolwijk, Pieter; Bullock, Alex N.; Hoflack, Jan; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">JBMR Plus</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e10230</span>CODEN:
                <span class="NLM_cas:coden">JPBLA6</span>;
        ISSN:<span class="NLM_cas:issn">2473-4039</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous mutations in the activin A type I receptor (ACVR1), that encodes the bone morphogenetic protein (BMP) type I receptor ALK2.  These mutations enable ALK2 to induce downstream signaling in response to activins, thereby turning them into bone-inducing agents.  To date, there is no cure for FOP.  The further development of FOP patient-derived models may contribute to the discovery of novel biomarkers and therapeutic approaches.  Nevertheless, this has traditionally been a challenge, as biopsy sampling often triggers HO.  We have characterized peripheral blood-derived endothelial colony-forming cells (ECFCs) from three independent FOP donors as a new model for FOP.  FOP ECFCs are prone to undergo endothelial-to-mesenchymal transition and exhibit increased ALK2 downstream signaling and subsequent osteogenic differentiation upon stimulation with activin A. Moreover, we have identified a new class of small mol. macrocycles with potential activity against ALK2 kinase.  Finally, using FOP ECFCs, we have selected OD36 and OD52 as potent inhibitors with excellent kinase selectivity profiles that potently antagonize mutant ALK2 signaling and osteogenic differentiation.  We expect that these results will contribute to the development of novel ALK2 clin. candidates for the treatment of FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdMImAbYILErVg90H21EOLACvtfcHk0lhy9s4hWWkwIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE&md5=19b74fb9ff4bc6c0cbc7a5071b876f87</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjbm4.10230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbm4.10230%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Duffhues%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBenderitter%26aufirst%3DP.%26aulast%3DOrlova%26aufirst%3DV.%26aulast%3Dvan%2BWijhe%26aufirst%3DM.%26aulast%3DGarcia%2Bde%2BVinuesa%26aufirst%3DA.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DCaradec%26aufirst%3DJ.%26aulast%3DLodder%26aufirst%3DK.%26aulast%3Dde%2BBoer%26aufirst%3DH.%2BC.%26aulast%3DGoumans%26aufirst%3DM.-J.%26aulast%3DEekhoff%26aufirst%3DE.%2BM.%2BW.%26aulast%3DMorales-Piga%26aufirst%3DA.%26aulast%3DBachiller-Corral%26aufirst%3DJ.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DHoflack%26aufirst%3DJ.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520macrocycle%2520kinase%2520inhibitors%2520for%2520ALK2%2520using%2520fibrodysplasia%2520ossificans%2520progressiva-derived%2520endothelial%2520cells%26jtitle%3DJBMR%2520Plus%26date%3D2019%26volume%3D3%26doi%3D10.1002%2Fjbm4.10230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wentworth, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masharani, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, E. C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1111/bcp.13823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1111%2Fbcp.13823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30501012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3crnt1Cisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2019&pages=1180-1187&author=K.+L.+Wentworthauthor=U.+Masharaniauthor=E.+C.+Hsiao&title=Therapeutic+advances+for+blocking+heterotopic+ossification+in+fibrodysplasia+ossificans+progressiva&doi=10.1111%2Fbcp.13823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva</span></div><div class="casAuthors">Wentworth Kelly L; Masharani Umesh; Hsiao Edward C; Wentworth Kelly L; Hsiao Edward C</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1180-1187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease in which heterotopic bone forms in muscle and soft tissue, leading to joint dysfunction and significant disability.  FOP is progressive and many patients are wheelchair-bound by the 3rd decade of life.  FOP is caused by an activating mutation in the ACVR1 gene, which encodes the activin A Type 1 receptor.  Aberrant signalling through this receptor leads to abnormal activation of the pSMAD 1/5/8 pathway and triggers the formation of bone outside of the skeleton.  There is no curative therapy for FOP; however, exciting advances in novel therapies have developed recently.  Here, we review the clinical and translational pharmacology of three drugs that are currently in clinical trials (palovarotene, REGN 2477 and rapamycin) as well as other emerging treatment strategies for FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBrTeTGtNRpZNiNltV31zlfW6udTcc2eYQi96cysICTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnt1Cisg%253D%253D&md5=fba969a5ffe82bc12e535b50d018c8bd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13823%26sid%3Dliteratum%253Aachs%26aulast%3DWentworth%26aufirst%3DK.%2BL.%26aulast%3DMasharani%26aufirst%3DU.%26aulast%3DHsiao%26aufirst%3DE.%2BC.%26atitle%3DTherapeutic%2520advances%2520for%2520blocking%2520heterotopic%2520ossification%2520in%2520fibrodysplasia%2520ossificans%2520progressiva%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D85%26spage%3D1180%26epage%3D1187%26doi%3D10.1111%2Fbcp.13823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaciregui, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcaboso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span> <span> </span><span class="NLM_article-title">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span>. <i>Commun. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">156</span> <span class="refDoi"> DOI: 10.1038/s42003-019-0420-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fs42003-019-0420-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=31098401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=D.+Carvalhoauthor=K.+R.+Taylorauthor=N.+G.+Olacireguiauthor=V.+Molinariauthor=M.+Clarkeauthor=A.+Mackayauthor=R.+Ruddleauthor=A.+Henleyauthor=M.+Valentiauthor=A.+Hayesauthor=A.+H.+Brandonauthor=S.+A.+Ecclesauthor=F.+Raynaudauthor=A.+Boudharauthor=M.+Monjeauthor=S.+Popovauthor=A.+S.+Mooreauthor=J.+Moraauthor=O.+Cruzauthor=M.+Vinciauthor=P.+E.+Brennanauthor=A.+N.+Bullockauthor=A.+M.+Carcabosoauthor=C.+Jones&title=ALK2+inhibitors+display+beneficial+effects+in+preclinical+models+of+ACVR1+mutant+diffuse+intrinsic+pontine+glioma&doi=10.1038%2Fs42003-019-0420-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma</span></div><div class="casAuthors">Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Popov Sergey; Vinci Mara; Jones Chris; Carvalho Diana; Taylor Kathryn R; Molinari Valeria; Clarke Matthew; Mackay Alan; Ruddle Ruth; Henley Alan; Valenti Melanie; Hayes Angela; Brandon Alexis De Haven; Eccles Suzanne A; Raynaud Florence; Popov Sergey; Vinci Mara; Jones Chris; Taylor Kathryn R; Monje Michelle; Olaciregui Nagore Gene; Mora Jaume; Cruz Ofelia; Carcaboso Angel Montero; Boudhar Aicha; Brennan Paul E; Bullock Alex N; Boudhar Aicha; Brennan Paul E; Popov Sergey; Moore Andrew S; Moore Andrew S; Vinci Mara</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2.  Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-derived tumour models.  Here we show the dependence of DIPG cells on the mutant receptor, and the preclinical efficacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo.  We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to be orally bioavailable and well-tolerated, with good brain penetration.  Treatment of immunodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-DIPG-007 cells with 25 mg/kg LDN-193189 or LDN-214117 for 28 days extended survival compared with vehicle controls.  Development of ALK2 inhibitors with improved potency, selectivity and advantageous pharmacokinetic properties may play an important role in therapy for DIPG patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZQ93BSEDMxWZyxfu64m4ffW6udTcc2ebfJ059pldWMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7mslajtQ%253D%253D&md5=bc5f88aabf7d4d758e1288df1e70d5cd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fs42003-019-0420-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-019-0420-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DK.%2BR.%26aulast%3DOlaciregui%26aufirst%3DN.%2BG.%26aulast%3DMolinari%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DRuddle%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DBrandon%26aufirst%3DA.%2BH.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DBoudhar%26aufirst%3DA.%26aulast%3DMonje%26aufirst%3DM.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DMora%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DO.%26aulast%3DVinci%26aufirst%3DM.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCarcaboso%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%26atitle%3DALK2%2520inhibitors%2520display%2520beneficial%2520effects%2520in%2520preclinical%2520models%2520of%2520ACVR1%2520mutant%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DCommun.%2520Biol.%26date%3D2019%26volume%3D2%26doi%3D10.1038%2Fs42003-019-0420-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span> <span> </span><span class="NLM_article-title">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span>. <i>Wellcome Open Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">154</span>, <span class="refDoi"> DOI: 10.12688/wellcomeopenres.14947.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.12688%2Fwellcomeopenres.14947.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=30705971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=154&author=M.+R.+Morganauthor=O.+G.+Robertsauthor=A.+M.+Edwards&title=Ideation+and+implementation+of+an+open+science+drug+discovery+business+model+-+M4K+Pharma&doi=10.12688%2Fwellcomeopenres.14947.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Ideation and implementation of an open science drug discovery business model - M4K Pharma</span></div><div class="casAuthors">Morgan Maxwell Robert; Edwards Aled Morgan; Morgan Maxwell Robert; Roberts Owen Gwilym; Edwards Aled Morgan; Morgan Maxwell Robert; Edwards Aled Morgan</div><div class="citationInfo"><span class="NLM_cas:title">Wellcome open research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">154</span>
        ISSN:<span class="NLM_cas:issn">2398-502X</span>.
    </div><div class="casAbstract">M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science.  The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5e8MVHlijOLZpSb_XWfMrfW6udTcc2ebfJ059pldWMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjnslSrsA%253D%253D&md5=375dea208c308eb3199d178e4b1977a3</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.12688%2Fwellcomeopenres.14947.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Fwellcomeopenres.14947.1%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DM.%2BR.%26aulast%3DRoberts%26aufirst%3DO.%2BG.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26atitle%3DIdeation%2520and%2520implementation%2520of%2520an%2520open%2520science%2520drug%2520discovery%2520business%2520model%2520-%2520M4K%2520Pharma%26jtitle%3DWellcome%2520Open%2520Res.%26date%3D2018%26volume%3D3%26spage%3D154%26doi%3D10.12688%2Fwellcomeopenres.14947.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span> <span> </span><span class="NLM_article-title">Fostering open collaboration in drug development for paediatric brain tumours</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1042/BST20190315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1042%2FBST20190315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=31551357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCntrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=1471-1479&author=J.+F.+Wongauthor=E.+J.+Brownauthor=E.+Williamsauthor=A.+N.+Bullock&title=Fostering+open+collaboration+in+drug+development+for+paediatric+brain+tumours&doi=10.1042%2FBST20190315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Fostering open collaboration in drug development for paediatric brain tumours</span></div><div class="casAuthors">Wong, Jong Fu; Brown, Elizabeth J.; Williams, Eleanor; Bullock, Alex N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1471-1479</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Brain tumors have become the leading cause of child mortality from cancer.  Indeed, aggressive brainstem tumors, such as diffuse intrinsic pontine glioma (DIPG), are nearly uniformly fatal.  These tumors display a unique set of driver mutations that distinguish them from adult gliomas and define new opportunity for the development of precision medicines.  The specific assocn. of ACVR1 mutations with DIPG tumors suggests a direct link to neurodevelopment and highlights the encoded bone morphogenetic protein receptor kinase ALK2 as a promising drug target.  Beneficial effects of ALK2 inhibition have now been obsd. in two different in vivo models of DIPG.  Nonetheless, such tumors present a huge challenge for traditional economic models of drug development due to their small market size, high failure rate, tumor location and paediatric population.  Moreover, a toolkit of different investigational drugs may be needed to fully address the heterogeneity of these tumors in clin. trials.  One new business model is suggested by M4K Pharma, a recent virtual start up that aims to align diffuse academic and industry research into a collaborative open science drug discovery program.  Fostering scientific collaboration may offer hope in rare conditions of dire unmet clin. need and provide an alternative route to affordable medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPjWKLvTZkN7Vg90H21EOLACvtfcHk0liViKeJsPIqrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCntrjF&md5=124c6674324227d7d9e0a1acfe893e43</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1042%2FBST20190315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20190315%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DJ.%2BF.%26aulast%3DBrown%26aufirst%3DE.%2BJ.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26atitle%3DFostering%2520open%2520collaboration%2520in%2520drug%2520development%2520for%2520paediatric%2520brain%2520tumours%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2019%26volume%3D47%26spage%3D1471%26epage%3D1479%26doi%3D10.1042%2FBST20190315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrem, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleverly, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaiah, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slapak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahn, M. M.</span></span> <span> </span><span class="NLM_article-title">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4479</span>– <span class="NLM_lpage">4499</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S86621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.2147%2FDDDT.S86621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26309397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4479-4499&author=S.+Herbertzauthor=J.+S.+Sawyerauthor=A.+J.+Stauberauthor=I.+Gueorguievaauthor=K.+E.+Driscollauthor=S.+T.+Estremauthor=A.+L.+Cleverlyauthor=D.+Desaiahauthor=S.+C.+Gubaauthor=K.+A.+Benhadjiauthor=C.+A.+Slapakauthor=M.+M.+Lahn&title=Clinical+development+of+galunisertib+%28LY2157299+monohydrate%29%2C+a+small+molecule+inhibitor+of+transforming+growth+factor-beta+signaling+pathway&doi=10.2147%2FDDDT.S86621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway</span></div><div class="casAuthors">Herbertz, Stephan; Sawyer, J. Scott; Stauber, Anja J.; Gueorguieva, Ivelina; Driscoll, Kyla E.; Estrem, Shawn T.; Cleverly, Ann L.; Desaiah, Durisala; Guba, Susan C.; Benhadji, Karim A.; Slapak, Christopher A.; Lahn, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4479-4499</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biol. processes.  TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance.  There are several pharmacol. approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small mol. inhibitors.  Galunisertib (LY2157299 monohydrate) is an oral small mol. inhibitor of the TGF-β receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway.  Furthermore, galunisertib has antitumor activity in tumor-bearing animal models such as breast, colon, lung cancers, and hepatocellular carcinoma.  Continuous long-term exposure to galunisertib caused cardiac toxicities in animals requiring adoption of a pharmacokinetic/pharmacodynamic-based dosing strategy to allow further development.  The use of such a pharmacokinetic/pharmacodynamic model defined a therapeutic window with an appropriate safety profile that enabled the clin. investigation of galunisertib.  These efforts resulted in an intermittent dosing regimen (14 days on/14 days off, on a 28-day cycle) of galunisertib for all ongoing trials.  Galunisertib is being investigated either as monotherapy or in combination with std. antitumor regimens (including nivolumab) in patients with cancer with high unmet medical needs such as glioblastoma, pancreatic cancer, and hepatocellular carcinoma.  The present review summarizes the past and current experiences with different pharmacol. treatments that enabled galunisertib to be investigated in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYOwgVYb7M2bVg90H21EOLACvtfcHk0lgQukJ0OGq_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOhu7c%253D&md5=f896505ddcd4dbc54bd59863588c4268</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S86621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S86621%26sid%3Dliteratum%253Aachs%26aulast%3DHerbertz%26aufirst%3DS.%26aulast%3DSawyer%26aufirst%3DJ.%2BS.%26aulast%3DStauber%26aufirst%3DA.%2BJ.%26aulast%3DGueorguieva%26aufirst%3DI.%26aulast%3DDriscoll%26aufirst%3DK.%2BE.%26aulast%3DEstrem%26aufirst%3DS.%2BT.%26aulast%3DCleverly%26aufirst%3DA.%2BL.%26aulast%3DDesaiah%26aufirst%3DD.%26aulast%3DGuba%26aufirst%3DS.%2BC.%26aulast%3DBenhadji%26aufirst%3DK.%2BA.%26aulast%3DSlapak%26aufirst%3DC.%2BA.%26aulast%3DLahn%26aufirst%3DM.%2BM.%26atitle%3DClinical%2520development%2520of%2520galunisertib%2520%2528LY2157299%2520monohydrate%2529%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520transforming%2520growth%2520factor-beta%2520signaling%2520pathway%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4479%26epage%3D4499%26doi%3D10.2147%2FDDDT.S86621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasteuning-Vuhman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boertje-van der Meulen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Putten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overzier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiełbasa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arindrarto, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolterbeek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezhnina, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliper, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogaars, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aartsma-Rus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomans, C. J. M.</span></span> <span> </span><span class="NLM_article-title">New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1096/fj.201600675r</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1096%2Ffj.201600675r" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=27733450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivV2rtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=238-255&author=S.+Pasteuning-Vuhmanauthor=J.+W.+Boertje-van+der+Meulenauthor=M.+van+Puttenauthor=M.+Overzierauthor=P.+ten+Dijkeauthor=S.+M.+Kie%C5%82basaauthor=W.+Arindrartoauthor=R.+Wolterbeekauthor=K.+V.+Lezhninaauthor=I.+V.+Ozerovauthor=A.+M.+Aliperauthor=W.+M.+Hoogaarsauthor=A.+Aartsma-Rusauthor=C.+J.+M.+Loomans&title=New+function+of+the+myostatin%2Factivin+type+I+receptor+%28ALK4%29+as+a+mediator+of+muscle+atrophy+and+muscle+regeneration&doi=10.1096%2Ffj.201600675r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration</span></div><div class="casAuthors">Pasteuning-Vuhman, Svitlana; Boertje-van der Meulen, Johanna; van Putten, Maaike; Overzier, Maurice; ten Dijke, Peter; Kielbasa, Szymon M.; Arindarto, Wibowo; Wolterbeek, Ron; Lezhnina, Ksenia V.; Ozerov, Ivan V.; Aliper, Aleksandr M.; Hoogaars, Willem M.; Aartsma-Rus, Annemieke; Loomans, Cindy J. M.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-256</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Skeletal muscle fibrosis and impaired muscle regeneration are major contributors to muscle wasting in Duchenne muscular dystrophy (DMD).  Muscle growth is neg. regulated by myostatin (MSTN) and activins.  Blockage of these pathways may improve muscle quality and function in DMD.  Antisense oligonucleotides (AONs) were designed specifically to block the function of ALK4, a key receptor for the MSTN/activin pathway in skeletal muscle.  AON-induced exon skipping resulted in specific Alk4 down-regulation, inhibition of MSTN activity, and increased myoblast differentiation in vitro.  Unexpectedly, a marked decrease in muscle mass (10%) was found after Alk4 AON treatment in mdx mice.  In line with in vitro results,muscle regeneration was stimulated, and muscle fiber size decreased markedly.  Notably, when Alk4 was down-regulated in adult wild-type mice, muscle mass decreased even more.  RNA sequence anal. revealed dysregulated metabolic functions and signs of muscle atrophy.  We conclude that ALK4 inhibition increases myogenesis but also regulates the tight balance of protein synthesis and degrdn.  Therefore, caution must be used when developing therapies that interfere with MSTN/activin pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXMHq5IysQDLVg90H21EOLACvtfcHk0lgQukJ0OGq_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivV2rtrY%253D&md5=5e353a06b36c0a0d1d3344b667cf9e17</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600675r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600675r%26sid%3Dliteratum%253Aachs%26aulast%3DPasteuning-Vuhman%26aufirst%3DS.%26aulast%3DBoertje-van%2Bder%2BMeulen%26aufirst%3DJ.%2BW.%26aulast%3Dvan%2BPutten%26aufirst%3DM.%26aulast%3DOverzier%26aufirst%3DM.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26aulast%3DKie%25C5%2582basa%26aufirst%3DS.%2BM.%26aulast%3DArindrarto%26aufirst%3DW.%26aulast%3DWolterbeek%26aufirst%3DR.%26aulast%3DLezhnina%26aufirst%3DK.%2BV.%26aulast%3DOzerov%26aufirst%3DI.%2BV.%26aulast%3DAliper%26aufirst%3DA.%2BM.%26aulast%3DHoogaars%26aufirst%3DW.%2BM.%26aulast%3DAartsma-Rus%26aufirst%3DA.%26aulast%3DLoomans%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DNew%2520function%2520of%2520the%2520myostatin%252Factivin%2520type%2520I%2520receptor%2520%2528ALK4%2529%2520as%2520a%2520mediator%2520of%2520muscle%2520atrophy%2520and%2520muscle%2520regeneration%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D238%26epage%3D255%26doi%3D10.1096%2Ffj.201600675r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roman, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinck, A. P.</span></span> <span> </span><span class="NLM_article-title">ALK1 signaling in development and disease: new paradigms</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4560</span>, <span class="refDoi"> DOI: 10.1007/s00018-017-2636-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1007%2Fs00018-017-2636-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=28871312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGjtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=4539-4560&author=B.+L.+Romanauthor=A.+P.+Hinck&title=ALK1+signaling+in+development+and+disease%3A+new+paradigms&doi=10.1007%2Fs00018-017-2636-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">ALK1 signaling in development and disease: new paradigms</span></div><div class="casAuthors">Roman, Beth L.; Hinck, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4539-4560</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Activin A receptor like type 1 (ALK1) is a transmembrane serine/threonine receptor kinase in the transforming growth factor-beta receptor family that is expressed on endothelial cells.  Defects in ALK1 signaling cause the autosomal dominant vascular disorder, hereditary hemorrhagic telangiectasia (HHT), which is characterized by development of direct connections between arteries and veins, or arteriovenous malformations (AVMs).  Although previous studies have implicated ALK1 in various aspects of sprouting angiogenesis, including tip/stalk cell selection, migration, and proliferation, recent work suggests an intriguing role for ALK1 in transducing a flow-based signal that governs directed endothelial cell migration within patent, perfused vessels.  In this review, we present an updated view of the mechanism of ALK1 signaling, put forth a unified hypothesis to explain the cellular missteps that lead to AVMs assocd. with ALK1 deficiency, and discuss emerging roles for ALK1 signaling in diseases beyond HHT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE3O14HSFxhrVg90H21EOLACvtfcHk0lgQukJ0OGq_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGjtrfK&md5=838c08a79918a1c4d7114e71dad88188</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs00018-017-2636-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-017-2636-4%26sid%3Dliteratum%253Aachs%26aulast%3DRoman%26aufirst%3DB.%2BL.%26aulast%3DHinck%26aufirst%3DA.%2BP.%26atitle%3DALK1%2520signaling%2520in%2520development%2520and%2520disease%253A%2520new%2520paradigms%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D4539%26epage%3D4560%26doi%3D10.1007%2Fs00018-017-2636-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbicker, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartnikas, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmeyer, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span> <span> </span><span class="NLM_article-title">Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4224</span>– <span class="NLM_lpage">4230</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-03-339952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1182%2Fblood-2011-03-339952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21841161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlKgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=4224-4230&author=A.+U.+Steinbickerauthor=T.+B.+Bartnikasauthor=L.+K.+Lohmeyerauthor=P.+Leytonauthor=C.+Mayeurauthor=S.+M.+Kaoauthor=A.+E.+Pappasauthor=R.+T.+Petersonauthor=D.+B.+Blochauthor=P.+B.+Yuauthor=M.+D.+Flemingauthor=K.+D.+Bloch&title=Perturbation+of+hepcidin+expression+by+BMP+type+I+receptor+deletion+induces+iron+overload+in+mice&doi=10.1182%2Fblood-2011-03-339952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice</span></div><div class="casAuthors">Steinbicker, Andrea U.; Bartnikas, Thomas B.; Lohmeyer, Lisa K.; Leyton, Patricio; Mayeur, Claire; Kao, Sonya M.; Pappas, Alexandra E.; Peterson, Randall T.; Bloch, Donald B.; Yu, Paul B.; Fleming, Mark D.; Bloch, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4224-4230</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Bone morphogenetic protein (BMP) signaling induces hepatic expression of the peptide hormone hepcidin.  Hepcidin reduces serum iron levels by promoting degrdn. of the iron exporter ferroportin.  A relative deficiency of hepcidin underlies the pathophysiol. of many of the genetically distinct iron overload disorders, collectively termed hereditary hemochromatosis.  Conversely, chronic inflammatory conditions and neoplastic diseases can induce high hepcidin levels, leading to impaired mobilization of iron stores and the anemia of chronic disease.  Two BMP type I receptors, Alk2 (Acvr1) and Alk3 (Bmpr1a), are expressed in murine hepatocytes.  We report that liver-specific deletion of either Alk2 or Alk3 causes iron overload in mice.  The iron overload phenotype was more marked in Alk3- than in Alk2-deficient mice, and Alk3 deficiency was assocd. with a nearly complete ablation of basal BMP signaling and hepcidin expression.  Both Alk2 and Alk3 were required for induction of hepcidin gene expression by BMP2 in cultured hepatocytes or by iron challenge in vivo.  These observations demonstrate that one type I BMP receptor, Alk3, is critically responsible for basal hepcidin expression, whereas 2 type I BMP receptors, Alk2 and Alk3, are required for regulation of hepcidin gene expression in response to iron and BMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrhUIYdi5xUrVg90H21EOLACvtfcHk0lhkGpKinWMJOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlKgtA%253D%253D&md5=7bcb4074bdc4b03c5dcc22403852af04</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-03-339952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-03-339952%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbicker%26aufirst%3DA.%2BU.%26aulast%3DBartnikas%26aufirst%3DT.%2BB.%26aulast%3DLohmeyer%26aufirst%3DL.%2BK.%26aulast%3DLeyton%26aufirst%3DP.%26aulast%3DMayeur%26aufirst%3DC.%26aulast%3DKao%26aufirst%3DS.%2BM.%26aulast%3DPappas%26aufirst%3DA.%2BE.%26aulast%3DPeterson%26aufirst%3DR.%2BT.%26aulast%3DBloch%26aufirst%3DD.%2BB.%26aulast%3DYu%26aufirst%3DP.%2BB.%26aulast%3DFleming%26aufirst%3DM.%2BD.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26atitle%3DPerturbation%2520of%2520hepcidin%2520expression%2520by%2520BMP%2520type%2520I%2520receptor%2520deletion%2520induces%2520iron%2520overload%2520in%2520mice%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D4224%26epage%3D4230%26doi%3D10.1182%2Fblood-2011-03-339952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goff, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyshchik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberasco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stampino, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghaei, H.</span></span> <span> </span><span class="NLM_article-title">A Phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2154</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1158%2F1078-0432.CCR-15-1622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=26655846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlOrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=2146-2154&author=L.+W.+Goffauthor=R.+B.+Cohenauthor=J.+D.+Berlinauthor=F.+G.+de+Braudauthor=A.+Lyshchikauthor=C.+Noberascoauthor=F.+Bertoliniauthor=M.+Carpentieriauthor=C.+G.+Stampinoauthor=A.+Abbattistaauthor=E.+Wangauthor=H.+Borghaei&title=A+Phase+I+study+of+the+anti-activin+receptor-like+kinase+1+%28ALK-1%29+monoclonal+antibody+PF-03446962+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-15-1622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Goff, Laura W.; Cohen, Roger B.; Berlin, Jordan D.; de Braud, Filippo G.; Lyshchik, Andrej; Noberasco, Cristina; Bertolini, Francesco; Carpentieri, Marina; Stampino, Corrado Gallo; Abbattista, Antonello; Wang, Erjan; Borghaei, Hossein</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2146-2154</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Objectives of this dose-finding study were to det. the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity in patients with advanced solid tumors.  Exptl. Design: This open-label, multicenter study was based on a 3+3 design.  PF-03446962 was administered biweekly by i.v. infusion, at doses ranging from 0.5 to 15 mg/kg.  Results: Forty-four patients received treatment with PF-03446962.  Dose-limiting toxicities obsd. during dose escalation included grade 3 increased amylase, grade 3/4 increased lipase, and grade 3/4 thrombocytopenia.  The MTD was detd. to be 10 mg/kg.  The RP2D was set at 7 mg/kg for patients with advanced solid tumors, based on the obsd. safety, pharmacokinetics, and antitumor activity.  The most-frequent treatment-related, all-grade adverse events included thrombocytopenia (20.5%), fatigue (15.9%), and nausea, increased amylase, and increased lipase (each 11.4%).  Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway.  None of the deaths was deemed to be treatment-related.  Three (6.8%) patients with advanced hepatocellular carcinoma, renal cell carcinoma, or non-small cell lung cancer achieved a partial response, and 12 (27.3%) patients had stable disease, across dose levels.  Contrast-enhanced ultrasound anal. of tumor vascularity showed redn. in tumor perfusion in 2 patients with stable disease following treatment with PF-03446962.  Conclusions: The clin. activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.  Clin Cancer Res; 22(9); 2146-54. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCU3F6ZAiwyrVg90H21EOLACvtfcHk0lhkGpKinWMJOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlOrsLc%253D&md5=3e31a8c14d25fefd58830f62a2b7c74c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1622%26sid%3Dliteratum%253Aachs%26aulast%3DGoff%26aufirst%3DL.%2BW.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DBerlin%26aufirst%3DJ.%2BD.%26aulast%3Dde%2BBraud%26aufirst%3DF.%2BG.%26aulast%3DLyshchik%26aufirst%3DA.%26aulast%3DNoberasco%26aufirst%3DC.%26aulast%3DBertolini%26aufirst%3DF.%26aulast%3DCarpentieri%26aufirst%3DM.%26aulast%3DStampino%26aufirst%3DC.%2BG.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DBorghaei%26aufirst%3DH.%26atitle%3DA%2520Phase%2520I%2520study%2520of%2520the%2520anti-activin%2520receptor-like%2520kinase%25201%2520%2528ALK-1%2529%2520monoclonal%2520antibody%2520PF-03446962%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D2146%26epage%3D2154%26doi%3D10.1158%2F1078-0432.CCR-15-1622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pajouhesh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G. R.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry properties of successful central nervous system drugs</span>. <i>NeuroRx</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1602/neurorx.2.4.541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1602%2Fneurorx.2.4.541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=16489364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=541-553&author=H.+Pajouheshauthor=G.+R.+Lenz&title=Medicinal+chemistry+properties+of+successful+central+nervous+system+drugs&doi=10.1602%2Fneurorx.2.4.541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemical properties of successful central nervous system drugs</span></div><div class="casAuthors">Pajouhesh Hassan; Lenz George R</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">541-53</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity.  Factors relevant to the success of CNS drugs are reviewed.  CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics.  Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent.  The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters.  The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems.  This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_ncsy3yuEinl8icjszYl0fW6udTcc2ebOICQY4YnBsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FpvVKqsg%253D%253D&md5=0815084e2d107b9243b785d0782dfc3a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.4.541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.4.541%26sid%3Dliteratum%253Aachs%26aulast%3DPajouhesh%26aufirst%3DH.%26aulast%3DLenz%26aufirst%3DG.%2BR.%26atitle%3DMedicinal%2520chemistry%2520properties%2520of%2520successful%2520central%2520nervous%2520system%2520drugs%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D541%26epage%3D553%26doi%3D10.1602%2Fneurorx.2.4.541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS drug design: balancing physicochemical properties for optimal brain exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0ljjCF0PkxzR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitors for the treatment of brain cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10030</span>– <span class="NLM_lpage">10066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10030-10066&author=T.+P.+Heffron&title=Small+molecule+kinase+inhibitors+for+the+treatment+of+brain+cancer&doi=10.1021%2Facs.jmedchem.6b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</span></div><div class="casAuthors">Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10030-10066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to each of the factors that govern the identification of a successful oncol. drug candidate, drug discovery aimed at treating neurol. cancer must also consider the presence of the blood-brain barrier (BBB).  The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small mols. from freely reaching the brain, where neurooncol. malignancies reside.  Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable.  This Perspective discusses the unmet need for neurooncol. treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clin. inhibitors of kinases that are of interest for the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqij86WIpk16LVg90H21EOLACvtfcHk0ljjCF0PkxzR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E&md5=7e184f17a60658174cb44a9fbadc8dfd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10030%26epage%3D10066%26doi%3D10.1021%2Facs.jmedchem.6b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanguinetti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tristani-Firouzi, M.</span></span> <span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>440</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1038/nature04710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia&doi=10.1038%2Fnature04710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0ljjCF0PkxzR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469%26doi%3D10.1038%2Fnature04710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, D. R.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1007/s40264-013-0047-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1007%2Fs40264-013-0047-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=23620167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=295-316&author=R.+R.+Shahauthor=J.+Morganrothauthor=D.+R.+Shah&title=Cardiovascular+safety+of+tyrosine+kinase+inhibitors%3A+with+a+special+focus+on+cardiac+repolarisation+%28QT+interval%29&doi=10.1007%2Fs40264-013-0047-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)</span></div><div class="casAuthors">Shah, Rashmi R.; Morganroth, Joel; Shah, Devron R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">295-316</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The development of tyrosine kinase inhibitors (TKI) represents a major milestone in oncol.  However, their use has been found to be assocd. with serious toxicities that impinge on various vital organs including the heart.  Sixteen TKIs have been approved for use in oncol. as of 30 Sept. 2012, and a large no. of others are in development or under regulatory review.  Cardiovascular safety of medicinal products is a major public health issue that has concerned all the stakeholders.  This review focuses on three specific cardiovascular safety aspects of TKIs, namely their propensity to induce QT interval prolongation, left ventricular (LV) dysfunction and hypertension (both systemic and pulmonary).  Analyses of information in drug labels, the data submitted to the regulatory authorities and the published literature show that a no. of TKIs are assocd. with these undesirable effects.  Whereas LV dysfunction and systemic hypertension are on-target effects related to the inhibition of ligand-related signalling pathways, QT interval prolongation appears to be an off-target class III electrophysiol. effect, possibly related to the presence of a fluorine-based pharmacophore.  If not adequately managed, these cardiovascular effects significantly increase the morbidity and mortality in a population already at high risk.  Hitherto, the QT effect of most QT-prolonging TKIs (except lapatinib, nilotinib, sunitinib and vandetanib) is relatively mild at clin. doses and has not led to appreciable morbidity clin.  In contrast, LV dysfunction and untreated hypertension have resulted in significant morbidity.  Inevitably, dilemmas arise in detg. the risk/benefit of a TKI therapy in an individual patient who develops any of these effects following the treatment of the TKI-sensitive cancer.  QT interval prolongation, hypertension and LV dysfunction can be managed effectively by using reliable methods of measurement and careful monitoring of patients whose clin. management requires optimization by a close collaboration between an oncologist and a cardiologist, an evolving subspecialty referred to as cardio-oncol.  Despite their potential adverse clin. impact, the effects of TKIs on hypertension and LV function are generally inadequately characterised during their development.  As has been the case with QT liability of drugs, there is now a persuasive case for a regulatory requirement to study TKIs systematically for these effects.  Furthermore, since most of these novel drugs are studied in trials with relatively small sample sizes and approved on an expedited basis, there is also a compelling case for their effective pharmacovigilance and on-going reassessment of their risk/benefit after approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgTIlxLItaUbVg90H21EOLACvtfcHk0lhCQA_ZYW7JUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsL3L&md5=7e24ea72e614d9b85a87dbc88a973c58</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs40264-013-0047-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-013-0047-5%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%2BR.%26aulast%3DMorganroth%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DD.%2BR.%26atitle%3DCardiovascular%2520safety%2520of%2520tyrosine%2520kinase%2520inhibitors%253A%2520with%2520a%2520special%2520focus%2520on%2520cardiac%2520repolarisation%2520%2528QT%2520interval%2529%26jtitle%3DDrug%2520Saf.%26date%3D2013%26volume%3D36%26spage%3D295%26epage%3D316%26doi%3D10.1007%2Fs40264-013-0047-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smil, D.</span>; <span class="NLM_string-name">McLeod, D. A.</span>; <span class="NLM_string-name">O’Meara, J. A.</span>; <span class="NLM_string-name">Isaac, M. B.</span></span> Unpublished results. Data can be viewed in presentations archived at <a href="https://m4kpharma.com/blog/" class="extLink">https://m4kpharma.com/blog/</a> (accessed Jul 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Smil%2C+D.%3B+McLeod%2C+D.+A.%3B+O%E2%80%99Meara%2C+J.+A.%3B+Isaac%2C+M.+B.+Unpublished+results.+Data+can+be+viewed+in+presentations+archived+at+https%3A%2F%2Fm4kpharma.com%2Fblog%2F+%28accessed+Jul+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DSmil%26aufirst%3DD." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ensan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zepeda-Velázquez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panagopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span> <span> </span><span class="NLM_article-title">Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4978</span>– <span class="NLM_lpage">4996</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVCms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4978-4996&author=D.+Ensanauthor=D.+Smilauthor=C.+A.+Zepeda-Vel%C3%A1zquezauthor=D.+Panagopoulosauthor=J.+F.+Wongauthor=E.+P.+Williamsauthor=R.+Adamsonauthor=A.+N.+Bullockauthor=T.+Kiyotaauthor=A.+Amanauthor=O.+G.+Robertsauthor=A.+M.+Edwardsauthor=J.+A.+O%E2%80%99Mearaauthor=M.+B.+Isaacauthor=R.+Al-awar&title=Targeting+ALK2%3A+an+open+science+approach+to+developing+therapeutics+for+the+treatment+of+diffuse+intrinsic+pontine+glioma&doi=10.1021%2Facs.jmedchem.0c00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma</span></div><div class="casAuthors">Ensan, Deeba; Smil, David; Zepeda-Velazquez, Carlos A.; Panagopoulos, Dimitrios; Wong, Jong Fu; Williams, Eleanor P.; Adamson, Roslin; Bullock, Alex N.; Kiyota, Taira; Aman, Ahmed; Roberts, Owen G.; Edwards, Aled M.; O'Meara, Jeff A.; Isaac, Methvin B.; Al-awar, Rima</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4978-4996</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist.  Anal. of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention.  In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant.  Initial efforts resulted in the discovery of M4K2009 (I), an analog of the previously reported ALK2 inhibitor LDN-214117.  Although highly selective for ALK2 over the TGF-βR1 receptor ALK5, M4K2009 is also moderately active against the hERG potassium channel.  Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analog M4K2149 (II) with reduced off-target affinity for the ion channel.  Addnl. modifications yielded 2-fluoro-6-methoxybenzamide derivs. (26a(III)-c), which possess high inhibitory activity against ALK2, excellent selectivity, and superior pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi_5prjgzaG7Vg90H21EOLACvtfcHk0lhCQA_ZYW7JUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVCms7Y%253D&md5=6213b81cf89f37b0b8157e0e799ed5d6</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00395%26sid%3Dliteratum%253Aachs%26aulast%3DEnsan%26aufirst%3DD.%26aulast%3DSmil%26aufirst%3DD.%26aulast%3DZepeda-Vel%25C3%25A1zquez%26aufirst%3DC.%2BA.%26aulast%3DPanagopoulos%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DJ.%2BF.%26aulast%3DWilliams%26aufirst%3DE.%2BP.%26aulast%3DAdamson%26aufirst%3DR.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DKiyota%26aufirst%3DT.%26aulast%3DAman%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DO.%2BG.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DJ.%2BA.%26aulast%3DIsaac%26aufirst%3DM.%2BB.%26aulast%3DAl-awar%26aufirst%3DR.%26atitle%3DTargeting%2520ALK2%253A%2520an%2520open%2520science%2520approach%2520to%2520developing%2520therapeutics%2520for%2520the%2520treatment%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4978%26epage%3D4996%26doi%3D10.1021%2Facs.jmedchem.0c00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span>Predicted
cLogP, pKa, and tPSA values were calculated using ChemDraw Professional
17.1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Predicted%0AcLogP%2C+pKa%2C+and+tPSA+values+were+calculated+using+ChemDraw+Professional%0A17.1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poluzzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ponti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span> <span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3844</span>– <span class="NLM_lpage">3853</span>, <span class="refDoi"> DOI: 10.1021/jm0208875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers&doi=10.1021%2Fjm0208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0lhCQA_ZYW7JUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853%26doi%3D10.1021%2Fjm0208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lhXdfceSamhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Röder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-R%C3%B6derauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+M%C3%BCller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lhXdfceSamhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-R%25C3%25B6der%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E. C. A.</span></span> <span> </span><span class="NLM_article-title">Rational use of plasma protein and tissue binding data in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8238</span>– <span class="NLM_lpage">8248</span>, <span class="refDoi"> DOI: 10.1021/jm5007935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8238-8248&author=X.+Liuauthor=M.+Wrightauthor=C.+E.+C.+A.+Hop&title=Rational+use+of+plasma+protein+and+tissue+binding+data+in+drug+design&doi=10.1021%2Fjm5007935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Use of Plasma Protein and Tissue Binding Data in Drug Design</span></div><div class="casAuthors">Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8238-8248</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is a commonly accepted assumption that only unbound drug mols. are available to interact with their targets.  Therefore, one of the objectives in drug design is to optimize the compd. structure to increase in vivo unbound drug concn.  In this review, theor. analyses and exptl. observations are presented to illustrate that low plasma protein binding does not necessarily lead to high in vivo unbound plasma concn.  Similarly, low brain tissue binding does not lead to high in vivo unbound brain tissue concn.  Instead, low intrinsic clearance leads to high in vivo unbound plasma concn., and low efflux transport activity at the blood-brain barrier leads to high unbound brain concn.  Plasma protein and brain tissue binding are very important parameters in understanding pharmacokinetics, pharmacodynamics, and toxicities of drugs, but these parameters should not be targeted for optimization in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKiYUz9ljIDrVg90H21EOLACvtfcHk0lhXdfceSamhaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77M&md5=53ffbdb88ddf500a90a0eee14b0e641f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm5007935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DHop%26aufirst%3DC.%2BE.%2BC.%2BA.%26atitle%3DRational%2520use%2520of%2520plasma%2520protein%2520and%2520tissue%2520binding%2520data%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8238%26epage%3D8248%26doi%3D10.1021%2Fjm5007935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakkalakal, S. A.</span>; <span class="NLM_string-name">Shore, E. M.</span></span> <span> </span><span class="NLM_article-title">Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva</span>. In  <i>Bone Morphogenetic Proteins: Methods and Protocols (Methods in Molecular Biology)</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. B.</span></span>, Ed.; <span class="NLM_publisher-name">Springer Nature</span>: <span class="NLM_publisher-loc">Berlin</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">1891</span>, pp  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">255</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1007%2F978-1-4939-8904-1_18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=247-255&author=S.+A.+Chakkalakal&author=E.+M.+Shoreauthor=M.+B.+Rogers&title=Bone+Morphogenetic+Proteins%3A+Methods+and+Protocols+%28Methods+in+Molecular+Biology%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-8904-1_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-8904-1_18%26sid%3Dliteratum%253Aachs%26aulast%3DChakkalakal%26aufirst%3DS.%2BA.%26atitle%3DHeterotopic%2520Ossification%2520in%2520Mouse%2520Models%2520of%2520Fibrodysplasia%2520Ossificans%2520Progressiva%26btitle%3DBone%2520Morphogenetic%2520Proteins%253A%2520Methods%2520and%2520Protocols%2520%2528Methods%2520in%2520Molecular%2520Biology%2529%26aulast%3DRogers%26aufirst%3DM.%2BB.%26pub%3DSpringer%2520Nature%26date%3D2019%26volume%3D1891%26spage%3D247%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span> <span> </span><span class="NLM_article-title">xia2: an expert system for macromolecular crystallography data reduction</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1107/S0021889809045701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0021889809045701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=186-190&author=G.+Winter&title=xia2%3A+an+expert+system+for+macromolecular+crystallography+data+reduction&doi=10.1107%2FS0021889809045701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">xia2: An expert system for macromolecular crystallography data reduction</span></div><div class="casAuthors">Winter, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">186-190, S186/1-S186/5</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An expert system for macromol. crystallog. data redn. is presented, which builds on existing software to automate the complete data redn. process from images to merged structure factor amplitudes.  This can automatically identify multi-wedge, multi-pass and multiwavelength data sets and includes explicit procedures to test for crystallog. special cases.  With the push towards high-throughput crystallog. at synchrotron beamlines and automation of structure soln., the ability to reduce data with no user input fills an important gap in the pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOi3u0ydXbSrVg90H21EOLACvtfcHk0lgPRJdTCIkD_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFalsrk%253D&md5=27771caa813f3e828abdf2a331ae55e3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1107%2FS0021889809045701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889809045701%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%26atitle%3Dxia2%253A%2520an%2520expert%2520system%2520for%2520macromolecular%2520crystallography%2520data%2520reduction%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2010%26volume%3D43%26spage%3D186%26epage%3D190%26doi%3D10.1107%2FS0021889809045701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lgPRJdTCIkD_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lgPRJdTCIkD_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0liOPzwIorvo8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0liOPzwIorvo8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaver-Fay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeyink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">W375</span>– <span class="NLM_lpage">W383</span>, <span class="refDoi"> DOI: 10.1093/nar/gkm216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=10.1093%2Fnar%2Fgkm216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=17452350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;key=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=W375-W383&author=I.+W.+Davisauthor=A.+Leaver-Fayauthor=V.+B.+Chenauthor=J.+N.+Blockauthor=G.+J.+Kapralauthor=X.+Wangauthor=L.+W.+Murrayauthor=W.+B.+Arendallauthor=J.+Snoeyinkauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+contacts+and+structure+validation+for+proteins+and+nucleic+acids&doi=10.1093%2Fnar%2Fgkm216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</span></div><div class="casAuthors">Davis Ian W; Leaver-Fay Andrew; Chen Vincent B; Block Jeremy N; Kapral Gary J; Wang Xueyi; Murray Laura W; Arendall W Bryan 3rd; Snoeyink Jack; Richardson Jane S; Richardson David C</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">Web Server issue</span>),
    <span class="NLM_cas:pages">W375-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">MolProbity is a general-purpose web server offering quality validation for 3D structures of proteins, nucleic acids and complexes.  It provides detailed all-atom contact analysis of any steric problems within the molecules as well as updated dihedral-angle diagnostics, and it can calculate and display the H-bond and van der Waals contacts in the interfaces between components.  An integral step in the process is the addition and full optimization of all hydrogen atoms, both polar and nonpolar.  New analysis functions have been added for RNA, for interfaces, and for NMR ensembles.  Additionally, both the web site and major component programs have been rewritten to improve speed, convenience, clarity and integration with other resources.  MolProbity results are reported in multiple forms: as overall numeric scores, as lists or charts of local problems, as downloadable PDB and graphics files, and most notably as informative, manipulable 3D kinemage graphics shown online in the KiNG viewer.  This service is available free to all users at http://molprobity.biochem.duke.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuyhuetoNS59bHMBt0mMIXfW6udTcc2eaveuuFpI7tWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svhsVGhtQ%253D%253D&md5=726ca1e7e162ab2a4a05048f493731fb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkm216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkm216%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DLeaver-Fay%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DBlock%26aufirst%3DJ.%2BN.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DSnoeyink%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520contacts%2520and%2520structure%2520validation%2520for%2520proteins%2520and%2520nucleic%2520acids%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2007%26volume%3D35%26spage%3DW375%26epage%3DW383%26doi%3D10.1093%2Fnar%2Fgkm216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG','PDB','4BGG'); return false;">PDB: 4BGG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM','PDB','6SZM'); return false;">PDB: 6SZM</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i87"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01199">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_25307"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01199?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01199</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Kinase selectivity panel, safety screen panel, ALK2·<b>M4K2009</b> cocrystal data collection and refinement statistics, <sup>1</sup>H spectra and HPLC traces of select compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_001.pdf">jm0c01199_si_001.pdf (585.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01199/suppl_file/jm0c01199_si_002.csv">jm0c01199_si_002.csv (1.85 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PBD ID codes: ALK2·<b>M4K2009</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SZM">6SZM</a>; ALK2·<b>LDN-213844</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BGG">4BGG</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01199&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01199%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01199" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679959e36fd63da0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
